<SEC-DOCUMENT>0001213900-17-000495.txt : 20170119
<SEC-HEADER>0001213900-17-000495.hdr.sgml : 20170119
<ACCEPTANCE-DATETIME>20170119172807
ACCESSION NUMBER:		0001213900-17-000495
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		47
FILED AS OF DATE:		20170119
DATE AS OF CHANGE:		20170119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			American BriVision (Holding) Corp
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-213618
		FILM NUMBER:		17536919

	BUSINESS ADDRESS:	
		STREET 1:		11 SAWYERS PEAK DRIVE
		CITY:			GOSHEN
		STATE:			NY
		ZIP:			10924
		BUSINESS PHONE:		845-551-8728

	MAIL ADDRESS:	
		STREET 1:		11 SAWYERS PEAK DRIVE
		CITY:			GOSHEN
		STATE:			NY
		ZIP:			10924

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Ecology Coatings, Inc.
		DATE OF NAME CHANGE:	20070711
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>fs12017a2i_americanbrivision.htm
<DESCRIPTION>AMENDMENT NO. 2 TO REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No.&nbsp;&nbsp;&nbsp;333-213618</B></FONT> </P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT
NO.2 TO</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMERICAN
BRIVISION (HOLDING) CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Exact
name of Registrant as specified in its charter)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5084
    </B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>26-0014658</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(State
    or Other Jurisdiction of</I><BR>
    <I>Incorporation or Organization)</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Primary
    Standard Industrial</I><BR>
    <I>Classification Code Number)</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(I.R.S.
Employer</I></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Identification&nbsp;Number)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11
Sawyers Peak Drive, Goshen, NY, 10924</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(845)
291-1291</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address,
including zip code, and telephone number,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">including
area code, of Registrant&rsquo;s principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Copies
to:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Louis
E. Taubman, Esq.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Joan
Wu Esq.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hunter
Taubman Fischer &amp; Li, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1450
Broadway, Floor 26</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
York, NY 10018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public: </B>From time to time after this Registration Statement becomes effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the
same offering.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company.&nbsp;&nbsp;&nbsp;See definitions of &ldquo;large accelerated filer&rdquo;, &ldquo;accelerated filer&rdquo;
and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act.&nbsp;&nbsp;(Check one):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 49.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</FONT></TD>
    <TD NOWRAP STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#9744;</TD>
    <TD NOWRAP STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer </FONT></TD>
    <TD NOWRAP STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#9744;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="padding: 0pt; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
        filer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Do
        not check if a smaller reporting company)</FONT></P></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#9744;</TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company </FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#9746;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CALCULATION
OF REGISTRATION FEE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Title of each class of securities to
    be registered </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Amount to <BR> be <BR>
    Registered&nbsp;(1) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Proposed<BR> maximum <BR>
    offering <BR> price per<BR> share(2) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Proposed <BR> maximum <BR>
    aggregate <BR> offering price </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Amount of <BR> registration
    <BR> fee </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt; padding-bottom: 1.5pt"> Common stock, par value $.001 per share
    offered by certain selling stockholders </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right; border-bottom: Black 1.5pt solid"> 32,409,505 </TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1.5pt"> (3) </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid"> $ </TD><TD STYLE="width: 9%; text-align: right; border-bottom: Black 1.5pt solid"> 2.00 </TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid"> $ </TD><TD STYLE="width: 9%; text-align: right; border-bottom: Black 1.5pt solid"> 64,819,010 </TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid"> $ </TD><TD STYLE="width: 9%; text-align: right; border-bottom: Black 1.5pt solid"> 6,528 </TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"> Total </TD><TD STYLE="font-weight: bold; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right"> 32,409,505 </TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 64,819,010 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 6,528 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> (4) </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
    to Rule 416 of the Securities Act of 1933, also registered hereby are such additional and indeterminable number of shares
    as may be issuable due to adjustments for changes resulting from stock dividends, stock splits and similar changes.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
    solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended,
    based on the average of the high and low sales price of the common stock on the OTCQB Market on August 24, 2016.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    32,409,505 shares of common stock are being registered for resale by certain selling stockholders named in this registration
    statement, which shares were issued by the registrant in the Share Exchange, as defined below.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    paid.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until
the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become
effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective
on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a) may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>The
information in this prospectus is not complete and may be changed.&nbsp;&nbsp;We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) is effective.&nbsp;&nbsp;This prospectus is not
an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale
is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 46%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>Preliminary
    Prospectus</B></FONT> </TD>
    <TD STYLE="width: 54%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>Subject
    to Completion, dated January 19, 2017</B></FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>American
BriVision (Holding) Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,409,505
Shares of Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the resale of up to 32,409,505 shares of common stock of American BriVision (Holding) Corporation, a Nevada
corporation (the &ldquo;Company&rdquo;), $0.001 par value (the &ldquo;Common Stock&rdquo;).&nbsp;The selling stockholders named
herein may sell common stock from time to time in the principal market on which the stock is traded at the prevailing market price,
at prices related to such prevailing market price, in negotiated transactions or a combination of such methods of sale. We will
not receive any proceeds from the sales by the selling stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is quoted on the OTC Markets under the symbol ABVC. On January 8, 2017, the closing price of our common stock was
$2.00 per share. Prior to January 14, 2016, our common stock was quoted under the symbol MTOO. Prior to December 15, 2015, our
common stock was quoted under the symbol ECOC.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders, and any broker-dealer executing sell orders on behalf of the selling stockholders, may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act of 1933, as amended.&nbsp;&nbsp;Commissions received by any broker-dealer may be deemed
underwriting commissions under the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 39.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
INVESTMENT INVOLVES A HIGH DEGREE OF RISK.&nbsp;&nbsp;YOU SHOULD PURCHASE SHARES ONLY IF YOU CAN AFFORD A COMPLETE LOSS OF YOUR
INVESTMENT.&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 39.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEITHER
THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THESE SECURITIES, OR DETERMINED
IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="toc"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 89%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART I. INFORMATION REQUIRED IN PROSPECTUS</B></FONT></A></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About This Prospectus </FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination of Offering Price</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s Discussion and Analysis</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">Management</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt">38</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationship and Related Transactions</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management </FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Stockholders</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt">47</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market For Our Common Stock, Dividends And Related Stockholder Information</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt">49</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
Matters</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure of Commission Position on Indemnification for Securities Act Liabilities</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    </TR>

<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 89%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_031"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART II. INFORMATION NOT REQUIRED IN PROSPECTUS</B></FONT></A></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-1</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_031"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Expenses of Issuances and Distribution</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-1</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_033"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification of Directors and Officers</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-1</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_034"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent Sales of Unregistered Securities</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-2</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><A HREF="#a_035"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits and Financial Statement Schedule</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-3</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_036">Undertakings</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-4</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_001"></A><B>PART
1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_002"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not authorized any person to give you any supplemental information or to make any representations for us. You should not
rely upon any information about us that is not contained in this prospectus or in one of our public reports filed with the Securities
and Exchange Commission (&ldquo;SEC&rdquo;) and incorporated into this prospectus. Information contained in this prospectus or
in our public reports may become stale. You should not assume that the information contained in this prospectus, any prospectus
supplement or the documents incorporated by reference are accurate as of any date other than their respective dates, regardless
of the time of delivery of this prospectus or of any sale of the shares. Our business, financial condition, results of operations
and prospects may have changed since those dates. The selling stockholders are offering to sell, and seeking offers to buy, shares
of our common stock only in jurisdictions where offers and sales are permitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 39.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this prospectus the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo; refer to American BriVision
(Holding) Corporation, a Nevada corporation and its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 39.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver
a prospectus.&nbsp;&nbsp;This is in addition to the dealers&rsquo; obligation to deliver a prospectus when acting as underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_003"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary highlights selected information appearing elsewhere in this prospectus. While this summary highlights what we consider
the most important information about us, you should carefully read this prospectus and the registration statement of which this
prospectus is a part in their entirety before investing in our common stock, and our financial statements and related notes beginning
on page F-1 and F-4, respectively. Unless the context requires otherwise, the words the &ldquo;Company,&rdquo; &ldquo;American
BriVision&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; or &ldquo;our&rdquo; are references to the combined business of American BriVision
(Holding) Corporation and its consolidated subsidiaries.&nbsp;&nbsp;References to &ldquo;BriVision&rdquo; are references to our
wholly owned subsidiary. All references to &ldquo;$&rdquo; and dollar are to the U.S. dollar, the legal currency of the United
States. All market and industry data provided in this prospectus represents information that&nbsp;is generally available to the
public and was not prepared for us for a fee. We did not fund nor were&nbsp;we otherwise affiliated with these sources and we
are not attempting to incorporate the information on external web sites into this prospectus. We are only providing textual reference
of the information of market and industry data and the web addresses provided in this prospectus are not intended to be hyperlinks
and we do not assure that those external web sites will remain active and current.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we are a holding company operating through our wholly owned subsidiary, American BriVision Corporation, a Delaware corporation,
or BriVision. BriVision was incorporated in 2015 in the State of Delaware. It is a biotechnology company focused on the development
of new drugs and innovative medical devices to fulfill unmet medical needs. Our business model is to integrate research achievements
from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (POC), out-license to international
pharmaceutical companies, and exploit global markets.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have sole licensing rights to the drug and therapeutic use for five compounds developed by BioLite, Inc. (&ldquo;BioLite&rdquo;).
BioLite is a botanical new drug developer incorporated under the laws of Taiwan in 2006. On December 29, 2015,&nbsp;BriVision
entered into a Collaborative Agreement (the &ldquo;Collaborative Agreement&rdquo;) with BioLite. Our CEO and sole director, Eugene
Jiang, is a director of BioLite and therefore BioLite is considered a related party.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>History
and Background</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the consummation of the share exchange transaction described below, we were a public reporting company with nominal operations.
Ecology Coatings Inc. incorporated on March 12, 1990 in California (&ldquo;Ecology-CA&rdquo;).&nbsp; OCIS Corp (&ldquo;OCIS&rdquo;)
was incorporated in Nevada on February&nbsp;6, 2002 as and was a public reporting company (&ldquo;OCIS&rdquo;).&nbsp;&nbsp;OCIS
completed a merger with Ecology-CA on July&nbsp;26, 2007 (the &ldquo;Merger&rdquo;). In the Merger, OCIS changed its name from
OCIS Corporation to Ecology Coatings, Inc.&nbsp;&nbsp;We filed for Chapter 7 bankruptcy protection on May 15, 2013 and subsequently
the corporate shell emerged as its only unencumbered asset on September 19, 2014 using &quot;fresh start&quot; accounting under
section 852-10-45-17 as of date of sale corporate shell to reflect intangible assets sale through section 363. Any business description
below and all reporting results of the operating results reported in this filing for the fiscal year ending September 30, 2015
are post &quot;fresh start&quot; activity and not comparable to prior results.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-bankruptcy,
we operated a web site for the sale of women's apparel. On November 14, 2014, a majority of our stockholders by unanimous written
consent in lieu of a special meeting of stockholders unanimously approved an amendment to the Articles of Incorporation to change
our name to Metu Brands, Inc. The Amendment the Articles of Incorporation was filed with the State of Nevada on April 28, 2015.
The name change was subsequently approved by the Financial Industry Regulatory Authority (&ldquo;FINRA&rdquo;) on August 13, 2015.
In conjunction with the name change, our ticker symbol was changed to &ldquo;MTOO&rdquo;.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2015, a Stock Purchase Agreement (&ldquo;Stock Purchase Agreement&rdquo;) was entered into by and among Euro-Asia
Investment &amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the
People's Republic of China (&ldquo;Euro-Asia&rdquo; or &ldquo;Buyers&rsquo; Representative&rdquo;), &nbsp;seven other buyers listed
in Schedule A attached thereto (together with Euro-Asia, collectively, &ldquo;Buyers&rdquo;), Shulamit Lazar (&ldquo;Lazar&rdquo;),
eleven other sellers listed in Schedule B attached thereto (together with Lazar, collectively, &ldquo;Sellers&rdquo;),. Pursuant
to the Stock Purchase Agreement, for a total consideration of $395,000, the Buyers acquired from the Sellers a total of 65,420,000
shares of our common stock, $0.001 par value per share (the &ldquo;Common Stock&rdquo;) which represented approximately 99.98%
of our 65,431,144 (pre-forward split) shares of issued and outstanding Common Stock at that time.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2015, the majority holders of our issued and outstanding shares of common stock approved the change of the Company&rsquo;s
name from Metu Brands, Inc. to American BriVision (Holding) Corporation (the &ldquo;Name Change&rdquo;), and the increase of its
authorized shares of Common Stock from 90,000,000 to 350,000,000, and authorized shares of preferred stock from 10,000,000 to
20,000,000, par value $0.001 per share (the &ldquo;Increase of Authorized Stock&rdquo;). A Certificate of Amendment (the &ldquo;Amendment&rdquo;)
to Articles of Incorporation effecting the Name Change and Increase of Authorized Stock was filed and became effective as of January
4, 2016. As a result of the Name Change, our trading symbol is changed from &ldquo;MTOO&rdquo; to &ldquo;ABVC&rdquo;.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reverse
Merger</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2016, a Share Exchange Agreement (&ldquo;Share Exchange Agreement&rdquo;) was entered into by and among American BriVision
(Holding) Corporation (the&nbsp;&ldquo;Company&rdquo;), American BriVision Corporation&nbsp;(&ldquo;BriVision&rdquo;), Euro-Asia
Investment &amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People's
Republic of China (&ldquo;Euro-Asia&rdquo;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of
our common stock, and the owners of record of all of the issued share capital of BriVision (the&nbsp;&ldquo;BriVision Stock&rdquo;).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates
evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the
Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates
evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company issued 52,936,583 pre-stock
split) shares (the&nbsp;&ldquo;Acquisition Stock&rdquo;) (subject to adjustment for fractionalized shares as set forth below)
of the Company&rsquo;s common stock to the BriVision Shareholders (or their designees), and cancelled 163,159,952 (51,945,225
pre-stock split) shares of the Company&rsquo;s common stock owned by Euro-Asia (such shares were retired to treasury.). The Acquisition
Stock collectively represents 79.70% of the issued and outstanding common stock of the Company immediately after the Closing,
in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Merger, all of the issued and outstanding shares of BriVision&rsquo;s common stock was converted, at an exchange ratio
of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of the Company&rsquo;s common stock and BriVision
became a wholly owned subsidiary, of the Company. The holders of Company&rsquo;s common stock as of immediately prior to the Merger
held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company&rsquo;s common stock,&nbsp;Because of the exchange
of the BriVision Stock for the Acquisition Stock (the&nbsp;&ldquo;Share Exchange&rdquo;), BriVision became a wholly owned subsidiary
(the &ldquo;Subsidiary&rdquo;) of the Company and there was a change of control of the Company following the closing.&nbsp;As
a result of Share Exchange, the selling stockholders named in this registration statement obtained their shares in the Company.&nbsp;There
were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</FONT> </P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 97%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Share Exchange, we have abandoned our prior business plan and we are now using BriVision&rsquo;s historical businesses and
proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs.&nbsp;&nbsp;Our
business model is to integrate research achievements from world-renown institutions, conduct clinical trials of translational
medicine for Proof of Concept (&ldquo;POC&rdquo;), out-license to international pharmaceutical companies, and exploit global markets.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward
Stock Split</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2016, our Board of Directors approved an amendment to Articles of Incorporation to effect a forward split at a ratio
of 1 to 3:141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, The
amendment to Articles of Incorporation was approved by the majority of our shareholders and became effective on April 8, 2016.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Merger
and Name Change</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ecology
Coatings, Inc. (&ldquo;Ecology-CA&rdquo;) was originally incorporated in California on March 12, 1990.&nbsp;&nbsp;OCIS Corp. (&ldquo;OCIS&rdquo;)
was incorporated in Nevada on February&nbsp;6, 2002.&nbsp;&nbsp;OCIS completed a merger with Ecology-CA on July&nbsp;27, 2007
(the &ldquo;Merger&rdquo;).&nbsp;&nbsp;In the Merger, OCIS issued approximately 6,106,137 shares of common stock to the Ecology-CA
stockholders.&nbsp;&nbsp;In this transaction, OCIS changed its name from OCIS Corporation to Ecology Coatings, Inc. and our ticker
symbol on the OTC Bulletin Board association changed to &ldquo;ECOC.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 14, 2014, Ecology-CA changed its name to Metu Brands, Inc., which the Financial Industry Regulatory Authority (&ldquo;FINRA&rdquo;)
approved on August 13, 2015. In conjunction with the name change, Ecology-CA&rsquo;s ticker symbol was changed to &ldquo;MTOO&rdquo;.
On January 14, 2016, Metu Brands, Inc. changed its name to American BriVision (Holding) Corporation and its OTCQB ticker symbol
changed from &ldquo;MTOO&rdquo; to &ldquo;ABVC&rdquo;, which was approved by FINRA and took effect as of January 14, 2016.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
Executive Office</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 11 Sawyers Peak Drive, Goshen, NY.</FONT></P>

</DIV>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock being offered by Selling Stockholders</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to 32,409,505 shares. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock outstanding prior to the Offering</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">213,303,222
    shares as of September 13, 2016</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock outstanding after the Offering</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">213,303,222
    shares</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of Proceeds</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will not receive any proceeds from the sale of shares by the Selling Stockholders</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    securities offered by this prospectus are speculative and involve a high degree of risk and investors purchasing securities
    should not purchase the securities unless they can afford the loss of their entire investment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 36pt">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_004"></A><B>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should carefully consider the risks described below as well as other information provided to you in this document, including information
in the section of this document entitled &ldquo;Forward Looking Statements&rdquo;. If any of the following risks actually occur,
our business, financial condition or results of operations could be materially adversely affected, the value of our common stock
could decline, and you may lose all or part of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are a pre-revenue biopharmaceutical company and are thus subject to the risks associated with new businesses in that industry.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
acquired the sole licensing rights to develop and commercialize for drug and therapeutic use of five compounds and have only recently
begun to pursue this new business opportunity. As such, we are a clinical stage biopharmaceutical company with no history of revenue-generating
operations, and our only assets consist of the intellectual property and related assets licensed to us by BioLite. Therefore,
we are, and expect for the foreseeable future to be, subject to all the risks and uncertainties inherent in a new business, in
particular new businesses engaged in the development of pharmaceuticals. We still must establish and implement many important
functions necessary to operate a business, including the clinical development of the five compounds, establishing our managerial
and administrative structure and implementing financial systems and controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies
in their pre-revenue generating stages, particularly those in the pharmaceutical field. Potential investors should carefully consider
the risks and uncertainties that a new company with no operating history will face. In particular, potential investors should
consider that there is a significant risk that we will not be able to:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.3in; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">implement
    or execute our current business plan, or create a business plan that is sound;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain
    our anticipated management team;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">raise
    sufficient funds in the capital markets or otherwise to effectuate our business plan;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    that the processes and technologies that we have developed are commercially viable; and/or</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract,
    enter into or maintain contracts with, potential commercial partners such as licensors of technology and suppliers.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot execute any one of the foregoing, our business may fail, in which case you may lose the entire amount of your investment
in our Company. To date, we are still setting up our pipeline products. We cannot assure that any of our efforts will be successful
or result in the development or timely launch of additional products, or ultimately produce any material revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as a pre-revenue biopharmaceutical company, we expect to encounter unforeseen expenses, difficulties, complications,
delays and other known and unknown factors. We will need to transition at some point from a company with a research and development
focus to a company capable of supporting commercial activities. We may not be able to reach such point of transition or make such
a transition, which would have a material adverse effect on our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to raise additional capital, our ability to implement our business model and strategy could be compromised.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited capital resources and operations. To date, our operations have been&nbsp;funded&nbsp;partial&nbsp;from the proceeds
from financings or loans from shareholders or our management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not raise a sufficient amount to fund our ongoing development activities, we will likely be unable to carry out our business.
We may not be able to obtain additional financing on terms acceptable to us, or at all. Even if we obtain financing for our near
term operations and product development, we may require additional capital beyond the near term. If we are unable to raise capital
when needed, our business, financial condition and results of operations would be materially adversely affected, and we could
be forced to reduce or discontinue our operations.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are highly dependent on our license agreement with BioLite, and the loss of this license would materially impair our business
plan and viability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have secured sole rights to develop and commercialize five products from BioLite in the North America, and these five products
are currently our only product candidates. As such, our Collaboration Agreement with BioLite is critical to our business. In the
event that our Collaboration Agreement with BioLite is terminated, we would lose the ability to develop and commercialize the
five products, and our business prospects would be materially damaged, which could lead to the loss of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have no experience as a company in obtaining regulatory approval for, or commercializing, any product candidate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a company, we have never obtained regulatory approval for, or commercialized, any product candidate. It is possible that the Food
and Drug Administration (&ldquo;FDA&rdquo;) may refuse to accept our planned New Drug Application (or NDA) for any of the five
products for substantive review, or may conclude after review of our data that our application is insufficient to obtain regulatory
approval of the five products or any future product candidates. If the FDA does not accept or approve our planned NDA for our
product candidates, it may require that we conduct additional clinical, preclinical or manufacturing validation studies, which
may be costly, and submit that data before it will reconsider our applications. Depending on the extent of these or any other
FDA required studies, approval of any NDA or application that we submit may be significantly delayed, possibly for several years,
or may require us to expend more resources than we have available. Any delay in obtaining, or an inability to obtain, regulatory
approvals would prevent us from commercializing the five products, generating revenues and achieving and sustaining profitability.
It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve
any NDA we submit. If any of these outcomes occur, we may be forced to abandon our planned NDA for The five products, which would
materially adversely affect our business and could potentially cause us to cease operations. We face similar risks for any approval
in a foreign jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dependence
on Key Existing and Future Personnel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend, to a large degree, upon the efforts and abilities of our officers and key employees. The loss of the services
of one or more of our key employees could have a material adverse effect on our operations. In addition, as our business model
is implemented, we will need to recruit and retain additional management and key employees in virtually all phases of our operations.
Key employees will require a strong background in our industry. We cannot assure that we will be able to successfully attract
and retain key personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
growth is dependent on our ability to successfully develop, acquire or license new drugs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
growth is supported by continuous investment in time, resources and capital to identify and develop new products or new formulations
for the market via&nbsp;geographic expansion and market penetration. If we are unable to either develop new products on our own
or acquire licenses for new products from third parties, our ability to grow revenues and market share will be adversely affected.&nbsp;In
addition, we may not be able to recover our investment in the development of new drugs and medical devices, given that projects
may be interrupted, unsuccessful, not as profitable as initially contemplated or we may not be able to obtain necessary financing
for such development. Similarly, there is no assurance that we can successfully secure such rights from third parties on an economically
feasible basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to develop our existing licensed compounds and our business plan is entirely dependent on entering into co-development
agreements with capable pharmaceutical companies for the development or commercialization of our product candidates.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no guarantee that any of our desired results will be realized by any of our licensed product candidates. We do not have the
resources to independently develop the licensed compounds and we intend to enter into co-development agreements with capable pharmaceutical
companies for the development or commercialization of our product candidates. We do not currently have any co-development agreements
with such pharmaceutical companies and there is no guarantee that we will enter into such agreements on terms acceptable to us.
Our business and plans to develop and commercialize our existing product candidates are entirely dependent on our ability to enter
into such agreements, and such inability would material adversely affect our business and could potentially cause us to cease
operations.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to secure financing needed for future operating needs on acceptable terms, or on any terms at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may seek additional financing to provide the capital required to expand our production facilities, R&amp;D initiatives
and/or working capital, as well as to repay outstanding loans if cash flow from operations is insufficient to do so.&nbsp;We cannot
predict with certainty the timing or amount of any such capital requirements.&nbsp;If such financing is not available on satisfactory
terms, we may be unable to expand our business or to develop new business at the rate desired.&nbsp;If we are able to incur debt,
we may be subject to certain restrictions imposed by the terms of the debt and the repayment of such debt may limit our cash flow
and growth.&nbsp;If we are unable to incur debt, we may be forced to issue additional equity, which could have a dilutive effect
on our current stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Expansion
of our business may put pressure on our management and the operational infrastructure, which could impede our ability to meet
an increased demand for our products</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business plan is to develop new drug (product) and finish Phase II clinical trials for our drugs. After finishing phase II clinical
trials with good results, proof of concept (POC) will have been achieved. Then, ABVC will engage with the world leading Pharmaceuticals
by out-licensing the new drug for the next stage development. The advantages are</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    diversify the risk involved with leading pharmaceuticals</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quick
    return on investment (ROI) &amp; Improve cash flow</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sustainable
    income</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Growth
in our business may place a significant strain on our personnel, management, financial systems and other resources.&nbsp;The evolution
of our business also presents numerous risks and challenges that include continued acceptance of our products, sales and market
share expansion, costs for expansion, technological evolvement and industrial dynamics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are successful in obtaining rapid market growth of our products, we will be required to deliver large volumes of quality products
and services on a timely basis at a reasonable cost to the customers.&nbsp;Meeting any such increased demands will require us
to expand our manufacturing facilities, to increase our ability to purchase raw materials, to expand our work force, to expand
our quality control capabilities and to increase the scale upon which we provide our products and services.&nbsp;&nbsp;Such demands
would require more capital and working capital than we currently have available and we may be unable to meet the needs of our
customers, which could adversely affect our relationship with our customers and reduce our revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
growth strategy includes the pursuit of acquisitions, and new product development, which could have a materially adverse effect
on our business, financial condition, results of operations and growth prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business strategy includes growth through strategic acquisitions, and the development of new products, medical devices and technologies,
which will involve significant capital expenditure and risks.&nbsp;Innovative pharmaceutical development involves R&amp;D costs,
but it may achieve no tangible results and instead may adversely affect our future profitability.&nbsp;In addition, any acquisition
or combination that we consummate will likely involve, among other things, the payment of cash, the incurrence of contingent liabilities
and the amortization of expenses related to goodwill and other intangible assets, and transaction costs, which may adversely affect
our business, financial condition, results of operations and growth prospects.&nbsp;Our ability to integrate and organize any
new businesses and/or products, whether internally developed or obtained by acquisition or combination, will likely require significant
expansion of our operations.&nbsp;There is no assurance that we will be able to obtain the necessary resources for such expansion,
and the failure to do so could have a materially adverse effect on our business, financial condition, results of operations and
growth prospects.&nbsp;&nbsp;In addition, future acquisitions or combinations by us involve risks of, among other things, entering
markets or segments in which we have no or limited prior experience, the potential loss of key employees or difficulty, delay
or failure in the integration of the operations of any such new business with our current business and operating and financial
difficulties of any new or newly combined operations, any of which could have a materially adverse effect on our business, financial
condition, results of operations and growth prospects.&nbsp;&nbsp;Moreover, there can be no assurance that the anticipated benefits
of any internally developed new business segment or business combination will be realized.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
current products have certain side effects.&nbsp;&nbsp;If the side effects associated with our current or future products are
not identified prior to their marketing and sale, we may be required to withdraw such products from the market, perform lengthy
additional clinical trials or change the labeling of our products, any of which could adversely impact our growth. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Side
effects associated with ABV-1501 and ABV-1502 &ldquo;Maitake mushroom extract&rdquo; include nausea, joint swelling, rash, pruritus,
eosinophilia, diarrhea, fainting, pain and/or bruising. Serious adverse events associated with this compound are listed below
and further detailed here: <U>https://clinicaltrials.gov/show/NCT01099917</U>. Pruritus means itching (according to WebMD) and
is defined as an unpleasant sensation that provokes the desire to scratch (according to Medscape). Eosinophilia is defined as
an increase in peripheral blood eosinophilic leukocytes to more than 600 cells per microliter (&mu;L) of blood. Emphasis is placed
on the number of eosinophils circulating in the peripheral blood. Parasitic diseases and allergic reactions to medication are
among the more common causes of eosinophilia. Eosinophils are derived from hematopoietic stem cells initially committed to the
myeloid line and then to the basophil-eosinophil granulocyte lineage. Nonpathologic functions of eosinophils and the cationic
enzymes of their granules include mediating parasite defense reactions, allergic response, tissue inflammation, and immune modulation.
The foregoing information was collected from the Mayo Clinic and Medscape.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the MSKCC clinical trial on Myelodysplastic Syndrome (MDS), &ldquo;Maitake mushroom extract,&rdquo; only two patients withdrew
prior to completion of the study due to grade I possibly related side effects: one reported nausea and joint swelling; the other
withdrew reportedly due to a grade I allergic reaction (rash and pruritus). Other serious side events were not reported in the
journal, as they were determined not relevant to this product after careful review by the principal investigator.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following serious adverse events were observed in 1 out of 21 participants, or at a rate of 4.76%: Total, serious adverse events,
Leukocytosis, Platelet count decreased, Eye disorders &ndash; Other, Abdominal pain, Gastrointestinal disorders &ndash; Other,
Aphonia, Lung infection, Muscle weakness right-sided, Confusion, Edema cerebral, Stroke, Dyspnea, Wheezing and Pruritus (itching).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Side
effects associated with ABV-1504 and ABV-1505 &ldquo;Radix Polygalae (Polygala tenuifolia Willd/PDC-1421 Capsule)&rdquo; may come
from administration of the study medicine or examination procedure such as the procedure of taking blood (fainting, pain and/or
bruising). Other side effects are described below and in this paper: Preclinical evidence of rapid-onset antidepressant-like effect
in Radix Polygalae extract.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Im-Joon
Shin, #1 Sung Un Son, #2 Hyunwoo Park,2 Yoorim Kim,2 Sung Hyun Park,2 Kelley Swanberg,2 Joo-Yeon Shin,2 Sang-Kyu Ha,2 Yoonju Cho,1
Soo-Yong Bang,2 Jae-Hwan Lew,2 Seung-Hun Cho,3 and Sungho Maeng2, *</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLoS
One. 2014; 9(2): e88617.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published
online 2014 Feb 10.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">doi:
10.1371/journal.pone.0088617.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the &ldquo;Phase I Study of PDC-1421&rdquo; &ldquo;Radix Polygalae (Polygala tenuifolia Willd/PDC-1421 Capsule)&rdquo; by BioLite,
radix polygalae has no serious adverse effects but did have adverse events, but such adverse events may not be the result of a
causal relationship with the study medication or clinical study.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Serious
Adverse Events</U></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PDC-1421
                                         </B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Placebo
                                         Control </B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"> Total, serious
    adverse events </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: 0pt; padding-left: 10pt"> # participants affected / at risk </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;0/23&nbsp;(0.00%)&nbsp;
                                         </FONT> </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;0/7&nbsp;(0.00%)&nbsp;
                                         </FONT> </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
Adverse Events</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> PDC-1421 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Placebo Control </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold"> Total, other (not including serious) adverse events </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 10pt"> # participants affected / at
    risk </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;3/23&nbsp;(13.04%)&nbsp;
                                         </FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;2/7&nbsp;(28.57%)&nbsp;
                                         </FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"> Gastrointestinal
    disorders </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abdominal
    fullness *<SUP>[2]&nbsp;</SUP></FONT> </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 20pt"> # participants affected / at
    risk </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;2/23&nbsp;(8.70%)&nbsp;
                                         </FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1/7&nbsp;(14.29%)&nbsp;
                                         </FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 20pt"> # events </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: center"> &nbsp; </TD><TD STYLE="width: 9%; text-align: center"> 2 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: center"> &nbsp; </TD><TD STYLE="width: 9%; text-align: center"> 1 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Constipation
    *<SUP>[3]&nbsp;</SUP></FONT> </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 20pt"> # participants affected / at
    risk </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1/23&nbsp;(4.35%)&nbsp;
                                         </FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;0/7&nbsp;(0.00%)&nbsp;
                                         </FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 20pt"> # events </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> 1 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> 0 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"> Nervous system
    disorders </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drowsiness
    *<SUP>[4]&nbsp;</SUP></FONT> </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 20pt"> # participants affected / at
    risk </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;0/23&nbsp;(0.00%)&nbsp;
                                         </FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1/7&nbsp;(14.29%)&nbsp;
                                         </FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 20pt"> # events </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> 0 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> 1 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sleepiness&nbsp;*<SUP>[5]&nbsp;</SUP></FONT> </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 20pt"> # participants affected / at
    risk </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1/23&nbsp;(4.35%)&nbsp;
                                         </FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1/7&nbsp;(14.29%)&nbsp;
                                         </FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 20pt"> # events </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> 1 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> 1 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oral
    ulcer *<SUP>[6]&nbsp;</SUP></FONT> </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 20pt"> # participants affected / at
    risk </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1/23&nbsp;(4.35%)&nbsp;
                                         </FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;0/7&nbsp;(0.00%)&nbsp;
                                         </FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 20pt"> # events </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> 1 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> 0 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PDC-1421
was observed to be associated with some adverse effects in serum electrolytes and GI function, but none were clinically significant.
Therefore, potential risks of PDC-1421 are fluctuated electrolyte levels and gastrointestinal discomfort. We monitored these in
the Phase I study and there was no deviation of electrolyte level and no significant gastrointestinal discomfort during monitoring
in the clinical trial. The cardiovascular systems will be monitored in the clinical study.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in; text-align: left"> &#9679; </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WebMD
warns that radix polygalae, when ingested on a long-term basis, can be unsafe, and that it is unsafe to ingest for pregnant women
because it can cause miscarriages. Other adverse effects of radix polygalae described on medical education websites like WebMD
and Medscape include nausea, vomiting and uterus contraction. None of the foregoing effects are applicable to our product candidate
because the dosage of radix polygalae used in our product candidate is smaller than would be necessary to trigger these effects.</FONT> </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
significant side effects of our medicines are identified after they are marketed and sold:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw or modify their approvals of such medicines;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to reformulate these medicines, change the ways in which they are marketed, conduct additional clinical trials,
    change the labeling of these medicines or implement changes to obtain new approvals for our manufacturing facilities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may have to recall these medicines from the market and may not be able to re-launch them;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may experience a significant decline in sales of the affected products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may become a target of lawsuits.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any of these events would harm our sales of these medicines and substantially increase the costs and expenses of
marketing these medicines, which in turn could cause our revenues and net income to decline.&nbsp;In addition, the reputation
and sales of our medicines could be adversely affected due to the severe side effects discovered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to product liability claims in the future, which could divert our resources, cause us to incur substantial liabilities
and limit commercialization of any products that we may develop.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face an inherent business risk of exposure to product liability claims in the event that the uses of our products are alleged
to have caused adverse side effects.&nbsp;Side effects or marketing or manufacturing problems pertaining to any of our products
could result in product liability claims or adverse publicity.&nbsp;These risks will exist for those products in clinical development
and with respect to those products that receive regulatory approval for commercial sale.&nbsp;&nbsp;Furthermore, although we have
not historically experienced any problems associated with claims by users of our products, we do not currently maintain product
liability insurance and&nbsp;there could be no assurance that we are able to acquire product liability insurance with terms that
are commercially feasible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face an inherent risk of product liability claims as a result of the clinical testing of our products and potentially commercially
selling any products that we may develop. For example, we may be sued if any product we develop allegedly causes injury or is
found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims
may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product,
negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If
we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required
to limit commercialization of our product candidate. Regardless of the merits or eventual outcome, liability claims may result
in:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for our product candidate or products that we may develop;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation and significant negative media attention;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical trial participants;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    costs to defend resulting litigation;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to trial participants or patients;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenue;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    resources of our management to pursue our business strategy; and</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize any products that we may develop.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not maintain general liability insurance; and even if we have a general liability insurance in the future this insurance
may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding,
even if resolved in our favor, could be substantial. We would need to increase our insurance coverage if and when we begin selling
any product candidate that receives marketing approval. In addition, insurance coverage is becoming increasingly expensive. If
we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential
product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidate,
which could adversely affect our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to keep up with rapid technological changes in our field or compete effectively, we will be unable to operate profitably.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are engaged in a rapidly changing field. Other products that will compete directly with the products that we are seeking to develop
and market currently exist or are being developed. Competition from fully integrated pharmaceutical companies and more established
biotechnology companies is intense and is expected to increase. Most of these companies have significantly greater financial resources
and expertise in discovery and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and
marketing than us. Smaller companies may also prove to be significant competitors, particularly through collaborative arrangements
with large pharmaceutical and established biopharmaceutical or biotechnology companies. Many of these competitors have significant
products that have been approved or are in development and operate large, well-funded discovery and development programs. Academic
institutions, governmental agencies and other public and private research organizations also conduct research, seek patent protection
and establish collaborative arrangements for therapeutic products and clinical development and marketing. These companies and
institutions compete with us in recruiting and retaining highly qualified scientific and management personnel. In addition to
the above factors, we will face competition based on product efficacy and safety, the timing and scope of regulatory approvals,
availability of supply, marketing and sales capability, reimbursement coverage, price and patent position. There is no assurance
that our competitors will not develop more effective or more affordable products, or achieve earlier patent protection or product
commercialization, than our own.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
companies may succeed in developing proof of concept (POC) earlier than ourselves, obtaining FDA approvals for such products more
rapidly than we will, or in developing products that are more effective than products we propose to develop. While we will seek
to expand our technological capabilities in order to remain competitive, there can be no assurance that research and development
by others will not render our technology or products obsolete or non-competitive or result in treatments or cures superior to
any therapy we develop, or that any therapy we develop will be preferred to any existing or newly developed technologies.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have conducted, and may in the future conduct, clinical trials for certain of our product candidate at sites outside the United
States, and the FDA may not accept data from trials conducted in such locations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have conducted and may in the future choose to conduct one or more of our clinical trials outside the United States. Although
the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain
conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified
investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population,
and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful.
Generally, the patient population for any clinical trials conducted outside of the United States must be representative of the
population for whom we intend to seek approval in the United States. In addition, while these clinical trials are subject to the
applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with
all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside
of the United States. If the FDA does not accept the data from any of our clinical trials that we determine to conduct outside
the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and delay
or permanently halt our development of the product candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the conduct of clinical trials outside the United States could have a significant impact on us. Risks inherent in conducting
international clinical trials include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    regulatory requirements that could restrict or limit our ability to conduct our clinical trials;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">administrative
    burdens of conducting clinical trials under multiple foreign regulatory schema;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    exchange fluctuations; and</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diminished
    protection of intellectual property in some countries.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA and comparable
non-U.S. regulators, we may incur additional costs or experience delays in completing, or ultimately be unable to complete the
development and commercialization of our product candidate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not permitted to commercialize market, promote or sell any product candidate in the United States without obtaining marketing
approval from the FDA. Comparable non-U.S. regulatory authorities impose similar restrictions. We may never receive such approvals.
We must complete extensive preclinical development and clinical trials to demonstrate the safety and efficacy of our product candidate
in humans before we will be able to obtain these approvals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome.
Any inability to successfully complete preclinical and clinical development could result in additional costs to us and impair
our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if
(1) we are required to conduct additional clinical trials or other testing of our product candidate beyond the trials and testing
that we contemplate, (2) we are unable to successfully complete clinical trials of our product candidate or other testing, (3)
the results of these trials or tests are unfavorable, uncertain or are only modestly favorable, or (4) there are unacceptable
safety concerns associated with our product candidate, we, in addition to incurring additional costs, may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    delayed in obtaining marketing approval for our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    obtain marketing approval at all;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    approval for indications or patient populations that are not as broad as we intended or desired;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including
    boxed warnings;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    subject to additional post-marketing testing or other requirements; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    required to remove the product from the market after obtaining marketing approval.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if our product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients,
third party payors and others in the medical community necessary for commercial success and the market opportunity for the product
candidate may be smaller than we estimate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never commercialized a product. Even if our products are approved by the appropriate regulatory authorities for marketing
and sale, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third party payors and others
in the medical community. For example, physicians are often reluctant to switch their patients from existing therapies even when
new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy
that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required
to switch therapies due to lack of reimbursement for existing therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to educate the medical community and third party payors on the benefits of our product candidate may require significant resources
and may not be successful. If our product candidates are approved but do not achieve an adequate level of market acceptance, we
may not generate significant revenues and we may not become profitable. The degree of market acceptance of our products, if approved
for commercial sale, will depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    efficacy and safety of the products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential advantages of the products compared to alternative treatments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of any side effects;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical indications for which the products are approved;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the products are designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    or warnings, including distribution or use restrictions, contained in the product approved labeling;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to offer the products for sale at competitive prices;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain pricing sufficient to realize a meaningful return on our investment;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    products&rsquo;&nbsp;convenience and ease of administration compared to alternative treatments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of the target patient population to try, and of physicians to prescribe, the products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    strength of sales, marketing and distribution support;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval of other new products for the same indications;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the standard of care for the targeted indications for the products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of market introduction of our approved products as well as competitive products and other therapies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 74.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    and amount of reimbursement from government payors, managed care plans and other third party payors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 74.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    publicity about the products or favorable publicity about competitive products; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 74.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    product liability claims.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potential market opportunities for our products are difficult to estimate precisely. Our estimates of the potential market opportunities
are predicated on many assumptions, including industry knowledge and publications, third party research reports and other surveys.
While we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment
on the part of our management, are inherently uncertain and the reasonableness of these assumptions has not been assessed by an
independent source. If any of the assumptions proves to be inaccurate, the actual markets for our products could be smaller than
our estimates of the potential market opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely on a limited number of suppliers and the loss of any of our suppliers, or delays or problems in the supply of materials used
in our products, could materially and adversely affect our operations and growth.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generally rely on a limited number of suppliers for most of the primary materials used in our products.&nbsp;&nbsp;Our suppliers
may not be able to supply the necessary materials without interruption and we may not have adequate remedies for such failure,
which could result in a shortage of our products.&nbsp;&nbsp;If one of our suppliers fails or refuses to supply us for any reason,
it could take time and expense to obtain a new supplier.&nbsp;&nbsp;In addition, our failure to maintain existing relationships
with our suppliers or to establish new relationships in the future could negatively affect our ability to obtain the materials
used in our products in a timely manner.&nbsp;&nbsp;The search for new suppliers could potentially delay the manufacture of our
products, resulting in shortages in the marketplace and may cause us to incur additional expense.&nbsp;&nbsp;Failure to comply
with applicable legal requirements subjects our suppliers to possible legal or regulatory action, including shutdown, which may
adversely affect their ability to supply us with the materials we need for our products.&nbsp;&nbsp;Any delay in supplying, or
failure to supply, materials for our products by any of our suppliers could result in our inability to meet the commercial demand
for our products, and could adversely affect our business, financial condition, results of operations and growth prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may seek to enter into collaborations with third parties for the development and commercialization of our product candidate. If
we fail to enter into such collaborations, or such collaborations are not successful, we may not be able to capitalize on the
market potential of our product candidate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek third-party collaborators for development and commercialization of our products. Our likely collaborators for any marketing,
distribution, development, licensing or broader collaboration arrangements include large and mid-size pharmaceutical companies,
regional and national pharmaceutical companies, non-profit organizations, government agencies, and biotechnology companies. Our
ability to generate revenues from these arrangements will depend on our collaborators&rsquo;&nbsp;abilities to successfully perform
the functions assigned to them in these arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborations
involving our products will pose, the following risks to us:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may have significant discretion in determining the efforts and resources that they will apply to these collaborations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 2.25pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not pursue development and commercialization of our product candidate or may elect not to continue or renew development
    or commercialization programs based on preclinical or clinical trial results, changes in the collaborators&rsquo;&nbsp;strategic
    focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product
    candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    could independently develop, or develop with third parties, products that compete directly or indirectly with our product
    candidate if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized
    under terms that are more economically attractive than ours;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution
    of such product or products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way
    as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose
    us to potential litigation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization
    of our product candidate or that result in costly litigation or arbitration that diverts management attention and resources;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborations
    may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization
    of the applicable product candidates.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration
agreements may not lead to development or commercialization of our product candidate in the most efficient manner or at all. If
a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development
or commercialization program could be delayed, diminished or terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are dependent on obtaining certain patents and protecting our proprietary rights.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend, in part, on our ability to obtain patents, maintain trade secret protection and operate without infringing
on the proprietary rights of third parties or having third parties circumvent our rights. We are licensing in patented technologies
for our products. The patent positions of biotechnology, biopharmaceutical and pharmaceutical companies can be highly uncertain
and involve complex legal and factual questions. Thus, there can be no assurance that any of our patent applications will result
in the issuance of patents, that we will develop additional proprietary products that are patentable, that any patents issued
to us or those that already have been issued will provide us with any competitive advantages or will not be challenged by any
third parties, that the patents of others will not impede our ability to do business or that third parties will not be able to
circumvent our patents. Furthermore, there can be no assurance that others will not independently develop similar products, duplicate
any of our products not under patent protection, or, if patents are issued to us, design around the patented products we developed
or will develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be required to obtain licenses from third parties to avoid infringing patents or other proprietary rights. No assurance can
be given that any licenses required under any such patents or proprietary rights would be made available, if at all, on terms
we find acceptable. If we do not obtain such licenses, we could encounter delays in the introduction of products or could find
that the development, manufacture or sale of products requiring such licenses could be prohibited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of pharmaceutical, biopharmaceutical and biotechnology companies and research and academic institutions have developed
technologies, filed patent applications or received patents on various technologies that may be related to or affect our business.
Some of these technologies, applications or patents may conflict with our technologies or patent applications. Such conflict could
limit the scope of the patents, if any, that we may be able to obtain or result in the denial of our patent applications. In addition,
if patents that cover our activities are issued to other companies, there can be no assurance that we would be able to obtain
licenses to these patents at a reasonable cost or be able to develop or obtain alternative technology. If we do not obtain such
licenses, we could encounter delays in the introduction of products, or could find that the development, manufacture or sale of
products requiring such licenses could be prohibited. In addition, we could incur substantial costs in defending ourselves in
suits brought against us on patents it might infringe or in filing suits against others to have such patents declared invalid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to various government regulations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacture and sale of human therapeutic and diagnostic products in the U.S. and foreign jurisdictions are governed by a variety
of statutes and regulations. These laws require approval of manufacturing facilities, controlled research and testing of products
and government review and approval of a submission containing manufacturing, preclinical and clinical data in order to obtain
marketing approval based on establishing the safety and efficacy of the product for each use sought, including adherence to current
PIC/S Guide to Good Manufacturing Practice for Medicinal Products during production and storage, and control of marketing activities,
including advertising and labeling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
product we are currently developing will require significant development, preclinical and clinical testing and investment of substantial
funds prior to its commercialization. The process of obtaining required approvals can be costly and time-consuming, and there
can be no assurance that future products will be successfully developed and will prove to be safe and effective in clinical trials
or receive applicable regulatory approvals. Markets other than the U.S. have similar restrictions. Potential investors and shareholders
should be aware of the risks, problems, delays, expenses and difficulties which we may encounter in view of the extensive regulatory
environment which controls our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
existing indebtedness may adversely affect our ability to obtain additional funds and may increase our vulnerability to economic
or business downturns. </I></B>We are subject to a number of risks associated with our indebtedness, including: 1) we must dedicate
a portion of our cash flows from operations to pay debt service costs, and therefore we have less funds available for operations
and other purposes; 2) it may be more difficult and expensive to obtain additional funds through financings, if available at all;
3) we are more vulnerable to economic downturns and fluctuations in interest rates, less able to withstand competitive pressures
and less flexible in reacting to changes in our industry and general economic conditions; and 4) if we default under any of our
existing credit facilities or if our creditors demand payment of a portion or all of our indebtedness, we may not have sufficient
funds to make such payments. As of June 30, 2016, our outstanding debt was $2,050,000 which was a short term loan. This loan was
subsequently paid off on August 9, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have recurring losses from operations and a significant accumulated deficit. In addition, we continue to experience negative cash
flows from operations. These factors raise substantial doubt about our ability to continue as a going concern. If we do not generate
revenues, do not achieve profitability and do not have other sources of financing for our business, we may have to curtail or
cease our development plans and operations, which could cause investors to lose the entire amount of their investment. With the
doubt about our ability to continue as a going concern, we may also face difficulties to raise additional funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face substantial competition from other pharmaceutical and biotechnology companies and our operating results may suffer if we
fail to compete effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of new drug products is highly competitive. We expect that we will face significant competition
from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect to
our products that we may seek to develop or commercialize in the future. Our competitors may succeed in developing, acquiring
or licensing technologies and drug products that are more effective, have fewer or more tolerable side effects or are less costly
than any product candidates that we are currently developing or that we may develop, which could render our product candidates
obsolete and noncompetitive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more
effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop.
Our competitors also may obtain FDA or other marketing approval for their products before we are able to obtain approval for ours,
which could result in our competitors establishing a strong market position before we are able to enter the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our existing and potential future competitors have significantly greater financial resources and expertise in research and
development, manufacturing, preclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved
products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources
being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete
with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient
registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to establish appropriate internal financial reporting controls and procedures, it could cause us to fail to meet
our reporting obligations, result in the restatement of our financial statements, harm our operating results, subject us to regulatory
scrutiny and sanction, cause investors to lose confidence in our reported financial information and have a negative effect on
the market price for shares of our Common Stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud. We maintain a system
of internal control over financial reporting, which is defined as a process designed by, or under the supervision of, our principal
executive officer and principal financial officer, or persons performing similar functions, and effected by our board of directors,
management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted accounting principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we will have significant additional requirements for enhanced financial reporting and internal controls.&nbsp;&nbsp;We
will be required to document and test our internal control procedures in order to satisfy the requirements of Section 404 of the
Sarbanes-Oxley Act of 2002, which requires annual management assessments of the effectiveness of our internal controls over financial
reporting. The process of designing and implementing effective internal controls is a continuous effort that requires us to anticipate
and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain
a system of internal controls that is adequate to satisfy our reporting obligations as a public company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that we will not, in the future, identify areas requiring improvement in our internal control over financial
reporting.&nbsp;&nbsp;We cannot assure you that the measures we will take to remediate any areas in need of improvement will be
successful or that we will implement and maintain adequate controls over our financial processes and reporting in the future as
we continue our growth.&nbsp;&nbsp;If we are unable to establish appropriate internal financial reporting controls and procedures,
it could cause us to fail to meet our reporting obligations, result in the restatement of our financial statements, harm our operating
results, subject us to regulatory scrutiny and sanction, cause investors to lose confidence in our reported financial information
and have a negative effect on the market price for shares of our Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
audit report included in the financial reports of this Registration was prepared by auditors who are not inspected by the Public
Company Accounting Oversight Board and, as a result, you are deprived of the benefits of such inspection </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our auditors are located in Hong Kong, Special Administrative Region of the People&rsquo;s Republic of China (&ldquo;PRC&rdquo;),
a jurisdiction where the PCAOB is currently unable to conduct inspections without the approval of the PRC authorities, our auditors
are not currently inspected by the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inspections
of other firms that the PCAOB has conducted outside PRC have identified deficiencies in those firms' audit procedures and quality
control procedures, which may be addressed as part of the inspection process to improve future audit quality. The inability of
the PCAOB to conduct inspections in PRC prevents the PCAOB from regularly evaluating our auditor's statements, audits and quality
control procedures. As a result, investors may be deprived of the benefits of PCAOB inspections.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
inability of the PCAOB to conduct inspections of auditors in PRC makes it more difficult to evaluate the effectiveness of our
auditor's quality control and audit procedures as compared to auditors outside of PRC that are subject to PCAOB inspections. Investors
may lose confidence in our reported financial information and procedures and the quality of our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Insiders
have substantial control over us, and they could delay or prevent a change in our corporate control even if our other stockholders
wanted it to occur.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive officers, directors, and principal stockholders own, in the aggregate, approximately 70.86% of our outstanding Common
Stock.&nbsp;As a result of their stockholdings, these stockholders are able to assert substantial control over matters requiring
stockholder approval, including the election of directors and approval of significant corporate transactions.&nbsp;This could
delay or prevent an outside party from acquiring or merging with us even if our other stockholders wanted it to occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market price of our Common Stock may be volatile</I>&nbsp;and&nbsp;<I>there may not be sufficient liquidity in the market for
our securities in order for investors to sell their securities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our Common Stock has been and will likely continue to be highly volatile, as is the stock market in general. Factors
that may materially affect the market price of our Common Stock are beyond our control, these factors may materially adversely
affect the market price of our Common Stock, regardless of our performance.&nbsp;&nbsp;In addition, the public stock markets have
experienced extreme price and trading volume volatility.&nbsp;These broad market fluctuations may influence the market price of
our Common Stock. There is currently only a limited public market for our Common Stock, which is listed on the OTCQB Market, and
there can be no assurance that a trading market will develop further or be maintained in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
articles of incorporation allow for our board to create new series of preferred stock without further approval by our stockholders,
which could adversely affect the rights of the holders of our common stock. </I></B>Our Board of Directors has the authority to
fix and determine the relative rights and preferences of preferred stock without stockholder approval. As a result, our Board
of Directors could authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our
assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock
and the right to the redemption of the shares, together with a premium, prior to the redemption of our common stock. In addition,
our Board of Directors could authorize the issuance of a series of preferred stock that has greater voting power than our common
stock or that is convertible into our common stock, which could decrease the relative voting power of our common stock or result
in dilution to our existing stockholders. Although we have no present intention to issue any additional shares of preferred stock
or to create any additional series of preferred stock, we may issue such shares in the future.<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
independent auditors have issued an audit opinion for our company, which includes a statement describing our going concern status.
Our financial status creates a doubt whether we will continue as a going concern.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
auditors have issued a going concern opinion regarding our company. This means there is substantial doubt we can continue as an
ongoing business for the next twelve months. The financial statements do not include any adjustments that might result from the
uncertainty regarding our ability to continue in business. As such we may have to cease operations and investors could lose part
or all of their investment in our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
audit report included in this Annual Report was prepared by auditors who may not be inspected by the Public Company Accounting
Oversight Board and, as a result, you are deprived of the benefits of such inspection </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
independent registered public accounting firm that issues the audit reports included in our financial reports filed with the SEC,
as auditors of companies that are traded publicly in the United States and a firm registered with the Public Company Accounting
Oversight Board (United States), or the &ldquo;PCAOB&rdquo;, is required by the laws of the United States to undergo regular inspections
by the PCAOB to assess its compliance with the laws of the United States and professional standards. Because our auditors are
located in Hong Kong, SAR, a jurisdiction where the PCAOB is currently unable to conduct inspections without the approval of the
Peoples&rsquo; Republic of China(PRC) authorities, our auditors are not currently inspected by the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inspections
of other firms that the PCAOB has conducted outside PRC have identified deficiencies in those firms' audit procedures and quality
control procedures, which may be addressed as part of the inspection process to improve future audit quality. The inability of
the PCAOB to conduct inspections in PRC prevents the PCAOB from regularly evaluating our auditor's statements, audits and quality
control procedures. As a result, investors may be deprived of the benefits of PCAOB inspections.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
inability of the PCAOB to conduct inspections of auditors in PRC makes it more difficult to evaluate the effectiveness of our
auditor's quality control and audit procedures as compared to auditors outside of PRC that are subject to PCAOB inspections. Investors
may lose confidence in our reported financial information and procedures and the quality of our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_005"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report contains forward-looking statements and information that are based on the beliefs of our management as well as assumptions
made by and information currently available to us.&nbsp;&nbsp;Such statements should not be unduly relied upon.&nbsp;&nbsp;When
used in this report, forward-looking statements include, but are not limited to, the words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan&rdquo; and similar expressions, as well as statements
regarding new and existing products, technologies and opportunities, statements regarding market and industry segment growth and
demand and acceptance of new and existing products, any projections of sales, earnings, revenue, margins or other financial items,
any statements of the plans, strategies and objectives of management for future operations, any statements regarding future economic
conditions or performance, uncertainties related to conducting business in China, any statements of belief or intention, and any
statements or assumptions underlying any of the foregoing.&nbsp;&nbsp;These statements reflect our current view concerning future
events and are subject to risks, uncertainties and assumptions.&nbsp;&nbsp;There are important factors that could cause actual
results to vary materially from those described in this report as anticipated, estimated or expected, including, but not limited
to:&nbsp;competition in the industry in which we operate and the impact of such competition on pricing, revenues and margins,
volatility in the securities market due to the general economic downturn; Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
regulations which affect trading in the securities of &ldquo;penny stocks,&rdquo; and other risks and uncertainties.&nbsp;&nbsp;Except
as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual
results could differ materially from those anticipated in any forward- looking statements, even if new information becomes available
in the future.&nbsp;&nbsp;Depending on the market for our stock and other conditional tests, a specific safe harbor under the
Private Securities Litigation Reform Act of 1995 may be available.&nbsp;&nbsp;Notwithstanding the above, Section 27A of the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and Section 21E of the Securities Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;) expressly state that the safe harbor for forward-looking statements does not apply to companies
that issue penny stock.&nbsp;&nbsp;Because we may from time to time be considered to be an issuer of penny stock, the safe harbor
for forward-looking statements may not apply to us at certain times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_006"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not receive any proceeds from the sale of shares by the selling stockholders named in this prospectus. All proceeds from
the sale of the common stock will be paid directly to the selling stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_007"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DETERMINATION
OF OFFERING PRICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders may sell these shares in the over-the-counter market or otherwise, at market prices prevailing at the time
of sale, at prices related to the prevailing market price, or at negotiated prices. We will not receive any proceeds from the
sale of shares by the selling stockholders.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <A NAME="a_008"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion provides information which management believes is relevant to an assessment and understanding of our results
of operations and financial condition. The discussion should be read along with our condensed consolidated financial statements
for the year ended September 30, 2016, and notes thereto contained elsewhere in this Report</I>, <I>and our annual report on Form
10--K for the period from July 21, 2015 (inception) to September 30, 2015 including the consolidated financial statements and
notes thereto. The following discussion and analysis contains forward-looking statements, which involve risks and uncertainties.
Our actual results may differ significantly from the results, expectations and plans discussed in these forward-looking statements.
See &ldquo;Cautionary Note Concerning Forward-Looking Statements.&rdquo;</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Report, the terms &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;, and &ldquo;our Company&rdquo; and &ldquo;the
Company&rdquo; refer to American BriVision (Holding) Corporation (formerly known as Metu Brands, Inc.) and its subsidiaries, unless
otherwise indicated.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Introduction</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we are a holding company operating through our wholly owned subsidiary, American BriVision Corporation, a Delaware corporation
(&ldquo;BriVision&rdquo;). BriVision was incorporated in 2015 in the State of Delaware. It is a biotechnology company focused
on the development of new drugs and innovative medical devices to fulfill unmet medical needs.&nbsp;&nbsp;Following the Share
Exchange (as described herein below), we have abandoned our prior business plan and we are now pursuing BriVision&rsquo;s historical
businesses and proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet
medical needs.&nbsp;&nbsp;The business model of the Company is to integrate research achievements from world-famous institutions,
conduct clinical trials of translational medicine for Proof of Concept (&ldquo;POC&rdquo;), out-license to international pharmaceutical
companies, and exploit global markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Share Exchange, we were&nbsp;a company&nbsp;operating a web site for the sale of women's apparel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have had limited operations and have been issued a &quot;going concern&quot; opinion by our auditor, based upon our reliance on
the sale of our common stock as the sole source of funds for our future operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2016, a Share Exchange Agreement (&ldquo;Share Exchange Agreement&rdquo;) was entered into by and among American BriVision
(Holding) Corporation (the&nbsp;&ldquo;Company&rdquo;),&nbsp;American BriVision&nbsp;Corporation, a Delaware Corporation&nbsp;(&ldquo;BriVision&rdquo;),
Euro-Asia Investment &amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region
of the People's Republic of China (&ldquo;Euro-Asia&rdquo;), being the owners of record of 164,387,376 (52,336,000 pre-stock split)
shares of common stock of the Company, and the persons listed in&nbsp;Exhibit A&nbsp;thereof (the&nbsp;&ldquo;BriVision Shareholders&rdquo;),
being the owners of record of all of the issued share capital of BriVision (the&nbsp;&ldquo;BriVision Stock&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates
evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the
Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates
evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583
pre-stock split) shares (the&nbsp;&ldquo;Acquisition Stock&rdquo;) (subject to adjustment for fractionalized shares as set forth
below) of the Company&rsquo;s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock
split) shares of the Company&rsquo;s common stock owned by Euro-Asia should be cancelled and retired to treasury.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after
the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger,
or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision&rsquo;s common stock were converted,
at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company&rsquo;s common
stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company&rsquo;s common stock as of immediately
prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company&rsquo;s common stock,&nbsp;Because
of the exchange of the BriVision Stock for the Acquisition Stock (the&nbsp;&ldquo;Share Exchange&rdquo;), BriVision became a wholly
owned subsidiary (the &ldquo;Subsidiary&rdquo;) of the Company and there was a change of control of the Company following the
closing.&nbsp;&nbsp;There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the consummation of the Share Exchange,&nbsp;BriVision&nbsp;is now our wholly-owned subsidiary and its shareholders
own approximately&nbsp;79.70% of our issued and outstanding common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references to the&nbsp;&ldquo;Combined Company&rdquo;&nbsp;refer to&nbsp;American&nbsp;BriVision&nbsp;(Holding) Corporation&nbsp;and
its wholly owned subsidiary,&nbsp;American&nbsp;BriVision&nbsp;Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Accounting
Treatment of the Merger</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
financial reporting purposes, the Share Exchange represents a &ldquo;reverse merger&rdquo; rather than a business combination
and BriVision is deemed the accounting acquirer in the transaction. The Share Exchange is being accounted for as a reverse-merger
and recapitalization. BriVision is the acquirer for financial reporting purposes and the Company is the acquired company. Consequently,
the assets and liabilities and the operations that will be reflected in the historical financial statements prior to the Share
Exchange will be those of BriVision and will be recorded at the historical cost basis of BriVision, and the consolidated financial
statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the
historical operations of BriVision and operations of the combined entities (American Brivision (Holding) Corporation and its wholly
owned subsidiary Brivision) from the closing date of the Share Exchange.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information about the Share Exchange, please refer to the current report on Form 8-K we filed on February 12, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Share Exchange, we have abandoned our prior business plan and we are now pursuing BriVision&rsquo;s historical businesses
and proposed businesses.&nbsp;BriVision is a biotechnology company focused on the development of new drugs to fulfill unmet medical
needs.&nbsp;&nbsp;Our business model is to integrate research achievements from world-famous institutions (such as Memorial Sloan
Kettering Cancer Center (&ldquo;MSKCC&rdquo;) and MD Anderson Cancer Center), conduct clinical trials for Proof of Concept (&ldquo;POC&rdquo;),
out-license to international pharmaceutical companies, and exploit global markets.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have five products&nbsp;that are licensed to us:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.3in; padding-top: 0pt; padding-right: 0pt">&#9679;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABV-1501&nbsp;Triple Negative Breast Cancer - Combination
therapy for Triple Negative Breast Cancer (TNBC)</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&#9679;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABV-1502 Solid Tumor with Anti-PD1 - Combination therapy
for solid tumors</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&#9679;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABV-1503 Chronic Lymphocytic Leukemia - Combination
therapy for Chronic Lymphocytic Leukemia</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&#9679;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABV-1504 Major Depressive Disorder - Major Depressive
Disorder (MDD)</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&#9679;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABV-1505 Attention Deficit Hyperactivity Disorder -
Attention Deficit Hyperactivity Disorder</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Those
5 drugs all are ready to go into phase II clinical study. ABV-1504 already starts phase II clinical study in Taiwan and we expect
it will start in the States this year. &nbsp;ABV-1505 got IND (Investigational New Drug Application) by US FDA on January&nbsp;25,
2016. &nbsp;ABV-1501 Phase II IND will be filed on February 2016. &nbsp;ABV-1502 and ABV-1503 are preparing IDE package now.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
Developments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Forward
Stock Split</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2016, our Board approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141
and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which went effective
on April 8, 2016. The amendment to Articles of Incorporation was approved by the majority of the shareholders of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Collaborative
Agreement</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 29, 2015, American BriVision Corporation (&ldquo;BriVision&rdquo;, a Delaware corporation and our wholly-owned subsidiary)
entered into a Collaborative Agreement with BioLite, of which our sole director, Eugene Jiang, is a director. Pursuant to the
Collaborative Agreement, BioLite granted BriVision sole licensing rights for drug and therapeutic use of five products (the &ldquo;Products&rdquo;):
BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination
Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic
Lymphocytic Leukemia, in USA and Canada.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Collaborative Agreement has a term of fifteen years from the first commercial sales of the Products in the U.S. or Canada and
automatically renews for five more years unless either party gives the other party six month written notice of termination prior
to the expiration date of the term.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Collaborative Agreement, an upfront payment of $3,500,000 (the &ldquo;Milestone Payment&rdquo;), which is 3.5% of total
payments due under the Collaborative Agreement, was to be paid upon execution of that agreement.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of BriVision with equivalent value,
according to the following schedule:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"> &#9679; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upfront
    payment shall upon the signing of this Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from
    BriVision, BioLite has to deliver all data to BriVision in one week.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"> &#9679; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving
    second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"> &#9679; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment.
    After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three
    months.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"> &#9679; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving
    fourth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"> &#9679; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    the completion of phase III, BriVision shall pay, but no later than September 15, 2019: 25% of total payment. After receiving
    fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"> &#9679; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    the NDA submission, BriVision shall pay, but no later than December 15, 2020, 30% of total payment. After receiving the sixth
    payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> On May 6, 2016, we and BioLite entered
into Milestone Payment Agreement in order to amend the Collaborative Agreement, whereby BriVision has agreed to pay the Milestone
Payment to BioLite $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share,
for an aggregate number of 562,500 shares. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Collaborative Agreement, BioLite is also entitled to 5% of net sales of the Products. There have not been any commercial sales
since the Collaborative Agreement became effective.&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our collaboration with BioLite continues under the Collaborative Agreement, we intend to work together to select potential drug
candidates (including but not limited to botanical drugs) from different research institutes, start to develop it from pre-clinical
stage (including all CMC process and animal study) to clinical study stage. When the phase II clinical trial is finished and the
efficacy is approved, we will have reached the &ldquo;proof of concept&rdquo; stage. We then plan to out license our drugs to
big pharmaceutical companies, coordinate with them to develop and enhance the drugs and exploit global markets.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revenue
Generation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
of our licensed products are still under development and trial stage. Therefore, no revenue is expected in near term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended September 30, 2016, we have spent approximately&nbsp;$92,823&nbsp;on&nbsp;research and development.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Critical
Accounting Policies and Estimates</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating this &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operation.&rdquo;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Basis
of Presentation</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying audited financial statements and related notes have been prepared in accordance with generally accepted accounting
principles in the United States of America (U.S. GAAP). This basis of accounting involves the application of accrual accounting
and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&rsquo;s
financial statements are expressed in U.S. dollars.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Forward
Stock split</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split
at a ratio of 1 to 3:141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000,
which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.
See Note 4 for more details.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Use
of Estimates</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could
differ materially from those results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Fair
Value Measurements</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the provisions of ASC Subtopic 820-10,&nbsp;&ldquo;Fair Value Measurements&rdquo;,&nbsp;for fair value measurements
of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed
at fair value in the financial statements.&nbsp;&nbsp;ASC 820 also establishes a framework for measuring fair value and expands
disclosures about fair value measurements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date.&nbsp;&nbsp;When determining the fair value measurements for assets and liabilities
required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it
would transact and it considers assumptions that market participants would use when pricing the asset or liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of
unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of
the fair value hierarchy are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.3in; padding-top: 0pt; padding-right: 0pt">&#9679;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 inputs to the valuation methodology are quoted
prices (unadjusted) for identical assets or liabilities in active markets.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&#9679;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 inputs to the valuation methodology include
quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability,
either directly or indirectly, for substantially the full term of the financial instruments.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt">&#9679;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 inputs to the valuation methodology are unobservable
and significant to the fair value.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as
of&nbsp;September 30, 2016.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cash
and Cash Equivalents</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of September
30, 2016 and September 30, 2015, our cash and cash equivalents amounted $173,537 and $994,830, respectively. All&nbsp;of our cash
deposit is held in a financial institution located in Taiwan where there is currently regulation mandated on obligatory insurance
of bank accounts. We believe this financial institution is of high credit quality.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Income
Taxes</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets
to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred
taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax
assets if it is more-likely-than-not that these items will expire before we are able to realize their benefits, or that future
deductibility is uncertain.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 740, a tax position is recognized as a benefit only if it is &ldquo;more likely than not&rdquo; that the tax position would
be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step
process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination,
including the resolution of any related appeals or litigations based on the technical merits of that position. The second step
is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized
in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely
of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition
threshold should be recognized in the first subsequent period in which the threshold is satisfied. Previously recognized tax positions
that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period
in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified
as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred during
the period from July 21, 2015 (inception) to September 30, 2016. GAAP also provides guidance on de-recognition, classification,
interest and penalties, accounting in interim periods, disclosures and transition.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2016 and September 30, 2015, our income tax expense amounted $836 and $0, respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Recent
Accounting Pronouncements</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting standards issued by the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) or other standard
setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact
of recently issued standards that are not yet effective will not have a material impact on its financial position or results of
operations upon adoption. The recent accounting standards are not expected to have a material impact on the consolidated financial
statements upon adoption.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Off-Balance
Sheet Arrangements</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital
resources that is material to investors.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limited
Operating History; Need for Additional Capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no historical financial information about us upon which to base an evaluation of our performance.&nbsp;&nbsp;As of the date
of this filing, we have not generated any revenues from operations. We cannot guarantee we will be successful in our business
operations.&nbsp;&nbsp;Our business is subject to risks inherent in the establishment of a new business enterprise, including
limited capital resources, possible delays in the launching of our games and market or wider economic downturns. We do not believe
we have sufficient funds to operate our business for the next 12 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no assurance that future financing will be available to us on acceptable terms, or at all.&nbsp;&nbsp;If financing is not
available on satisfactory terms, we may be unable to continue, develop or expand our operations.&nbsp;&nbsp;Equity financing could
result in additional dilution to existing shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to raise additional capital to maintain our operations in the future, we may be unable to carry out our full business
plan or we may be forced to cease operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion and analysis should be read in conjunction with our audited financial statements&nbsp;for the period ended
September 30, 2016 and accompanying notes that appear in our Annual Report on Form 10-K, as filed with the Securities and Exchange
Commission on January 12, 2017 and the financial statements included in this Report.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments
relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be
unable to continue in operation. We expect we will require additional capital to meet our long term operating requirements. We
expect to raise additional capital through, among other things, the sale of equity or debt securities, but we cannot guarantee
that we will be able to achieve the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations &mdash; Fiscal Year Ended September 30, 2016 Compared to The Period from July 21, 2015 (Inception) to September
2015.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents, for the period indicated, our consolidated statements of operations information.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Fiscal
    year<BR> ended<BR> September&nbsp;30,<BR> 2016 </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> For&nbsp;the&nbsp;period<BR>
    From<BR> July&nbsp;21,<BR> 2015<BR> (inception)&nbsp;to<BR> September&nbsp;30,<BR> 2015 </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> REVENUE </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> COST OF REVENUE </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> 32 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> GROSS LOSS </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (32 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> OPERATING EXPENSES </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Selling, general and administrative expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 4,497,263 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 315,602 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Total Operating Expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> 4,497,263 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> 315,602 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> NET LOSS FROM OPERATIONS </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (4,497,295 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (315,602 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> OTHER INCOME (EXPENSES), NET </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Interest income </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 361 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Gain on exchange differences </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 141 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Interest expense </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (10,170 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Total Other Expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (9,668 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> NET LOSS BEFORE TAXES </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (4,506,963 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (315,602 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Income tax expense </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (836 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> NET LOSS </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (4,507,799 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (315,602 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revenues.&nbsp;&nbsp;</I></B>&nbsp;We
generated zero and zero in revenues and $32 and zero in cost of sales for the year ended September 30, 2016 and the period from
July 21, 2015 (inception) to September 30, 2015.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Operating Expenses.&nbsp;&nbsp;</I></B>&nbsp;Our
operating expenses were $4,497,263 for the year ended September 30, 2016 as compared to $315,602 for the period from July 21,
2015 (inception) to September 30, 2015. The increase of $4,181,661 in the current year was the result of more professional fees,
as well as the $3,500,000 for the Milestone payment for royalty fee. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Interest Expense.</I></B>
The interest expense was $10,170 for the year ended September 30, 2016 as compared to $0 for the period from July 21, 2015 (inception)
to September 30, 2015&nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Net Loss.&nbsp;&nbsp;&nbsp;</I></B>&nbsp;The
net loss was $4,507,799 for the year ended September 30, 2016 compared to a loss of $315,602 for the period from July 21, 2015
(inception) to September 30, 2015. The result of increase of net loss in the current year was due to the increased professional
fees and the Milestone payment incurred during the year ended September 30, 2016. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Balance
Sheet Data</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> As of September&nbsp;30, 2016<BR> ($) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> As of September&nbsp;30, 2015<BR> ($) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-indent: 0pt; padding-left: 0pt"> Cash </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 173,537 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 994,830 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt"> Total Assets </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 177,352 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,002,460 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt"> Total Liabilities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 56,470 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 369,103 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt"> Stockholders&rsquo; Equity </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 120,882 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 633,357 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>For
The Year Ended September 30, 2016</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> During
the year ended September 30, 2016, we did not generate any revenue and incurred general and administrative expenses of $4,497,263,
and resulted in a net loss of $4,507,799. The expenses were mainly expense related to daily operation costs and the professional
fees, as well as the Milestone payment. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>For
The Period from July 21, 2015 (Inception) to September 30, 2015</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from July 21, 2015 (inception) through September 30, 2015, we did not generate any revenue and incurred general and
administrative expenses of $315,602, and resulted in a net loss of $315,602. The expenses were mainly expense related to daily
operation costs and the professional fees.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Working
Capital</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> As of September&nbsp;30, 2016<BR> ($) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> As of September&nbsp;30, 2015<BR> ($) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt"> Current Assets </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 173,537 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 998,645 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt"> Current Liabilities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 56,470 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 369,103 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt"> Working Capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 117,067 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 629,542 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cash
Flows</U></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> As
    of September&nbsp;30, 2016<BR> ($) </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> As
    of September&nbsp;30, 2015<BR> ($) </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"> Cash Flows Used in Operating Activities </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"> (3,474,707 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"> (517 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Cash Flows Provided by Financing Activities </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2,653,414 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 995,545 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Net (Decrease) Increase in Cash During Period </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (821,293 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 994,830 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
Flow from Operating Activities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> During the year ended September
30, 2016 and the period from July 21, 2015 (inception) to September 30, 2015, the net cash used in operating activities were $3,474,707
and $517 respectively. There was decrease in other non-current assets and accounts payable during the year ended September 30,
2016. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
Flow from Investing Activities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended September 30, 2016 and the period from July 21, 2015 (inception) to September 30, 2015, there were no net cash
used in or generated from investing activities.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
Flow from Financing Activities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> During the year ended September
30, 2016 and the period from July 21, 2015 (inception) to September 30, 2015, the net cash generated from financing activities
were $2,653,414 and $995,545 respectively. Shares were issued during the year ended September 30, 2016. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policy and Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating this &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operation.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern Consideration</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> We have incurred losses since its
inception resulting in an accumulated deficit of $4,823,401 as of September 30, 2016 and net losses of $4,507,799 and negative
cash flow of $821,293 during the year ended September 30, 2016. These conditions raise substantial doubt about our ability to
continue as a going concern. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to finance operations primarily through capital contributions from principal shareholders. In the event that we require
additional funding to finance the growth of our current and expected future operations as well as to achieve our strategic objectives,
our principal shareholders have indicated the intent and ability to provide additional equity financing.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital
resources that is material to investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_009"></A>BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Industry</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biotechnology
industry provides breakthrough products and technologies to combat debilitating and rare diseases, reduce our environmental footprint,
feed the hungry,&nbsp;use&nbsp;less and cleaner energy, and have safer, cleaner and more efficient industrial manufacturing process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology industry is an extremely important sector in the developed world's economies&nbsp;and human health. Biotechnology&nbsp;companies&nbsp;need
to spend large research budgets&nbsp;during the R&amp;D period. &nbsp;Usually it will take 12-16 years to develop a new drug and
a new medical device. &nbsp;Not only is a small biotechnology company&rsquo;s R&amp;D budget smaller than a large, well-known
biotechnology company or&nbsp;an&nbsp;international company, but the larger companies are typically more attractive to researchers
or employers and maintains better R&amp;D resources. However,&nbsp;at this early stage, we are developing our products, which
are licensed&nbsp;from a related party which&nbsp;substantially reduces our R&amp;D cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>





<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Business
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are a clinical stage biopharmaceutical company focused on utilizing our licensed technology to (i) enhance the development of
pre-existing pharmaceutical products for the treatment of various cancer indications and other diseases, (ii) prospectively identify
patients that may respond to such pharmaceutical products and (iii) commercialize such pharmaceutical products for license in
various markets. Our business strategy is to integrate research achievements from medical research institutions (such as Memorial
Sloan Kettering Cancer Center (&ldquo;MSKCC&rdquo;) and MD Anderson Cancer Center), by engaging them to conduct clinical trials
of translational medicine for Proof of Concept (&ldquo;POC&rdquo;) while we retain ownership of the Products, and then out-license
the Products to pharmaceutical companies. We currently have no revenue generated from our principal operations in clinical product
development through research and development efforts. Currently, our only operation is the research and development of five compound
licensed to us by BioLite Inc. (&ldquo;BioLite&rdquo;), a company formed in Taiwan who is one of our principal shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Collaboration
Agreement with BioLite</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 29, 2015, American BriVision Corporation (&ldquo;BriVision&rdquo;), a Delaware corporation and our wholly owned subsidiary,
entered into a Collaborative Agreement with BioLite pursuant to which BioLite granted to BriVision sole licensing rights for drug
and therapeutic use of the following Products: BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity
Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple
Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia, in USA and Canada. Our CEO and director, Eugene
Jiang, is also a director of BioLite.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material terms of the Collaborative Agreement are as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; padding-right: -18pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BriVision
                                         is responsible to make up-front, milestone and royalty payments to BioLite, as further
                                         described below.</FONT> </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;
        By oral agreement and mutual understanding: between BioLite and BriVision, BioLite owns all files, data, confidential
        and non-public information, including, without limitation, all IND packages and clinical study reports, regarding the
        Compounds (collectively, the &ldquo;Compound IP&rdquo;), to the extent developed in Taiwan, and BriVision owns all Compound
        IP to the extent developed in North America. BioLite grants an exclusive license to its Compound IP to BriVision for the
        purpose of further development and commercialization of the Products in North America. BioLite and BriVision share the
        responsibility of preparing for clinical trials by delivering Compound IP and preparing related materials. As between
        BriVision and its clinical trial partners in North America, all Compound IP is owned by us, as all such clinical trials
        are industrially sponsored.</FONT> </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BriVision
    is and has &nbsp;been responsible for all clinical trial expenses incurred in North America.&nbsp;&nbsp;BioLite paid all clinical
    trial expenses for trials conducted in Taiwan thus far. </FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Collaborative Agreement will remain in effect for fifteen years from the date of first commercial sale of Product in the U.S.
    or Canada. Either party may terminate upon thirty days&rsquo; prior written notice for breach or insolvency.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BriVision
    agreed to pay to BioLite an aggregate of One Hundred Million Dollars ($100,000,000) (the &ldquo;Aggregate Amount&rdquo;) in
    milestone payments during the term of the agreement, payable in cash or Company equity. A percentage of the Aggregate Amount
    will be paid to BioLite upon each completion of a milestone by BioLite as set forth in the Collaborative Agreement. An upfront
    payment of $3,500,000 (the &ldquo;Milestone Payment&rdquo;), which is 3.5% of total payments due under the Collaborative Agreement,
    was to be paid by us upon signing of the Collaboration Agreement. On May 6, 2016, BriVision and BioLite amended the payment
    terms under the Collaborative Agreement by entering into a Milestone Payment Agreement, pursuant to which we paid $2,600,000
    in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share, for an aggregate number
    of 562,500 shares.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Milestones
    are reached by BioLite upon submissions of IND and NDAs for the Products, and completion of phases in the application processes,
    as set forth in the Collaborative Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition to the Aggregate Amount, BriVision will pay to BioLite five percent (5%) of net sales of Products in the U.S. and
    Canada.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Our&nbsp;Licensed
Compound</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have renamed the five compounds for our purpose and below a brief description of each of the five compounds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ABV-
    1501 &nbsp;Triple Negative Breast Cancer - Combination therapy for Triple Negative Breast Cancer (TNBC)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Maitake
    mushroom extract Phase I clinical trial was performed by MSKCC.&nbsp;&nbsp;&ldquo;A phase I/II trial of a polysaccharide extract
    from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects:&rdquo; &ldquo;No dose-limiting
    toxicity was encountered. Oral administration of a polysaccharide extract from Maitake mushroom is associated with both immunologically
    stimulatory and inhibitory measurable effects in peripheral blood.&nbsp;&nbsp;Cancer patients should be made aware of the
    fact that botanical agents produce more complex effects than assumed, and may depress as well as enhance immune function&rdquo;.&nbsp;&nbsp;The
    IND Number is 68853 and MSKCC received confirmation of filing from the FDA on January 22, 2004.</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ABV-1501
    US FDA Phase II IND cross reference with MSKCC Maitake and Phase II Investigational New Drug (IND) was approved in March 2016.</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
    are currently negotiating with MSKCC for Phase II clinical study. If MSKCC agrees with our terms, we anticipate to start phase
    II clinical trial during 2017 Q1and finish the phase II clinical trial by 2018 Q3.</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">BioLite
    has received approval from Institutional Review Board and (IRB) of Taipei Medical University in September 2016 in Taiwan</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font: 10pt Calibri,sans-serif; text-indent: 0pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font: 10pt Calibri,sans-serif; text-indent: 0pt; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman,serif">II.</FONT></TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font: 10pt Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">ABV-1502 &nbsp;Solid Tumor with Anti-PD1 - Combination therapy for solid tumors with Anti-PD-1</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri,sans-serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman,serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman,serif">This is a kind of anti-tumor Combination therapy of Maitake mushroom extract with standard therapy and anti- PD1 drug for solid tumor.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">Maitake mushroom extract Phase I clinical trial was performed by MSKCC.&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman,serif">Currently, we are cooperating with MD Anderson Cancer Center and one of the top cancer centers in the U.S. to develop Phase II clinical trial IND package.&nbsp;&nbsp;Due to confidentiality obligations, we are not permitted to disclose the name of such cancer center at this time.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri,sans-serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman,serif">III.</FONT></TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">ABV-1503 &nbsp;Chronic Lymphocytic Leukemia - Combination therapy for Chronic Lymphocytic Leukemia (CLL)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri,sans-serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman,serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">Phase II study of Epigallocatechin gallate (EGCG) for CLL.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">We are cooperating with MSKCC to prepare clinical trial agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">We are currently preparing the IND package.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri,sans-serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman,serif">IV.</FONT></TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">ABV-1504 &nbsp;Major Depressive Disorder - Major Depressive Disorder (MDD)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri,sans-serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman,serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">This is Polygala extract for Major Depressive Disorder</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">BioLite performed Phase I clinical trial.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman,serif">BioLite has obtained US FDA Phase II Part One/Part Two IND approval and the Phase II Part One was completed with good result.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Times New Roman,serif; margin: 0">For ABV-1504, the Phase II part one results are described below.</P>
        <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Phase II part two: this phase is currently being conducted in 5 clinical
        sites in Taiwan (started in Q3 2016) and one US site is under IRB review.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri,sans-serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">V.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ABV-1505
    &nbsp;Attention Deficit Hyperactivity Disorder - Attention Deficit Hyperactivity Disorder</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
    is Polygala extract for Attention Deficit Hyperactivity Disorder.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Same
    Active Pharmaceutical Ingredients (API) with ABV-1504. </FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite
    has obtained U.S. FDA Phase II IND approval for IND number 129107 on January 25, 2016, and is currently negotiating with top
    medical site for Phase II clinical trial.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite
    intends to submit for IRB approval during 2017 Q1</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite
    plans to start Phase II clinical trial during 2017 Q2 and complete by 2018 Q3.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABV-1501
and ABV-1502 have the same Active Pharmaceutical Ingredient:&rdquo; Maitake mushroom extract&rdquo;. IND and study details are
as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    Phase I/II clinical trial was conducted by MSKCC. A total of 34 eligible study subjects was enrolled from 3/2004 to 1/2007.
    The primary endpoints were safety and tolerability. The test drug was oral administration and a polysaccharide extract from
    Maitake mushroom is associated with both immunologically stimulatory and inhibitory measurable effects in peripheral blood.
    Cancer patients should be made aware of the fact that botanical agents produce more complex effects than assumed, and may
    depress as well as enhance immune function. (<U>A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake
    mushroom) in breast cancer patients: immunological effects by Gary Deng &middot; Hong Lin &middot; Andrew Seidman &middot;
    Monica Fornier &middot; Gabriella D&rsquo;Andrea &middot;Kathleen Wesa &middot; Simon Yeung &middot; Susanna Cunningham Rundles
    &middot;Andrew J. Vickers &middot; Barrie Cassileth; J Cancer Res Clin Oncol (2009) 135:1215&ndash;1221.</U>) The IND number
    is </FONT> <FONT STYLE="font: 10pt Times New Roman,serif">68853 and MSKCC received filing confirmation
    from the FDA on Jan 22, 2004.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Does
    Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients? A Phase II clinical trial.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Primary
endpoint: To describe changes in neutrophil counts and neutrophil function in MDS patients following administration of Maitake
mushroom extract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
study to see whether Maitake improves the neutrophil count and function in patients with MDS. The neutrophils are white blood
cells which help to fight infection.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total
45 subjects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Start
Date: April 2010</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Completion
Date: September 2014</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sponsor:
Memorial Sloan Kettering Cancer Center</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Collaborator:
YUKIGUNI COMPANY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Collaborator:
Weill Medical College of Cornell University</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal
Investigator: Kathleen Wesa, MD Memorial Sloan Kettering Cancer Center</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Full
Source of Clinical Trial Data: https://clinicaltrials.gov/show/NCT01099917</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Normally,
for non-cancer patients, phase I clinical trials are performed with healthy subjects to test for safety and phase II clinical
trials are performed with patient subjects for efficacy as well as safety. But for cancer patients, however, trials of cancer
drugs must necessarily involve subjects with cancer, and as such, phase I/II studies involving cancer patients include primary
endpoints relating to safety and tolerability, while at times including efficacy as a secondary endpoint.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
&ldquo;Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients? A Phase II clinical trial,&rdquo; conclusions
are described as follows: &ldquo;Maitake was well tolerated. Enhanced in vitro neutrophil and monocyte function following treatment
demonstrate that Maitake has beneficial immunomodulatory potential in MDS. Further study is warranted&rdquo;.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
32 of the journal article, &ldquo; Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients?&rdquo; indicates
that there were 45 subjects were enrolled at the beginning of the study, 18 subjects completed treatment, 3 subjects had adverse
effects and 24 subjects were not treated.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; padding-left: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Hematopoiesis:
    is the formation of blood cellular components. All cellular blood components are derived from haematopoietic stem cells. In
    a healthy adult person, approximately 1011&ndash;1012 new blood cells are produced daily in order to maintain steady state
    levels in the peripheral circulation (Wikipedia).</FONT> </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Myelodysplastic:
    are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells (Medscape).
    Myelodysplastic syndromes are a group of disorders caused by poorly formed or dysfunctional blood cells. Myelodysplastic syndromes
    occur when something goes wrong in your bone marrow &mdash; the spongy material inside your bones where blood cells are made.
    Treatment for myelodysplastic syndromes usually focuses on reducing or preventing complications of the disease and its treatments.
    In certain cases, myelodysplastic syndromes are treated with a bone marrow transplant (Mayo Clinic).</FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
ABV-1503, we are currently preparing the IND package. BioLite is preparing the Compound IP for the Chemistry, Manufactural, and
Control (CMC) part, we and MSKCC are collaborating to prepare for protocol design and prepare the IRB documents. The trial period,
test subject number, primary and secondary endpoint and method of administration have not been decided yet, and are still being
negotiated between us and MSKCC.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ABV-1504
and ABV-1505 have the same Active Pharmaceutical Ingredient: the extract of Radix Polygalae (Polygala tenuifolia Willd/PDC-1421
Capsule). IND and study information are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
    Dose Escalation Phase I Study of PDC-1421 Capsule to Evaluate the Safety in Healthy Volunteers.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">IND
Number: 112567</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trial
period:11/13/2012-7/5/2013, Final Report Date 11/12/2013</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total
30 study subjects were enrolled. The test drug was oral administration. The primary endpoint is to assess the safety profile of
PDC-1421 Capsule in healthy volunteers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sponsor:
BioLite, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
    Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients with Major Depressive Disorder</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">IND
Number: 112567</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Primary
Study Objective: To assess the efficacy profile of PDC-1421 Capsule in major depressive disorder with Montgomery-Asberg Depression
Rating Scale (MADRS).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Secondary
Study Objective: To evaluate the efficacy and safety profile</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Study
period: 2 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
72 study subjects will be enrolled.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"> Study site: There are five
sites in Taiwan and one site in US (Stanford University, currently preparing for IRB approval and Clinical Trial Agreement.) </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sponsor:
BioLite, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
ABV-1504 Phase II part one---total subject: 12, trial period: 2/11/2016-7/14/2016, administered route: oral, test results are
as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trial
Progress Report:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Part I trial has been completed with 12 subjects (screening: 14, enrolling: 12). The six subjects were in the Part I high dosage
group.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Under the suicide risk assessment (C-SSRS) Subject X indicated that the suicidal ideation scores were 4 for both Visit 7 and Visit
8. The PI confirmed that the subject had external pressures (moving, etc.), which produced constant suicidal thoughts, and such
observation was reflected in Dr. A&rsquo;s (PI) evaluation. The subject expressed his/her intention to stay positive in a counseling
session, and the subject was contacted by a researcher (Research Nurse) after leaving the facility. After reviewing by the researcher,
a justification was made that the suicidal behavior was irrelevant to the drug administered.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Clinical data of the six high-dosage administered subjects with data exceeding normal value:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;-
NCS- Non-Clinical Significant judged by PI. CS: Clinical Significant judged by PI.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;-After
data safety review board carefully reviewed, they agree to proceed to part two clinical trial.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
ABV-1504 Phase II part two: this phase currently is conducted in 5 clinical sites in Taiwan (started in Q3 2016) and one US site
is under IRB review.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
&ldquo;A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression:&rdquo; Trial period: 11/13/2012-7/5/2013,
final report date 11/12/2013. Enroll subject: 30, 23 PDC-1421, 7 placebo control.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Study
Conclusions:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;(1)
No subject had serious adverse event and no subject discontinued due to adverse event;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)
No clinically significant findings were observed in physical examinations; vital signs, electrocardiograms, laboratory measurements,
and C-SSRS were observed throughout the treatment period;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
The oral administration of PDC-1421 in healthy volunteers was safe and well-tolerated for the dose from 380 mg to 3800 mg&rdquo;.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
&ldquo;A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients with Major Depressive Disorder&rdquo;:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
One- study period 2/11/2016-7/12/2016. Total subject: 12</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Maitake
mushroom extract is sourced from YUKIGUNI COMPANY, Japan, and processed by YUSHENG PHARMACEUTICAL COMPANY in Taiwan (cGMP).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extract of Radix Polygalae (Polygala tenuifolia Willd/PDC-1421 Capsule) is purchased from Herng Fa Fa Pharmaceutical Technology,
and processed by Industrial Technology Research Institute (ITRI). There are no limits on availability to us on any of these ingredients.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Market
Opportunity and Growth Strategy/Business Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC
will focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of
ABVC is to integrate research achievements from world-renowned medical research institutions (Such as MSKCC and MD Anderson Cancer
Center), conduct clinical trials of translational medicine for POC (Proof of Concept), out-license to international pharmaceutical
companies, and tap into global market opportunities. In the USA, any qualified clinic can conduct clinical trials. Though we will
strive to continue collaborating with top medical research institutions, if for any reason we cannot cooperate with such medical
centers, we will select a qualified clinic to further develop the Products. Our primary goal is to pursue collaborations with
top medical centers.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business plan is to conduct and complete Phase II clinical trials for all five of our Products in the US and/or Canada and if
we obtain satisfactory results in the Phase II clinical trial for POC for any such compounds, we will seek to out-license any
such compounds to big international pharmaceutical companies for further development. Furthermore, we will continue to search
for potential products (drugs or medical devices) worldwide to license and develop in North America.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
competitive advantages of our business model are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> 1. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intrinsic
value of the five compounds licensed from BioLite.&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Once we complete POC, we will co-develop our product with leading big international pharmaceuticals and in turn, receive more
funding for our research and development. In the unlikely event that such pharmaceutical companies cannot be engaged by us to
further develop our product, we will seek a qualified clinic as licensee to develop our product, however, our goal is to secure
co-development agreements with leading pharmaceutical companies.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Our business model is to seek sub-licensee companies in the U.S. and Canada and give them rights to manufacture and commercialize
Product. We will collect licensing fees in the form of milestone payments and royalties which will allow us to obtain return on
investment (ROI) as milestones are reached, prior to first commercial sale, and thus improve our cash flow circumstances.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
By receiving milestone payments and royalties from sub-licensees, we will have sustainable income to develop our company.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
biotechnology industry is an extremely important sector in the developed world's economies&nbsp;and human health. Biotechnology&nbsp;companies&nbsp;need
to spend large amount of&nbsp;research budget&nbsp;during R&amp;D period. &nbsp;Usually it will take 12-16 years to develop new
drug and new medical device. &nbsp;For&nbsp;a small biotechnology company,&nbsp;the R&amp;D budget amount is much smaller compared
to a&nbsp;large biotechnology company or&nbsp;an&nbsp;international company.&nbsp;Moreover, a large company can be more attractive
to a researcher or employer and maintain better R&amp;D resources. However,&nbsp;at this early stage, we are developing the Products
and licensing them from&nbsp;a related party which can&nbsp;substantially&nbsp;reduce our R&amp;D cost.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently in confidential negotiations regarding clinical trial agreements for certain of the above-described compounds with
potential medical center partners &ndash; we are not permitted at this time to disclose any specifics surrounding the negotiations
nor the identifies of the potential partners, pursuant to confidentiality agreements. We will disclose the clinical trial agreement
details as soon as any are executed. Furthermore, international pharmaceutical companies have contacted us to express interest
in certain of our licensed compounds, however, due to confidentiality concerns we are not able to disclose the substance or nature
of these discussions at this time.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the risks presented in our risk factors relating to potential side effects and product liability are inherent to any company engaged
in drug-development activities, we do not intend to develop any Products beyond the end of phase 2 clinical trials. We anticipate
that upon completion of phase 2 clinical trials, we will seek suitable licensees so that all our Products will be licensed out
for further development, marketing and sale by large pharmaceutical companies. In such event, we would seek to mitigate this risk
in any and all such licensing agreements so that any such potential occurrences will not cause material setbacks to us or its
business<B><I>. </I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Collaborative Agreement with BioLite and pursuant to existing practice, we shall own all intellectual property developed with
respect to the Products in Canada and the U.S., while BioLite shall own all intellectual property developed with respect to the
Products outside of Canada and the U.S. We have the right to sublicense our owned intellectual property to develop Products in
Canada and the U.S. These rights have been orally granted to us and we intend to amend the Collaborative Agreement to expressly
state these rights.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Currently,
we are in the process of developing five products, but we will continue to search for the appropriate products including potential
medical device for in-licensing to our company for further development and generate more revenue for our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Products are dependent on, or are the subject of the following patents and patent applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Title </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Patent Number </TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Type </TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Country </TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Issue Date </TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Expiration Date </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; text-align: left"> Anti-depression pharmaceutical composition containing polygala extract </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: center"> &nbsp; </TD><TD STYLE="width: 9%; text-align: center"> 6911222 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: center"> &nbsp; </TD><TD STYLE="width: 9%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: center"> &nbsp; </TD><TD STYLE="width: 9%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT> </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: center"> 6/28/2005 </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: center"> 8/24/2022 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Anti-depression pharmaceutical composition containing Polygala extract </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> 7175861 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 2/13/2007 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 4/28/2023 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Anti-depression pharmaceutical composition containing Polygala extract </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> 7179496 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 2/20/2007 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 4/28/2023 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Anti-depression pharmaceutical composition containing polygala extract </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> 7223425 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 5/29/2007 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 4/26/2023 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Anti-depression Pharmaceutical Composition Containing Polygala Extract </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> 1337647 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 1/31/2007 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 4/24/2022 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Anti-depression Pharmaceutical Composition Containing Polygala Extract </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> 693499 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CH</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 9/15/2003 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 5/2/2022 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Anti-depression Pharmaceutical Composition Containing Polygala Extract </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> 10220149 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DE</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 4/26/2007 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 5/26/2022 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Anti-depression Pharmaceutical Composition Containing Polygala Extract </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GB2383951</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GB</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 6/7/2006 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 5/10/2020 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Anti-depression Pharmaceutical Composition Containing Polygala Extract </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> 4109907 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 4/11/2008 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 6/6/2022 </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    Number</B></FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Type</B></FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issue
    Date</B></FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B></FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 40%; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-depression
    Pharmaceutical Composition Containing Polygala Extract</FONT> </TD>
    <TD STYLE="width: 1%; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">207794</FONT> </TD>
    <TD STYLE="width: 1%; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD>
    <TD STYLE="width: 1%; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FR</FONT> </TD>
    <TD STYLE="width: 1%; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/15/2005</FONT> </TD>
    <TD STYLE="width: 1%; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/24/2022</FONT> </TD>
    <TD STYLE="width: 1%; line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polygalatenosides
    and use thereof as an antidepressant agent</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">202007003503</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DE</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/19/2007</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/9/2025</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polygalatenosides
    and use thereof as an antidepressant agent</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7531519</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2009</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/11/2028</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polygalatenosides
    and use thereof as an antidepressant agent</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4620652</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/5/2011</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/20/2026</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-depression
    Pharmaceutical Composition Containing Polygala Extract</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    295576</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TW</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/11/2008</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/11/2022</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polygalatenosides
    and use thereof as an antidepressant agent</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    314453</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TW</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/11/2009</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/11/2026</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"> <FONT STYLE="font-size: 10pt">&#24478;<FONT STYLE="font-family: Times New Roman, Times, Serif">Grifola</FONT>&#25552;&#21462;&#30340;&#25239;&#33131;&#30244;&#29289;&#36074;<FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN1120173</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/3/2003</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/3/2023&nbsp;</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Antitumor substance
    extracted from grifola*</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US5854404
    A</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/29/1998</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;6/22/2022</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Antitumor substance
    extracted from hen-of-the-woods*</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP0893449</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2004/8/25</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;3/31/2015</FONT> </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="line-height: 107%"> &nbsp; </TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 107%"> <FONT STYLE="font-size: 10pt">&#12510;&#12452;&#12479;&#12465;&#12363;&#12425;&#25277;&#20986;&#12375;&#12383;&#25239;&#33131;&#30221;&#29289;&#36074;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"> <FONT STYLE="font-size: 10pt">&#29305;&#35377;<FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT>&#12288;&#31532;<FONT STYLE="font-family: Times New Roman, Times, Serif">2859843</FONT>&#21495;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</FONT> </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT> </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/8/2002</FONT> </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;3/8/2016</FONT> </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Employees</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of&nbsp;the date of the prospectus, we have&nbsp;nine&nbsp;full-time employees&nbsp;and&nbsp;one&nbsp;consultant. None of our
employees are represented by a labor organization and we consider our relationship with our employees to be good.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*&nbsp;These
last four patents were listed as dated &ldquo;2006&rdquo; in error in the 8-K filed by us on February 16, 2016.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Our
Facilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Address</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center">Size</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">Leased/Owned/</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Granted</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center">Function</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center">Monthly<BR> Rent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="text-align: right; background-color: rgb(204,238,255); vertical-align: top">
    <TD STYLE="width: 47%; text-align: left">Building 27, 238 North City Road II,<BR> Xitun District,<BR> Taizhong City <BR>Taiwan</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">2,772 sq. feet</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 12%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Leased</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">Corporate office</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="text-align: right; background-color: rgb(204,238,255); vertical-align: top">
    <TD STYLE="text-align: left">11 Sawyers Peak Drive,<BR> Goshen, NY 10924</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1,000 sq. feet</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Leased</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Corporate office</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Government
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Regulation
by governmental authorities in the U.S. and other countries is a significant factor in development, manufacture and marketing
of our proposed pharmaceutical products and in our ongoing research and product development activities. The nature and extent
to which such regulation applies to us will vary depending on the nature of any products that may be developed by us. We anticipate
that many, if not all, of our proposed products will require regulatory approval by governmental agencies prior to commercialization.
Our products are subject to rigorous pre-clinical test and clinical trial and other approval procedures of the FDA, and similar
regulatory authorities in European and other countries. Various governmental statutes and regulations also govern or influence
clinical trial, Chemistry, Manufacture and Control (CMC) related to such products and their marketing. The process of obtaining
these approvals and the subsequent compliance with appropriate statutes and regulations require the expenditure of substantial
time and money, and there can be no guarantee that approvals will be granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>FDA
Approval Process</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Prior
to commencement of clinical studies involving humans, pre-clinical testing of new pharmaceutical products is generally conducted
on animals in the laboratory to evaluate the potential efficacy and safety of the product candidate. The results of these studies
are submitted to the FDA as a part of an Investigational New Drug (&ldquo;IND&rdquo;) application, which must become effective
before clinical testing in humans can begin. Typically, human clinical evaluation involves a time-consuming and costly three-phase
process. In Phase I, clinical trials are conducted with a small number of people to establish safety pattern of drug distribution
and metabolism within the body. In Phase II, clinical trials are conducted with groups of patients afflicted with a specific disease
in order to determine preliminary efficacy, possible dosages and expanded evidence of safety. In some cases, an initial trial
is conducted in diseased patients to assess both preliminary efficacy and preliminary safety and patterns of drug metabolism and
distribution, in which case it is referred to as a Phase I/II trial. In Phase III, large-scale, multi-center, comparative trials
are conducted with patients afflicted with a target disease in order to provide enough data to demonstrate the efficacy and safety
required by the FDA. The FDA closely monitors the progress of each of the three phases of clinical testing; and may, at its discretion,
re-evaluate, alter, suspend or terminate the testing based upon the data which have been accumulated to that point and its assessment
of the risk/benefit ratio to the patient. Monitoring of all aspects of the study to minimize risks is a continuing process. All
adverse events must be reported to the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
results of the pre-clinical and clinical testing on a non-biologic drug and certain diagnostic drugs are submitted to the FDA
in the form of a New Drug Application (&ldquo;NDA&rdquo;) for approval prior to commencement of commercial sales. In the case
of vaccines or gene and cell therapies, the results of clinical trials are submitted as a Biologics License Application (&ldquo;BLA&rdquo;).
In responding to a NDA or BLA, the FDA may grant marketing approval, request additional information or refuse to approve if the
FDA determines that the application does not satisfy its regulatory approval criteria. There can be no assurance that approvals
will be granted on a timely basis, if at all, for any of our proposed products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>European
and Other Regulatory Approval</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Whether
or not FDA approval has been obtained, approval of a product by comparable regulatory authorities in Europe and other countries
will likely be necessary prior to commencement of marketing the product in such countries. The regulatory authorities in each
country may impose their own requirements and may refuse to grant an approval, or may require additional data before granting
it, even though the relevant product has been approved by the FDA or another authority. As with the FDA, the regulatory authorities
in the European Union (&ldquo;EU&rdquo;), Australia and other developed countries have lengthy approval processes for pharmaceutical
products. The process for gaining approval in particular countries varies, but generally follows a similar sequence to that described
for FDA approval. In Europe, the European Committee for Proprietary Medicinal Products provides a mechanism for EU-member states
to exchange information on all aspects of product licensing. The EU has established a European agency for the evaluation of medical
products, with both a centralized community procedure and a decentralized procedure, the latter being based on the principle of
licensing within one-member country followed by mutual recognition by the other member countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are also subject to various U.S. federal, state, local and international laws, regulations and recommendations relating to the
treatment of oocyte donors, the manufacturing environment under which human cells for therapy are derived, safe working conditions,
laboratory and manufacturing practices and the use and disposal of hazardous or potentially hazardous substances, including radioactive
compounds and infectious disease agents, used in connection with our research work. We cannot accurately predict the extent of
government regulation which might result from future legislation or administrative action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
filed for Chapter 7 bankruptcy protection on May 15, 2013 and subsequently the corporate shell emerged as its only unencumbered
asset on September 19, 2014 using &quot;fresh start&quot; accounting under section 852-10-45-17 as of date of sale corporate shell
to reflect intangible assets sale through section 363 of the US bankruptcy code. &nbsp;Any business description below and all
reporting results of the operating results reported in this filing for the fiscal year ending September 30, 2015 and 2014 are
post &quot;fresh start&quot; activity and not comparable to prior results. Post-bankruptcy&nbsp;we had been operating a web site
for the sale of women's apparel.&nbsp;Other than disclosed herein, we&nbsp;are currently not a party to any material legal or
administrative proceedings and are not aware of any pending legal or administrative proceedings against us. We may from time to
time become a party to various legal or administrative proceedings arising in the ordinary course of our business.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_010"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the name, age, and position of our sole officer and director as of the date of this prospectus. Executive
officers are elected annually by our Board of Directors. Each executive officer holds his office until he resigns, is removed
by the Board, or his successor is elected and qualified. Directors are elected annually by our stockholders at the annual meeting.
Each director holds his office until his successor is elected and qualified or his earlier resignation or removal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
officers of our company are appointed by the board of directors and hold office until their death, resignation or removal from
office. The directors and executive officers, their ages, positions held, and duration as such, are as set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 18%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Name</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Position
    Held</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 12%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Age</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Eugene
    Jiang</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
        Executive Officer,</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman,
        Director, President,</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">29</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Kira
    Huang</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
    Financial Officer, Secretary, Treasurer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">46</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Eugene
Jiang&nbsp;&ndash;&nbsp;Chief Executive Officer, Chairman, Director, President,</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Eugene Jiang, age 29, has served as our CEO/Director since we started our business in July 2015 through the present. From June
2015 until present, Mr. Jiang also serves as Director for&nbsp;BioLite&nbsp;Incorporation. He also serves as&nbsp;CEO for&nbsp;Genepro&nbsp;Investment
Company since March 2010.&nbsp;Mr&nbsp;Jiang obtained an EMBA degree from The University of&nbsp;Texas&nbsp;in Arrington in 2009.
And in 2008, Mr. Jiang received a bachelor&rsquo;s degree in Physical Education from Fu Jen Catholic University.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Kira
Huang-Chief&nbsp;Financial&nbsp;Officer, Secretary, Treasurer</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kira
Huang, has served as our Chief Financial Officer&nbsp;since February 2016. She served as Finance Manager in&nbsp;Coface&nbsp;credit
insurance company from 2010 to 2014, and as country controlling of Moody&rsquo;s Taiwan&nbsp;Corporation&nbsp;from 2008 to 2010.
She holds&nbsp;an accounting bachelor degree from Eastern Michigan University and also is a certified public accountant.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Significant
Employees</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following are employees who are not executive officers, but who are expected to make significant contributions to our business:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Frank)Chih-Chung&nbsp;Liu-&nbsp;Chief
Scientific&nbsp;Officer of&nbsp;American&nbsp;BriVision&nbsp;Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mr.
Frank Liu, age&nbsp;52,&nbsp;has served as the&nbsp;Chief Scientific Officer since our inception. From 2010-2014, he was an associate
researcher/cross strait medical affair project manager, Division of Resource Development, Center for Drug Evaluation, Taiwan.
From&nbsp;April&nbsp;2014&nbsp;until&nbsp;present, Mr. Liu also&nbsp;serves as&nbsp;Director of&nbsp;Research and Development&nbsp;for&nbsp;BioFirst
Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">He
received his&nbsp;Bachelor of Medical Science&nbsp;degree from&nbsp;Medical College, Jinan University,&nbsp;China.&nbsp;Major
in Clinical Medicine&nbsp;and he got&nbsp;both of&nbsp;his&nbsp;Master of Science&nbsp;degree from&nbsp;California University
of Pennsylvania,&nbsp;Pennsylvania&nbsp;U.S.A.&nbsp;major in Biology&nbsp;and his&nbsp;Bachelor of Science degree from&nbsp;&nbsp;Geneva
College,&nbsp;Pennsylvania U.S.A.&nbsp;Major&nbsp;in Biology, Minor in Chemistry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
16(a) Beneficial Ownership Reporting Compliance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Section&nbsp;16(a)
of the Exchange Act and the rules thereunder require our officers and directors, and persons that own more than 10% of a registered
class of our equity securities, to file reports of ownership and changes in ownership with the Securities and Exchange Commission
and to furnish us with copies. Based solely on our review of the copies of the Section&nbsp;16(a) forms received by us, or written
representations from certain reporting persons, we believe that none of our officers, directors, and greater than 10% beneficial
owners filed on a timely basis reports required by Section&nbsp;16(a) of the Exchange Act prior to the Share Exchange on November&nbsp;30,
2012 during the fiscal year ended December&nbsp;31, 2012. After the Share Exchange, we believe that none of our officers, directors,
and greater than 10% beneficial owners failed to file on a timely basis reports required by Section&nbsp;16(a) of the Exchange
Act during the fiscal year ended September 30, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Code
of Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has adopted a Policy Statement on Business Ethics and Conflicts of Interest (&ldquo;Code of Ethics&rdquo;)
applicable to all employees, including our chief executive officer and chief financial officer. A copy of the Code of Ethics and
Business Conduct is annexed hereto as Exhibit 14.1.&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Board
Leadership Structure and the Board&rsquo;s Role in Risk Oversight.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors is led by the Chairman who is also the Chief Executive Officer. Although our sole officer is also our sole
director, the Board believes that the most effective leadership structure at this time is not to separate the roles of Chairman
and Chief Executive Officer. A combined structure provides us with a single leader who represents us to our stockholders, regulators,
business partners and other stakeholders, among other reasons set forth below. Should the Board conclude otherwise, the Board
will separate the roles and appoint an independent director.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
structure creates efficiency in the preparation of the meeting agendas and related Board materials as our Chief Executive Officer
works directly with those individuals preparing the necessary Board materials and is more connected to our overall daily operations.
Agendas are also prepared with the permitted input of the full Board of Directors allowing for any concerns or risks of any individual
director to be discussed as deemed appropriate. The Board believes that we have benefited from this structure, and Dr. Jiang's
continuation in the combined role of the Chairman and Chief Executive Officer is in the best interest of the stockholders.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the combined structure is necessary and allows for efficient and effective oversight, given our relatively small
size, its corporate strategy and focus</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors does not have a specific role in risk oversight of the Company. The Chairman, President and Chief Executive
Officer and other executive officers and employees of the Company provide the Board of Directors with information regarding our
risks.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presently,
we are not required to comply with the director independence requirements of any securities exchange since we are listed on OTC
markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="a_011"></A><B>EXECUTIVE
COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following tables set forth, for each of the last two completed fiscal years of the Company, the total compensation awarded to,
earned by or paid to any person who was a principal executive officer during the preceding fiscal year and every other highest
compensated executive officers earning more than $100,000 during the last fiscal year (together, the&nbsp;&ldquo;Named Executive
Officers&rdquo;). The tables set forth below reflect the compensation of the Named Executive Officers.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Summary
Compensation Table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name&nbsp;and&nbsp;Principal&nbsp;Position</B></FONT> </P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Year </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Salary<BR> ($) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Bonus<BR> ($) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Awards</B></FONT><BR>
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT> </P></TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Awards</B></FONT><BR>
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT> </P></TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-Equity</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incentive
                                         Plan</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT><BR>
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT> </P></TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Change
                                         in</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pension</B></FONT><BR>
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Value&nbsp;and</B></FONT><BR>
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nonqualified</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Earnings</B></FONT><BR>
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT> </P></TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All
                                         Other</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT><BR>
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT> </P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Total<BR> ($) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 18%; text-align: left"> Shulamit Lazar (1) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; text-align: right"> 2015 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT> </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT> </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; text-align: right"> 30,000 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 7%; text-align: right"> Nil </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 7%; text-align: right"> Nil </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 7%; text-align: right"> Nil </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 7%; text-align: right"> Nil </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; text-align: right"> 30,000 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2016 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Eugene Jiang (2) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2016 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"><P STYLE="margin: 0"> 40,000 </P>


</TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2015 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Kira Huang (3) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2016 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 36,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 79,592 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> Nil </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 115,592 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Ms. Lazar was our sole executive officer until December 18, 2015.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Mr. Jiang was elected our sole executive officer since December 18, 2015.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
We entered into an employment contract with Kira Huang on February 1, 2016 according to which Ms. Huang was employed as
Chief Financial Officer. Pursuant to the employment agreement, we agree to compensate Ms. Huang salary of $4,500 per month
subject to normal statutory deduction and annual review. The employment contract is terminable by Ms. Huang at will upon
three weeks&rsquo; prior written notice, and by us at any time for cause or without cause provided we pay to Ms. Huang an
amount required by then-existing law.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Narrative
Disclosure to Summary Compensation Table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other
than set out below, there are no arrangements or plans in which we provide pension, retirement or similar benefits for directors
or executive officers. Our directors and executive officers may receive share options at the discretion of our board of directors
in the future. We do not have any material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or
may be paid to our directors or executive officers, except that share options may be granted at the discretion of our board of
directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stock
Option Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
adopted an Equity Incentive Plan on February 17, 2016.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Grants
of Plan-Based Awards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no grants of plan-based awards during the year ended&nbsp;September 30, 2015. In fiscal year 2016, we awarded 10,000 shares
of common stock to each of five employees: 50,000. Due to the forward split detailed in our 10-Q filed June 30, 2016, each of
such employees has been awarded 31,410 shares of common stock.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Outstanding
Equity Awards at Fiscal Year End</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
former Chief Executive Officer,&nbsp;Shulamit&nbsp;Lazar, received compensation of 30,000,000 shares valued at $30,000 during
the year ended September 30, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Option
Exercises and Stock Vested</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">No
options have been awarded by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Compensation
of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
do not have any agreements for compensating our directors for their services in their capacity as directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Pension,
Retirement or Similar Benefit Plans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers.
We have no material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors
or executive officers, except that stock options may be granted at the discretion of the board of directors or a committee thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Employment
Contracts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment
contract with the CFO&nbsp;of BriVision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We&nbsp;
entered into an employment contract with Kira Huang on March 1, 2016 according to which, among other terms, &nbsp;Ms. Huang is
required to, as Chief Financial Officer, &nbsp;perform duties and undertake the responsibilities&nbsp;in a professional manner
including reporting on&nbsp;financials and related matters to&nbsp;our&nbsp;Board of Directors; developing the financial planning
and overseeing tax reporting activities; monitoring and submitting all required reports to SEC on timely basis, planning and overseeing
annual budgets and other duties as may arise from time to time and as may be assigned to her. Pursuant to such employment agreement,&nbsp;we
shall&nbsp; compensate Mrs. Huang with salary&nbsp;of $4,500 per month subject to normal statutory deduction and annual review.
Additional bonus or stock options will be determined by&nbsp;its&nbsp;Board. The employment agreement may be terminated at-will
by Ms. Huang upon three weeks&rsquo; prior written notice, at-will by us for no cause provided that we pay Ms. Huang an amount
required by law, and at will by us without prior notice for cause.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="a_012"></A><B>CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fiscal year ended September 30, 2015, we had an unsecured demand note payable due of $9,000 to&nbsp;Shulamit&nbsp;Lazar, our
sole officer and director for funds advanced to us through the bankruptcy process. This is unsecured with a zero percent interest
rate and is payable on demand. The note was cancelled as of December 2, 2015.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 29, 2015, BriVision entered into a Collaborative Agreement (the&nbsp;&ldquo;Collaborative Agreement&rdquo;) with&nbsp;BioLite,
of which our sole officer and director, Eugene Jiang, is a director. Pursuant to the Collaborative Agreement,&nbsp;BioLite&nbsp;shall
grant sole licensing rights to&nbsp;BriVision&nbsp;of drug and therapeutic use of five products for 10 years: BLI-1005 CNS-Major
Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor
with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic
Leukemia, in USA and Canada. Under the&nbsp;Collaborative Agreement,&nbsp;BriVision&nbsp;shall pay a total of $100,000,000 in
cash or stock of&nbsp;BriVision&nbsp;with equivalent value, according to the following schedule:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.3in; padding-right: 0pt">&#9679;</TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">upfront&nbsp;payment shall upon the signing of this
Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from&nbsp;BriVision,&nbsp;BioLite&nbsp;has to
deliver all data to BriVision&nbsp;in one week.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom; width: 0.5in; padding: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: top; width: 0.3in; padding: 0pt; text-indent: 0pt; text-align: left">&#9679;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify; padding: 0pt; text-indent: 0pt">upon&nbsp;the first IND submission,&nbsp;BriVision&nbsp;shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from&nbsp;BriVision,&nbsp;BioLite&nbsp;has to deliver IND package to&nbsp;BriVision&nbsp;in one week.</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom; padding: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: top; padding: 0pt; text-indent: 0pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify; padding: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom; padding: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: top; padding: 0pt; text-indent: 0pt; text-align: left">&#9679;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify; padding: 0pt; text-indent: 0pt">at&nbsp;the completion of first phase II clinical trial,&nbsp;BriVision&nbsp;shall pay, but no later than September&nbsp;15, 2017: 15% of total payment. After receiving third payment from&nbsp;BriVision, BioLite&nbsp;has to deliver phase II clinical study report to&nbsp;BriVision&nbsp;in three months.</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom; padding: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: top; padding: 0pt; text-indent: 0pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify; padding: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom; padding: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: top; padding: 0pt; text-indent: 0pt; text-align: left">&#9679;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify; padding: 0pt; text-indent: 0pt">upon&nbsp;the phase III IND submission,&nbsp;BriVision&nbsp;shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from&nbsp;BriVision,&nbsp;BioLite&nbsp;has to deliver IND package to&nbsp;BriVision&nbsp;in one week.</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom; padding: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: top; padding: 0pt; text-indent: 0pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify; padding: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom; padding: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: top; padding: 0pt; text-indent: 0pt; text-align: left">&#9679;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify; padding: 0pt; text-indent: 0pt">at&nbsp;the completion of phase III,&nbsp;BriVision&nbsp;shall pay, but no later than September 15, 2019: 25% of total payment. After receiving fifth payment from&nbsp;BriVision,&nbsp;BioLite&nbsp;has to deliver phase III clinical study report to&nbsp;BriVision&nbsp;in three months</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom; padding: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: top; padding: 0pt; text-indent: 0pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify; padding: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Calibri, sans-serif; padding: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; padding: 0pt; text-indent: 0pt; text-align: left; vertical-align: top">&#9679;</TD>
    <TD STYLE="font-family: Times New Roman, serif; padding: 0pt; text-indent: 0pt; text-align: justify">upon&nbsp;the NDA submission,&nbsp;BriVision&nbsp;shall pay, but no later than December 15, 2020, BriVision&nbsp;shall pay: 30% of total payment. After receiving sixth payment from&nbsp;BriVision, BioLite&nbsp;has to deliver NDA package to&nbsp;BriVision&nbsp;in one week&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
May 6, 2016, we and BioLite amended the payment terms under the Collaborative Agreement by entering into a Milestone Payment Agreement,
pursuant to which we paid $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per
share, for an aggregate number of 562,500 shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2016 and September 30, 2015, the amount due to a related party, BioLite was $0 and $22,517, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2016 and September 30, 2015, the amount due to shareholder, YuanGene Corporation, was $5,723 and $46,586, respectively;
Mr. Jiang maintains voting control over the shares of the Company&rsquo;s common stock that YuanGene Corporation owns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Promoters
and Certain Control Persons</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our management or other control persons were &ldquo;promoters&rdquo; (within the meaning of Rule&nbsp;405 under the Securities
Act), and none of such persons took the initiative in the formation of our business or received any of our debt or equity securities
or any of the proceeds from the sale of such securities in exchange for the contribution of property or services, during the last
five years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_013"></A>SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table sets forth certain information regarding beneficial ownership of our common stock as of&nbsp;August 10, 2016 (i)
each person (or group of affiliated persons) who is known by us to own more than five percent (5%) of the outstanding shares of
our common stock, (ii) each director, executive officer and director nominee, and (iii) all of our directors, executive officers
and director nominees as a group.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Beneficial
ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities.
For purposes of this table, a person or group of persons is deemed to have&nbsp;&ldquo;beneficial ownership&rdquo;&nbsp;of any
shares of common stock that such person has the right to acquire within 60 days of the date of the respective table. For purposes
of computing the percentage of outstanding shares of our common stock held by each person or group of persons named above, any
shares that such person or persons has the right to acquire within 60 days of the date of the respective table is deemed to be
outstanding for such person, but is not deemed to be outstanding for the purpose of computing the percentage ownership of any
other person. The inclusion herein of any shares listed as beneficially owned does not constitute an admission of beneficial ownership.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unless
otherwise noted, the business address of each beneficial owner listed is&nbsp;11 Sawyers Peak Drive,&nbsp;Goshen, NY 10924. Except
as otherwise indicated, the persons listed below have sole voting and investment power with respect to all shares of our common
stock owned by them, except to the extent that power may be shared with a spouse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of&nbsp;September 13,&nbsp;2016, we had&nbsp;213,303,222 shares of common stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Name of Beneficial Owner </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&nbsp;<B>Amount
    and</B></FONT><BR> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>Nature of</B></FONT><BR> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>Beneficial</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>Ownership</B> &nbsp; </FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center"> Percent<BR> of Class </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 73%; text-align: left"> Eugene Jiang, Chairman and CEO (1) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 147,842,856 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 12%; text-align: right"> 69.3 </TD><TD STYLE="width: 1%; text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Kira Huang </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 31,410 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Less
                                         than 1</FONT> </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> All officers and directors as a group (2 persons) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 147,874,266 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 69.3 </TD><TD STYLE="text-align: left"> % </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These shares are owned by YuanGene&nbsp;Corporation,
a corporation incorporated in&nbsp;Samoa.&nbsp; Eugene Jiang is the sole director of YuanGene Corporation and therefore will be
deemed as the beneficial owner of the shares held by YuanGene Corporation.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Changes
in Control</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
a result of the Share Exchange,&nbsp;BriVision&nbsp;became our wholly owned subsidiary and the former shareholders of&nbsp;BriVision&nbsp;collectively
own approximately&nbsp;79.70% of the shares of the Company outstanding post-exchange common stock. As a result, such persons now
collectively control the Company&rsquo;s shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Equity
Compensation Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently
10% of our issued and outstanding shares are authorized under our 2016 Equity Incentive Plan and we do not have any outstanding
stock options.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DESCRIPTION
OF SECURITIES TO BE REGISTERED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Authorized
Capital Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company&rsquo;s authorized capital stock consists of&nbsp;360,000,000 shares of common stock,&nbsp;$0.001 par value per share
and&nbsp;20,000,000 shares of preferred stock&nbsp;$0.001 par value per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 13, 2016, 213,303,222 shares of our Common Stock are issued and outstanding. Holders of Common Stock are entitled
to cast one vote for each share on all matters submitted to a vote of shareholders, including the election of directors. The holders
of Common Stock are entitled to receive ratably such dividends, if any, as may be declared by the Board out of funds legally available
therefore. Such holders do not have any preemptive or other rights to subscribe for additional shares. All holders of Common Stock
are entitled to share ratably in any assets for distribution to shareholders upon the liquidation, dissolution or winding up of
the Company. There are no conversions, redemptions or sinking fund provisions applicable to the Common Stock. All outstanding
shares of Common Stock are fully paid and non-assessable.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Registration
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
are no outstanding stockholders&rsquo; agreements, voting trusts or arrangements, registration rights agreements, rights of first
refusal or other contracts pertaining to the capital stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Transfer
Agent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
transfer agent and registrar for our common stock&nbsp;is:&nbsp;Olde&nbsp;Monmouth Stock Transfer, Inc.; Address: 200 Memorial
Pkwy, Atlantic Highlands, NJ 07716;&nbsp;Phone:&nbsp;(732) 872-2727;&nbsp;website:www.oldemonmouth.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="a_014"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SELLING
STOCKHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
prospectus relates to the offering and sale, from time to time, of up to 32,409,505 shares of our common stock held by the stock
holders named in the table below. We are registering the shares to permit the Selling Stockholders and their pledgees, donees,
transferees and other successors-in-interest that receive their shares from a Selling Stockholder as a gift, partnership distribution
or other non-sale related transfer after the date of this prospectus to resell the shares when and as they deem appropriate in
the manner described in the &ldquo;Plan of Distribution.&rdquo;&nbsp;&nbsp;As of the date of September 13, 2016, there were 213,303,222
shares of Common Stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 39.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table sets forth:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    name of the Selling Stockholders,</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    number of shares of our Common Stock that the Selling Stockholders beneficially owned prior to the offering for resale of
    the shares under this prospectus,</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    maximum number of shares of our Common Stock that may be offered for resale for the account of the Selling Stockholders under
    this prospectus, and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    number and percentage of shares of our Common Stock beneficially owned by the Selling Stockholders after the offering of the
    shares (assuming all of the offered shares are sold by the Selling Stockholders).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.6pt">&nbsp;</P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Each
Selling Stockholder may offer for sale all or part of the Shares from time to time. The table below assumes that the Selling Stockholders
will sell all of the Shares offered for sale. A Selling Stockholder is under no obligation, however, to sell any Shares pursuant
to this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Name&nbsp;of&nbsp;Selling&nbsp;Stockholder </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Shares&nbsp;of<BR> Common
    Stock<BR> Beneficially<BR> Owned&nbsp;Prior<BR> to&nbsp;Offering&nbsp;(1) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Maximum<BR> Number&nbsp;of<BR>
    Shares&nbsp;of<BR> Common<BR> Stock&nbsp;to&nbsp;be Sold </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Number&nbsp;of<BR> Shares&nbsp;of<BR>
    Common<BR> Stock<BR> Owned&nbsp;After<BR> Offering&nbsp;(2) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Percentage<BR> Ownership<BR>
    After<BR> Offering&nbsp;(3) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left"> LU, PO-YEN </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 599,994 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 200,000 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 399,994 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 0 </TD><TD STYLE="width: 1%; text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> CHANG, YANG-CHING </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 449,996 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 134,998 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 314,998 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> LEE, WU-HIS </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 699,994 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 250,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 449,994 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> CHAO, YU-LIEN </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 100,001 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 30,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 70,001 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> WU, HSIN-CHOU </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 199,997 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 60,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 139,997 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> KUO, KUN-JUNG </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 200,098 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 60,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 140,098 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> TENG, CHIN-CHUN </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,499,985 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,499,985 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> LIN, YI-LUN </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 149,999 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 50,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 99,999 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> YU, LI-LING </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 166,665 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 25,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 141,665 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> HUANG, WEI-TAO </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 249,999 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 70,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 179,999 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> CHANG, CHIA-HAO </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 154,535 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 23,180 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 131,355 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> TSAI, MING-SHIH </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 299,997 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,000,</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 254,997 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> PACIFIC CONCORD INTERNATIOINAL (4) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 499,997 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 150,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 349,997 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> LEE, TSUNG-LIN </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 206,999 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 31,050 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 175,949 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> LIU, CHUN-AN </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 549,996 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 549,996 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> YUANGENE CORPORATION (5) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 147,842,856 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 8,000,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 139,842,856 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 65.5 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> EURO-ASIA INVESTMENT &amp; FINANCE CORP LTD (6) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,227,425 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,227,425 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> BIOHOPEKING CORPORATION (7) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,484,987 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,484,987 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> BUFFETT INVESTMENT CORPORATION (8) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9,094,917 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,000,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5,094,917 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> LIONGENE CORPORATION (9) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9,657,913 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9,657,913 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> CHEN YANG, LAI-CHUN </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 199,997 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 199,997 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> SHEN, SHU-HUI </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 199,997 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 199,997 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> SHEN, CHIA-CHI </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 100,001 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 100,001 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> LIU, SU-LIEN </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 349,996 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 349,996 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> WU, PENG-YU </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 999,991 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 999,991 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> CHEN, YEN-CHIA </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,001 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,001 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> FAITH TEAM CORPORATION LIMITED (10) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 299,997 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 299,997 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> THALIA MEDIA LIMITED (11) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 249,999 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 249,999 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> KIMHO CONSULTANTS CO,(12) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 49,999 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 49,999 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> RGENE CORPORATION (13) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9,319,916 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,500,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,819,916 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3.7 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> WU, TZY-YN </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,499,988 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 749,994 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 749,994 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> CHANG, ERIC-YUAN </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 999,991 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 149,999 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 849,992 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The selling stockholders acquired their shares pursuant
to the Share Exchange.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since we do not have the ability to control how many,
if any, of their shares each of the selling shareholders listed above will sell, we have assumed that the selling shareholders
will sell all of the shares offered herein for purposes of determining how many shares they will own after the Offering and their
percentage of ownership following the offering.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All Percentages have been rounded up to the nearest
one hundredth of one percent.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The person having voting, dispositive or investment
power over Pacific Concord International is Shih Yun Lin. The address for Pacific Concord International is Level 2, Lotemau Centre,
Vaea Street, P.O. Box 3271, Apia, Western Samoa.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The person having voting, dispositive or investment
power over Yuangene Corporation is Eugene Jiang. The address for YuangeneCorporation is 3F, No. 248, Sec 1 Neihu Rd, Taipei City
11493, Taiwan.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The person having voting, dispositive or investment
power over Euro-Asia Investment &amp; Finance Corp Ltd is Shum Kwok Keung. The address for Euro-Asia Investment &amp; Finance
Corp Ltd is Unit 604G, Block A, Po Lung Centre, No. 11 Wang Chiu Road, Kowloon Bay Kin, Hong Kong.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The person having voting, dispositive or investment
power over Biohopeking Corporation is Mei Na Huang. The address for Biohopeking Corporation is 3F, No. 248 Sect 1 Neihu Rd, Taipei
City 11493, Taiwan.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The person having voting, dispositive or investment
power over Buffett Investment Corporation is Yu ChingKuo. The address for Buffett Investment Corporation is 3F, No. 248 Sect 1
Neihu Rd, Taipei City 11493, Taiwan.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The person having voting, dispositive or investment
power over Liongene Corporation is Ya Jing Rui. The address for Liongene Corporation is 3F, No. 248, Sect 1 Neihu Rd, Taipei City
11493, Taiwan.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The person having voting, dispositive or investment
power over Faith Team Corporation Limited is Shum Kwok Keung. The address for Faith Team Corporation Limited is BLK 1, 7/F, Enterprise
Square I 9, Sheung Yuet Road, Kowloon bay, Kowloon, HongKong.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The person having voting, dispositive or investment
power over Thalia Media Limited is Sze Ho Yeung Freddy. The address for Thalia Media Limited is RM 604 G, Block A, 6/F, Po Lung
Centre 11 Wang Chiu Road, Kowloon Bay Kowloon, HongKong.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The person having voting, dispositive or investment
power over Kimho Consultants Co. is Kimberly Leung. The address for Kimho Consultants Co. is RM 3, Block 2, 13/F Greerpark Villa,
Sheung Shui, NT, HongKong.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The person having voting, dispositive or investment
power over Rgene Corporation is Ya Jing Rui. The address for Rgene Corporation is 3F, No. 248, Sec 1 Neihu Rd, Taipei City 11493,
Taiwan.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_015"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
selling stockholders and any of their respective pledgees, donees, assignees and other successors-in-interest may, from time to
time, sell any or all of their shares of common stock on any stock exchange, market or trading facility on which the shares are
traded or in private transactions. These sales may be at fixed or negotiated prices. The selling stockholders may use any one
or more of the following methods when selling shares:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ordinary
    brokerage transactions and transactions in which the broker-dealer solicits the purchaser;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">block
    trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block
    as principal;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">facilitate
    the transaction;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">purchases
    by a broker-dealer as principal and resale by the broker-dealer for its account;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">an
    exchange distribution in accordance with the rules of the applicable exchange;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">privately-negotiated
    transactions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">broker-dealers
    may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">through
    the writing of options on the shares;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
    combination of any such methods of sale; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    other method permitted pursuant to applicable law.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
selling stockholders may also sell shares under Rule 144 of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
if available, rather than under this prospectus. The selling stockholders shall have the sole and absolute discretion not to accept
any purchase offer or make any sale of shares if it deems the purchase price to be unsatisfactory at any particular time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
selling stockholders or their respective pledgees, donees, transferees or other successors in interest, may also sell the shares
directly to market makers acting as principals and/or broker-dealers acting as agents for themselves or their customers. Such
broker-dealers may receive compensation in the form of discounts, concessions or commissions from the selling stockholders and/or
the purchasers of shares for whom such broker-dealers may act as agents or to whom they sell as principal or both, which compensation
as to a particular broker-dealer might be in excess of customary commissions. Market makers and block purchasers purchasing the
shares will do so for their own account and at their own risk. It is possible that a selling stockholder will attempt to sell
shares of common stock in block transactions to market makers or other purchasers at a price per share which may be below the
then existing market price. We cannot assure that all or any of the shares offered in this prospectus will be issued to, or sold
by, the selling stockholders. The selling stockholders and any brokers, dealers or agents, upon effecting the sale of any of the
shares offered in this prospectus, may be deemed to be &ldquo;underwriters&rdquo; as that term is defined under the Securities
Act, the Exchange Act and the rules and regulations of such acts. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are required to pay all fees and expenses incident to the registration of the shares, including fees and disbursements of counsel
to the selling stockholders, but excluding brokerage commissions or underwriter discounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
selling stockholders, alternatively, may sell all or any part of the shares offered in this prospectus through an underwriter.&nbsp;&nbsp;The
selling stockholders have not entered into any agreement with a prospective underwriter and there is no assurance that any such
agreement will be entered into.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
selling stockholders may pledge their shares to their brokers under the margin provisions of customer agreements. If a selling
stockholder defaults on a margin loan, the broker may, from time to time, offer and sell the pledged shares. The selling stockholders
and any other persons participating in the sale or distribution of the shares will be subject to applicable provisions of the
Exchange Act, and the rules and regulations under such act, including, without limitation, Regulation M. These provisions may
restrict certain activities of, and limit the timing of purchases and sales of any of the shares by, the selling stockholders
or any other such person. In the event that any of the selling stockholders are deemed an affiliated purchaser or distribution
participant within the meaning of Regulation M, then the selling stockholders will not be permitted to engage in short sales of
common stock. Furthermore, under Regulation M, persons engaged in a distribution of securities are prohibited from simultaneously
engaging in market making and certain other activities with respect to such securities for a specified period of time prior to
the commencement of such distributions, subject to specified exceptions or exemptions. In addition, if a short sale is deemed
to be a stabilizing activity, then the selling stockholders will not be permitted to engage in a short sale of our common stock.
All of these limitations may affect the marketability of the shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
a selling stockholder notifies us that it has a material arrangement with a broker-dealer for the resale of the common stock,
then we would be required to amend the registration statement of which this prospectus is a part, and file a prospectus supplement
to describe the agreements between the selling stockholder and the broker-dealer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
compliance with the guidelines of the Financial Industry Regulatory Authority, Inc., or FINRA, the maximum consideration or discount
to be received by any member of the FINRA may not exceed 8% of the aggregate amount of the securities offered pursuant to this
prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
stockholders hereunder that are FINRA members, or affiliates of FINRA members, are precluded from, directly or indirectly, offering,
selling, agreeing to offer or sell, transferring, assigning, pledging, hypothecating or subjecting to hedging, short sale, derivative,
put or call transaction, all or any portion of those certain placement agents&rsquo; warrants of the Company issued to such selling
stockholders on January 5, 2010, or any shares of the Company&rsquo;s common stock thereunder, for the period beginning on the
later of: (i) the date of effectiveness of the registration statement of which this prospectus forms a part or (ii) the date of
commencement of sales pursuant to this prospectus and ending on the six (6) month anniversary of such date, except in accordance
with FINRA Rule 5110 (g)(2).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Reports
to Security Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are not required to deliver an annual report to security holders. However, we intend to voluntarily send an annual report to security
holders and this annual report will include audited financial statements. This prospectus and exhibits will be contained in a
Form S-1 registration statement that will be filed with the Securities and Exchange Commission. We will become a reporting company
after this prospectus has been declared effective by the Securities and Exchange Commission (&ldquo;SEC&rdquo;). As a reporting
company we will file quarterly, annual, beneficial ownership and other reports with the SEC. You may read and copy any materials
we file with the SEC at the SEC's Public Reference Room at 100 F. Street NE., Washington, D.C.20549. You may obtain information
from the Public Reference Room by calling the SEC at 1800 SEC-0330 or (202) 551-8090. The SEC also maintains an Internet website
that contains reports, proxy and information statements and other information regarding registrants that file electronically with
the SEC. The address of the website is&nbsp;<U>www.sec.gov.</U>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_016"></A>MARKET
FOR OUR COMMON STOCK, DIVIDENDS AND</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RELATED
STOCKHOLDER INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of September 13, 2016, our company's common stock is quoted on the&nbsp;OTCQB&nbsp;under the symbol&nbsp;ABVC; prior thereto,
since December 16, 2015, our symbol was MTOO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the quarterly high and low bid prices for&nbsp;the last two fiscal years.&nbsp;&nbsp;The prices set
forth below represent inter-dealer quotations, without retail markup, markdown or commission and may not be reflective of actual
transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> High </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Low </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic"> Fiscal 2014 </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%"> Quarter ended December 31, 2013 </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 0.02 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 0.00 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Quarter ended March 31, 2014 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Quarter ended June 30, 2014 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Quarter ended September 30, 2014 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.02 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic"> Fiscal 2015 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Quarter ended December 31, 2014 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.02 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Quarter ended March 31, 2015 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.00 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Quarter ended June 30, 2015 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.00 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.00 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Quarter ended September 30, 2015 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 28.00 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.00 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic"> Fiscal 2016 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Quarter ended December 31, 2015 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 25.00 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.00 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Quarter ended March 31, 2016 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7.96 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1.62 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Quarter ended June 30, 2016 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2.00 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1.00 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Quarter ended September 30, 2016 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2.00 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2.00 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On&nbsp;September
10, 2016, the closing bid price of the common stock was $2.00.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Holders</U>.&nbsp;&nbsp;As
of September 13, 2016, there were&nbsp;171 stockholders of record and an aggregate of 213,303,222 shares of our common stock were
issued and outstanding. Our common shares are issued in registered form.&nbsp;&nbsp;The transfer agent of our company's common
stock is&nbsp;Olde&nbsp;Monmouth Stock Transfer, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Dividend
Policy</U>.&nbsp;We have not paid any cash dividends on our common stock and have no present intention of paying any dividends
on the shares of our common stock. Our current policy is to retain earnings, if any, for use in our operations and in the development
of our business. Our future dividend policy will be determined from time to time by our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Securities
Authorized for Issuance under Equity Compensation Plans</U>. We do not have in effect any compensation plans under which our equity
securities are authorized for issuance and we do not have any outstanding stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="a_017"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certain
legal matters with respect to the shares of common stock offered hereby have be passed upon for us by Hunter Taubman&nbsp;Fischer
&amp; Li LLC, New York, New York 10018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_018"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audited consolidated financial statements of American BriVision (Holding) Inc. and subsidiaries included herein and elsewhere
in the registration statement have been audited by <FONT STYLE="background-color: white">Centurion ZD CPA Limited </FONT>for the
periods and to the extent set forth in their Report appearing herein and elsewhere in the registration statement. Such financial
statements have been so included in reliance upon the report of such firm given upon the firm&rsquo;s authority as experts in
accounting and auditing.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><A NAME="a_019"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DISCLOSURE
OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling
persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC&nbsp;such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by us of expenses incurred or paid by one of our directors, officers or controlling
persons in the successful defense of any action, suit or proceeding) is asserted by that director, officer or controlling person
in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled
by controlling precedent, submit to a court of appropriate jurisdiction the question whether that indemnification by us is against
public policy as expressed in the Securities Act and will be governed by the final adjudication of that issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TABLE
OF CONTENTS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 90%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pages</B></FONT> </TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_020"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of September 30, 2016 and September 30, 2015</FONT> </A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT> </TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_021"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations for the year ended September 30, 2016 and for the period from July 21, 2015 (inception) to September&nbsp;30,&nbsp;2015</FONT> </A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT> </TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_022"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of stockholders&rsquo; equity for the year ended September 30, 2016 and for the period from July 21, 2015
    (inception) to September&nbsp;30,&nbsp;2015</FONT> </A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT> </TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_023"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the year ended September 30, 2016 and for the period from July 21, 2015 (inception) to September&nbsp;30,&nbsp;2015</FONT> </A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT> </TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_024"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</FONT> </A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT> </TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_025"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm</FONT> </A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-17</FONT> </TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A HREF="#a_026"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets at September 30, 2015</FONT> </A></P></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-18</FONT> </TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_027"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations for the period from July 21, 2015 (inception) to September 30, 2015</FONT> </A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-19</FONT> </TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_028"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the period from July 21, 2015 (inception) to September 30, 2015</FONT> </A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-20</FONT> </TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_029"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the period from July 21, 2015 (inception) to September 30, 2015</FONT> </A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-21</FONT> </TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_030"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</FONT> </A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-22</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 55; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_020"></A>American
BriVision (Holding) Corporation.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(formerly
METU BRANDS, INC.)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CONDENSED
CONSOLIDATED BALANCE SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0; text-align: center"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> September&nbsp;30, <BR>
    2016 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> September&nbsp;30,<BR>
    2015 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0; text-indent: 0"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; padding-left: 0; text-indent: 0"> Assets </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-left: 0; text-indent: 0"> Current assets </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; padding-left: 10pt; text-indent: 0"> Cash </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 173,537 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 994,830 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-indent: 0"> Prepayment </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 3,815 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 20pt; text-indent: 0"> Total Current Assets </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 173,537 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 998,645 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0; text-indent: 0"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-indent: 0"> Deposit </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,815 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,815 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0; text-indent: 0"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: 0"> Total Assets </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 177,352 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 1,002,460 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0; text-indent: 0"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-left: 0; text-indent: 0"> Liabilities and Equity </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0"> Accounts Payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 18,370 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0"> Accrued expense </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 38,100 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0"> Other payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 300,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0"> Due to related party </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 22,517 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"> Due to shareholder </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 46,586 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0"> Total Liabilities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 56,470 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 369,103 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0; text-indent: 0"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0; text-indent: 0"> Commitments and Contingencies </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0; text-indent: 0"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0; text-indent: 0"> Stockholders&rsquo; equity </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt"> Common Stock 360,000,000 authorized at $0.001 par
    value; shares issued and outstanding 210,821,647 and&nbsp;166,273,921 at September 30, 2016 and September 30, 2015 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 210,822 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 166,274 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 10pt"> Additional paid-in capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,733,401 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,132,685 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 10pt"> Subscription receivable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (350,000 </TD><TD STYLE="text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 10pt"> Accumulated deficit </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (4,823,401 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (315,602 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: 0"> Total equity </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 120,882 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 633,357 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: 0"> Total liabilities
    and equity </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 177,352 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 1,002,460 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*
All shares outstanding for all periods have been retroactively restated to reflect Company&rsquo;s 1 to 3:141 forward stock split,
which was effective on April 8, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;The
accompanying notes are an integral part of these condensed consolidated financial statements.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="a_021"></A><B>American
BriVision (Holding) Corporation.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(formerly
METU BRANDS, INC.)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> For&nbsp;the&nbsp;<BR>
    year&nbsp;ended<BR> September&nbsp;30,<BR>
    2016 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> For&nbsp;the<BR>
    period&nbsp;From&nbsp;<BR>
    July&nbsp;21,<BR>
    2015<BR> (inception)&nbsp;to&nbsp;<BR> September&nbsp;30,<BR>
    2015 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"> Revenues </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; padding-bottom: 1.5pt"> Cost of sales </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> 32 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"> Gross loss </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (32 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"> Operating expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Selling, general and administrative expenses </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 4,497,263 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 315,602 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Net loss from operations </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (4,497,295 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (315,602 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"> Other income(expenses) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9.9pt"> Bank Interest Income </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 361 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9.9pt"> Gain on exchange differences </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 141 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9.9pt"> Interest Expense </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (10,170 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 29.7pt"> Total Other Expenses </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (9,668 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -5.5pt; padding-left: 5.5pt"> Loss from continuing operations
    before income taxes </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (4,506,963 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (315,602 </TD><TD STYLE="text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Income taxes </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (836 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt"> Net loss </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (4,507,799 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (315,602 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"> Basic and Diluted loss per share </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 9.9pt"> Basic and diluted loss per share </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (0.02 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (0.00 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -5.5pt; padding-left: 5.5pt"> Weighted average number of
    shares outstanding basic and diluted </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 193,981,153 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 160,823,831 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*
All shares outstanding for all periods have been retroactively restated to reflect Company&rsquo;s 1 to 3:141 forward stock split,
which was effective on April 8, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;The
accompanying notes are an integral part of these condensed consolidated financial statements.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="a_022"></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>American
BriVision (Holding) Corporation.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(formerly
METU BRANDS, INC.)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDENSED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS&rsquo; EQUITY</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Common
    stock </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> additional </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> Number of </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> paid-in </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> Subscription </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> Accumulated </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> Stockholders&rsquo; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Shares </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Amount </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> capital </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> receivable </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Deficit </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> equity </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"> Balance at July
    21, 2015 (inception) </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"> 159,622,964 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"> 159,623 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,087,378 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"> (350,000 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"> 897,001 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"> Issuance of common shares </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 6,650,957 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 6,651 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 45,307 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 51,958 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"> Net
    loss for the period </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (315,602 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (315,602 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"> Balance at September 30, 2015 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 166,273,921 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 166,274 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,132,685 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (350,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (315,602 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 633,357 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"> Reverse
    merger recapitalization </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 42,359,253 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 42,359 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (45,055 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (2,696 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> )&nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"> Issuance of common shares </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2,031,423 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2,032 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 3,247,968 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 3,250,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"> Stock based
    compensation </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 157,050 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 157 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 397,803 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 397,960 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"> Receipt
    of subscription receivable </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 350,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 350,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"> Net
    loss for the year </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (4,507,799 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (4,507,799 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"> Balance
    at September 30, 2016 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> 210,821,647 </TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> 210,822 </TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> 4,733,401 </TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> (4,823,401 </TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> 120,882 </TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="a_023"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>American
BriVision (Holding) Corporation.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(formerly
METU BRANDS, INC.)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOW</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> For&nbsp;the
    <BR> year<BR> ended<BR> September&nbsp;30,<BR> 2016 </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> For&nbsp;the<BR>
    period&nbsp;<BR> From<BR> July&nbsp;21,<BR> 2015<BR> (inception)&nbsp;to<BR> September&nbsp;30,<BR> 2015 </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> Cash flows from operating activities </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> Net loss from continuing
    operations </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"> (4,507,799 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"> (315,602 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> Adjustments to reconcile net
    loss to net cash used by operating activities: </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> Issuance of common stock for
    compensation </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,295,324 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> Change in operating assets and
    liabilities: </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> Increase in deposit </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (3,815 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> Decrease (increase) in prepayment </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 3,815 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (3,815 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> (Decrease) increase in other
    payable </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (300,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 300,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> (Decrease) increase in due to
    related party </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (22,517 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 22,517 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> Increase in accounts payable </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 18,370 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"> Increase
    in accrued expense </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> 38,100 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Net cash used in operating
    activities </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (3,474,707 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (517 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> Cash flows from investing activities </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Net cash provided by
    (used in) investing activities </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> Cash flows from financing activities </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (Decrease) increase in due to shareholder </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (46,586 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 46,586 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Proceeds from subscription receivable </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 350,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> Proceeds from issuance of shares </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> 2,350,000 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> 948,959 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Net cash provided by
    financing activities </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> 2,653,414 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> 995,545 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Effect Of Exchange Rates
    On Cash </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> Net (decrease) increase in cash </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (821,293 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 994,830 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> Cash, beginning of period </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> 994,830 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> Cash, end of period </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> 173,537 </TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> 994,830 </TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> Non cash investing and financing activities </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Prepayment </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 900,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> Supplemental disclosure of cash flow information </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"> Interest paid </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"> Income taxes paid </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;The
accompanying notes are an integral part of these condensed consolidated financial statements.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="a_024"></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>American
BriVision (Holding) Corporation.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(formerly
METU BRANDS, INC.)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
OF SEPTEMBER 30, 2016 AND SEPTEMBER 30, 2015</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>1.
ORGANIZATION AND DESCRIPTION OF BUSINESS</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">American
BriVision (Holding) Corporation (the &ldquo;Company&rdquo; or &ldquo;Holding entity&rdquo;), a Nevada corporation, thru the Company&rsquo;s
operating entity, American BriVision Corporation (&ldquo;BriVision&rdquo;), which was incorporated in July 2015 in the State of
Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet
medical needs. &nbsp;The business model of the Company is to integrate research achievements from world-famous institutions (such
as Memorial Sloan Kettering Cancer Center (&ldquo;MSKCC&rdquo;) and MD Anderson Cancer Center), conduct clinical trials of translational
medicine for Proof of Concept (&ldquo;POC&rdquo;), out-license to international pharmaceutical companies, and exploit global markets.
BriVision had to predecessor operations prior to its formation on July 21, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">REVERSE
MERGER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
February 8, 2016, a Share Exchange Agreement (&ldquo;Share Exchange Agreement&rdquo;) was entered into by and among American BriVision
(Holding) Corporation (the&nbsp;&ldquo;Company&rdquo;), American BriVision Corporation&nbsp;(&ldquo;BriVision&rdquo;), Euro-Asia
Investment &amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the
People's Republic of China (&ldquo;Euro-Asia&rdquo;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares
of common stock of the Company, and the owners of record of all of the issued share capital of the Company(the&nbsp;&ldquo;BriVision
Stock&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates
evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the
Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates
evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583
pre-stock split) shares (the&nbsp;&ldquo;Acquisition Stock&rdquo;) (subject to adjustment for fractionalized shares as set forth
below) of the Company&rsquo;s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock
split) shares of the Company&rsquo;s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition
Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing,
in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the Merger, all of the issued and outstanding shares of BriVision&rsquo;s common stock were converted, at an exchange ratio
of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583pre-stock split) shares of Company&rsquo;s common stock and BriVision
became a wholly owned subsidiary, of the Company. The holders of Company&rsquo;s common stock as of immediately prior to the Merger
held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company&rsquo;s common stock,&nbsp;Because of the exchange
of the BriVision Stock for the Acquisition Stock (the&nbsp;&ldquo;Share Exchange&rdquo;), BriVision became a wholly owned subsidiary
(the &ldquo;Subsidiary&rdquo;) of the Company and there was a change of control of the Company following the closing.&nbsp;&nbsp;There
were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Because&nbsp;of
the consummation of the Share Exchange,&nbsp;BriVision&nbsp;is now our wholly owned subsidiary and its shareholders own approximately&nbsp;79.70%
of our issued and outstanding common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.2pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Following
the Share Exchange, we have abandoned our prior business plan and we are now pursuing&nbsp;BriVision&rsquo;s&nbsp;historical businesses
and proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs.&nbsp;&nbsp;The
business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of
translational medicine for Proof of Concept (&ldquo;POC&rdquo;), out-license to international pharmaceutical companies, and exploit
global markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.2pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accounting
Treatment of the Reverse Merger</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
financial reporting purposes, the Share Exchange represents a&nbsp;&ldquo;reverse merger&rdquo;&nbsp;rather than a business combination
and&nbsp;BriVision&nbsp;is deemed the accounting acquirer in the transaction. The&nbsp;Share Exchange is being accounted for as
a reverse-merger and recapitalization. BriVision&nbsp;is the acquirer for financial reporting purposes and the&nbsp;Company&nbsp;is
the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements
prior to the Share Exchange will be those of&nbsp;BriVision&nbsp;and recorded at the historical cost basis of&nbsp;BriVision.
In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities
of the Company and BriVision, and the historical operations of&nbsp;BriVision&nbsp;and operations of the Combined Company from
the closing date of the Share Exchange.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Basis
of Presentation</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United
States (&quot;U.S. GAAP&quot;).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned,
and expenses and losses are recognized when incurred. The Company&rsquo;s financial statements are expressed in U.S. dollars.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Use
of Estimates</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could
differ materially from those results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Forward
Stock split</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split
at a ratio of 1 to 3:141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000,
which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Fair
Value Measurements</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company applies the provisions of ASC Subtopic 820-10,&nbsp;&ldquo;Fair Value Measurements&rdquo;,&nbsp;for fair value measurements
of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed
at fair value in the financial statements.&nbsp;&nbsp;ASC 820 also establishes a framework for measuring fair value and expands
disclosures about fair value measurements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date.&nbsp;&nbsp;When determining the fair value measurements for assets and liabilities,
the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market
participants would use when pricing the asset or liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ASC
820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of
unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of
the fair value hierarchy are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs
that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial
instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as
of&nbsp;September 30, 2016.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Cash
and Cash Equivalents</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As
of September 30, 2016, the Company&rsquo;s cash and cash equivalents amounted $173,537. As of September 30, 2015, the Company&rsquo;s
cash and cash equivalents amounted $994,830. All&nbsp;of the Company&rsquo;s cash deposits are held in a financial institution
located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes
this financial institution is of high credit quality.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Income
Taxes</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.2pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred
tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach,
deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities
for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred
tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future
deductibility is uncertain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.2pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Under
ASC 740, a tax position is recognized as a benefit only if it is&nbsp;&ldquo;more likely than not&rdquo;&nbsp;that the tax position
would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a
two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon
examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The
second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized
in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely
of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition
threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions
that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period
in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified
as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred during
the period from July 21, 2015 (inception) to September 30, 2015. GAAP also provides guidance on de-recognition, classification,
interest and penalties, accounting in interim periods, disclosures and transition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2016 and September 30, 2015, the Company&rsquo;s income tax expense amounted $836 and $0, respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Recent
Accounting Pronouncements</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">From
time to time, new accounting standards issued by the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) or other standard
setting bodies are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes
that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position
or results of operations upon adoption. The recent accounting standards are not expected to have a material impact on the consolidated
financial statements upon adoption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>3.
GOING CONCERN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> The accompanying financial statements
have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since its inception
resulting in an accumulated deficit of $4,823,401 as of September 30, 2016. The Company also incurred net losses of $4,507,799
and negative cash flow of $821,293 during the year ended September 30, 2016. The ability to continue as a going concern is dependent
upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations
and repay its liabilities arising from normal business operations when they become due. These combined financial statements do
not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities
that might be necessary should the Company be unable to continue as a going concern. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to finance operations primarily through capital contributions from principal shareholders. In the event that we
require additional funding to finance the growth of the Company&rsquo;s current and expected future operations as well as to achieve
our strategic objectives, our principal shareholders have indicated the intent and ability to provide additional equity financing.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">These
conditions raise substantial doubt about the Company&rsquo;s ability to continue as a going concern. The Company&rsquo;s continuation
as a going concern is dependent on our ability to meet obligations as they become due and to obtain additional equity or alternative
financing required to fund operations until sufficient sources of recurring revenues can be generated. There can be no assurance
that the Company will be successful in its plans described above or in attracting equity or alternative financing on acceptable
terms, or if at all. The financial statements do not include any adjustments that might result from the outcome of this- uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
COLLABORATIVE AGREEMENT</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 29, 2015, American BriVision Corporation entered into a Collaborative Agreement with BioLite Inc., a related party, pursuant
to which BioLite granted the Company sole licensing rights for drug and therapeutic use of five products: BLI-1005 CNS-Major Depressive
Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1;
BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia,
in USA and Canada. Under the Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of BriVision
with equivalent value, according to the following schedule:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; text-align: left; width: 0.3in; vertical-align: top">&#9679;&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify">upfront payment shall upon the signing of this Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify">upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; text-align: left; vertical-align: top">&#9679;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify">at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; text-align: left; vertical-align: top">&#9679;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify">upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; text-align: left; vertical-align: top">&#9679;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify">at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.</TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, sans-serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, serif; vertical-align: middle; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Calibri, sans-serif">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, sans-serif; text-align: left; vertical-align: top">&#9679;</TD>
    <TD STYLE="font-family: Times New Roman, serif">upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Collaborative Agreement is attached as an exhibit to the registration statement of which this prospectus is a part. The material
terms of the Collaborative Agreement are as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is responsible to make up-front, milestone and royalty payments to BioLite, as described in the foregoing paragraph and
below.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> &#9679; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: -58.5pt; text-align: justify"> As between BioLite and
    ABVC, BioLite owns all files, data, confidential and non-public information, including, without limitation, all IND packages
    and clinical study reports, regarding the Compounds (collectively, the &ldquo;Compound IP&rdquo;), to the extent developed
    in Taiwan, and the Company owns all Compound IP to the extent developed in North America. BioLite grants an exclusive license
    to its Compound IP to the Company for the purpose of further development and commercialization of the Compounds in North America.
    BioLite and the Company share the responsibility of preparing for clinical trials by delivering Compound IP and preparing
    related materials. </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: -58.5pt; text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: -58.5pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company is responsible for all clinical trial expenses incurred in North America.&nbsp;&nbsp;BioLite paid all clinical trial
    expenses for trials conducted in Taiwan thus far. </FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Collaborative Agreement will remain in effect for fifteen years from the date of first commercial sale of Product in the U.S.
    or Canada. Either party may terminate upon thirty days&rsquo; prior written notice for breach or insolvency.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company agreed to pay to BioLite an aggregate of One Hundred Million Dollars ($100,000,000) (the &ldquo;Aggregate Amount&rdquo;)
    in milestone payments during the term of the agreement, payable in cash or Company equity. A percentage of the Aggregate Amount
    will be paid to BioLite upon each completion of a milestone by BioLite as set forth in the Collaborative Agreement. An upfront
    payment of $3,500,000 (the &ldquo;Milestone Payment&rdquo;), which is 3.5% of total payments due under the Collaborative Agreement,
    was to be paid by us upon signing of the Collaboration Agreement. On May 6, 2016, we and BioLite amended the payment terms
    under the Collaborative Agreement by entering into a Milestone Payment Agreement, pursuant to which we paid $2,600,000 in
    cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share, for an aggregate number of
    562,500 shares.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestones
    are reached by BioLite upon submissions of IND and NDAs for the Products, and completion of phases in the application processes,
    as set forth in the Collaborative Agreement.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition to the Aggregate Amount, the Company will pay to BioLite five percent (5%) of net sales of Products in the U.S. and
    Canada.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our&nbsp;Licensed
Compound</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have renamed the five compounds for our purposes and include below a brief description of each of the five compounds.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABV-
    1501 &nbsp;Triple Negative Breast Cancer - Combination therapy for Triple Negative Breast Cancer (TNBC)</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maitake
    mushroom extract Phase I clinical trial was performed by MSKCC.&nbsp;&nbsp;&ldquo;A phase I/II trial of a polysaccharide extract
    from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects:&rdquo; &ldquo;No dose-limiting
    toxicity was encountered. Oral administration of a polysaccharide extract from Maitake mushroom is associated with both immunologically
    stimulatory and inhibitory measurable effects in peripheral blood.&nbsp;&nbsp;Cancer patients should be made aware of the
    fact that botanical agents produce more complex effects than assumed, and may depress as well as enhance immune function&rdquo;.&nbsp;&nbsp;The
    IND number is 68853 and MSKCC received filing confirmation from the FDA on Jan 22, 2004.</FONT> </TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABV-1501
    US FDA Phase II IND cross reference with MSKCC Maitake and Phase II Investigational New Drug (IND) was approved in March 2016.</FONT> </TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are currently negotiating with MSKCC for Phase II clinical study. If MSKCC agreed with our terms, we anticipate to start phase
    II clinical trial during 2017 Q1and finish the phase II clinical trial by 2018 Q3.</FONT> </TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite
    has received approval from Institutional Review Board and (IRB) of Taipei Medical University in September 2016 in Taiwan</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 90pt; text-indent: -18pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 90pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 90pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font: 10pt Calibri,sans-serif; text-indent: 0pt; width: 0.25in"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font: 10pt Calibri,sans-serif; text-indent: 0pt; width: 0.25in"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">II.</FONT> </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font: 10pt Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">ABV-1502
    &nbsp;Solid Tumor with Anti-PD1 - Combination therapy for solid tumors with Anti-PD-1</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri,sans-serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.5in"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.3in"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">This
    is a kind of anti-tumor Combination therapy of Maitake mushroom extract with standard therapy and anti- PD1 drug for solid
    tumor.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Maitake
    mushroom extract Phase I clinical trial was performed by MSKCC.&nbsp;&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Currently,
    we are cooperating with MD Anderson Cancer Center and one of the top cancer centers in the U.S. to develop Phase II clinical
    trial IND package.&nbsp;&nbsp;Due to confidentiality obligations, we are not permitted to disclose the name of such cancer
    center at this time.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri,sans-serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.25in"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.25in"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">III.</FONT> </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">ABV-1503
    &nbsp;Chronic Lymphocytic Leukemia - Combination therapy for Chronic Lymphocytic Leukemia (CLL)</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri,sans-serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.5in"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.3in"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Phase
    II study of Epigallocatechin gallate (EGCG) for CLL.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">We
    are cooperating with MSKCC to prepare clinical trial agreement.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">We
    are currently preparing the IND package.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri,sans-serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.25in"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.25in"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">IV.</FONT> </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">ABV-1504
    &nbsp;Major Depressive Disorder - Major Depressive Disorder (MDD)</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri,sans-serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.5in"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; width: 0.3in"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">This
    is Polygala extract for Major Depressive Disorder</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">BioLite
    performed Phase I clinical trial.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">BioLite
    has obtained US FDA Phase II Part One/Part Two IND approval and the Phase II Part One was completed with good result.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman,serif; margin: 0"> For ABV-1504 Phase II part one results are described below. </P>
        <P STYLE="font: 10pt Times New Roman,serif; margin: 0"> Phase II part two: this phase currently is conducted in 5 clinical
        sites in Taiwan (started in Q3 2016) and one US site is under IRB review. </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri,sans-serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">V.</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABV-1505
    &nbsp;Attention Deficit Hyperactivity Disorder - Attention Deficit Hyperactivity Disorder</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    is Polygala extract for Attention Deficit Hyperactivity Disorder.</FONT> </TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Same
    Active Pharmaceutical Ingredients (API) with ABV-1504. </FONT> </TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite
    has obtained U.S. FDA Phase II IND approval and is currently negotiating with top medical site for Phase II clinical trial.</FONT> </TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite
    intends to submit for IRB approval during 2016 Q4</FONT> </TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite
    plans to start Phase II clinical trial during 2017 Q1 and complete by 2018 Q3.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABV-1501
and ABV-1502 have the same Active Pharmaceutical Ingredient:&rdquo; Maitake mushroom extract&rdquo;. IND and study details are
as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Phase I/II clinical trial was conducted by MSKCC. A total of 34 eligible study subjects was enrolled from 3/2004 to 1/2007.
    The primary endpoints were safety and tolerability. The test drug was oral administration and a polysaccharide extract from
    Maitake mushroom is associated with both immunologically stimulatory and inhibitory measurable effects in peripheral blood.
    Cancer patients should be made aware of the fact that botanical agents produce more complex effects than assumed, and may
    depress as well as enhance immune function. (<U>A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake
    mushroom) in breast cancer patients: immunological effects by Gary Deng &middot; Hong Lin &middot; Andrew Seidman &middot;
    Monica Fornier &middot; Gabriella D&rsquo;Andrea &middot;Kathleen Wesa &middot; Simon Yeung &middot; Susanna Cunningham Rundles
    &middot;Andrew J. Vickers &middot; Barrie Cassileth; J Cancer Res Clin Oncol (2009) 135:1215&ndash;1221.</U>) The IND number
    is </FONT> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">68853 and MSKCC received filing confirmation
    from the FDA on Jan 22, 2004</FONT>. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
    Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients? A Phase II clinical trial.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
endpoint: To describe changes in neutrophil counts and neutrophil function in MDS patients following administration of Maitake
mushroom extract.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">This study to see whether Maitake improves the neutrophil count and function in patients with MDS. The neutrophils
are white blood cells which help to fight infection.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
45 subjects.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Start
Date: April 2010</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
Date: September 2014</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsor:
Memorial Sloan Kettering Cancer Center</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborator:
YUKIGUNI COMPANY</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborator:
Weill Medical College of Cornell University</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
Investigator: Kathleen Wesa, MD Memorial Sloan Kettering Cancer Center</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full
Source of Clinical Trial Data: https://clinicaltrials.gov/show/NCT01099917</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Normally,
for non-cancer patients, phase I clinical trials are performed with healthy subjects to test for safety and phase II clinical
trials are performed with healthy patient subjects for efficacy. But for cancer patients, however, trials of cancer drugs must
necessarily involve subjects with cancer, and as such, phase I/II studies include primary endpoints relating to safety and tolerability,
not efficacy.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
&ldquo;Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients? A Phase II clinical trial,&rdquo; conclusions
are described as follows: &ldquo;Maitake was well tolerated. Enhanced in vitro neutrophil and monocyte function following treatment
demonstrate that Maitake has beneficial immunomodulatory potential in MDS. Further study is warranted&rdquo;.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
32 of the journal article, &ldquo;Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients?&rdquo; indicates
that there were 45 subjects were enrolled at the beginning of the study, 18 subjects completed treatment, 3 subjects had adverse
effects and 24 subjects were not treated.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0pt; text-indent: 0pt; width: 0.5in"> &nbsp; </TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.3in; padding-right: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hematopoiesis:
    is the formation of blood cellular components. All cellular blood components are derived from haematopoietic stem cells. In
    a healthy adult person, approximately 1011&ndash;1012 new blood cells are produced daily in order to maintain steady state
    levels in the peripheral circulation (Wikipedia).</FONT> </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0"> &nbsp; </TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; padding-right: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Myelodysplastic:
    are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells (Medscape).
    Myelodysplastic syndromes are a group of disorders caused by poorly formed or dysfunctional blood cells. Myelodysplastic syndromes
    occur when something goes wrong in your bone marrow &mdash; the spongy material inside your bones where blood cells are made.
    Treatment for myelodysplastic syndromes usually focuses on reducing or preventing complications of the disease and its treatments.
    In certain cases, myelodysplastic syndromes are treated with a bone marrow transplant (Mayo Clinic).</FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
ABV-1503, we are currently preparing the IND package. BioLite is preparing the Compound IP for the Chemistry, Manufactural, and
Control (CMC) part, MSKCC and the Company are collaborating to prepare for protocol design and prepare the IRB documents. The
trial period, test subject number, primary and secondary endpoint and method of administration have not been decided yet, and
are still being negotiated between we and MSKCC.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABV-1504
and ABV-1505 have the same Active Pharmaceutical Ingredient: the extract of Radix Polygalae (Polygala tenuifolia Willd/PDC-1421
Capsule). IND and study information are as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    Dose Escalation Phase I Study of PDC-1421 Capsule to Evaluate the Safety in Healthy Volunteers.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IND
Number: 112567</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trial
period: 11/13/2012-7/5/2013, Final Report Date 11/12/2013</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
30 study subjects were enrolled. The test drug was oral administration. The primary endpoint is to assess the safety profile of
PDC-1421 Capsule in healthy volunteers.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsor:
BioLite, Inc.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"> &#9679; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients with Major Depressive Disorder</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IND
Number: 112567</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
Study Objective: To assess the efficacy profile of PDC-1421 Capsule in major depressive disorder with Montgomery-Asberg Depression
Rating Scale (MADRS).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary
Study Objective: To evaluate the efficacy and safety profile</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Study
period: 2 years.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
72 study subjects will be enrolled.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Study
site: There are five sites in Taiwan and one site in US (Stanford University, which is currently preparing for IRB approval and
Clinical Trial Agreement.)&#9;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsor:
BioLite, Inc.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
ABV-1504 Phase II part one---total subject: 12, trial period: 2/11/2016-7/14/2016, administered route: oral, test results are
as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trial
Progress Report:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Part I trial has been completed with 12 subjects (screening: 14, enrolling: 12). The six subjects were in the Part I high dosage
group.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Under the suicide risk assessment (C-SSRS) Subject X indicated that the suicidal ideation scores were 4 for both Visit 7 and Visit
8. The PI confirmed that the subject had external pressures (moving, etc.), which produced constant suicidal thoughts, and such
observation was reflected in Dr. A&rsquo;s (PI) evaluation. The subject expressed his/her intention to stay positive in a counseling
session, and the subject was contacted by a researcher (Research Nurse) after leaving the facility. After reviewing by the researcher,
a justification was made that the suicidal behavior was irrelevant to the drug administered.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Clinical data of the six high-dosage administered subjects with data exceeding normal value:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
NCS- Non-Clinical Significant judged by PI. CS: Clinical Significant judged by PI.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-After
data safety review board carefully reviewed, they agree to proceed to part two clinical trial.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
ABV-1504 Phase II part two: this phase currently is conducted in 5 clinical sites in Taiwan (started in Q3 2016) and one US site
is under IRB review.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
&ldquo;A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression:&rdquo; Trial period: 11/13/2012-7/5/2013,
final report date 11/12/2013. Enroll subject: 30, 23 PDC-1421, 7 placebo control.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Study
Conclusions:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;(1)
No subject had serious adverse event and no subject discontinued due to adverse event;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
No clinically significant findings were observed in physical examinations; vital signs, </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">electrocardiograms,
laboratory measurements, and C-SSRS were observed throughout the treatment period;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
The oral administration of PDC-1421 in healthy volunteers was safe and well-tolerated for the dose from 380 mg to 3800 mg&rdquo;.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
&ldquo;A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients with Major Depressive Disorder&rdquo;:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
One- study period 2/11/2016-7/12/2016. Total subject: 12</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maitake
mushroom extract is sourced from YUKIGUNI COMPANY, Japan, and processed by YUSHENG PHARMACEUTICAL COMPANY in Taiwan (cGMP).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extract of Radix Polygalae (Polygala tenuifoliaWilld/PDC-1421 Capsule) is purchased from HERNG FA PHARMACEUTICAL TECHNOLOGY, and
processed by Industrial Technology Research Institute (ITRI). There are no limits on availability to the Company on any of these
ingredients.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the Collaborative Agreement, an upfront payment of $3,500,000 (the &ldquo;Milestone Payment&rdquo;), which is 3.5% of total
payments due under the Collaborative Agreement, was to be paid by the Company upon signing of that agreement. On May 6, 2016,
we and BioLite agreed to amend the Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby we have
agreed to pay the Milestone Payment to BioLite $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at
the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in
June 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales
of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month
written notice of termination prior to the expiration date of the term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined to fully expense the entire amount of $3,500,000 since currently the related licensing rights do not have alternative
future uses. . According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research
and development activities must be charged to research and development expenses immediately. Hence the entire amount is fully
expensed as research and development expense.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>5.
RELATED PARTIES TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2016 and September 30, 2015, the amount due to a related party, BioLite, Inc (&ldquo;Biolite&rdquo;) was $0 and
$22,517 respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2016 and September 30, 2015, the amount due to shareholder, YuanGene Corporation, was $0 and $46,586 respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
ACCOUNTS PAYABLE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">As
of September 30, 2016 and September 30, 2015, the amount of Accounts Payable to LiteArt, Inc. was $18,370 and $0 respectively.</FONT></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>7.
                                         EQUITY</B></FONT></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
October 2015, $350,000 of subscription receivable was fully collected from the shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2016, a Share Exchange Agreement (&ldquo;Share Exchange Agreement&rdquo;) was entered into by and among American BriVision
(Holding) Corporation (the&nbsp;&ldquo;Company&rdquo;), American BriVision Corporation&nbsp;(&ldquo;BriVision&rdquo;), Euro-Asia
Investment &amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People's
Republic of China (&ldquo;Euro-Asia&rdquo;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of
common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the&nbsp;&ldquo;BriVision
Stock&rdquo;). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by
BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant
to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock
and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company,
the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the&nbsp;&ldquo;Acquisition Stock&rdquo;) (subject to
adjustment for fractionalized shares as set forth below) of the Company&rsquo;s common stock to the BriVision Shareholders (or
their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&rsquo;s common stock owned by Euro-Asia should
be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding
common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued
share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares
of BriVision&rsquo;s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583
pre-stock split) shares of Company&rsquo;s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders
of Company&rsquo;s common stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split)
shares of Company&rsquo;s common stock,&nbsp;Because of the exchange of the BriVision Stock for the Acquisition Stock (the&nbsp;&ldquo;Share
Exchange&rdquo;), BriVision became a wholly owned subsidiary (the &ldquo;Subsidiary&rdquo;) of the Company and there was a change
of control of the Company following the closing.&nbsp;&nbsp;There were no warrants, options or other equity instruments issued
in connection with the share exchange agreement.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> On February 17, 2016, pursuant to
the 2016 Equity Incentive Plan (the &ldquo;2016 Plan&rdquo;), 157,050 (50,000 pre-stock split) shares were granted to the employees. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split
at a ratio of 1 to 3:141 (the &ldquo;Forward&nbsp;Stock&nbsp;Split&rdquo;) and increase the number of our authorized shares of
common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
majority of the shareholders of the Company approved the amendment to Articles of Incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> On May 6, 2016, we and BioLite agreed to
amend the Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby we have agreed to issue shares
of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of our first installation
of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 26, 2016, the Company issued 1,468,750 shares (&ldquo;Shares&rdquo;) of the Company&rsquo;s common stock, par value $0.001
(the &ldquo;Offering&rdquo;) to BioLite, Inc., a non-U.S. accredited investor (the &ldquo;Purchaser&rdquo;) pursuant to a certain
Stock Purchase Agreement dated August 26, 2016 (the &ldquo;SPA&rdquo;). The Shares are exempt from the registration requirements
of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), pursuant to Regulation&nbsp;S of the Securities
Act promulgated thereunder. Our sole director, Eugene Jiang, is a director of BioLite and it is therefore considered a related
party.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000.
The proceeds may be used for general corporate purposes.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
EARNINGS PER SHARE</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year.
Diluted earnings per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential
common shares outstanding during the year.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Calibri,sans-serif; text-align: center; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>For&nbsp;the&nbsp;Year</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>Ended </B></FONT><BR> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>September&nbsp;30,</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>2016</B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> For the period from<BR>
    &nbsp;July 21, <BR> 2015<BR> &nbsp;(Inception)<BR> &nbsp;to September&nbsp;30, <BR> 2015 </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> Numerator: </TD><TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"> Net loss </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> (4,507,799 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> (315,602 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Denominator: </TD><TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Weighted-average shares outstanding: </TD><TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt"> Weighted-average shares outstanding - Basic </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 193,981,153 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 160,823,831 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt"> Stock options </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Calibri,sans-serif; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt; font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt"> Weighted-average shares outstanding - Diluted </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 193,981,153 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 160,823,831 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Earnings per share </TD><TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif"> &nbsp; </TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right"> &nbsp; </TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt"> -Basic </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 0.02 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 0.00 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt"> -Diluted </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 0.02 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 0.00 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Diluted
earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common
stock were exercised and converted into common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
COMMITMENTS AND CONTINGENCIES</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Capital
Commitment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 29, 2015, the Company entered into the agreement with Biolite, a related party, that Biolite would grant the Company
sole licensing rights of a series of technology for 15 years. The total consideration of obtaining such grant would be $100,000,000.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
Commitment</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total future minimum lease payments under the non-cancellable operating lease with respect to the office&nbsp;as of September
30, 2016 are payable as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 384.25pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%"> Remaining 2016 </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 5,948 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Year ending September 30, 2017 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 23,793 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Year ending September 30, 2018 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 17,845 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt"> Total </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 47,586 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rental
expense of the Company was $29,129 and nil for the year ended September 30, 2016 and 2015, respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
SUBSEQUENT EVENT</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated and concluded that no subsequent events have occurred that would require recognition or disclosure in the consolidated
financial statements.&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_025"></A><U>REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
the Board of Directors and Shareholders of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">American
BriVision Corporation and subsidiaries</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have audited the accompanying balance sheets of American BriVision Corporation and subsidiaries (&ldquo;the Company&rdquo;) as
of September 30, 2015 and the related statements of operations, stockholders&rsquo; equity and cash flows for the period from
July 21, 2015 (inception) to September 30, 2015. These financial statements are the responsibility of the Company&rsquo;s management.
Our responsibility is to express an opinion on these financial statements based on our audit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are
free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control
over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing
audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness
of the company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes
examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting
principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the
Company as of September 30, 2015 and the results of its operations and its cash flows for the period from July 21, 2015 (inception)
to September 30, 2015 in conformity with accounting principles generally accepted in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.
As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and
has a significant accumulated deficit. In addition, the Company continues to experience negative cash flows from operations. These
factors raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
Centurion ZD CPA Limited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certified
Public Accountants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Hong
Kong, China</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November
11, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_026"></A>American
BriVision Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Balance
Sheet</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Stated
in US Dollars)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September&nbsp;30,<BR> 2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Current assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">994,830</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">Prepayment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,815</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total Current Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">998,645</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Non-current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">Deposit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,815</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total Non-Current Assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,815</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,002,460</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Other payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Due to related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,517</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Due to shareholder</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">46,586</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">369,103</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">166,274</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,132,685</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(350,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(315,602</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total Stockholders&rsquo; Equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">633,357</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,002,460</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="text-align: left; width: 97%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All shares outstanding for all periods have been retroactively
restated to reflect Company&rsquo;s 1 to 3:141 forward stock split, which was effective on April 8, 2016.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_027"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>American
BriVision Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Statement
of Operations and Comprehensive Loss</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Stated
in US Dollars)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&nbsp;the&nbsp;period
    from&nbsp;July&nbsp;21, <BR> 2015<BR> (inception) to<BR> September&nbsp;30, <BR> 2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Operating expenses</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">General and administrative expenses</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">315,602</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(315,602</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Loss before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(315,602</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(315,602</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Basic and Diluted loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Weighted average number of shares outstanding&nbsp;&nbsp;basic and diluted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Basic and diluted loss per share</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">160,823,831</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="text-align: left; width: 97%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All shares outstanding for all periods have been retroactively
restated to reflect Company&rsquo;s 1 to 3:141 forward stock split, which was effective on April 8, 2016.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_028"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>American
BriVision Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Statement
of Stockholder&rsquo;s Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Stated
in US Dollars)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Additional</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Number</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Common</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>paid-in</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Subscription</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Accumulated</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Stockholders&rsquo;</B></TD><TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>of&nbsp;shares</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>stock</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>capital</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Receivable</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Deficit</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Equity</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; padding-left: 10pt; text-indent: -10pt">Balance, July 21, 2015 (Inception)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">159,622,964</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">159,623</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,087,378</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(350,000-</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">897,001</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Issuance of common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,650,957</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,651</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,307</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,958</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(315,602</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(315,602</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Balance, September 30, 2015</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">166,273,921</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">166,274</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,132,685</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(350,000-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(315,602</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">633,357</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="text-align: left; width: 97%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All shares outstanding for all periods have been retroactively
restated to reflect Company&rsquo;s 1 to 3:141 forward stock split, which was effective on April 8, 2016.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_029"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>American
BriVision Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Statement
of Cash Flow</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Stated
in US Dollars)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&nbsp;the&nbsp;period
    <BR>
from&nbsp;July&nbsp;21, <BR> 2015<BR> (inception) to<BR> September&nbsp;30, <BR> 2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; padding-left: 10pt">Net Loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(315,602</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,815</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Prepayment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,815</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Other payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Due to related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,517</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Due to shareholder</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">46,586</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash provided by operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,871</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">Proceeds from issuance of shares</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">948,959</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">948,959</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Effect of exchange rate on cash</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net change in cash</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">994,830</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, beginning balance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, ending balance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">994,830</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="a_030"></A><B>American
BriVision Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Stated
in US Dollars)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>1.
ORGANIZATION AND DESCRIPTION OF BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company&rsquo;s operating company, American BriVision Corporation (&ldquo;BriVision&rdquo;), was incorporated in July 2015 in
the State of Delaware. It is a biotechnology company focused on the development of new drugs and innovative medical devices to
fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions
(such as Memorial Sloan Kettering Cancer Center (&ldquo;MSKCC&rdquo;) and MD Anderson Cancer Center), conduct clinical trials
of translational medicine for Proof of Concept (&ldquo;POC&rdquo;), out-license to international pharmaceutical companies, and
exploit global markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Basis
of Presentation</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
accompanying audited financial statements and related notes have been prepared in accordance with generally accepted accounting
principles in the United States of America (U.S. GAAP). This basis of accounting involves the application of accrual accounting
and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&rsquo;s
financial statements are expressed in U.S. dollars.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Use
of Estimates</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could
differ materially from those results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Fair
Value Measurements</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company applies the provisions of ASC Subtopic 820-10,&nbsp;&ldquo;Fair Value Measurements&rdquo;,&nbsp;for fair value measurements
of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed
at fair value in the financial statements.&nbsp;&nbsp;ASC 820 also establishes a framework for measuring fair value and expands
disclosures about fair value measurements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date.&nbsp;&nbsp;When determining the fair value measurements for assets and liabilities
required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it
would transact and it considers assumptions that market participants would use when pricing the asset or liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ASC
820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of
unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The
three levels of the fair value hierarchy are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 2%">&#9679;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level 1 inputs to the valuation methodology are quoted
prices (unadjusted) for identical assets or liabilities in active markets.</FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 2%">&#9679;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level 2 inputs to the valuation methodology include
quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability,
either directly or indirectly, for substantially the full term of the financial instruments.</FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 2%">&#9679;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level 3 inputs to the valuation methodology are unobservable
and significant to the fair value.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as
of&nbsp;September 30, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Cash
and Cash Equivalents</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As
of September 30, 2015, the Company&rsquo;s cash and cash equivalents amounted $994,830. All&nbsp;of the Company&rsquo;s cash deposit
is held in a financial institution located in Republic of China where there is currently regulation mandated on obligatory insurance
of bank accounts. The Company believes this financial institution is of high credit quality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Income
Taxes</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company accounts for income taxes using an asset and liability approach which allows for the recognition and measurement of deferred
tax assets based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred
taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax
assets if it is more likely than not these items will either expire before the Company is able to realize their benefits, or that
future deductibility is uncertain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Under
ASC 740, a tax position is recognized as a benefit only if it is &ldquo;more likely than not&rdquo; that the tax position would
be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step
process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination,
including the resolution of any related appeals or litigations based on the technical merits of that position. The second step
is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized
in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely
of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition
threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions
that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period
in which the threshold is no longer met. Penalties and interest incurred related to underpayment of income tax are classified
as income tax expense in the year incurred. No significant penalties or interest relating to income taxes have been incurred during
the period from July 22, 2015 (inception) to September 30, 2015. GAAP also provides guidance on de-recognition, classification,
interest and penalties, accounting in interim periods, disclosures and transition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Recent
Accounting Pronouncements</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">From
time to time, new accounting standards are issued by the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) or other standard
setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes
that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position
or results of operations upon adoption. The recent accounting standards are not expected to have a material impact on the consolidated
financial statements upon adoption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>3.
GOING CONCERN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred
losses since its inception resulting in an accumulated deficit of $315,602 as of September 30, 2015. The ability to continue as
a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing
to meet its obligations and repay its liabilities arising from normal business operations when they become due. These combined
financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification
of liabilities that might be necessary should the Company be unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company expects to finance operations primarily through cash flow from revenue and capital contributions from principal shareholders.
In the event that we require additional funding to finance the growth of the Company&rsquo;s current and expected future operations
as well as to achieve our strategic objectives, our principal shareholders have indicated the intent and ability to provide additional
equity financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">These
conditions raise substantial doubt about the Company&rsquo;s ability to continue as a going concern. The Company&rsquo;s continuation
as a going concern is dependent on our ability to meet obligations as they become due and to obtain additional equity or alternative
financing required to fund operations until sufficient sources of recurring revenues can be generated. There can be no assurance
that the Company will be successful in its plans described above or in attracting equity or alternative financing on acceptable
terms, or if at all. The financial statements do not include any adjustments that might result from the outcome of this- uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>4.
DUE TO RELATED PARTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2015, the amount due to a related party, BioLite, Inc. (&ldquo;BioLite&rdquo;) was $22,517.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2015, the amount due to shareholder, YuanGene Corporation, was $46,586.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>5.
EARNINGS PER SHARE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Basic
earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period.
Diluted earnings per share is computed by dividing net income by the weighted-average number of common shares and dilutive potential
common shares outstanding during the period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> For&nbsp;the&nbsp;period
    from July&nbsp;21, <BR> 2015 <BR> (inception) to<BR> September 30,<BR> 2015 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2015 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> Numerator: </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left"> Net income </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> (315,602 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Denominator: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Weighted-average shares outstanding </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt"> Weighted-average shares outstanding - Basic </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 160,823,831 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt"> Stock options </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt"> Weighted-average shares outstanding - Diluted </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 160,823,831 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Earnings per share </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt"> -Basic </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 0.00 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt"> -Diluted </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 0.00 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Diluted
earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common
stock were exercised and converted into common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>6.
SUBSEQUENT EVENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
October 2015, $350,000 of subscription receivable was fully collected from the shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
December 29, 2015, the Company entered into the agreement with BioLite, a related party, that BioLite would grant the Company
sole licensing rights of s series of technology for 10 years. The total consideration of obtaining such grant would be $100,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Reverse
Merger</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
February 8, 2016, a Share Exchange Agreement (&ldquo;Share Exchange Agreement&rdquo;) was entered into by and among American BriVision
(Holding) Corporation (the&nbsp;&ldquo;Company&rdquo;), American BriVision Corporation&nbsp;(&ldquo;BriVision&rdquo;), Euro-Asia
Investment &amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the
People's Republic of China (&ldquo;Euro-Asia&rdquo;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares
of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the&nbsp;&ldquo;BriVision
Stock&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates
evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the
Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates
evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583
pre-stock split) shares (the&nbsp;&ldquo;Acquisition Stock&rdquo;) (subject to adjustment for fractionalized shares as set forth
below) of the Company&rsquo;s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock
split) shares of the Company&rsquo;s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition
Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing,
in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the Merger, all of the issued and outstanding shares of BriVision&rsquo;s common stock were converted, at an exchange ratio
of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company&rsquo;s common stock and BriVision
became a wholly owned subsidiary, of the Company. The holders of Company&rsquo;s common stock as of immediately prior to the Merger
held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company&rsquo;s common stock,&nbsp;Because of the exchange
of the BriVision Stock for the Acquisition Stock (the&nbsp;&ldquo;Share Exchange&rdquo;), BriVision became a wholly owned subsidiary
(the &ldquo;Subsidiary&rdquo;) of the Company and there was a change of control of the Company following the closing.&nbsp;&nbsp;There
were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Forward
Stock Split</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split
at a ratio of 1 to 3:141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000. The amendment to Articles of Incorporation was approved by the majority of the shareholders of the Company and became effective
on April 8, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>American
BriVision (Holding) Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32,409,505
Shares of Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
____________________, 2017 all dealers that effect transactions in these securities, whether or not participating in this offering,
may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as
underwriters and with respect to their unsold allotments or subscriptions.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><A NAME="a_031"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><A NAME="a_032"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
13.&nbsp;&nbsp;OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table sets forth estimated expenses we expect to incur in connection with the sale of the shares being registered. All
such expenses are estimated except for the SEC and FINRA registration fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,528</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Printing expenses*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,550</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fee and expenses of counsel for the Company*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fee and expenses of accountants for Company**</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Miscellaneous*</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">500</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Total**</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double"></TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Estimated.</FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">**</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To be provided by amendment.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><A NAME="a_033"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
14.&nbsp;&nbsp;INDEMNIFICATION OF DIRECTORS AND OFFICERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
officers and directors are indemnified as provided by the Nevada Revised Statutes (&ldquo;NRS&rdquo;) and our bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Under
the NRS, director immunity from liability to a company or its shareholders for monetary liabilities applies automatically unless
it is specifically limited by a company&rsquo;s articles of incorporation that is not the case with our articles of incorporation.
Excepted from that immunity are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)&nbsp;&nbsp;a
willful failure to deal fairly with the company or its shareholders in connection with a matter in which the director has a material
conflict of interest;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)&nbsp;&nbsp;a
violation of criminal law (unless the director had reasonable cause to believe that his or her conduct was lawful or no reasonable
cause to believe that his or her conduct was unlawful);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)&nbsp;&nbsp;a
transaction from which the director derived an improper personal profit; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4)&nbsp;&nbsp;willful
misconduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
Articles of Incorporation permits us to indemnify our officers and directors to the fullest extent authorized or permitted by
law in connection with any proceeding arising by reason of the fact any person is or was our officer or director. Notwithstanding
this indemnity, a director shall be liable to the extent provided by law for any liability incurred by him by his own fraud or
willful default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
bylaws provide that we will indemnify our directors and officers to the fullest extent not prohibited by Nevada law. Our bylaws
provide that we will advance all expenses incurred to any person who was or is a party or is threatened to be made a party to
any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by
reason of the fact that he is or was our director or officer, or is or was serving at our request as a director or executive officer
of another company, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly
following request. This advance of expenses is to be made upon receipt of an undertaking by or on behalf of such person to repay
said amounts should it be ultimately determined that the person was not entitled to be indemnified under our bylaws or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 81; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_034"></A>ITEM
15.&nbsp;&nbsp;RECENT SALES OF UNREGISTERED SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Recent
Sales of Unregistered Equity Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
more fully described above, in connection with the Exchange Agreement, the Company issued a total of&nbsp;52,936,583&nbsp;shares
of our common stock to&nbsp;our&nbsp;shareholders. Reference is made to the disclosures set forth under Item 2.01 of this Form
8-K, which disclosures are incorporated herein by reference. The issuance of the common stock to the&nbsp;our shareholders pursuant
to the Exchange Agreement was exempt from registration in reliance upon Section 4(a)(2) of the Securities Act of 1933, as amended
(the&nbsp;&ldquo;Securities Act&rdquo;) and Regulation S of the Securities Act.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
September 2015, 30,000,000 shares of common stock was issued to Shulamit Lazar &ndash; the Company&rsquo;s former CEO - for her
initial $20,000 deposit to purchase the company; she also received another 30,000,000 shares in September 2015 pursuant to an
employment agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Innovation
Consulting LLC paid $5,000 for 271 shares of preferred stock. The shares converted into 5,420,000 shares of common stocks on November
30, 2015. These shares were sold to Euro-Asia Investment &amp; Finance Corp. Limited on December 18, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
May 6, 2016, we issued an aggregate number of 562,500 shares to BioLite pursuant to certain Milestone Payment Agreement. The issuance
of the common stock to BioLite was exempt from registration in reliance upon Section 4(a)(2) of the Securities Act and Regulation
S of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
August 26, 2016, we issued an aggregate number of 1,468,750 newly issued restricted shares to BioLite pursuant to certain Stock
Purchase Agreement. The issuance of the common stock to BioLite was exempt from registration in reliance upon Section 4(a)(2)
of the Securities Act and Regulation S of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Repurchases
of Equity Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have not repurchased&nbsp;any equity securities during the periods covered by this Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_035"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
16.&nbsp; EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a).
Exhibits</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following exhibits are filed as part of this registration statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.1</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Share
    Exchange Agreement, dated February 8, 2016 (1)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Articles
    of Incorporation of the Company (2)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bylaws
    of the Company (3)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.3</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate
    of Amendment to Articles of Incorporation filed on March 21, 2016 (4)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.4</FONT> </TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate
    of Amendment to Articles of Incorporation filed on December 21, 2016 *</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.1</FONT> </TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal
    Opinion of Hunter Taubman Fischer &amp; Li, LLC +</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Collaboration
    Agreement dated December 29, 2015 (5)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Collaborative
                                         Agreement and Milestone Payment Agreement dated June 9, 2016 (6)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3</FONT> </TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment
    Agreement with Kira Huang +&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</FONT> </TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code
    of Ethics *</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">21.1</FONT> </TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Subsidiaries
    of the Registrant *</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.1</FONT> </TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent
    of <FONT STYLE="background-color: white">Centurion ZD CPA Limited</FONT>+</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.2</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent
    of Hunter Taubman Fischer &amp; Li, LLC (included in Exhibit 5.1)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.INS***</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Instance Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.SCH***</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Schema Document&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.CAL***</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Calculation Linkbase Document&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.DEF***</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Definition Linkbase Document&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.LAB***</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Label Linkbase Document XBRL&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.PRE***</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Taxonomy
    Extension Presentation Linkbase Document&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD STYLE="width: 96%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    (Extensible Business Reporting Language) information is furnished and not filed herewith, is not a part of a registration
    statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for
    purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under
    these sections.</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.1 the Company&rsquo;s Current Report of Form 8-K, filed on February 16, 2016.</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 3.01 to the Company&rsquo;s Form SB-2 filed on June 28, 2002</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 3.02 to the Company&rsquo;s Form SB-2, filed on June 28, 2002</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K, filed on March 28, 2016.</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 10.2 the Company&rsquo;s Current Report of Form 8-K, filed on February 16, 2016.</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to Exhibit 99.1 to the Company&rsquo;s Current Report on Form 8-K, filed on June 9, 2016.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_036"></A>ITEM
17.&nbsp;&nbsp;UNDERTAKINGS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
undersigned registrant hereby undertakes to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)
File, during any period in which offers or sales are being made, a post-effective amendment to this registration statement to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)
Include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the &quot;Securities Act&quot;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)
Reflect in the prospectus any facts or events which, individually or together, represent a fundamental change in the information
in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the
total dollar value of the securities offered would not exceed that which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected in the form of a prospectus filed with the Commission pursuant to
Rule 424(b) under the Securities Act if, in the aggregate, the changes in volume and price represent no more than a 20% change
in the maximum aggregate offering price set forth in the &quot;Calculation of Registration Fee&quot; table in the effective registration
statement, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iii)
Include any additional or changed material information on the plan of distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)
For determining liability under the Securities Act, treat each post-effective amendment as a new registration statement of the
securities offered, and the offering of the securities at that time to be the initial bona fide offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)
File a post-effective amendment to remove from registration any of the securities that remain unsold at the end of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion
of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and
is, therefore, unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(5)
Each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration
statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included
in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in
a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to
a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration
statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date
of first use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of&nbsp; appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will
be governed by the final adjudication of such issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 49.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it
meets all of the requirements for filing on Form S-1 and has duly caused this Form S-1 Registration Statement to be signed on
its behalf by the undersigned, thereunto duly authorized, in the City of Taipei, Taiwan, on January 19, 2017.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">American&nbsp;BriVision&nbsp;(Holding)
    Corporation</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 36%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Eugene Jiang&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Eugene
    Jiang</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons
in the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; width: 40%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Signature</B></FONT></P></TD>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 43%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Title</B></FONT></P></TD>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 15%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date</B></FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Eugene Jiang</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">E
    Eugene Jiang </FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">January
    19, 2017</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</FONT> </TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Kira Huang</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Kira
    Huang</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">January
    19, 2017</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
    Financial Officer, Principal Accounting Officer</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>



<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INDEX
TO EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following exhibits are filed as part of this registration statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.1</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Share
    Exchange Agreement, dated February 8, 2016 (1)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Articles
    of Incorporation of the Company (2)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bylaws
    of the Company (3)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.3</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate
    of Amendment to Articles of Incorporation filed on March 21, 2016 (4)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.4</FONT> </TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate
    of Amendment to Articles of Incorporation filed on December 21, 2016 *</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.1</FONT> </TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal
    Opinion of Hunter Taubman Fischer &amp; Li, LLC +</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Collaboration
    Agreement dated December 29, 2015 (5)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Collaborative
                                         Agreement and Milestone Payment Agreement dated June 9, 2016 (6)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3</FONT> </TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment
    Agreement with Kira Huang +&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">14.1</FONT> </TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Code
    of Ethics *</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">21.1</FONT> </TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Subsidiaries
    of the Registrant *</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.1</FONT> </TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent
    of <FONT STYLE="background-color: white">Centurion ZD CPA Limited</FONT>+</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.2</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent
    of Hunter Taubman Fischer &amp; Li, LLC (included in Exhibit 5.1)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.INS***</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Instance Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.SCH***</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Schema Document&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.CAL***</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Calculation Linkbase Document&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.DEF***</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Definition Linkbase Document&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.LAB***</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Label Linkbase Document XBRL&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.PRE***</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Taxonomy
    Extension Presentation Linkbase Document&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT> </TD>
    <TD STYLE="width: 96%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Previously
    filed</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">+</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed
    herewith</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">***</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    (Extensible Business Reporting Language) information is furnished and not filed herewith, is not a part of a registration
    statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for
    purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under
    these sections.</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated
    by reference to Exhibit 10.1 the Company&rsquo;s Current Report of Form 8-K, filed on February 16, 2016.</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated
    by reference to Exhibit 3.01 to the Company&rsquo;s Form SB-2 filed on June 28, 2002</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated
    by reference to Exhibit 3.02 to the Company&rsquo;s Form SB-2, filed on June 28, 2002</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated
    by reference to Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K, filed on March 28, 2016.</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(5)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated
    by reference to Exhibit 10.2 the Company&rsquo;s Current Report of Form 8-K, filed on February 16, 2016.</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(6)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated
    by reference to Exhibit 99.1 to the Company&rsquo;s Current Report on Form 8-K, filed on June 9, 2016.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-6</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>fs12017a2iex5i_american.htm
<DESCRIPTION>LEGAL OPINION OF HUNTER TAUBMAN FISCHER & LI, LLC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex5i_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hunter
Taubman Fischer &amp; Li LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1450
Broadway, 26<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(917)
512-0827 Fax: (212) 202-6380</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
<U>ltaubman@huntertaubmanlaw.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
12, 2017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 534.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>American
BriVision (Holding) Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11
Sawyers Peak Drive</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goshen,
NY 10924</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to American BriVision (Holding) Corporation<B>,</B> a Nevada company (the &ldquo;Company&rdquo;), in connection
with the preparation and filing with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the
&ldquo;Act&rdquo;), of this Registration Statement on Form S-1 (the &ldquo;Registration Statement&rdquo;), relating to the proposed
sale by the selling shareholders listed therein (the &ldquo;Selling Shareholders&rdquo;) of 32,409,505 shares of the Company&rsquo;s
common stock (the &ldquo;Common Stock&rdquo;). &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
so acting, we have examined and relied upon the originals or copies, certified or otherwise identified to our satisfaction, of
such Company records, documents, certificates and other instruments as in our judgment are necessary or appropriate to enable
us to render the opinions expressed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the foregoing and such examination of law as we have deemed necessary, we are of the opinion that the Common Stock to be
offered by the Selling Shareholders, when sold under the circumstances contemplated in the Registration Statement, will be legally
issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
confirm that we furnish no opinion with respect to the truth and accuracy or the completeness of the Registration Statement. The
opinions we express herein are limited to matters involving the Nevada corporate laws and the federal laws of the United States
and are further expressly limited to the matters set forth herein and we render no opinion, whether by implication or otherwise,
as to any other matters relating to the Company, its securities or the Common Stock. Accordingly, no provision of this letter
is intended to be, nor shall any such provision be construed as, an opinion concerning any matter not specified in this letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinion specified in this letter is as of the date of this letter, and we assume no obligation to update or supplement that opinion,
if any applicable law changes after the date of this letter or if we become aware after the date of this letter of any fact, whether
existing before or occurring after the date of this letter, that might change the opinion specified in this letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the use of this letter as an Exhibit to the Registration Statement and to the use of our name under the heading &ldquo;Interest
of Named Experts and Counsel&rdquo; included in the Prospectus forming a part of the Registration Statement. In giving the foregoing
consent, we do not hereby admit that we are in the category of persons whose consent is required pursuant to Section 7 of the
Securities Act of 1933, or the rules and regulations of the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/
Hunter Taubman Fischer &amp; Li LLC</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hunter
Taubman Fischer &amp; Li LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>fs12017a2iex10iii_american.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT WITH KIRA HUANG
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.3</B></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>American
BriVision (Holding) Corporation Employment Agreement </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
AGREEMENT made as of the First day of February, 2016 , between <U>American BriVision (Holding) Corporation</U>, a corporation
incorporated under the laws of the State of Nevada, U.S.A. , and having its principal place of business at Taipei, Taiwan Republic
of China ROC (the &quot;Employer&quot;); and <U>Fan-Ling (Kira) Huang,</U> (the &quot;Employee&quot;). WHEREAS the Employer desires
to obtain the benefit of the services of the Employee, and the Employee desires to render such services on the terms and conditions
set forth. IN CONSIDERATION of the promises and other good and valuable consideration (the sufficiency and receipt of which are
hereby acknowledged) the parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Employment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employee agrees that at all times faithfully, industriously, and to the best of skill, ability, experience and talents, perform
all of the duties required of job position. In carrying out these duties and responsibilities, the Employee shall comply with
all Employer policies, procedures, rules and regulations, both written and oral, as are announced by the Employer from time to
time. It is also understood and agreed to by the Employee that his assignment, duties and responsibilities and reporting arrangements
may be changed by the Employer in its sole discretion without causing termination of this agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Position</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
as Chief Financial Officer, the Employee is required to perform duties and undertake the following responsibilities in a professional
manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&ndash; Report all the financials related matters to Company Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
&ndash; Develop financial planning and oversee tax reporting activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
&ndash; Monitor and submit all required reports to SEC on timely basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
&ndash; Plan and oversee annual budgets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
&ndash; Other duties as may arise from time to time and as may be assigned to the employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Compensation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
As full compensation for all services provided the employee shall be paid at the rate of USD 4,500 per month. Such payments shall
be subject to such normal statutory deductions by the Employer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -5.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Additional bonus calculations or stock options issuance will be determined regularly by Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The salary mentioned in paragraph 3 (a) shall be review on an annual basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
All reasonable expenses arising out of employment shall be reimbursed assuming same have been authorized prior to being incurred
and with the provision of appropriate receipts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
Vacation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employee shall be entitled to vacations in the amount of 3 weeks per annum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
Benefits</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employer shall at its expense provide the Employee with the Health Plan that is currently in place or as may be in place from
time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
Probation Period</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is understood and agreed that the first thirty days of employment shall constitute a probationary period during which period the
Employer may, in its absolute discretion, terminate the Employee's employment, for any reason without notice or cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
Performance Reviews</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employee may be provided with a written performance appraisal at least once per year and said appraisal will be reviewed at which
time all aspects of the assessment can be fully discussed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
Termination</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Employee may at any time terminate this agreement and his employment by giving not less than three weeks written notice to
the Employer. (b) The Employer may terminate this Agreement and the Employee&rsquo;s employment at any time, without notice or
payment in lieu of notice, for sufficient cause. (c) The Employer may terminate the employment of the Employee at any time without
the requirement to show sufficient cause pursuant to (b) above, provided the Employer pays to the Employee an amount as required
by the government legislation as may be in effect at the time of termination. This payment shall constitute the employees entire
entitlement arising from said termination. (d) The employee agrees to return any employer property at the time of termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
Laws</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
agreement shall be governed by the laws of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
Entire Agreement This agreement contains the entire agreement between the parties, superseding in all respects any and all prior
oral or written agreements or understandings pertaining to the employment of the Employee by the Employer and shall be amended
or modified only by written instrument signed by both of the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
Severability The parties hereto agree that in the event any article or part thereof of this agreement is held to be unenforceable
or invalid then said article or part shall be struck and all remaining provision shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF the Employer has caused this agreement to be executed by its duly authorized officers and the Employee has set
his hand as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED,
SEALED AND DELIVERED in the presence of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fan
    Ling (Kira) Huang</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-top: 0pt; padding-right: 0pt; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-indent: 0pt">/s/
    Kira Huang</TD>
    <TD STYLE="padding: 0pt 0pt 1.5pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    of Employee</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>American BriVision (Holding) Corporation</TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-top: 0pt; padding-right: 0pt; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-indent: 0pt">/s/
    Eugene Jiang</TD>
    <TD STYLE="padding: 0pt 0pt 1.5pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 39%">Eugene Jiang</TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 55%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&nbsp;</TD>
    <TD>CEO</TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>fs12017a2iex23i_american.htm
<DESCRIPTION>CONSENT OF CENTURION ZD CPA LIMITED
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="ex23i_002.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/11.25pt Times New Roman, Times, Serif; margin: 30.1pt 0 0; text-align: center"><B><U>INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM&rsquo;S CONSENT</U></B></P>

<P STYLE="font: 10pt/11.75pt Times New Roman, Times, Serif; margin: 23.35pt 0 0; text-align: justify">We consent to the inclusion
in this Registration Statement of American BriVision (Holding) Corp (the &ldquo;Company&rdquo;) on Form S-1/A (Amendment no.2)
, of our report dated January 11, 2017, which includes an explanatory paragraph as to the Company&rsquo;s ability to continue as
a going concern, with respect to our audit of the financial statements of the Company as of September 30, 2016 and 2015 and for
the years then ended, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to
the reference to our Firm under the heading &ldquo;Experts&rdquo; in such Prospectus.</P>

<P STYLE="font: 10pt/11.75pt Times New Roman, Times, Serif; margin: 70.5pt 0 0">/s/ Centurion ZD CPA Limited</P>

<P STYLE="font: 10pt/11.75pt Times New Roman, Times, Serif; margin: 0">Certified Public Accountants (Practising)</P>

<P STYLE="font: 10pt/11.75pt Times New Roman, Times, Serif; margin: 0">Hong Kong</P>

<P STYLE="font: 10pt/11.75pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">Dated: January 11, 2017</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>mtoo-20160930.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 8.0.0.0 [01/13/2017 03:22:29 AM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Friday, January 13, 2017 03:22:45 AM -->
<xbrli:xbrl xmlns:mtoo="http://metuboutique.com/20160930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="mtoo-20160930.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_As_Of_20_Jul_2015T00_00_00_TO_20_Jul_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-07-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Jul_2015T00_00_00_TO_20_Jul_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-07-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Jul_2015T00_00_00_TO_20_Jul_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-07-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Jul_2015T00_00_00_TO_20_Jul_2015T00_00_00_StatementEquityComponentsAxis_SubscriptionReceivableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mtoo:SubscriptionReceivableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-07-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Jul_2015T00_00_00_TO_20_Jul_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-07-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_SubscriptionReceivableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mtoo:SubscriptionReceivableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-21
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-21
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-21
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_SubscriptionReceivableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mtoo:SubscriptionReceivableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-21
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-21
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Oct_2015T00_00_00_TO_30_Oct_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-10-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_29_Dec_2015T00_00_00_TO_29_Dec_2015T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-29
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_26_Dec_2015T00_00_00_TO_29_Dec_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-12-26
</xbrli:startDate>
<xbrli:endDate>
2015-12-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_08_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mtoo:ShareExchangeAgreementTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-02-08
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_08_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mtoo:ShareExchangeAgreementFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-02-08
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mtoo:ShareExchangeAgreementTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-02-04
</xbrli:startDate>
<xbrli:endDate>
2016-02-08
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mtoo:ShareExchangeAgreementFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-02-04
</xbrli:startDate>
<xbrli:endDate>
2016-02-08
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mtoo:ShareExchangeAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-02-04
</xbrli:startDate>
<xbrli:endDate>
2016-02-08
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mtoo:ShareExchangeAgreementOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-02-04
</xbrli:startDate>
<xbrli:endDate>
2016-02-08
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mtoo:ShareExchangeAgreementThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-02-04
</xbrli:startDate>
<xbrli:endDate>
2016-02-08
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_10_Feb_2016T00_00_00_TO_17_Feb_2016T00_00_00_PlanNameAxis_EquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtoo:EquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-02-10
</xbrli:startDate>
<xbrli:endDate>
2016-02-17
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_21_Mar_2016T00_00_00_TO_21_Mar_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-21
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_20_Mar_2016T00_00_00_TO_21_Mar_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-03-20
</xbrli:startDate>
<xbrli:endDate>
2016-03-21
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_06_May_2016T00_00_00_TO_06_May_2016T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-05-06
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_05_May_2016T00_00_00_TO_06_May_2016T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-05-05
</xbrli:startDate>
<xbrli:endDate>
2016-05-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_26_Aug_2016T00_00_00_TO_26_Aug_2016T00_00_00_LegalEntityAxis_BioliteIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mtoo:BioliteIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-08-26
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2016T00_00_00_TO_26_Aug_2016T00_00_00_LegalEntityAxis_BioliteIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mtoo:BioliteIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-08-01
</xbrli:startDate>
<xbrli:endDate>
2016-08-26
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_SubscriptionReceivableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mtoo:SubscriptionReceivableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_SubscriptionReceivableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mtoo:SubscriptionReceivableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevEkirxw;6c444c555cT{h>IEE<64;918EFI18JI71F5;<1J:I8F6==G;G9 -->
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">American BriVision (Holding) Corp</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">0001173313</dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">true</dei:AmendmentFlag>
<dei:AmendmentDescription contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a) may determine.</dei:AmendmentDescription>
<dei:DocumentType contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">S-1</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">2016-09-30</dei:DocumentPeriodEndDate>
<dei:EntityFilerCategory contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_20_Jul_2015T00_00_00_TO_20_Jul_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">994830</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">173537</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3815</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">998645</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">173537</us-gaap:AssetsCurrent>
<us-gaap:DepositsAssetsNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3815</us-gaap:DepositsAssetsNoncurrent>
<us-gaap:DepositsAssetsNoncurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">3815</us-gaap:DepositsAssetsNoncurrent>
<us-gaap:AssetsNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3815</us-gaap:AssetsNoncurrent>
<us-gaap:AssetsNoncurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1002460</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">177352</us-gaap:Assets>
<us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">18370</us-gaap:AccountsPayableCurrentAndNoncurrent>
<us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">38100</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:AccountsPayableOtherCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">300000</us-gaap:AccountsPayableOtherCurrentAndNoncurrent>
<us-gaap:AccountsPayableOtherCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">22517</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="Context_As_Of_29_Dec_2015T00_00_00_TO_29_Dec_2015T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember" unitRef="USD" decimals="0">100000000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">46586</us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent>
<us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:Liabilities contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">369103</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">56470</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">166274</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">210822</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1132685</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">4733401</us-gaap:AdditionalPaidInCapital>
<us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">350000</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
<us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="Context_As_Of_30_Oct_2015T00_00_00_TO_30_Oct_2015T00_00_00" unitRef="USD" decimals="INF">-350000</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
<us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-315602</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-4823401</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_20_Jul_2015T00_00_00_TO_20_Jul_2015T00_00_00" unitRef="USD" decimals="0">897001</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_20_Jul_2015T00_00_00_TO_20_Jul_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">159623</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_20_Jul_2015T00_00_00_TO_20_Jul_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1087378</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_20_Jul_2015T00_00_00_TO_20_Jul_2015T00_00_00_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="0">-350000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_20_Jul_2015T00_00_00_TO_20_Jul_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">633357</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">166274</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1132685</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="0">-350000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-315602</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">120882</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">210822</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4733401</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-4823401</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1002460</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">177352</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_21_Mar_2016T00_00_00_TO_21_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_26_Aug_2016T00_00_00_TO_26_Aug_2016T00_00_00_LegalEntityAxis_BioliteIncMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">360000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_21_Mar_2016T00_00_00_TO_21_Mar_2016T00_00_00" unitRef="shares" decimals="INF">360000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">360000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">166273921</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">210821647</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF" id="Footnote-1_1">166273921</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF" id="Footnote-1_2">210821647</us-gaap:CommonStockSharesOutstanding>
<us-gaap:Revenues contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:Revenues contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CostOfRevenue contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CostOfRevenue contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">32</us-gaap:CostOfRevenue>
<us-gaap:GrossProfit contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GrossProfit contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-32</us-gaap:GrossProfit>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">315602</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">4497263</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:OperatingIncomeLoss contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-315602</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-4497295</us-gaap:OperatingIncomeLoss>
<us-gaap:InvestmentIncomeInterest contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InvestmentIncomeInterest contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">361</us-gaap:InvestmentIncomeInterest>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">141</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:InterestExpense contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestExpense contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">10170</us-gaap:InterestExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-9668</us-gaap:NonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-315602</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-4506963</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">836</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLoss contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-315602</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-315602</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-4507799</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-4507799</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="2">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="0">160823831</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="0">193981153</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_20_Jul_2015T00_00_00_TO_20_Jul_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">159622964</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">166273921</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">210821647</us-gaap:SharesOutstanding>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">51958</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">6651</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">45307</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_05_May_2016T00_00_00_TO_06_May_2016T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember" unitRef="USD" decimals="0">900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_01_Aug_2016T00_00_00_TO_26_Aug_2016T00_00_00_LegalEntityAxis_BioliteIncMember" unitRef="USD" decimals="INF">1468750</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">3250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">2032</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3247968</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">6650957</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_05_May_2016T00_00_00_TO_06_May_2016T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember" unitRef="shares" decimals="INF">562500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">2031423</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<mtoo:StockIssuedDuringPeriodReceiptOfSubscriptionReceivable contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">350000</mtoo:StockIssuedDuringPeriodReceiptOfSubscriptionReceivable>
<mtoo:StockIssuedDuringPeriodReceiptOfSubscriptionReceivable contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<mtoo:StockIssuedDuringPeriodReceiptOfSubscriptionReceivable contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<mtoo:StockIssuedDuringPeriodReceiptOfSubscriptionReceivable contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" decimals="0">350000</mtoo:StockIssuedDuringPeriodReceiptOfSubscriptionReceivable>
<mtoo:StockIssuedDuringPeriodReceiptOfSubscriptionReceivable contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3815</us-gaap:IncreaseDecreaseInDepositOtherAssets>
<us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<mtoo:IncreaseDecreaseInPrepayment contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3815</mtoo:IncreaseDecreaseInPrepayment>
<mtoo:IncreaseDecreaseInPrepayment contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-3815</mtoo:IncreaseDecreaseInPrepayment>
<us-gaap:IncreaseDecreaseDueFromAffiliates contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-46586</us-gaap:IncreaseDecreaseDueFromAffiliates>
<us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">300000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
<us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-300000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
<us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">22517</us-gaap:IncreaseDecreaseInDueToRelatedParties>
<us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-22517</us-gaap:IncreaseDecreaseInDueToRelatedParties>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">18370</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">38100</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-517</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-3474707</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">46586</us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders>
<us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-46586</us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">948959</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">2350000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">995545</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">2653414</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">994830</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-821293</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:InterestPaid contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaid contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;1. ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company&amp;#8217;s operating company, American BriVision Corporation (&amp;#8220;BriVision&amp;#8221;), was incorporated in July 2015 in the State of Delaware. It is a biotechnology company focused on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center (&amp;#8220;MSKCC&amp;#8221;) and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept (&amp;#8220;POC&amp;#8221;), out-license to international pharmaceutical companies, and exploit global markets.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;1. ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;American BriVision (Holding) Corporation (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Holding entity&amp;#8221;), a Nevada corporation, thru the Company&amp;#8217;s operating entity, American BriVision Corporation (&amp;#8220;BriVision&amp;#8221;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs. &amp;#160;The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center (&amp;#8220;MSKCC&amp;#8221;) and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept (&amp;#8220;POC&amp;#8221;), out-license to international pharmaceutical companies, and exploit global markets. BriVision had to predecessor operations prior to its formation on July 21, 2015.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;REVERSE MERGER&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;On February 8, 2016, a Share Exchange Agreement (&amp;#8220;Share Exchange Agreement&amp;#8221;) was entered into by and among American BriVision (Holding) Corporation (the&amp;#160;&amp;#8220;Company&amp;#8221;), American BriVision Corporation&amp;#160;(&amp;#8220;BriVision&amp;#8221;), Euro-Asia Investment &amp;amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People's Republic of China (&amp;#8220;Euro-Asia&amp;#8221;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of the Company(the&amp;#160;&amp;#8220;BriVision Stock&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the&amp;#160;&amp;#8220;Acquisition Stock&amp;#8221;) (subject to adjustment for fractionalized shares as set forth below) of the Company&amp;#8217;s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&amp;#8217;s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times
 new roman',
 times, serif; font-stretch: normal;"&gt;Pursuant to the Merger, all of the issued and outstanding shares of BriVision&amp;#8217;s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583pre-stock split) shares of Company&amp;#8217;s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company&amp;#8217;s common stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company&amp;#8217;s common stock,&amp;#160;Because of the exchange of the BriVision Stock for the Acquisition Stock (the&amp;#160;&amp;#8220;Share Exchange&amp;#8221;), BriVision became a wholly owned subsidiary (the &amp;#8220;Subsidiary&amp;#8221;) of the Company and there was a change of control of the Company following the closing.&amp;#160;&amp;#160;There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Because&amp;#160;of the consummation of the Share Exchange,&amp;#160;BriVision&amp;#160;is now our wholly owned subsidiary and its shareholders own approximately&amp;#160;79.70% of our issued and outstanding common stock.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 40.2pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Following the Share Exchange, we have abandoned our prior business plan and we are now pursuing&amp;#160;BriVision&amp;#8217;s&amp;#160;historical businesses and proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs.&amp;#160;&amp;#160;The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (&amp;#8220;POC&amp;#8221;), out-license to international pharmaceutical companies, and exploit global markets.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 40.2pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Accounting Treatment of the Reverse Merger&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;For financial reporting purposes, the Share Exchange represents a&amp;#160;&amp;#8220;reverse merger&amp;#8221;&amp;#160;rather than a business combination and&amp;#160;BriVision&amp;#160;is deemed the accounting acquirer in the transaction. The&amp;#160;Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision&amp;#160;is the acquirer for financial reporting purposes and the&amp;#160;Company&amp;#160;is the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of&amp;#160;BriVision&amp;#160;and recorded at the historical cost basis of&amp;#160;BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of&amp;#160;BriVision&amp;#160;and operations of the Combined Company from the closing date of the Share Exchange.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Basis of Presentation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The accompanying audited financial statements and related notes have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&amp;#8217;s financial statements are expressed in U.S. dollars.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Fair Value Measurements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company applies the provisions of ASC Subtopic 820-10,&amp;#160;&amp;#8220;Fair Value Measurements&amp;#8221;,&amp;#160;for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.&amp;#160;&amp;#160;ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal;
 background-color:
 white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&amp;#160;&amp;#160;When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 32px; text-align: justify;"&gt;&amp;#9679;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 32px; text-align: justify;"&gt;&amp;#9679;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 32px; text-align: justify;"&gt;&amp;#9679;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of&amp;#160;September 30, 2015.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Cash and Cash Equivalents&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none;
 text-indent: 0px; letter-spacing: normal;
 word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2015, the Company&amp;#8217;s cash and cash equivalents amounted $994,830. All&amp;#160;of the Company&amp;#8217;s cash deposit is held in a financial institution located in Republic of China where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company accounts for income taxes using an asset and liability approach which allows for the recognition and measurement of deferred tax assets based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before the Company is able to realize their benefits, or that future deductibility is uncertain.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Under ASC 740, a tax position is recognized as a benefit only if it is &amp;#8220;more likely than not&amp;#8221; that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalties or interest relating to income taxes have been incurred during the period from July 22, 2015 (inception) to September 30, 2015. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Recent Accounting Pronouncements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color:
 #000000; text-transform: none; text-indent: 0px;
 letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;From time to time, new accounting standards are issued by the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The recent accounting standards are not expected to have a material impact on the consolidated financial statements upon adoption.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
<us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Basis of Presentation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States ("U.S. GAAP").&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&amp;#8217;s financial statements are expressed in U.S. dollars.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Forward Stock split&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority
 of the
 shareholders of the Company approved the amendment to Articles of Incorporation.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Fair Value Measurements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company applies the provisions of ASC Subtopic 820-10,&amp;#160;&amp;#8220;Fair Value Measurements&amp;#8221;,&amp;#160;for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.&amp;#160;&amp;#160;ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&amp;#160;&amp;#160;When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#9679;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#9679;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#9679;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt;
 letter-spacing:
 normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of&amp;#160;September 30, 2016.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Cash and Cash Equivalents&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2016, the Company&amp;#8217;s cash and cash equivalents amounted $173,537. As of September 30, 2015, the Company&amp;#8217;s cash and cash equivalents amounted $994,830. All&amp;#160;of the Company&amp;#8217;s cash deposits are held in a financial institution located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 40.2pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 40.2pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Under ASC 740, a tax position is recognized as a benefit only if it is&amp;#160;&amp;#8220;more likely than not&amp;#8221;&amp;#160;that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized
 in the first subsequent
 financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred during the period from July 21, 2015 (inception) to September 30, 2015. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;As of September 30, 2016 and September 30, 2015, the Company&amp;#8217;s income tax expense amounted $836 and $0, respectively.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Recent Accounting Pronouncements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;From time to time, new accounting standards issued by the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) or other standard setting bodies are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The recent accounting standards are not expected to have a material impact on the consolidated financial statements upon adoption.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
<mtoo:GoingConcernDisclosureTextBlock contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;3. GOING CONCERN&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since its inception resulting in an accumulated deficit of $315,602 as of September 30, 2015. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. These combined financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company expects to finance operations primarily through cash flow from revenue and capital contributions from principal shareholders. In the event that we require additional funding to finance the growth of the Company&amp;#8217;s current and expected future operations as well as to achieve our strategic objectives, our principal shareholders have indicated the intent and ability to provide additional equity financing.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;These conditions raise substantial doubt about the Company&amp;#8217;s ability to continue as a going concern. The Company&amp;#8217;s continuation as a going concern is dependent on our ability to meet obligations as they become due and to obtain additional equity or alternative financing required to fund operations until sufficient sources of recurring revenues can be generated. There can be no assurance that the Company will be successful in its plans described above or in attracting equity or alternative financing on acceptable terms, or if at all. The financial statements do not include any adjustments that might result from the outcome of this- uncertainty.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</mtoo:GoingConcernDisclosureTextBlock>
<mtoo:GoingConcernDisclosureTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;3. GOING CONCERN&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since its inception resulting in an accumulated deficit of $4,823,401 as of September 30, 2016. The Company also incurred net losses of $4,507,799 and negative cash flow of $821,293 during the year ended September 30, 2016. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. These combined financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company expects to finance operations primarily through capital contributions from principal shareholders. In the event that we require additional funding to finance the growth of the Company&amp;#8217;s current and expected future operations as well as to achieve our strategic objectives, our principal shareholders have indicated the intent and ability to provide additional equity financing.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;These conditions raise substantial doubt about the Company&amp;#8217;s ability to continue as a going concern. The Company&amp;#8217;s continuation as a going concern is dependent on our ability to meet obligations as they become due and to obtain additional equity or alternative financing required to fund operations until sufficient sources of recurring revenues can be generated. There can be no assurance that the Company will be successful in its plans described above or in attracting equity or alternative financing on acceptable terms, or if at all. The financial statements do not include any adjustments that might result from the outcome of this- uncertainty.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</mtoo:GoingConcernDisclosureTextBlock>
<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;4. COLLABORATIVE AGREEMENT&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;On December 29, 2015, American BriVision Corporation entered into a Collaborative Agreement with BioLite Inc., a related party, pursuant to which BioLite granted the Company sole licensing rights for drug and therapeutic use of five products: BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia, in USA and Canada. Under the Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of BriVision with equivalent value, according to the following schedule:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td style="width: 0.5in; font-family: calibri, sans-serif; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.3in; text-align: left; font-family: calibri, sans-serif; vertical-align: top;"&gt;&amp;#9679;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;"&gt;upfront payment shall upon the signing of this Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-family: calibri, sans-serif; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-family: calibri, sans-serif; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;"&gt;upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-family: calibri, sans-serif; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-family: calibri, sans-serif; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;"&gt;at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-family: calibri, sans-serif; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-family: calibri, sans-serif; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;"&gt;upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-family: calibri, sans-serif; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-family: calibri, sans-serif; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;"&gt;at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-family: calibri, sans-serif; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr
 style="vertical-align: bottom;"&gt;&lt;td style="font-family:
 calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="font-family: 'times new roman', serif;"&gt;upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Collaborative Agreement is attached as an exhibit to the registration statement of which this prospectus is a part. The material terms of the Collaborative Agreement are as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company is responsible to make up-front, milestone and royalty payments to BioLite, as described in the foregoing paragraph and below.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;As between BioLite and ABVC, BioLite owns all files, data, confidential and non-public information, including, without limitation, all IND packages and clinical study reports, regarding the Compounds (collectively, the &amp;#8220;Compound IP&amp;#8221;), to the extent developed in Taiwan, and the Company owns all Compound IP to the extent developed in North America. BioLite grants an exclusive license to its Compound IP to the Company for the purpose of further development and commercialization of the Compounds in North America. BioLite and the Company share the responsibility of preparing for clinical trials by delivering Compound IP and preparing related materials.&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company is responsible for all clinical trial expenses incurred in North America.&amp;#160;&amp;#160;BioLite paid all clinical trial expenses for trials conducted in Taiwan thus far.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Collaborative Agreement will remain in effect for fifteen years from the date of first commercial sale of Product in the U.S. or Canada. Either party may terminate upon thirty
 days&amp;#8217; prior written notice for breach or insolvency.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company agreed to pay to BioLite an aggregate of One Hundred Million Dollars ($100,000,000) (the &amp;#8220;Aggregate Amount&amp;#8221;) in milestone payments during the term of the agreement, payable in cash or Company equity. A percentage of the Aggregate Amount will be paid to BioLite upon each completion of a milestone by BioLite as set forth in the Collaborative Agreement. An upfront payment of $3,500,000 (the &amp;#8220;Milestone Payment&amp;#8221;), which is 3.5% of total payments due under the Collaborative Agreement, was to be paid by us upon signing of the Collaboration Agreement. On May 6, 2016, we and BioLite amended the payment terms under the Collaborative Agreement by entering into a Milestone Payment Agreement, pursuant to which we paid $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Milestones are reached by BioLite upon submissions of IND and NDAs for the Products, and completion of phases in the application processes, as set forth in the Collaborative Agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In addition to the Aggregate Amount, the Company will pay to BioLite five percent (5%) of net sales of Products in the U.S. and Canada.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Our&amp;#160;Licensed Compound&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;We have renamed the five
 compounds for our purposes and include below a brief description of each of the five compounds.&lt;/font&gt;&lt;/p&gt;&lt;p style="font:
 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;I.&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;ABV- 1501 &amp;#160;Triple Negative Breast Cancer - Combination therapy for Triple Negative Breast Cancer (TNBC)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Maitake mushroom extract Phase I clinical trial was performed by MSKCC.&amp;#160;&amp;#160;&amp;#8220;A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects:&amp;#8221; &amp;#8220;No dose-limiting toxicity was encountered. Oral administration of a polysaccharide extract from Maitake mushroom is associated with both immunologically stimulatory and inhibitory measurable effects in peripheral blood.&amp;#160;&amp;#160;Cancer patients should be made aware of the fact that botanical agents produce more complex effects than assumed, and may depress as well as enhance immune function&amp;#8221;.&amp;#160;&amp;#160;The IND number is 68853 and MSKCC received filing confirmation from the FDA on Jan 22, 2004.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;ABV-1501 US FDA Phase II IND cross reference with MSKCC Maitake and Phase II Investigational New Drug (IND) was approved in March 2016.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;We are currently negotiating with MSKCC for Phase II clinical study. If MSKCC agreed with our terms, we anticipate to start phase II clinical trial during 2017 Q1and finish the phase II clinical trial by 2018 Q3.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch:
 normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new
 roman', times, serif; width: 0.5in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;BioLite has received approval from Institutional Review Board and (IRB) of Taipei Medical University in September 2016 in Taiwan&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 90pt; color: #000000; text-transform: none; text-indent: -18pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 90pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font: 10pt/normal calibri, sans-serif; width: 0.25in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, sans-serif; width: 0.25in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;II.&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, sans-serif; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;ABV-1502 &amp;#160;Solid Tumor with Anti-PD1 - Combination therapy for solid tumors with Anti-PD-1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal calibri, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.3in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;This is a kind of anti-tumor Combination therapy of Maitake mushroom extract with standard therapy and anti- PD1 drug for solid tumor.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;Maitake mushroom extract Phase I clinical trial was performed by MSKCC.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;Currently, we are cooperating with MD Anderson Cancer Center and one of the top cancer centers in the U.S. to develop Phase II clinical trial IND package.&amp;#160;&amp;#160;Due to confidentiality obligations, we are not permitted to disclose the name of such cancer center at this time.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal calibri, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.25in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;III.&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt;
 padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;ABV-1503 &amp;#160;Chronic Lymphocytic Leukemia - Combination therapy for Chronic Lymphocytic Leukemia
 (CLL)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal calibri, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.3in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;Phase II study of Epigallocatechin gallate (EGCG) for CLL.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;We are cooperating with MSKCC to prepare clinical trial agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;We are currently preparing the IND package.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal calibri, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.25in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;IV.&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;ABV-1504 &amp;#160;Major Depressive Disorder - Major Depressive Disorder (MDD)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal calibri, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.3in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;This is Polygala extract for Major Depressive Disorder&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;BioLite performed Phase I clinical trial.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt;
 padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt;
 padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;BioLite has obtained US FDA Phase II Part One/Part Two IND approval and the Phase II Part One was completed with good result.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; font-stretch: normal;"&gt;For ABV-1504 Phase II part one results are described below.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; font-stretch: normal;"&gt;Phase II part two: this phase currently is conducted in 5 clinical sites in Taiwan (started in Q3 2016) and one US site is under IRB review.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal calibri, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;V.&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;ABV-1505 &amp;#160;Attention Deficit Hyperactivity Disorder - Attention Deficit Hyperactivity Disorder&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;This is Polygala extract for Attention Deficit Hyperactivity Disorder.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Same Active Pharmaceutical Ingredients (API) with ABV-1504.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;BioLite has obtained U.S. FDA Phase II IND approval and is currently negotiating with top medical site for Phase II clinical trial.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;BioLite intends to submit for IRB approval during 2016 Q4&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif;
 width: 0.5in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;
 font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;BioLite plans to start Phase II clinical trial during 2017 Q1 and complete by 2018 Q3.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;ABV-1501 and ABV-1502 have the same Active Pharmaceutical Ingredient:&amp;#8221; Maitake mushroom extract&amp;#8221;. IND and study details are as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Phase I/II clinical trial was conducted by MSKCC. A total of 34 eligible study subjects was enrolled from 3/2004 to 1/2007. The primary endpoints were safety and tolerability. The test drug was oral administration and a polysaccharide extract from Maitake mushroom is associated with both immunologically stimulatory and inhibitory measurable effects in peripheral blood. Cancer patients should be made aware of the fact that botanical agents produce more complex effects than assumed, and may depress as well as enhance immune function. (&lt;u&gt;A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects by Gary Deng &amp;#183; Hong Lin &amp;#183; Andrew Seidman &amp;#183; Monica Fornier &amp;#183; Gabriella D&amp;#8217;Andrea &amp;#183;Kathleen Wesa &amp;#183; Simon Yeung &amp;#183; Susanna Cunningham Rundles &amp;#183;Andrew J. Vickers &amp;#183; Barrie Cassileth; J Cancer Res Clin Oncol (2009) 135:1215&amp;#8211;1221.&lt;/u&gt;) The IND number is&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;68853 and MSKCC received filing confirmation from the FDA on Jan 22, 2004&lt;/font&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: -18pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients&amp;#63; A Phase II clinical trial.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Primary endpoint: To describe changes in neutrophil counts and neutrophil function in MDS patients following administration of Maitake mushroom extract.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;This study to see whether Maitake improves the neutrophil count and function in
 patients with MDS. The neutrophils are white blood cells which help to fight infection.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal;
 -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Total 45 subjects.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Start Date: April 2010&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Completion Date: September 2014&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Sponsor: Memorial Sloan Kettering Cancer Center&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Collaborator: YUKIGUNI COMPANY&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Collaborator: Weill Medical College of Cornell University&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Principal Investigator: Kathleen Wesa, MD Memorial Sloan Kettering Cancer Center&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Full Source of Clinical Trial Data: https://clinicaltrials.gov/show/NCT01099917&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Normally, for non-cancer patients, phase I clinical trials are performed with healthy subjects to test for safety and phase II clinical trials are performed with healthy patient subjects for efficacy. But for cancer patients, however, trials of cancer drugs must necessarily involve subjects with cancer, and as such, phase I/II studies include primary endpoints relating to safety and tolerability, not efficacy.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;For &amp;#8220;Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients&amp;#63; A Phase II clinical trial,&amp;#8221; conclusions are described as follows: &amp;#8220;Maitake was well tolerated. Enhanced in vitro neutrophil and monocyte function following treatment demonstrate that Maitake has beneficial immunomodulatory potential in MDS. Further study is warranted&amp;#8221;.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Page 32 of the journal article, &amp;#8220;Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients&amp;#63;&amp;#8221; indicates that there were 45 subjects were enrolled at the beginning of the study, 18 subjects completed treatment, 3 subjects had adverse effects and 24 subjects were not treated.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify;
 color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; text-indent: 0pt; padding-right: 0px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.3in; text-align: justify; text-indent: 0pt; padding-right: 0px; padding-left: 0pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; text-indent: 0pt; padding-right: 0px; padding-left: 0pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Hematopoiesis: is the formation of blood cellular components. All cellular blood components are derived from haematopoietic stem cells. In a healthy adult person, approximately 1011&amp;#8211;1012 new blood cells are produced daily in order to maintain steady state levels in the peripheral circulation (Wikipedia).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; text-indent: 0pt; padding-right: 0px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; text-indent: 0pt; padding-right: 0px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; text-indent: 0pt; padding-right: 0px; padding-left: 0pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; text-indent: 0pt; padding-right: 0px; padding-left: 0pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Myelodysplastic: are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells (Medscape). Myelodysplastic syndromes are a group of disorders caused by poorly formed or dysfunctional blood cells. Myelodysplastic syndromes occur when something goes wrong in your bone marrow &amp;#8212; the spongy material inside your bones where blood cells are made. Treatment for myelodysplastic syndromes usually focuses on reducing or preventing complications of the disease and its treatments. In certain cases, myelodysplastic syndromes are treated with a bone marrow transplant (Mayo Clinic).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;For ABV-1503, we are currently preparing the IND package. BioLite is preparing the Compound IP for the Chemistry, Manufactural, and Control (CMC) part, MSKCC and the Company are collaborating to prepare for protocol design and prepare the IRB documents. The trial period, test subject number, primary and secondary endpoint and method of administration have not been decided yet, and are still being negotiated between we and MSKCC.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;ABV-1504 and ABV-1505 have the same Active Pharmaceutical Ingredient: the extract of Radix Polygalae (Polygala tenuifolia Willd/PDC-1421 Capsule). IND and study information are as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 24px; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 24px; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;A Dose Escalation Phase I Study of PDC-1421 Capsule to Evaluate the Safety in Healthy Volunteers.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;IND Number: 112567&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform:
 none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Trial period: 11/13/2012-7/5/2013, Final Report Date 11/12/2013&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt;
 text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Total 30 study subjects were enrolled. The test drug was oral administration. The primary endpoint is to assess the safety profile of PDC-1421 Capsule in healthy volunteers.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Sponsor: BioLite, Inc.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 24px; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 24px; text-align: justify; font-stretch: normal;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients with Major Depressive Disorder&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;IND Number: 112567&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Primary Study Objective: To assess the efficacy profile of PDC-1421 Capsule in major depressive disorder with Montgomery-Asberg Depression Rating Scale (MADRS).&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Secondary Study Objective: To evaluate the efficacy and safety profile&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Study period: 2 years.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Total 72 study subjects will be enrolled.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Study site: There are five sites in Taiwan and one site in US (Stanford University, which is currently preparing for IRB approval and Clinical Trial Agreement.)&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Sponsor: BioLite, Inc.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;For ABV-1504 Phase II part one---total subject: 12, trial period: 2/11/2016-7/14/2016, administered route: oral, test results are as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width:
 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Trial Progress Report:&lt;/font&gt;&lt;/p&gt;&lt;p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1. Part I trial has been completed with 12 subjects (screening: 14, enrolling: 12). The six subjects were in the Part I high dosage group.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2. Under the suicide risk assessment (C-SSRS) Subject X indicated that the suicidal ideation scores were 4 for both Visit 7 and Visit 8. The PI confirmed that the subject had external pressures (moving, etc.), which produced constant suicidal thoughts, and such observation was reflected in Dr. A&amp;#8217;s (PI) evaluation. The subject expressed his/her intention to stay positive in a counseling session, and the subject was contacted by a researcher (Research Nurse) after leaving the facility. After reviewing by the researcher, a justification was made that the suicidal behavior was irrelevant to the drug administered.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;3. Clinical data of the six high-dosage administered subjects with data exceeding normal value:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 20pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;- NCS- Non-Clinical Significant judged by PI. CS: Clinical Significant judged by PI.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 20pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-After data safety review board carefully reviewed, they agree to proceed to part two clinical trial.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;For ABV-1504 Phase II part two: this phase currently is conducted in 5 clinical sites in Taiwan (started in Q3 2016) and one US site is under IRB review.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;For &amp;#8220;A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression:&amp;#8221; Trial period: 11/13/2012-7/5/2013, final report date 11/12/2013. Enroll subject: 30, 23 PDC-1421, 7 placebo control.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Study Conclusions:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align:
 justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1;
 font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#8220;(1) No subject had serious adverse event and no subject discontinued due to adverse event;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;(2) No clinically significant findings were observed in physical examinations; vital signs,&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;electrocardiograms, laboratory measurements, and C-SSRS were observed throughout the treatment period;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;(3) The oral administration of PDC-1421 in healthy volunteers was safe and well-tolerated for the dose from 380 mg to 3800 mg&amp;#8221;.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;For &amp;#8220;A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients with Major Depressive Disorder&amp;#8221;:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Part One- study period 2/11/2016-7/12/2016. Total subject: 12&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Maitake mushroom extract is sourced from YUKIGUNI COMPANY, Japan, and processed by YUSHENG PHARMACEUTICAL COMPANY in Taiwan (cGMP).&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The extract of Radix Polygalae (Polygala tenuifoliaWilld/PDC-1421 Capsule) is purchased from HERNG FA PHARMACEUTICAL TECHNOLOGY, and processed by Industrial Technology Research Institute (ITRI). There are no limits on availability to the Company on any of these ingredients.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Pursuant to the Collaborative Agreement, an upfront payment of $3,500,000 (the &amp;#8220;Milestone Payment&amp;#8221;), which is 3.5% of total payments due under the Collaborative Agreement, was to be paid by the Company upon signing of that agreement. On May 6, 2016, we and BioLite agreed to amend the Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby we have agreed to pay the Milestone Payment to BioLite $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were
 completed in June 2016.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal
 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;This Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company determined to fully expense the entire amount of $3,500,000 since currently the related licensing rights do not have alternative future uses. . According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount is fully expensed as research and development expense.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;4. DUE TO RELATED PARTIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;As of September 30, 2015, the amount due to a related party, BioLite, Inc. (&amp;#8220;BioLite&amp;#8221;) was $22,517.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;As of September 30, 2015, the amount due to shareholder, YuanGene Corporation, was $46,586.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;5. RELATED PARTIES TRANSACTIONS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;As of September 30, 2016 and September 30, 2015, the amount due to a related party, BioLite, Inc (&amp;#8220;Biolite&amp;#8221;) was $0 and $22,517 respectively.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;As of September 30, 2016 and September 30, 2015, the amount due to shareholder, YuanGene Corporation, was $0 and $46,586 respectively.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;6. ACCOUNTS PAYABLE&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;As of September 30, 2016 and September 30, 2015, the amount of Accounts Payable to LiteArt, Inc. was $18,370 and $0 respectively.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;7. EQUITY&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;During October 2015, $350,000 of subscription receivable was fully collected from the shareholders.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;On February 8, 2016, a Share Exchange Agreement (&amp;#8220;Share Exchange Agreement&amp;#8221;) was entered into by and among American BriVision (Holding) Corporation (the&amp;#160;&amp;#8220;Company&amp;#8221;), American BriVision Corporation&amp;#160;(&amp;#8220;BriVision&amp;#8221;), Euro-Asia Investment &amp;amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People's Republic of China (&amp;#8220;Euro-Asia&amp;#8221;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the&amp;#160;&amp;#8220;BriVision Stock&amp;#8221;). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the&amp;#160;&amp;#8220;Acquisition Stock&amp;#8221;) (subject to adjustment for fractionalized shares as set forth below) of the Company&amp;#8217;s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&amp;#8217;s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision&amp;#8217;s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company&amp;#8217;s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company&amp;#8217;s common stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company&amp;#8217;s common stock,&amp;#160;Because of the exchange of the BriVision Stock for the Acquisition Stock (the&amp;#160;&amp;#8220;Share Exchange&amp;#8221;), BriVision became a wholly owned subsidiary (the &amp;#8220;Subsidiary&amp;#8221;) of the Company and there was a change of control of the Company following the closing.&amp;#160;&amp;#160;There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On February 17, 2016, pursuant to the 2016 Equity Incentive Plan (the &amp;#8220;2016 Plan&amp;#8221;), 157,050 (50,000 pre-stock split) shares were granted to the employees.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the &amp;#8220;Forward&amp;#160;Stock&amp;#160;Split&amp;#8221;) and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April
 8, 2016.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On May 6, 2016, we and BioLite agreed to amend the Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby we have agreed to issue shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of our first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;On August 26, 2016, the Company issued 1,468,750 shares (&amp;#8220;Shares&amp;#8221;) of the Company&amp;#8217;s common stock, par value $0.001 (the &amp;#8220;Offering&amp;#8221;) to BioLite, Inc., a non-U.S. accredited investor (the &amp;#8220;Purchaser&amp;#8221;) pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &amp;#8220;SPA&amp;#8221;). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;), pursuant to Regulation&amp;#160;S of the Securities Act promulgated thereunder. Our sole director, Eugene Jiang, is a director of BioLite and it is therefore considered a related party.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. The proceeds may be used for general corporate purposes.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:EarningsPerShareTextBlock contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;5. EARNINGS PER SHARE&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Basic earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted-average number of common shares and dilutive potential common shares outstanding during the period.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;For&amp;#160;the&amp;#160;period from July&amp;#160;21,&amp;#160;&lt;br /&gt;2015&amp;#160;&lt;br /&gt;(inception) to&lt;br /&gt;September 30,&lt;br /&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left;"&gt;Net income&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;(315,602&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Weighted-average shares outstanding&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Weighted-average shares outstanding - Basic&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;160,823,831&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Weighted-average shares outstanding - Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;160,823,831&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Earnings per share&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;-Basic&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;-Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style:
 double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt;
 border-bottom-style: double;"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Diluted earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
<us-gaap:EarningsPerShareTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;8. EARNINGS PER SHARE&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Basic earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted earnings per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the year.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 1.5pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&lt;b&gt;For&amp;#160;the&amp;#160;Year&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&lt;b&gt;Ended&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;For the period from&lt;br /&gt;&amp;#160;July 21,&amp;#160;&lt;br /&gt;2015&lt;br /&gt;&amp;#160;(Inception)&lt;br /&gt;&amp;#160;to September&amp;#160;30,&amp;#160;&lt;br /&gt;2015&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;Numerator:&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1191px; text-align: left;"&gt;Net loss&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;(4,507,799&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;(315,602&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;Denominator:&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Weighted-average shares outstanding:&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Weighted-average shares outstanding - Basic&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style:
 double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;193,981,153&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;160,823,831&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Stock options&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Weighted-average shares outstanding - Diluted&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;193,981,153&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;160,823,831&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;Earnings per share&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 4pt;"&gt;-Basic&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;0.02&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;0.00&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 4pt;"&gt;-Diluted&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;0.02&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;0.00&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Diluted earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;9. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Capital Commitment&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;On December 29, 2015, the Company entered into the agreement with Biolite, a related party, that Biolite would grant the Company sole licensing rights of a series of technology for 15 years. The total consideration of obtaining such grant would be $100,000,000.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Operating Commitment&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The total future minimum lease payments under the non-cancellable operating lease with respect to the office&amp;#160;as of September 30, 2016 are payable as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 384.25pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1379px;"&gt;Remaining 2016&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;5,948&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;Year ending September 30, 2017&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;23,793&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;Year ending September 30, 2018&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;17,845&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 4pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;47,586&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color:
 #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Rental expense of the Company was $29,129 and nil for the year ended September 30, 2016 and 2015, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;6. SUBSEQUENT EVENT&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;During October 2015, $350,000 of subscription receivable was fully collected from the shareholders.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;On December 29, 2015, the Company entered into the agreement with BioLite, a related party, that BioLite would grant the Company sole licensing rights of s series of technology for 10 years. The total consideration of obtaining such grant would be $100,000,000.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Reverse Merger&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;On February 8, 2016, a Share Exchange Agreement (&amp;#8220;Share Exchange Agreement&amp;#8221;) was entered into by and among American BriVision (Holding) Corporation (the&amp;#160;&amp;#8220;Company&amp;#8221;), American BriVision Corporation&amp;#160;(&amp;#8220;BriVision&amp;#8221;), Euro-Asia Investment &amp;amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People's Republic of China (&amp;#8220;Euro-Asia&amp;#8221;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the&amp;#160;&amp;#8220;BriVision Stock&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the&amp;#160;&amp;#8220;Acquisition Stock&amp;#8221;) (subject to adjustment for fractionalized shares as set forth below) of the Company&amp;#8217;s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&amp;#8217;s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color:
 #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Pursuant to the Merger, all of the issued and outstanding shares of BriVision&amp;#8217;s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company&amp;#8217;s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company&amp;#8217;s common stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company&amp;#8217;s common stock,&amp;#160;Because of the exchange of the BriVision Stock for the Acquisition Stock (the&amp;#160;&amp;#8220;Share Exchange&amp;#8221;), BriVision became a wholly owned subsidiary (the &amp;#8220;Subsidiary&amp;#8221;) of the Company and there was a change of control of the Company following the closing.&amp;#160;&amp;#160;There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Forward Stock Split&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000. The amendment to Articles of Incorporation was approved by the majority of the shareholders of the Company and became effective on April 8, 2016.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;10. SUBSEQUENT EVENT&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company evaluated and concluded that no subsequent events have occurred that would require recognition or disclosure in the consolidated financial statements.&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Basis of Presentation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The accompanying audited financial statements and related notes have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&amp;#8217;s financial statements are expressed in U.S. dollars.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Basis of Presentation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States ("U.S. GAAP").&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&amp;#8217;s financial statements are expressed in U.S. dollars.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
<us-gaap:UseOfEstimates contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
<mtoo:ForwardStockSplitPolicyTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Forward Stock split&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</mtoo:ForwardStockSplitPolicyTextBlock>
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Fair Value Measurements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company applies the provisions of ASC Subtopic 820-10,&amp;#160;&amp;#8220;Fair Value Measurements&amp;#8221;,&amp;#160;for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.&amp;#160;&amp;#160;ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&amp;#160;&amp;#160;When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 32px; text-align: justify;"&gt;&amp;#9679;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 32px; text-align: justify;"&gt;&amp;#9679;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:
 32px; text-align:
 justify;"&gt;&amp;#9679;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of&amp;#160;September 30, 2015.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Fair Value Measurements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company applies the provisions of ASC Subtopic 820-10,&amp;#160;&amp;#8220;Fair Value Measurements&amp;#8221;,&amp;#160;for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.&amp;#160;&amp;#160;ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&amp;#160;&amp;#160;When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#9679;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#9679;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#9679;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal;
 -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of&amp;#160;September 30, 2016.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Cash and Cash Equivalents&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2015, the Company&amp;#8217;s cash and cash equivalents amounted $994,830. All&amp;#160;of the Company&amp;#8217;s cash deposit is held in a financial institution located in Republic of China where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Cash and Cash Equivalents&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2016, the Company&amp;#8217;s cash and cash equivalents amounted $173,537. As of September 30, 2015, the Company&amp;#8217;s cash and cash equivalents amounted $994,830. All&amp;#160;of the Company&amp;#8217;s cash deposits are held in a financial institution located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company accounts for income taxes using an asset and liability approach which allows for the recognition and measurement of deferred tax assets based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before the Company is able to realize their benefits, or that future deductibility is uncertain.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Under ASC 740, a tax position is recognized as a benefit only if it is &amp;#8220;more likely than not&amp;#8221; that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalties or interest relating to income taxes have been incurred during the period from July 22, 2015 (inception) to September 30, 2015. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 40.2pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 40.2pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Under ASC 740, a tax position is recognized as a benefit only if it is&amp;#160;&amp;#8220;more likely than not&amp;#8221;&amp;#160;that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred during the period from July 21, 2015 (inception) to September 30, 2015. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;As of September 30, 2016 and September 30, 2015, the Company&amp;#8217;s income tax expense amounted $836 and $0, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Recent Accounting Pronouncements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;From time to time, new accounting standards are issued by the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The recent accounting standards are not expected to have a material impact on the consolidated financial statements upon adoption.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Recent Accounting Pronouncements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;From time to time, new accounting standards issued by the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) or other standard setting bodies are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The recent accounting standards are not expected to have a material impact on the consolidated financial statements upon adoption.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;For&amp;#160;the&amp;#160;period from July&amp;#160;21,&amp;#160;&lt;br /&gt;2015&amp;#160;&lt;br /&gt;(inception) to&lt;br /&gt;September 30,&lt;br /&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left;"&gt;Net income&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;(315,602&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Weighted-average shares outstanding&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Weighted-average shares outstanding - Basic&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;160,823,831&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Weighted-average shares outstanding - Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;160,823,831&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Earnings per share&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;-Basic&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;-Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 1.5pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&lt;b&gt;For&amp;#160;the&amp;#160;Year&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&lt;b&gt;Ended&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;For the period from&lt;br /&gt;&amp;#160;July 21,&amp;#160;&lt;br /&gt;2015&lt;br /&gt;&amp;#160;(Inception)&lt;br /&gt;&amp;#160;to September&amp;#160;30,&amp;#160;&lt;br /&gt;2015&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;Numerator:&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1191px; text-align: left;"&gt;Net loss&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;(4,507,799&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;(315,602&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;Denominator:&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Weighted-average shares outstanding:&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Weighted-average shares outstanding - Basic&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;193,981,153&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;160,823,831&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Stock options&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Weighted-average shares outstanding - Diluted&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;193,981,153&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom:
 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;160,823,831&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;Earnings per share&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 4pt;"&gt;-Basic&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;0.02&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;0.00&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 4pt;"&gt;-Diluted&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;0.02&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;0.00&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px;"&gt;Remaining 2016&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;5,948&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Year ending September 30, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;23,793&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Year ending September 30, 2018&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;17,845&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;47,586&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
<mtoo:CommonStockIssuedAfterStockSplit contextRef="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementTwoMember" unitRef="shares" decimals="INF">163159952</mtoo:CommonStockIssuedAfterStockSplit>
<mtoo:CommonStockIssuedAfterStockSplit contextRef="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementFourMember" unitRef="shares" decimals="INF">205519223</mtoo:CommonStockIssuedAfterStockSplit>
<mtoo:CommonStockIssuedAfterStockSplit contextRef="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementMember" unitRef="shares" decimals="INF">164387376</mtoo:CommonStockIssuedAfterStockSplit>
<mtoo:CommonStockIssuedAfterStockSplit contextRef="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementOneMember" unitRef="shares" decimals="INF">166273921</mtoo:CommonStockIssuedAfterStockSplit>
<mtoo:CommonStockIssuedAfterStockSplit contextRef="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementThreeMember" unitRef="shares" decimals="INF">166273921</mtoo:CommonStockIssuedAfterStockSplit>
<mtoo:CommonStockIssuedAfterStockSplit contextRef="Context_Custom_10_Feb_2016T00_00_00_TO_17_Feb_2016T00_00_00_PlanNameAxis_EquityIncentivePlanMember" unitRef="shares" decimals="0">157050</mtoo:CommonStockIssuedAfterStockSplit>
<mtoo:CommonStockIssuedBeforeStockSplit contextRef="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementTwoMember" unitRef="shares" decimals="INF">51945225</mtoo:CommonStockIssuedBeforeStockSplit>
<mtoo:CommonStockIssuedBeforeStockSplit contextRef="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementFourMember" unitRef="shares" decimals="INF">65431144</mtoo:CommonStockIssuedBeforeStockSplit>
<mtoo:CommonStockIssuedBeforeStockSplit contextRef="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementMember" unitRef="shares" decimals="INF">52336000</mtoo:CommonStockIssuedBeforeStockSplit>
<mtoo:CommonStockIssuedBeforeStockSplit contextRef="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementOneMember" unitRef="shares" decimals="INF">52936583</mtoo:CommonStockIssuedBeforeStockSplit>
<mtoo:CommonStockIssuedBeforeStockSplit contextRef="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementThreeMember" unitRef="shares" decimals="INF">52936583</mtoo:CommonStockIssuedBeforeStockSplit>
<mtoo:CommonStockIssuedBeforeStockSplit contextRef="Context_Custom_10_Feb_2016T00_00_00_TO_17_Feb_2016T00_00_00_PlanNameAxis_EquityIncentivePlanMember" unitRef="shares" decimals="0">50000</mtoo:CommonStockIssuedBeforeStockSplit>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_08_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementTwoMember" unitRef="pure" decimals="4">0.7970</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_08_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementFourMember" unitRef="pure" decimals="4">0.7970</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<mtoo:PercentageOfIssuedShareCapital contextRef="Context_As_Of_08_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementTwoMember" unitRef="pure" decimals="2">1.00</mtoo:PercentageOfIssuedShareCapital>
<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementThreeMember" unitRef="pure" decimals="4">0.2536</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
<us-gaap:StockholdersEquityReverseStockSplit contextRef="Context_Custom_20_Mar_2016T00_00_00_TO_21_Mar_2016T00_00_00">1 to 3:141</us-gaap:StockholdersEquityReverseStockSplit>
<us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;upfront payment shall upon the signing of this Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#9679;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal;"&gt;&amp;#160;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none;
 text-indent: 0px; letter-spacing: normal;
 margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
<us-gaap:CollaborativeArrangementRightsAndObligations contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-indent: 0px; padding-left: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; text-indent: 0px; padding-left: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; text-indent: 0px; padding-left: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;is responsible to make up-front, milestone and royalty payments to BioLite, as described in the foregoing paragraph and below.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.25in; text-align: justify; color: #000000; text-transform: none; text-indent: -0.25in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;As between BioLite and ABVC, BioLite owns all files, data, confidential and non-public information, including, without limitation, all IND packages and clinical study reports, regarding the Compounds (collectively, the &amp;#8220;Compound IP&amp;#8221;), to the extent developed in Taiwan, and owns all Compound IP to the extent developed in North America. BioLite grants an exclusive license to its Compound IP to for the purpose of further development and commercialization of the Compounds in North America. BioLite and share the responsibility of preparing for clinical trials by delivering Compound IP and preparing related materials.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;is responsible for all clinical trial expenses incurred in North America.&amp;#160;&amp;#160;BioLite paid all clinical trial expenses for trials conducted in Taiwan thus far.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Collaborative Agreement will remain in effect for fifteen years from the date of first commercial sale of Product in the U.S. or Canada. Either party may terminate upon thirty days&amp;#8217; prior written notice for breach or
 insolvency.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font:
 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;agreed to pay to BioLite an aggregate of One Hundred Million Dollars ($100,000,000) (the &amp;#8220;Aggregate Amount&amp;#8221;) in milestone payments during the term of the agreement, payable in cash or Company equity. A percentage of the Aggregate Amount will be paid to BioLite upon each completion of a milestone by BioLite as set forth in the Collaborative Agreement. An upfront payment of $3,500,000 (the &amp;#8220;Milestone Payment&amp;#8221;), which is 3.5% of total payments due under the Collaborative Agreement, was to be paid by us upon signing of the Collaboration Agreement. On May 6, 2016, we and BioLite amended the payment terms under the Collaborative Agreement by entering into a Milestone Payment Agreement, pursuant to which we paid $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Milestones are reached by BioLite upon submissions of IND and NDAs for the Products, and completion of phases in the application processes, as set forth in the Collaborative Agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In addition to the Aggregate Amount, &amp;#160;will pay to BioLite five percent (5%) of net sales of Products in the U.S. and Canada.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CollaborativeArrangementRightsAndObligations>
<mtoo:UpfrontPayments contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember" unitRef="USD" decimals="0">3500000</mtoo:UpfrontPayments>
<mtoo:PercentageOfPaymentsUnderCollaborativeAgreement contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember" unitRef="pure" decimals="3">0.035</mtoo:PercentageOfPaymentsUnderCollaborativeAgreement>
<mtoo:MilestonePayments contextRef="Context_Custom_05_May_2016T00_00_00_TO_06_May_2016T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember" unitRef="USD" decimals="0">2600000</mtoo:MilestonePayments>
<us-gaap:SharePrice contextRef="Context_As_Of_06_May_2016T00_00_00_TO_06_May_2016T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember" unitRef="USD_per_Share" decimals="2">1.60</us-gaap:SharePrice>
<us-gaap:DueToOfficersOrStockholdersCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">46586</us-gaap:DueToOfficersOrStockholdersCurrent>
<us-gaap:DueToOfficersOrStockholdersCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">0</us-gaap:DueToOfficersOrStockholdersCurrent>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_26_Aug_2016T00_00_00_TO_26_Aug_2016T00_00_00_LegalEntityAxis_BioliteIncMember" unitRef="USD_per_Share" decimals="2">1.60</us-gaap:SaleOfStockPricePerShare>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Context_Custom_01_Aug_2016T00_00_00_TO_26_Aug_2016T00_00_00_LegalEntityAxis_BioliteIncMember" unitRef="USD" decimals="0">2350000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<mtoo:ConversionOfExchangeRatio contextRef="Context_Custom_04_Feb_2016T00_00_00_TO_08_Feb_2016T00_00_00_TypeOfArrangementAxis_ShareExchangeAgreementThreeMember">0.2536-for-1</mtoo:ConversionOfExchangeRatio>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">160823831</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">193981153</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">160823831</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">193981153</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:EarningsPerShareBasic contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.02</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.02</us-gaap:EarningsPerShareDiluted>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">5948</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">23793</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">17845</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">47586</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
<us-gaap:LongTermPurchaseCommitmentAmount contextRef="Context_Custom_26_Dec_2015T00_00_00_TO_29_Dec_2015T00_00_00" unitRef="USD" decimals="0">100000000</us-gaap:LongTermPurchaseCommitmentAmount>
<us-gaap:LongtermPurchaseCommitmentPeriod contextRef="Context_Custom_26_Dec_2015T00_00_00_TO_29_Dec_2015T00_00_00">P15Y</us-gaap:LongtermPurchaseCommitmentPeriod>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">29129</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms contextRef="Context_Custom_26_Dec_2015T00_00_00_TO_29_Dec_2015T00_00_00">10 years</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms>
<mtoo:StockIssuedDuringPeriodReverseMergerRecapitalization contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-2696</mtoo:StockIssuedDuringPeriodReverseMergerRecapitalization>
<mtoo:StockIssuedDuringPeriodReverseMergerRecapitalization contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">42359</mtoo:StockIssuedDuringPeriodReverseMergerRecapitalization>
<mtoo:StockIssuedDuringPeriodReverseMergerRecapitalization contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-45055</mtoo:StockIssuedDuringPeriodReverseMergerRecapitalization>
<mtoo:StockIssuedDuringPeriodReverseMergerRecapitalization contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" xsi:nil="true"/>
<mtoo:StockIssuedDuringPeriodReverseMergerRecapitalization contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<mtoo:StockIssuedDuringPeriodReverseMergerRecapitalizationShares contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="INF">42359253</mtoo:StockIssuedDuringPeriodReverseMergerRecapitalizationShares>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">397960</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">157</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">397803</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_SubscriptionReceivableMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">157050</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-1295324</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
<mtoo:ProceedsFromSubscriptionReceivable contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<mtoo:ProceedsFromSubscriptionReceivable contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">350000</mtoo:ProceedsFromSubscriptionReceivable>
<mtoo:Prepayment contextRef="Context_Custom_21_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<mtoo:Prepayment contextRef="Context_FYE_01_Oct_2015T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">900000</mtoo:Prepayment>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Footnote-1_1" xlink:label="lab_Footnote-1_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_2" xlink:label="lab_Footnote-1_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_2"/>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-1">All shares outstanding for all periods have been retroactively restated to reflect Company's 1 to 3:141 forward stock split, which was effective on April 8, 2016.</link:footnote>
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>mtoo-20160930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Friday, January 13, 2017 03:22:45 AM -->
<schema targetNamespace="http://metuboutique.com/20160930" elementFormDefault="qualified" xmlns:mtoo="http://metuboutique.com/20160930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation><appinfo>
<link:roleType roleURI="http://metuboutique.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/Condensedconsolidatedbalancesheets" id="Condensedconsolidatedbalancesheets">
<link:definition>002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/Condensedconsolidatedbalancesheetsparenthetical" id="Condensedconsolidatedbalancesheetsparenthetical">
<link:definition>003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
<link:definition>004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" id="CondensedConsolidatedStatementsOfStockholdersEquity">
<link:definition>005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/Condensedconsolidatedstatementsofcashflow" id="Condensedconsolidatedstatementsofcashflow">
<link:definition>006 - Statement - Condensed Consolidated Statements of Cash Flow</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/OrganizationAndDescriptionOfBusiness" id="OrganizationAndDescriptionOfBusiness">
<link:definition>007 - Disclosure - Organization and Description of Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/GoingConcern" id="GoingConcern">
<link:definition>009 - Disclosure - Going Concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/CollaborativeAgreement" id="CollaborativeAgreement">
<link:definition>010 - Disclosure - Collaborative Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/RelatedPartiesTransactions" id="RelatedPartiesTransactions">
<link:definition>011 - Disclosure - Related Parties Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/AccountsPayable" id="AccountsPayable">
<link:definition>012 - Disclosure - Accounts Payable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/Equity" id="Equity">
<link:definition>013 - Disclosure - Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/EarningsPerShare" id="EarningsPerShare">
<link:definition>014 - Disclosure - Earnings Per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>015 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/SubsequentEvent" id="SubsequentEvent">
<link:definition>016 - Disclosure - Subsequent Event</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>017 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/EarningsPerShareTables" id="EarningsPerShareTables">
<link:definition>018 - Disclosure - Earnings Per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/CommitmentsandContingenciesTables" id="CommitmentsandContingenciesTables">
<link:definition>019 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/OrganizationAndDescriptionOfBusinessDetails" id="OrganizationAndDescriptionOfBusinessDetails">
<link:definition>020 - Disclosure - Organization and Description of Business (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
<link:definition>021 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/GoingConcernDetails" id="GoingConcernDetails">
<link:definition>022 - Disclosure - Going Concern (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/CollaborativeAgreementDetails" id="CollaborativeAgreementDetails">
<link:definition>023 - Disclosure - Collaborative Agreement (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsDetails" id="RelatedPartiesTransactionsDetails">
<link:definition>024 - Disclosure - Related Parties Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/AccountsPayableDetails" id="AccountsPayableDetails">
<link:definition>025 - Disclosure - Accounts Payable (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/EquityDetails" id="EquityDetails">
<link:definition>026 - Disclosure - Equity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/EarningsPerShareDetails" id="EarningsPerShareDetails">
<link:definition>027 - Disclosure - Earnings Per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
<link:definition>028 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/CommitmentsAndContingenciesDetailsTextual" id="CommitmentsAndContingenciesDetailsTextual">
<link:definition>029 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://metuboutique.com/role/SubsequentEventDetails" id="SubsequentEventDetails">
<link:definition>030 - Disclosure - Subsequent Event (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="mtoo-20160930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="mtoo-20160930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="mtoo-20160930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="mtoo-20160930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="mtoo_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SubscriptionReceivableMember" id="mtoo_SubscriptionReceivableMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodReverseMergerRecapitalization" id="mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodReverseMergerRecapitalizationShares" id="mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodReceiptOfSubscriptionReceivable" id="mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseDecreaseInPrepayment" id="mtoo_IncreaseDecreaseInPrepayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromSubscriptionReceivable" id="mtoo_ProceedsFromSubscriptionReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="Prepayment" id="mtoo_Prepayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GoingConcernAbstract" id="mtoo_GoingConcernAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GoingConcernDisclosureTextBlock" id="mtoo_GoingConcernDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CollaobrativeAgreementsAbstract" id="mtoo_CollaobrativeAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ForwardStockSplitPolicyTextBlock" id="mtoo_ForwardStockSplitPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareExchangeAgreementMember" id="mtoo_ShareExchangeAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareExchangeAgreementOneMember" id="mtoo_ShareExchangeAgreementOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareExchangeAgreementTwoMember" id="mtoo_ShareExchangeAgreementTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareExchangeAgreementThreeMember" id="mtoo_ShareExchangeAgreementThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareExchangeAgreementFourMember" id="mtoo_ShareExchangeAgreementFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmericanBriVisionHoldingCorporationMember" id="mtoo_AmericanBriVisionHoldingCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EuroAsiaInvestmentAndFinanceCorpLimitedMember" id="mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmericanBriVisionCorporationMember" id="mtoo_AmericanBriVisionCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OrganizationAndDescriptionOfBusinessTextualAbstract" id="mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockIssuedAfterStockSplit" id="mtoo_CommonStockIssuedAfterStockSplit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockIssuedBeforeStockSplit" id="mtoo_CommonStockIssuedBeforeStockSplit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfIssuedShareCapital" id="mtoo_PercentageOfIssuedShareCapital" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SummaryOfSignificantAccountingPoliciesTextualAbstract" id="mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GoingConcernTextualAbstract" id="mtoo_GoingConcernTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CollaborativeAgreementTextualAbstract" id="mtoo_CollaborativeAgreementTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UpfrontPayments" id="mtoo_UpfrontPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfPaymentsUnderCollaborativeAgreement" id="mtoo_PercentageOfPaymentsUnderCollaborativeAgreement" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MilestonePayments" id="mtoo_MilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RelatedPartiesTransactionsTextualAbstract" id="mtoo_RelatedPartiesTransactionsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccountsPayableTextualAbstract" id="mtoo_AccountsPayableTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BioliteIncMember" id="mtoo_BioliteIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EquityIncentivePlanMember" id="mtoo_EquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EquityTextualAbstract" id="mtoo_EquityTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConversionOfExchangeRatio" id="mtoo_ConversionOfExchangeRatio" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumeratorAbstract" id="mtoo_NumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DenominatorAbstract" id="mtoo_DenominatorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommitmentsAndContingenciesTextualAbstract" id="mtoo_CommitmentsAndContingenciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>mtoo-20160930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Friday, January 13, 2017 03:22:45 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#Condensedconsolidatedbalancesheets" roleURI="http://metuboutique.com/role/Condensedconsolidatedbalancesheets"/>
<calculationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Condensedconsolidatedbalancesheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrentAndNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_AccountsPayableOtherCurrentAndNoncurrent" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" order="50" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" order="30" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="30" use="optional" weight="1"/></calculationLink>





<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://metuboutique.com/role/CondensedConsolidatedStatementsOfOperations"/>
<calculationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_Revenues" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_CostOfRevenue" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GrossProfit" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeInterest" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" order="30" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" order="20" use="optional" weight="-1"/></calculationLink>




<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#Condensedconsolidatedstatementsofcashflow" roleURI="http://metuboutique.com/role/Condensedconsolidatedstatementsofcashflow"/>
<calculationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Condensedconsolidatedstatementsofcashflow">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets" order="30" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_IncreaseDecreaseInPrepayment" xlink:label="loc_mtoo_IncreaseDecreaseInPrepayment"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_mtoo_IncreaseDecreaseInPrepayment" order="40" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:label="loc_us-gaap_IncreaseDecreaseDueFromAffiliates"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseDueFromAffiliates" order="50" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties" order="70" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="80" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" order="90" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ProceedsFromSubscriptionReceivable" xlink:label="loc_mtoo_ProceedsFromSubscriptionReceivable"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_mtoo_ProceedsFromSubscriptionReceivable" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="30" use="optional" weight="1"/></calculationLink>


<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://metuboutique.com/role/CommitmentsAndContingenciesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="30" use="optional" weight="1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>mtoo-20160930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Friday, January 13, 2017 03:22:45 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://metuboutique.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#OrganizationAndDescriptionOfBusinessDetails" roleURI="http://metuboutique.com/role/OrganizationAndDescriptionOfBusinessDetails"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#CollaborativeAgreementDetails" roleURI="http://metuboutique.com/role/CollaborativeAgreementDetails"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#EquityDetails" roleURI="http://metuboutique.com/role/EquityDetails"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#SubsequentEventDetails" roleURI="http://metuboutique.com/role/SubsequentEventDetails"/>
<definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CondensedConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_SubscriptionReceivableMember" xlink:label="loc_mtoo_SubscriptionReceivableMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_mtoo_SubscriptionReceivableMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization" xlink:label="loc_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares" xlink:label="loc_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares_13" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensation_14" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_15" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable" xlink:label="loc_mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable_16" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_17" order="100" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/OrganizationAndDescriptionOfBusinessDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementMember" xlink:label="loc_mtoo_ShareExchangeAgreementMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementOneMember" xlink:label="loc_mtoo_ShareExchangeAgreementOneMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementOneMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementTwoMember" xlink:label="loc_mtoo_ShareExchangeAgreementTwoMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementTwoMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementThreeMember" xlink:label="loc_mtoo_ShareExchangeAgreementThreeMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementThreeMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementFourMember" xlink:label="loc_mtoo_ShareExchangeAgreementFourMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementFourMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9" xlink:to="loc_dei_EntityDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9" xlink:to="loc_dei_EntityDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_AmericanBriVisionHoldingCorporationMember" xlink:label="loc_mtoo_AmericanBriVisionHoldingCorporationMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_10" xlink:to="loc_mtoo_AmericanBriVisionHoldingCorporationMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember" xlink:label="loc_mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_10" xlink:to="loc_mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_AmericanBriVisionCorporationMember" xlink:label="loc_mtoo_AmericanBriVisionCorporationMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_10" xlink:to="loc_mtoo_AmericanBriVisionCorporationMember_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract" xlink:label="loc_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommonStockIssuedAfterStockSplit" xlink:label="loc_mtoo_CommonStockIssuedAfterStockSplit_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract_14" xlink:to="loc_mtoo_CommonStockIssuedAfterStockSplit_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommonStockIssuedBeforeStockSplit" xlink:label="loc_mtoo_CommonStockIssuedBeforeStockSplit_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract_14" xlink:to="loc_mtoo_CommonStockIssuedBeforeStockSplit_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract_14" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_17" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_PercentageOfIssuedShareCapital" xlink:label="loc_mtoo_PercentageOfIssuedShareCapital_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract_14" xlink:to="loc_mtoo_PercentageOfIssuedShareCapital_18" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract_14" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_19" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CollaborativeAgreementDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CollaborativeAgreementTextualAbstract" xlink:label="loc_mtoo_CollaborativeAgreementTextualAbstract_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_mtoo_CollaborativeAgreementTextualAbstract_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:label="loc_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_5" xlink:to="loc_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:label="loc_us-gaap_CollaborativeArrangementRightsAndObligations_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_5" xlink:to="loc_us-gaap_CollaborativeArrangementRightsAndObligations_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_5" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_UpfrontPayments" xlink:label="loc_mtoo_UpfrontPayments_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_5" xlink:to="loc_mtoo_UpfrontPayments_9" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_PercentageOfPaymentsUnderCollaborativeAgreement" xlink:label="loc_mtoo_PercentageOfPaymentsUnderCollaborativeAgreement_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_5" xlink:to="loc_mtoo_PercentageOfPaymentsUnderCollaborativeAgreement_10" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_MilestonePayments" xlink:label="loc_mtoo_MilestonePayments_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_5" xlink:to="loc_mtoo_MilestonePayments_11" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_5" xlink:to="loc_us-gaap_SharePrice_14" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/EquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_0" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementMember" xlink:label="loc_mtoo_ShareExchangeAgreementMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementOneMember" xlink:label="loc_mtoo_ShareExchangeAgreementOneMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementOneMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementTwoMember" xlink:label="loc_mtoo_ShareExchangeAgreementTwoMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementTwoMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementThreeMember" xlink:label="loc_mtoo_ShareExchangeAgreementThreeMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementThreeMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementFourMember" xlink:label="loc_mtoo_ShareExchangeAgreementFourMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementFourMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1" xlink:to="loc_dei_LegalEntityAxis_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_10" xlink:to="loc_dei_EntityDomain_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_10" xlink:to="loc_dei_EntityDomain_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_AmericanBriVisionHoldingCorporationMember" xlink:label="loc_mtoo_AmericanBriVisionHoldingCorporationMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_11" xlink:to="loc_mtoo_AmericanBriVisionHoldingCorporationMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember" xlink:label="loc_mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_11" xlink:to="loc_mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_AmericanBriVisionCorporationMember" xlink:label="loc_mtoo_AmericanBriVisionCorporationMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_11" xlink:to="loc_mtoo_AmericanBriVisionCorporationMember_14" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_BioliteIncMember" xlink:label="loc_mtoo_BioliteIncMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_11" xlink:to="loc_mtoo_BioliteIncMember_15" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1" xlink:to="loc_us-gaap_PlanNameAxis_16" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_16" xlink:to="loc_us-gaap_PlanNameDomain_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_17_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_16" xlink:to="loc_us-gaap_PlanNameDomain_17_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_EquityIncentivePlanMember" xlink:label="loc_mtoo_EquityIncentivePlanMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_17" xlink:to="loc_mtoo_EquityIncentivePlanMember_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_EquityTextualAbstract" xlink:label="loc_mtoo_EquityTextualAbstract_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_0" xlink:to="loc_mtoo_EquityTextualAbstract_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_EquityTextualAbstract_19" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_EquityTextualAbstract_19" xlink:to="loc_us-gaap_SharePrice_21" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_EquityTextualAbstract_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_22" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_EquityTextualAbstract_19" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_23" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_EquityTextualAbstract_19" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_24" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_EquityTextualAbstract_19" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_25" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommonStockIssuedAfterStockSplit" xlink:label="loc_mtoo_CommonStockIssuedAfterStockSplit_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_EquityTextualAbstract_19" xlink:to="loc_mtoo_CommonStockIssuedAfterStockSplit_26" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommonStockIssuedBeforeStockSplit" xlink:label="loc_mtoo_CommonStockIssuedBeforeStockSplit_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_EquityTextualAbstract_19" xlink:to="loc_mtoo_CommonStockIssuedBeforeStockSplit_27" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_EquityTextualAbstract_19" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_28" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_PercentageOfIssuedShareCapital" xlink:label="loc_mtoo_PercentageOfIssuedShareCapital_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_EquityTextualAbstract_19" xlink:to="loc_mtoo_PercentageOfIssuedShareCapital_29" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_EquityTextualAbstract_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_30" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_EquityTextualAbstract_19" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_31" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_EquityTextualAbstract_19" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_32" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ConversionOfExchangeRatio" xlink:label="loc_mtoo_ConversionOfExchangeRatio_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mtoo_EquityTextualAbstract_19" xlink:to="loc_mtoo_ConversionOfExchangeRatio_33" order="130" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SubsequentEventDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementMember" xlink:label="loc_mtoo_ShareExchangeAgreementMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_mtoo_ShareExchangeAgreementMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementOneMember" xlink:label="loc_mtoo_ShareExchangeAgreementOneMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_mtoo_ShareExchangeAgreementOneMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementTwoMember" xlink:label="loc_mtoo_ShareExchangeAgreementTwoMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_mtoo_ShareExchangeAgreementTwoMember_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementThreeMember" xlink:label="loc_mtoo_ShareExchangeAgreementThreeMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_mtoo_ShareExchangeAgreementThreeMember_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementFourMember" xlink:label="loc_mtoo_ShareExchangeAgreementFourMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_mtoo_ShareExchangeAgreementFourMember_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommonStockIssuedAfterStockSplit" xlink:label="loc_mtoo_CommonStockIssuedAfterStockSplit_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_mtoo_CommonStockIssuedAfterStockSplit_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommonStockIssuedBeforeStockSplit" xlink:label="loc_mtoo_CommonStockIssuedBeforeStockSplit_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_mtoo_CommonStockIssuedBeforeStockSplit_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_15" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_PercentageOfIssuedShareCapital" xlink:label="loc_mtoo_PercentageOfIssuedShareCapital_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_mtoo_PercentageOfIssuedShareCapital_16" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ConversionOfExchangeRatio" xlink:label="loc_mtoo_ConversionOfExchangeRatio_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_mtoo_ConversionOfExchangeRatio_17" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_18" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_19" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_20" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_21" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_22" order="110" use="optional"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>mtoo-20160930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Friday, January 13, 2017 03:22:45 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_DocumentAndEntityInformationAbstract" xlink:label="loc_K1J9G744H2H0_mtoo_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_DocumentAndEntityInformationAbstract" xlink:to="lab_M3L1I966J4J2_mtoo_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_JFF375209FGJ9KJ8G623_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_dei_EntityRegistrantName" xlink:to="lab_LHH597421HIL1ML0I845_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_K1J9G744H2H0_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_dei_EntityCentralIndexKey" xlink:to="lab_M3L1I966J4J2_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_JFF375209FGJ9KJ8G623_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_dei_AmendmentFlag" xlink:to="lab_LHH597421HIL1ML0I845_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_K1J9G744H2H0_dei_AmendmentDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_dei_AmendmentDescription" xml:lang="en-US">Amendment Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_dei_AmendmentDescription" xlink:to="lab_M3L1I966J4J2_dei_AmendmentDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_JFF375209FGJ9KJ8G623_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_dei_DocumentType" xlink:to="lab_LHH597421HIL1ML0I845_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_K1J9G744H2H0_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_dei_DocumentPeriodEndDate" xlink:to="lab_M3L1I966J4J2_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_JFF375209FGJ9KJ8G623_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_dei_EntityFilerCategory" xlink:to="lab_LHH597421HIL1ML0I845_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_K1J9G744H2H0_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_M3L1I966J4J2_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_AssetsAbstract" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_K1J9G744H2H0_us-gaap_AssetsCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_AssetsCurrentAbstract" xlink:to="lab_M3L1I966J4J2_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents amounted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_K1J9G744H2H0_us-gaap_PrepaidExpenseCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepayment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_M3L1I966J4J2_us-gaap_PrepaidExpenseCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_AssetsCurrent" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_K1J9G744H2H0_us-gaap_AssetsNoncurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_AssetsNoncurrentAbstract" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_AssetsNoncurrentAbstract" xml:lang="en-US">Non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_M3L1I966J4J2_us-gaap_AssetsNoncurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_DepositsAssetsNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_DepositsAssetsNoncurrent" xml:lang="en-US">Deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_DepositsAssetsNoncurrent" xml:lang="en-US">Deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_DepositsAssetsNoncurrent" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_DepositsAssetsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_K1J9G744H2H0_us-gaap_AssetsNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_AssetsNoncurrent" xml:lang="en-US">Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_AssetsNoncurrent" xml:lang="en-US">Total Non-Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_AssetsNoncurrent" xml:lang="en-US">Total Non-Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_AssetsNoncurrent" xlink:to="lab_M3L1I966J4J2_us-gaap_AssetsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_Assets" xml:lang="en-US">Assets [Default Label]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_Assets" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_K1J9G744H2H0_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_M3L1I966J4J2_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_AccountsPayableCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_AccountsPayableCurrentAndNoncurrent" xml:lang="en-US">Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_AccountsPayableCurrentAndNoncurrent" xml:lang="en-US">Accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_AccountsPayableCurrentAndNoncurrent" xml:lang="en-US">Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_AccountsPayableCurrentAndNoncurrent" xml:lang="en-US">Accounts payable to LiteArt, Inc.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_AccountsPayableCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_K1J9G744H2H0_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_M3L1I966J4J2_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_AccountsPayableOtherCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xml:lang="en-US">Accounts Payable, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xml:lang="en-US">Other payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_AccountsPayableOtherCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_K1J9G744H2H0_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Due to Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Due to related party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Amount received from BriVision</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Due to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_M3L1I966J4J2_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xml:lang="en-US">Due to Officers or Stockholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xml:lang="en-US">Due to shareholder</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_K1J9G744H2H0_us-gaap_Liabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_Liabilities" xlink:to="lab_M3L1I966J4J2_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_CommitmentsAndContingencies"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_CommitmentsAndContingencies" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_K1J9G744H2H0_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders'equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_StockholdersEquityAbstract" xlink:to="lab_M3L1I966J4J2_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock 360,000,000 authorized at $0.001 par value; shares issued and outstanding 209,352,897 and 3,113,856 at June 30, 2016 and September 30, 2015</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock 360,000,000 authorized at $0.001 par value; shares issued and outstanding 210,821,647 and 166,273,921 at September 30, 2016 and September 30, 2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_CommonStockValue" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_K1J9G744H2H0_us-gaap_AdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_AdditionalPaidInCapital" xlink:to="lab_M3L1I966J4J2_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xml:lang="en-US">Subscription receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xml:lang="en-US">Subscription receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xml:lang="en-US">Subscription receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_K1J9G744H2H0_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_M3L1I966J4J2_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StockholdersEquity" xml:lang="en-US">Total equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StockholdersEquity" xml:lang="en-US">Total equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_StockholdersEquity" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_K1J9G744H2H0_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity [Default Label]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_M3L1I966J4J2_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_K1J9G744H2H0_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_M3L1I966J4J2_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_CommonStockSharesIssued" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_K1J9G744H2H0_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_M3L1I966J4J2_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_IncomeStatementAbstract" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_K1J9G744H2H0_us-gaap_Revenues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_Revenues" xlink:to="lab_M3L1I966J4J2_us-gaap_Revenues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_CostOfRevenue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_CostOfRevenue" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_CostOfRevenue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_K1J9G744H2H0_us-gaap_GrossProfit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_GrossProfit" xml:lang="en-US">Gross loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_GrossProfit" xlink:to="lab_M3L1I966J4J2_us-gaap_GrossProfit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_OperatingExpensesAbstract" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_K1J9G744H2H0_us-gaap_SellingGeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, general and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_M3L1I966J4J2_us-gaap_SellingGeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_OperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Net loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_OperatingIncomeLoss" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_K1J9G744H2H0_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income(expenses)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_M3L1I966J4J2_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_InvestmentIncomeInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Bank Interest Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_InvestmentIncomeInterest" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_InvestmentIncomeInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_K1J9G744H2H0_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Gain on exchange differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_M3L1I966J4J2_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_InterestExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_InterestExpense" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_InterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_K1J9G744H2H0_us-gaap_NonoperatingIncomeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total Other Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_M3L1I966J4J2_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss from continuing operations before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_K1J9G744H2H0_us-gaap_IncomeTaxExpenseBenefit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_M3L1I966J4J2_us-gaap_IncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss for the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_NetIncomeLoss" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_K1J9G744H2H0_us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Basic and Diluted loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_M3L1I966J4J2_us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_EarningsPerShareBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and Diluted loss per share (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_K1J9G744H2H0_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of shares outstanding basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_M3L1I966J4J2_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_StatementOfStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_StatementOfStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_K1J9G744H2H0_us-gaap_StatementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_StatementTable" xlink:to="lab_M3L1I966J4J2_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_StatementEquityComponentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_K1J9G744H2H0_us-gaap_EquityComponentDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_EquityComponentDomain" xlink:to="lab_M3L1I966J4J2_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_CommonStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockMember" xml:lang="en-US">Common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_CommonStockMember" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_K1J9G744H2H0_us-gaap_AdditionalPaidInCapitalMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_M3L1I966J4J2_us-gaap_AdditionalPaidInCapitalMember"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_SubscriptionReceivableMember" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_SubscriptionReceivableMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_SubscriptionReceivableMember" xml:lang="en-US">Subscription Receivable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_SubscriptionReceivableMember" xml:lang="en-US">Subscription receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_SubscriptionReceivableMember" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_SubscriptionReceivableMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_K1J9G744H2H0_us-gaap_RetainedEarningsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_RetainedEarningsMember" xlink:to="lab_M3L1I966J4J2_us-gaap_RetainedEarningsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_StatementLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_StatementLineItems" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_K1J9G744H2H0_us-gaap_SharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_SharesOutstanding" xlink:to="lab_M3L1I966J4J2_us-gaap_SharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of common shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Common stock newly issued, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_K1J9G744H2H0_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common shares, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock newly issued, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_M3L1I966J4J2_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock newly issued, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_M3L1I966J4J2_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization" xml:lang="en-US">Stock Issued During Period Reverse Merger Recapitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization" xml:lang="en-US">Reverse merger recapitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization" xml:lang="en-US">Stock issued during period reverse merger recapitalization.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares" xlink:label="loc_K1J9G744H2H0_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares" xml:lang="en-US">Stock Issued During Period Reverse Merger Recapitalization Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares" xml:lang="en-US">Reverse merger recapitalization, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M3L1I966J4J2_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares" xml:lang="en-US">Stock issued during period reverse merger recapitalization shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares" xlink:to="lab_M3L1I966J4J2_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_ShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_ShareBasedCompensation" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_K1J9G744H2H0_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Stock based compensation, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_M3L1I966J4J2_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable" xml:lang="en-US">Stock Issued During Period Receipt Of Subscription Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable" xml:lang="en-US">Receipt of subscription receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable" xml:lang="en-US">Stock issued during period receipt of subscription receivable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_K1J9G744H2H0_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_M3L1I966J4J2_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_K1J9G744H2H0_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used by operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_M3L1I966J4J2_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xml:lang="en-US">Issuance of common stock for compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xml:lang="en-US">Issuance of common stock for compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_K1J9G744H2H0_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Change in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_M3L1I966J4J2_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_IncreaseDecreaseInDepositOtherAssets" xml:lang="en-US">Increase (Decrease) in Deposit Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_IncreaseDecreaseInDepositOtherAssets" xml:lang="en-US">Increase in deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_IncreaseDecreaseInPrepayment" xlink:label="loc_K1J9G744H2H0_mtoo_IncreaseDecreaseInPrepayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_IncreaseDecreaseInPrepayment" xml:lang="en-US">IncreaseDecreaseInPrepayment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M3L1I966J4J2_mtoo_IncreaseDecreaseInPrepayment" xml:lang="en-US">Represents information pertaining to increase decrease in prepayment.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M3L1I966J4J2_mtoo_IncreaseDecreaseInPrepayment" xml:lang="en-US">Decrease (increase) in prepayment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_IncreaseDecreaseInPrepayment" xlink:to="lab_M3L1I966J4J2_mtoo_IncreaseDecreaseInPrepayment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_IncreaseDecreaseDueFromAffiliates"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_IncreaseDecreaseDueFromAffiliates" xml:lang="en-US">Increase (Decrease) Due from Affiliates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_IncreaseDecreaseDueFromAffiliates" xml:lang="en-US">Due to shareholder</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_IncreaseDecreaseDueFromAffiliates" xml:lang="en-US">Due to shareholder</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_IncreaseDecreaseDueFromAffiliates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_K1J9G744H2H0_us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xml:lang="en-US">Increase (decrease) in other payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xml:lang="en-US">(Decrease) increase in other payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="lab_M3L1I966J4J2_us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_IncreaseDecreaseInDueToRelatedParties" xml:lang="en-US">Increase (Decrease) in Due to Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_IncreaseDecreaseInDueToRelatedParties" xml:lang="en-US">(Decrease) increase in due to related party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_IncreaseDecreaseInDueToRelatedParties" xml:lang="en-US">Increase (decrease) in due to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_K1J9G744H2H0_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (decrease) in accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase in accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_M3L1I966J4J2_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase in accrued expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_K1J9G744H2H0_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_M3L1I966J4J2_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_K1J9G744H2H0_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided(used) by investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_M3L1I966J4J2_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="loc_K1J9G744H2H0_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xml:lang="en-US">Increase (Decrease) in Due to Officers and Stockholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xml:lang="en-US">(Decrease) increase in due to shareholder</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:to="lab_M3L1I966J4J2_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ProceedsFromSubscriptionReceivable" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_ProceedsFromSubscriptionReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_ProceedsFromSubscriptionReceivable" xml:lang="en-US">Proceeds From Subscription Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_ProceedsFromSubscriptionReceivable" xml:lang="en-US">Proceeds from subscription receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_ProceedsFromSubscriptionReceivable" xml:lang="en-US">The cash inflow from proceeds from Subscription of receivables.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_ProceedsFromSubscriptionReceivable" xml:lang="en-US">Proceeds from subscription receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_ProceedsFromSubscriptionReceivable" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_ProceedsFromSubscriptionReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_K1J9G744H2H0_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_M3L1I966J4J2_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_K1J9G744H2H0_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">Effect Of Exchange Rates On Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_M3L1I966J4J2_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Negative cash flow</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net (decrease) increase in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_K1J9G744H2H0_us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Non cash investing and financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_M3L1I966J4J2_us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_Prepayment" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_Prepayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_Prepayment" xml:lang="en-US">Prepayment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_Prepayment" xml:lang="en-US">Prepayment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_Prepayment" xml:lang="en-US">Prepayment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_Prepayment" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_Prepayment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_K1J9G744H2H0_us-gaap_SupplementalCashFlowInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_M3L1I966J4J2_us-gaap_SupplementalCashFlowInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_InterestPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_InterestPaid" xml:lang="en-US">Interest paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_InterestPaid" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_K1J9G744H2H0_us-gaap_IncomeTaxesPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income taxes paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_IncomeTaxesPaid" xlink:to="lab_M3L1I966J4J2_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization and Description of Business [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_K1J9G744H2H0_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_M3L1I966J4J2_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_AccountingPoliciesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_K1J9G744H2H0_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_M3L1I966J4J2_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_GoingConcernAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_GoingConcernAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_GoingConcernAbstract" xml:lang="en-US">Going Concern [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_GoingConcernAbstract" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_GoingConcernAbstract"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_GoingConcernDisclosureTextBlock" xlink:label="loc_K1J9G744H2H0_mtoo_GoingConcernDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_GoingConcernDisclosureTextBlock" xml:lang="en-US">Going Concern Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_GoingConcernDisclosureTextBlock" xml:lang="en-US">GOING CONCERN</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M3L1I966J4J2_mtoo_GoingConcernDisclosureTextBlock" xml:lang="en-US">Going concern disclosure.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_GoingConcernDisclosureTextBlock" xlink:to="lab_M3L1I966J4J2_mtoo_GoingConcernDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CollaobrativeAgreementsAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_CollaobrativeAgreementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_CollaobrativeAgreementsAbstract" xml:lang="en-US">Collaborative Agreement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_CollaobrativeAgreementsAbstract" xml:lang="en-US"></label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_CollaobrativeAgreementsAbstract" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_CollaobrativeAgreementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_K1J9G744H2H0_us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">COLLABORATIVE AGREEMENT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_M3L1I966J4J2_us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_RelatedPartyTransactionsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Parties Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_K1J9G744H2H0_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">RELATED PARTIES TRANSACTIONS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">RELATED PARTIES TRANSACTIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_M3L1I966J4J2_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_PayablesAndAccrualsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Accounts Payable [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_PayablesAndAccrualsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_K1J9G744H2H0_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">ACCOUNTS PAYABLE</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">ACCOUNTS PAYABLE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_M3L1I966J4J2_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_EquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_EquityAbstract" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_EquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_K1J9G744H2H0_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_M3L1I966J4J2_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_EarningsPerShareAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_EarningsPerShareAbstract" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_EarningsPerShareAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_K1J9G744H2H0_us-gaap_EarningsPerShareTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">EARNINGS PER SHARE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_M3L1I966J4J2_us-gaap_EarningsPerShareTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_K1J9G744H2H0_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_M3L1I966J4J2_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_SubsequentEventsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Event [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_SubsequentEventsAbstract" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_K1J9G744H2H0_us-gaap_SubsequentEventsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">SUBSEQUENT EVENT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_M3L1I966J4J2_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_K1J9G744H2H0_us-gaap_UseOfEstimates"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_UseOfEstimates" xlink:to="lab_M3L1I966J4J2_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ForwardStockSplitPolicyTextBlock" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_ForwardStockSplitPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_ForwardStockSplitPolicyTextBlock" xml:lang="en-US">Forward Stock split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_ForwardStockSplitPolicyTextBlock" xml:lang="en-US">Represents information pertaining to forward stock split policy.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_ForwardStockSplitPolicyTextBlock" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_ForwardStockSplitPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_K1J9G744H2H0_us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_M3L1I966J4J2_us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_K1J9G744H2H0_us-gaap_IncomeTaxPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_M3L1I966J4J2_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_K1J9G744H2H0_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_M3L1I966J4J2_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of future minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_K1J9G744H2H0_us-gaap_TypeOfArrangementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_TypeOfArrangementAxis" xlink:to="lab_M3L1I966J4J2_us-gaap_TypeOfArrangementAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementMember" xlink:label="loc_K1J9G744H2H0_mtoo_ShareExchangeAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_ShareExchangeAgreementMember" xml:lang="en-US">Share Exchange Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_ShareExchangeAgreementMember" xml:lang="en-US">Share Exchange Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M3L1I966J4J2_mtoo_ShareExchangeAgreementMember" xml:lang="en-US">Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_ShareExchangeAgreementMember" xlink:to="lab_M3L1I966J4J2_mtoo_ShareExchangeAgreementMember"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementOneMember" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_ShareExchangeAgreementOneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_ShareExchangeAgreementOneMember" xml:lang="en-US">Share Exchange Agreement One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_ShareExchangeAgreementOneMember" xml:lang="en-US">Share Exchange Agreement 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_ShareExchangeAgreementOneMember" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_ShareExchangeAgreementOneMember"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementTwoMember" xlink:label="loc_K1J9G744H2H0_mtoo_ShareExchangeAgreementTwoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_ShareExchangeAgreementTwoMember" xml:lang="en-US">Share Exchange Agreement Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_ShareExchangeAgreementTwoMember" xml:lang="en-US">Share Exchange Agreement 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_ShareExchangeAgreementTwoMember" xlink:to="lab_M3L1I966J4J2_mtoo_ShareExchangeAgreementTwoMember"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementThreeMember" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_ShareExchangeAgreementThreeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_ShareExchangeAgreementThreeMember" xml:lang="en-US">Share Exchange Agreement Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_ShareExchangeAgreementThreeMember" xml:lang="en-US">Share Exchange Agreement 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_ShareExchangeAgreementThreeMember" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_ShareExchangeAgreementThreeMember"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementFourMember" xlink:label="loc_K1J9G744H2H0_mtoo_ShareExchangeAgreementFourMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_ShareExchangeAgreementFourMember" xml:lang="en-US">Share Exchange Agreement Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_ShareExchangeAgreementFourMember" xml:lang="en-US">Share Exchange Agreement 4 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_ShareExchangeAgreementFourMember" xlink:to="lab_M3L1I966J4J2_mtoo_ShareExchangeAgreementFourMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_JFF375209FGJ9KJ8G623_dei_LegalEntityAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_dei_LegalEntityAxis" xlink:to="lab_LHH597421HIL1ML0I845_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_K1J9G744H2H0_dei_EntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_dei_EntityDomain" xlink:to="lab_M3L1I966J4J2_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_AmericanBriVisionHoldingCorporationMember" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_AmericanBriVisionHoldingCorporationMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_AmericanBriVisionHoldingCorporationMember" xml:lang="en-US">American BriVision (Holding) Corporation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_AmericanBriVisionHoldingCorporationMember" xml:lang="en-US">American BriVision (Holding) Corporation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_AmericanBriVisionHoldingCorporationMember" xml:lang="en-US">The set of legal entities associated with a report.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_AmericanBriVisionHoldingCorporationMember" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_AmericanBriVisionHoldingCorporationMember"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember" xlink:label="loc_K1J9G744H2H0_mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember" xml:lang="en-US">Euro-Asia Investment &amp; Finance Corp. Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember" xml:lang="en-US">Euro-Asia Investment &amp; Finance Corp. Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M3L1I966J4J2_mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember" xml:lang="en-US">The set of legal entities associated with a report.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember" xlink:to="lab_M3L1I966J4J2_mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_AmericanBriVisionCorporationMember" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_AmericanBriVisionCorporationMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_AmericanBriVisionCorporationMember" xml:lang="en-US">American BriVision Corporation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_AmericanBriVisionCorporationMember" xml:lang="en-US">American BriVision Corporation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_AmericanBriVisionCorporationMember" xml:lang="en-US">The set of legal entities associated with a report.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_AmericanBriVisionCorporationMember" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_AmericanBriVisionCorporationMember"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract" xlink:label="loc_K1J9G744H2H0_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract" xml:lang="en-US">Organization And Description Of Business Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract" xml:lang="en-US">Organization and Description of Business (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M3L1I966J4J2_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract" xml:lang="en-US">Organization and description of business textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract" xlink:to="lab_M3L1I966J4J2_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommonStockIssuedAfterStockSplit" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_CommonStockIssuedAfterStockSplit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_CommonStockIssuedAfterStockSplit" xml:lang="en-US">Common Stock Issued After Stock Split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_CommonStockIssuedAfterStockSplit" xml:lang="en-US">Common stock issued post-stock split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_CommonStockIssuedAfterStockSplit" xml:lang="en-US">Common stock issued after stock split.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_CommonStockIssuedAfterStockSplit" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_CommonStockIssuedAfterStockSplit"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommonStockIssuedBeforeStockSplit" xlink:label="loc_K1J9G744H2H0_mtoo_CommonStockIssuedBeforeStockSplit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_CommonStockIssuedBeforeStockSplit" xml:lang="en-US">Common Stock Issued Before Stock Split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_CommonStockIssuedBeforeStockSplit" xml:lang="en-US">Common stock issued pre-stock split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M3L1I966J4J2_mtoo_CommonStockIssuedBeforeStockSplit" xml:lang="en-US">Common stock issued before stock split.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_CommonStockIssuedBeforeStockSplit" xlink:to="lab_M3L1I966J4J2_mtoo_CommonStockIssuedBeforeStockSplit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage of common shares issued and outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage of common shares issued and outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_PercentageOfIssuedShareCapital" xlink:label="loc_K1J9G744H2H0_mtoo_PercentageOfIssuedShareCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_PercentageOfIssuedShareCapital" xml:lang="en-US">Percentage Of Issued Share Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_PercentageOfIssuedShareCapital" xml:lang="en-US">Percentage of issued share capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M3L1I966J4J2_mtoo_PercentageOfIssuedShareCapital" xml:lang="en-US">Percentage of issued share capital.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_PercentageOfIssuedShareCapital" xlink:to="lab_M3L1I966J4J2_mtoo_PercentageOfIssuedShareCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Common stock converted to exchange ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_K1J9G744H2H0_mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary Of Significant Accounting Policies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary of Significant Accounting Policies (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M3L1I966J4J2_mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary of significant accounting policies textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="lab_M3L1I966J4J2_mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_StockholdersEquityReverseStockSplit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Description of forward split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Forward split ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_StockholdersEquityReverseStockSplit" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_StockholdersEquityReverseStockSplit"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_GoingConcernTextualAbstract" xlink:label="loc_K1J9G744H2H0_mtoo_GoingConcernTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_GoingConcernTextualAbstract" xml:lang="en-US">Going Concern Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_GoingConcernTextualAbstract" xml:lang="en-US">Going Concern (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M3L1I966J4J2_mtoo_GoingConcernTextualAbstract" xml:lang="en-US">Going concern textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_GoingConcernTextualAbstract" xlink:to="lab_M3L1I966J4J2_mtoo_GoingConcernTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_K1J9G744H2H0_us-gaap_CollaborativeArrangementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_CollaborativeArrangementMember" xml:lang="en-US">Collaborative Arrangement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_CollaborativeArrangementMember" xml:lang="en-US">Collaborative Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_CollaborativeArrangementMember" xlink:to="lab_M3L1I966J4J2_us-gaap_CollaborativeArrangementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CollaborativeAgreementTextualAbstract" xlink:label="loc_K1J9G744H2H0_mtoo_CollaborativeAgreementTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_CollaborativeAgreementTextualAbstract" xml:lang="en-US">Collaborative Agreement Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_CollaborativeAgreementTextualAbstract" xml:lang="en-US">Collaborative Agreement (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_CollaborativeAgreementTextualAbstract" xlink:to="lab_M3L1I966J4J2_mtoo_CollaborativeAgreementTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xml:lang="en-US">Related Party Transaction, Terms and Manner of Settlement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xml:lang="en-US">Collaborative agreement schedule of settlement, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:label="loc_K1J9G744H2H0_us-gaap_CollaborativeArrangementRightsAndObligations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_CollaborativeArrangementRightsAndObligations" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_CollaborativeArrangementRightsAndObligations" xml:lang="en-US">Collaborative agreement material terms, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_CollaborativeArrangementRightsAndObligations" xlink:to="lab_M3L1I966J4J2_us-gaap_CollaborativeArrangementRightsAndObligations"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_UpfrontPayments" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_UpfrontPayments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_UpfrontPayments" xml:lang="en-US">Upfront Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_UpfrontPayments" xml:lang="en-US">Upfront payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_UpfrontPayments" xml:lang="en-US">The amount of upfront payments which are paid during the term of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_UpfrontPayments" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_UpfrontPayments"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_PercentageOfPaymentsUnderCollaborativeAgreement" xlink:label="loc_K1J9G744H2H0_mtoo_PercentageOfPaymentsUnderCollaborativeAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_PercentageOfPaymentsUnderCollaborativeAgreement" xml:lang="en-US">Percentage Of Payments Under Collaborative Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_PercentageOfPaymentsUnderCollaborativeAgreement" xml:lang="en-US">Percentage of payments under collaborative agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M3L1I966J4J2_mtoo_PercentageOfPaymentsUnderCollaborativeAgreement" xml:lang="en-US">Percentage of payments under collaborative agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_PercentageOfPaymentsUnderCollaborativeAgreement" xlink:to="lab_M3L1I966J4J2_mtoo_PercentageOfPaymentsUnderCollaborativeAgreement"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_MilestonePayments" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_MilestonePayments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_MilestonePayments" xml:lang="en-US">Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_MilestonePayments" xml:lang="en-US">Milestone payments to BioLite in cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_MilestonePayments" xml:lang="en-US">The payments which are paid during the term of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_MilestonePayments" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_MilestonePayments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_K1J9G744H2H0_us-gaap_SharePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_SharePrice" xml:lang="en-US">Share price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_SharePrice" xlink:to="lab_M3L1I966J4J2_us-gaap_SharePrice"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_RelatedPartiesTransactionsTextualAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_RelatedPartiesTransactionsTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_RelatedPartiesTransactionsTextualAbstract" xml:lang="en-US">Related Parties Transactions Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_RelatedPartiesTransactionsTextualAbstract" xml:lang="en-US">Related Parties Transactions (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_RelatedPartiesTransactionsTextualAbstract" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_RelatedPartiesTransactionsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_K1J9G744H2H0_us-gaap_DueToOfficersOrStockholdersCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_DueToOfficersOrStockholdersCurrent" xml:lang="en-US">Due to Officers or Stockholders, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_DueToOfficersOrStockholdersCurrent" xml:lang="en-US">Due to shareholder, YuanGene Corporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_DueToOfficersOrStockholdersCurrent" xlink:to="lab_M3L1I966J4J2_us-gaap_DueToOfficersOrStockholdersCurrent"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_AccountsPayableTextualAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_AccountsPayableTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_AccountsPayableTextualAbstract" xml:lang="en-US">Accounts Payable Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_AccountsPayableTextualAbstract" xml:lang="en-US">Accounts Payable (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_AccountsPayableTextualAbstract" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_AccountsPayableTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_K1J9G744H2H0_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_M3L1I966J4J2_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_BioliteIncMember" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_BioliteIncMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_BioliteIncMember" xml:lang="en-US">Biolite Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_BioliteIncMember" xml:lang="en-US">The set of legal entities associated with a report.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_BioliteIncMember" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_BioliteIncMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_K1J9G744H2H0_us-gaap_PlanNameAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_PlanNameAxis" xlink:to="lab_M3L1I966J4J2_us-gaap_PlanNameAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_PlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_PlanNameDomain" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_PlanNameDomain"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_EquityIncentivePlanMember" xlink:label="loc_K1J9G744H2H0_mtoo_EquityIncentivePlanMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_EquityIncentivePlanMember" xml:lang="en-US">Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_EquityIncentivePlanMember" xml:lang="en-US">2016 Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M3L1I966J4J2_mtoo_EquityIncentivePlanMember" xml:lang="en-US">Equity incentive plan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_EquityIncentivePlanMember" xlink:to="lab_M3L1I966J4J2_mtoo_EquityIncentivePlanMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_SubsidiarySaleOfStockLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_SubsidiarySaleOfStockLineItems" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_SubsidiarySaleOfStockLineItems"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_EquityTextualAbstract" xlink:label="loc_K1J9G744H2H0_mtoo_EquityTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_EquityTextualAbstract" xml:lang="en-US">Equity Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_EquityTextualAbstract" xml:lang="en-US">Equity (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_EquityTextualAbstract" xlink:to="lab_M3L1I966J4J2_mtoo_EquityTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_SaleOfStockPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Purchase price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_SaleOfStockPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_K1J9G744H2H0_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Net proceeds from offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_M3L1I966J4J2_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ConversionOfExchangeRatio" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_ConversionOfExchangeRatio"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_ConversionOfExchangeRatio" xml:lang="en-US">Conversion Of Exchange Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_ConversionOfExchangeRatio" xml:lang="en-US">Exchange ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_ConversionOfExchangeRatio" xml:lang="en-US">The exchange ratio per stock split.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_ConversionOfExchangeRatio" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_ConversionOfExchangeRatio"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_NumeratorAbstract" xlink:label="loc_K1J9G744H2H0_mtoo_NumeratorAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_mtoo_NumeratorAbstract" xml:lang="en-US">Numerator [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_mtoo_NumeratorAbstract" xml:lang="en-US">Numerator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_mtoo_NumeratorAbstract" xlink:to="lab_M3L1I966J4J2_mtoo_NumeratorAbstract"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_DenominatorAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_DenominatorAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_DenominatorAbstract" xml:lang="en-US">Denominator [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_DenominatorAbstract" xml:lang="en-US">Denominator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_DenominatorAbstract" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_DenominatorAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_K1J9G744H2H0_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted-average shares outstanding:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_M3L1I966J4J2_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted-average shares outstanding - Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_K1J9G744H2H0_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xml:lang="en-US">Stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="lab_M3L1I966J4J2_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted-average shares outstanding - Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_K1J9G744H2H0_us-gaap_EarningsPerShareBasic"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_EarningsPerShareBasic" xml:lang="en-US">-Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_EarningsPerShareBasic" xlink:to="lab_M3L1I966J4J2_us-gaap_EarningsPerShareBasic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_EarningsPerShareDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">-Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_EarningsPerShareDiluted" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_EarningsPerShareDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_K1J9G744H2H0_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xml:lang="en-US">Operating Leases, Future Minimum Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_M3L1I966J4J2_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Remaining 2016</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_K1J9G744H2H0_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">Year ending September 30, 2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_M3L1I966J4J2_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">Year ending September 30, 2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_K1J9G744H2H0_us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_M3L1I966J4J2_us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_JFF375209FGJ9KJ8G623_mtoo_CommitmentsAndContingenciesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments And Contingencies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_mtoo_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_mtoo_CommitmentsAndContingenciesTextualAbstract" xlink:to="lab_LHH597421HIL1ML0I845_mtoo_CommitmentsAndContingenciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_K1J9G744H2H0_us-gaap_LongTermPurchaseCommitmentAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_LongTermPurchaseCommitmentAmount" xml:lang="en-US">Long-term Purchase Commitment, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_LongTermPurchaseCommitmentAmount" xml:lang="en-US">Total consideration amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_M3L1I966J4J2_us-gaap_LongTermPurchaseCommitmentAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_LongtermPurchaseCommitmentPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_LongtermPurchaseCommitmentPeriod" xml:lang="en-US">Long-term Purchase Commitment, Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_LongtermPurchaseCommitmentPeriod" xml:lang="en-US">Commitment consderation, period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_LongtermPurchaseCommitmentPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_K1J9G744H2H0_us-gaap_OperatingLeasesRentExpenseNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Rent expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_M3L1I966J4J2_us-gaap_OperatingLeasesRentExpenseNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_SubsequentEventTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_SubsequentEventTable" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_K1J9G744H2H0_us-gaap_SubsequentEventTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_M3L1I966J4J2_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_SubsequentEventTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_K1J9G744H2H0_us-gaap_SubsequentEventMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_SubsequentEventMember" xlink:to="lab_M3L1I966J4J2_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_JFF375209FGJ9KJ8G623_us-gaap_SubsequentEventLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LHH597421HIL1ML0I845_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JFF375209FGJ9KJ8G623_us-gaap_SubsequentEventLineItems" xlink:to="lab_LHH597421HIL1ML0I845_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:label="loc_K1J9G744H2H0_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M3L1I966J4J2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Description and Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M3L1I966J4J2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xml:lang="en-US">Licensing rights term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K1J9G744H2H0_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:to="lab_M3L1I966J4J2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>mtoo-20160930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Friday, January 13, 2017 03:22:45 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#DocumentAndEntityInformation" roleURI="http://metuboutique.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#Condensedconsolidatedbalancesheets" roleURI="http://metuboutique.com/role/Condensedconsolidatedbalancesheets"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#Condensedconsolidatedbalancesheetsparenthetical" roleURI="http://metuboutique.com/role/Condensedconsolidatedbalancesheetsparenthetical"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://metuboutique.com/role/CondensedConsolidatedStatementsOfOperations"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://metuboutique.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#Condensedconsolidatedstatementsofcashflow" roleURI="http://metuboutique.com/role/Condensedconsolidatedstatementsofcashflow"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#OrganizationAndDescriptionOfBusiness" roleURI="http://metuboutique.com/role/OrganizationAndDescriptionOfBusiness"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://metuboutique.com/role/SummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#GoingConcern" roleURI="http://metuboutique.com/role/GoingConcern"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#CollaborativeAgreement" roleURI="http://metuboutique.com/role/CollaborativeAgreement"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#RelatedPartiesTransactions" roleURI="http://metuboutique.com/role/RelatedPartiesTransactions"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#AccountsPayable" roleURI="http://metuboutique.com/role/AccountsPayable"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#Equity" roleURI="http://metuboutique.com/role/Equity"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#EarningsPerShare" roleURI="http://metuboutique.com/role/EarningsPerShare"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#CommitmentsAndContingencies" roleURI="http://metuboutique.com/role/CommitmentsAndContingencies"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#SubsequentEvent" roleURI="http://metuboutique.com/role/SubsequentEvent"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#EarningsPerShareTables" roleURI="http://metuboutique.com/role/EarningsPerShareTables"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#CommitmentsandContingenciesTables" roleURI="http://metuboutique.com/role/CommitmentsandContingenciesTables"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#OrganizationAndDescriptionOfBusinessDetails" roleURI="http://metuboutique.com/role/OrganizationAndDescriptionOfBusinessDetails"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#GoingConcernDetails" roleURI="http://metuboutique.com/role/GoingConcernDetails"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#CollaborativeAgreementDetails" roleURI="http://metuboutique.com/role/CollaborativeAgreementDetails"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#RelatedPartiesTransactionsDetails" roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#AccountsPayableDetails" roleURI="http://metuboutique.com/role/AccountsPayableDetails"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#EquityDetails" roleURI="http://metuboutique.com/role/EquityDetails"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#EarningsPerShareDetails" roleURI="http://metuboutique.com/role/EarningsPerShareDetails"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://metuboutique.com/role/CommitmentsAndContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://metuboutique.com/role/CommitmentsAndContingenciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="mtoo-20160930.xsd#SubsequentEventDetails" roleURI="http://metuboutique.com/role/SubsequentEventDetails"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_DocumentAndEntityInformationAbstract" xlink:label="loc_mtoo_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentDescription_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_7" order="60" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Condensedconsolidatedbalancesheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrent_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrentAndNoncurrent_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_AccountsPayableOtherCurrentAndNoncurrent_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_Liabilities_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_CommitmentsAndContingencies_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_StockholdersEquityAbstract_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_CommonStockValue_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_AdditionalPaidInCapital_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquity_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_24" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Condensedconsolidatedbalancesheetsparenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_CostOfRevenue_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GrossProfit_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_InterestExpense_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_15" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_15" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CondensedConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_SubscriptionReceivableMember" xlink:label="loc_mtoo_SubscriptionReceivableMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_mtoo_SubscriptionReceivableMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockholdersEquity_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_SharesOutstanding_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization" xlink:label="loc_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares" xlink:label="loc_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensation_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_16" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable" xlink:label="loc_mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable_17" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_NetIncomeLoss_18" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockholdersEquity_19" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_SharesOutstanding_20" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Condensedconsolidatedstatementsofcashflow">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_IncreaseDecreaseInPrepayment" xlink:label="loc_mtoo_IncreaseDecreaseInPrepayment_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_mtoo_IncreaseDecreaseInPrepayment_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:label="loc_us-gaap_IncreaseDecreaseDueFromAffiliates_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseDueFromAffiliates_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_14" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_16" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ProceedsFromSubscriptionReceivable" xlink:label="loc_mtoo_ProceedsFromSubscriptionReceivable_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_16" xlink:to="loc_mtoo_ProceedsFromSubscriptionReceivable_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_16" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_16" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_16" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_Prepayment" xlink:label="loc_mtoo_Prepayment_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_25" xlink:to="loc_mtoo_Prepayment_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_27" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_27" xlink:to="loc_us-gaap_InterestPaid_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_27" xlink:to="loc_us-gaap_IncomeTaxesPaid_29" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/OrganizationAndDescriptionOfBusiness">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/GoingConcern">
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_GoingConcernAbstract" xlink:label="loc_mtoo_GoingConcernAbstract_0"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_GoingConcernDisclosureTextBlock" xlink:label="loc_mtoo_GoingConcernDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_GoingConcernAbstract_0" xlink:to="loc_mtoo_GoingConcernDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CollaborativeAgreement">
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CollaobrativeAgreementsAbstract" xlink:label="loc_mtoo_CollaobrativeAgreementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_CollaobrativeAgreementsAbstract_0" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/RelatedPartiesTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/AccountsPayable">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Equity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/EarningsPerShare">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SubsequentEvent">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ForwardStockSplitPolicyTextBlock" xlink:label="loc_mtoo_ForwardStockSplitPolicyTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_mtoo_ForwardStockSplitPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/EarningsPerShareTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CommitmentsandContingenciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/OrganizationAndDescriptionOfBusinessDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementMember" xlink:label="loc_mtoo_ShareExchangeAgreementMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementOneMember" xlink:label="loc_mtoo_ShareExchangeAgreementOneMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementOneMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementTwoMember" xlink:label="loc_mtoo_ShareExchangeAgreementTwoMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementTwoMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementThreeMember" xlink:label="loc_mtoo_ShareExchangeAgreementThreeMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementThreeMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementFourMember" xlink:label="loc_mtoo_ShareExchangeAgreementFourMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementFourMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9" xlink:to="loc_dei_EntityDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_AmericanBriVisionHoldingCorporationMember" xlink:label="loc_mtoo_AmericanBriVisionHoldingCorporationMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_10" xlink:to="loc_mtoo_AmericanBriVisionHoldingCorporationMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember" xlink:label="loc_mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_10" xlink:to="loc_mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_AmericanBriVisionCorporationMember" xlink:label="loc_mtoo_AmericanBriVisionCorporationMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_10" xlink:to="loc_mtoo_AmericanBriVisionCorporationMember_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract" xlink:label="loc_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_14" xlink:to="loc_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommonStockIssuedAfterStockSplit" xlink:label="loc_mtoo_CommonStockIssuedAfterStockSplit_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract_15" xlink:to="loc_mtoo_CommonStockIssuedAfterStockSplit_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommonStockIssuedBeforeStockSplit" xlink:label="loc_mtoo_CommonStockIssuedBeforeStockSplit_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract_15" xlink:to="loc_mtoo_CommonStockIssuedBeforeStockSplit_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract_15" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_PercentageOfIssuedShareCapital" xlink:label="loc_mtoo_PercentageOfIssuedShareCapital_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract_15" xlink:to="loc_mtoo_PercentageOfIssuedShareCapital_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract_15" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/GoingConcernDetails">
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_GoingConcernAbstract" xlink:label="loc_mtoo_GoingConcernAbstract_0"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_GoingConcernTextualAbstract" xlink:label="loc_mtoo_GoingConcernTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_GoingConcernAbstract_0" xlink:to="loc_mtoo_GoingConcernTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_GoingConcernTextualAbstract_1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_GoingConcernTextualAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_GoingConcernTextualAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CollaborativeAgreementDetails">
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CollaobrativeAgreementsAbstract" xlink:label="loc_mtoo_CollaobrativeAgreementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_CollaobrativeAgreementsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CollaborativeAgreementTextualAbstract" xlink:label="loc_mtoo_CollaborativeAgreementTextualAbstract_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5" xlink:to="loc_mtoo_CollaborativeAgreementTextualAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:label="loc_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_6" xlink:to="loc_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:label="loc_us-gaap_CollaborativeArrangementRightsAndObligations_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_6" xlink:to="loc_us-gaap_CollaborativeArrangementRightsAndObligations_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_6" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_UpfrontPayments" xlink:label="loc_mtoo_UpfrontPayments_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_6" xlink:to="loc_mtoo_UpfrontPayments_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_PercentageOfPaymentsUnderCollaborativeAgreement" xlink:label="loc_mtoo_PercentageOfPaymentsUnderCollaborativeAgreement_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_6" xlink:to="loc_mtoo_PercentageOfPaymentsUnderCollaborativeAgreement_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_MilestonePayments" xlink:label="loc_mtoo_MilestonePayments_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_6" xlink:to="loc_mtoo_MilestonePayments_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_CollaborativeAgreementTextualAbstract_6" xlink:to="loc_us-gaap_SharePrice_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/RelatedPartiesTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_RelatedPartiesTransactionsTextualAbstract" xlink:label="loc_mtoo_RelatedPartiesTransactionsTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_mtoo_RelatedPartiesTransactionsTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_RelatedPartiesTransactionsTextualAbstract_1" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrent_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_RelatedPartiesTransactionsTextualAbstract_1" xlink:to="loc_us-gaap_DueToOfficersOrStockholdersCurrent_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/AccountsPayableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_AccountsPayableTextualAbstract" xlink:label="loc_mtoo_AccountsPayableTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_mtoo_AccountsPayableTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_AccountsPayableTextualAbstract_1" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/EquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementMember" xlink:label="loc_mtoo_ShareExchangeAgreementMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementOneMember" xlink:label="loc_mtoo_ShareExchangeAgreementOneMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementOneMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementTwoMember" xlink:label="loc_mtoo_ShareExchangeAgreementTwoMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementTwoMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementThreeMember" xlink:label="loc_mtoo_ShareExchangeAgreementThreeMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementThreeMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementFourMember" xlink:label="loc_mtoo_ShareExchangeAgreementFourMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_mtoo_ShareExchangeAgreementFourMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1" xlink:to="loc_dei_LegalEntityAxis_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_10" xlink:to="loc_dei_EntityDomain_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_AmericanBriVisionHoldingCorporationMember" xlink:label="loc_mtoo_AmericanBriVisionHoldingCorporationMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_11" xlink:to="loc_mtoo_AmericanBriVisionHoldingCorporationMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember" xlink:label="loc_mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_11" xlink:to="loc_mtoo_EuroAsiaInvestmentAndFinanceCorpLimitedMember_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_AmericanBriVisionCorporationMember" xlink:label="loc_mtoo_AmericanBriVisionCorporationMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_11" xlink:to="loc_mtoo_AmericanBriVisionCorporationMember_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_BioliteIncMember" xlink:label="loc_mtoo_BioliteIncMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_11" xlink:to="loc_mtoo_BioliteIncMember_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1" xlink:to="loc_us-gaap_PlanNameAxis_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_16" xlink:to="loc_us-gaap_PlanNameDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_EquityIncentivePlanMember" xlink:label="loc_mtoo_EquityIncentivePlanMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_17" xlink:to="loc_mtoo_EquityIncentivePlanMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_EquityTextualAbstract" xlink:label="loc_mtoo_EquityTextualAbstract_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_19" xlink:to="loc_mtoo_EquityTextualAbstract_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_EquityTextualAbstract_20" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_EquityTextualAbstract_20" xlink:to="loc_us-gaap_SharePrice_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_EquityTextualAbstract_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_EquityTextualAbstract_20" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_EquityTextualAbstract_20" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_EquityTextualAbstract_20" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommonStockIssuedAfterStockSplit" xlink:label="loc_mtoo_CommonStockIssuedAfterStockSplit_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_EquityTextualAbstract_20" xlink:to="loc_mtoo_CommonStockIssuedAfterStockSplit_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommonStockIssuedBeforeStockSplit" xlink:label="loc_mtoo_CommonStockIssuedBeforeStockSplit_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_EquityTextualAbstract_20" xlink:to="loc_mtoo_CommonStockIssuedBeforeStockSplit_28" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_EquityTextualAbstract_20" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_29" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_PercentageOfIssuedShareCapital" xlink:label="loc_mtoo_PercentageOfIssuedShareCapital_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_EquityTextualAbstract_20" xlink:to="loc_mtoo_PercentageOfIssuedShareCapital_30" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_EquityTextualAbstract_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_31" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_EquityTextualAbstract_20" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_32" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_EquityTextualAbstract_20" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_33" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ConversionOfExchangeRatio" xlink:label="loc_mtoo_ConversionOfExchangeRatio_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_EquityTextualAbstract_20" xlink:to="loc_mtoo_ConversionOfExchangeRatio_34" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/EarningsPerShareDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_NumeratorAbstract" xlink:label="loc_mtoo_NumeratorAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_mtoo_NumeratorAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_NumeratorAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_DenominatorAbstract" xlink:label="loc_mtoo_DenominatorAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_mtoo_DenominatorAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_DenominatorAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8" xlink:to="loc_us-gaap_EarningsPerShareBasic_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CommitmentsAndContingenciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_mtoo_CommitmentsAndContingenciesTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_mtoo_CommitmentsAndContingenciesTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_CommitmentsAndContingenciesTextualAbstract_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_CommitmentsAndContingenciesTextualAbstract_1" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mtoo_CommitmentsAndContingenciesTextualAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SubsequentEventDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementMember" xlink:label="loc_mtoo_ShareExchangeAgreementMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_mtoo_ShareExchangeAgreementMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementOneMember" xlink:label="loc_mtoo_ShareExchangeAgreementOneMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_mtoo_ShareExchangeAgreementOneMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementTwoMember" xlink:label="loc_mtoo_ShareExchangeAgreementTwoMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_mtoo_ShareExchangeAgreementTwoMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementThreeMember" xlink:label="loc_mtoo_ShareExchangeAgreementThreeMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_mtoo_ShareExchangeAgreementThreeMember_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ShareExchangeAgreementFourMember" xlink:label="loc_mtoo_ShareExchangeAgreementFourMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_mtoo_ShareExchangeAgreementFourMember_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_12" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommonStockIssuedAfterStockSplit" xlink:label="loc_mtoo_CommonStockIssuedAfterStockSplit_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_12" xlink:to="loc_mtoo_CommonStockIssuedAfterStockSplit_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_CommonStockIssuedBeforeStockSplit" xlink:label="loc_mtoo_CommonStockIssuedBeforeStockSplit_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_12" xlink:to="loc_mtoo_CommonStockIssuedBeforeStockSplit_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_12" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_PercentageOfIssuedShareCapital" xlink:label="loc_mtoo_PercentageOfIssuedShareCapital_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_12" xlink:to="loc_mtoo_PercentageOfIssuedShareCapital_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="mtoo-20160930.xsd#mtoo_ConversionOfExchangeRatio" xlink:label="loc_mtoo_ConversionOfExchangeRatio_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_12" xlink:to="loc_mtoo_ConversionOfExchangeRatio_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_12" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_12" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_12" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_21" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_12" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_22" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_12" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_23" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex5i_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5i_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "% 8 # 2(  A$! Q$!_\0
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ML/\ ^H] _0,O_P!PP'_8#@?_ %"P84J]1]1_.DI5ZCZC^=;G6?FW_P $RO\
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M3A.$E*$X25XRC)74HR3336C3NA5ZCZC^=?GQ_P $L_\ DQWX6?\ 8Z?M$_\
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MW_*;+PC_ -G9_M!?S^*U?WIU\3P/_N6:?]C?$?\ I#/RCPD_Y%?$/_93X_\
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M!!Y!'(/-?WMU_!'_ ,%-O^4QOQ#_ .RX?LY?^FSX85\3QS_R+\O_ .QK0_\
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MA']KK]J?]I'X<>-/V??@GKGQ,\+:-\ _^$3U36-,UWP?I<-GXC_X3/Q-J?\
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MD\+>*-+^(?PA^/5I'XD\-6WQ,^'$WPIU/X6ZG)X/U'6+"S\5ZY\*/%&G>/\
MQ4+;Q%X6TRXO-:TOPWXUT[7;/Q/!82Z/)KNBWUW;ZC%G_M;_ !S^+7PA^+7[
M#O@WX<7G@N'P_P#M&?M+7'P6^(G_  E/AG4]<U2Q\-P?"'XG?%3^UO"-WI_B
M+1;?3]:,OPV&A'^UK/5[!;;7)=0^S&;3XX+D ^Y**^'?VZ/CE\6?@/H?[..H
M?">[\%VMW\6/VN_@%^S[XK/C;PUJGB2"U\(_&+Q4/#6JZWH<>E^(O#DEMXBT
M-,7FEF]EO=,N9"T%[:%=CBI^W7\</C)\#M/_ &8H_@]J?@73]2^-O[6GPE_9
MT\27?CKPCJGBNUTW0?BC#XACF\2Z-9Z3XJ\*R)K6A7&B136UK>74^GWT5Q-#
M<"!DCFH ^[:*\;^%.@?';0M0\7Q_&7XC^ ?B)IMY+H4_@>;P7\.-1^'5]HD:
M6UY#XBL-?MKWQKXVAUH7%XMC>:3J%M<Z:T,,EU9W%E*88[J;\JM5_;(_;2T[
MX+?\%"OVB-)UC]GC7-#_ &#/CI\?_" ^%^N> /%WAJ3XI?#+X">#?"_Q#U@W
M'Q(M_B1?Q^#O'NM^&=>U'3M(U!?".L>&H/$&FZ;-?:4VG7UW%; '[<T5QGPX
M\;6/Q+^'?@+XCZ98W^EZ;\0/!7A7QOI^FZK&L.J:=8^*]"L->M+'4H5++%?V
MD%_';WD:LPCN(Y%#$#)^8/V[_P!I#QA^S+\'/"?B3X?Z5X6NO&GQ/^//P*_9
MZ\-^(O'[:@/AS\.]4^.?Q&T;P!;_ !%^($>E7%EJ-[X;\+'53<+I%IJ>D2:_
MKDVC:"=8TI-3:_@ /M*BOG?X467[2WA[QYXL\,_%[Q#X!^)/PX7PKX;UGP3\
M2O#GA>X^'_BU?%L]_J]EXO\ !GB?P>GB#Q+I%UI=E9VVB:YX;\2:7=Z=,T6J
M7^BZI87,^FQ:M>_1% !17PQ^QA\=OBS\;?%'[9>E_$R\\%3:=\ OVMO&W[/_
M (!3PCX:U/0;N\\*^%/!O@+Q9;:WXKN-1\1:[%?^(;R3QR^GW/\ 9<&DZ;'%
MI,-Q%:"2\E2)?VW/CI\6?@9/^R9'\++SP5;I\</VP?A+^SOXV'C+PSJ?B%K3
MPC\1K+Q3>:AKGAIM,\1^'Q9^)-+_ .$96/3_ .T5U+2Y_M\C7=K_ */&) #[
MFHI3P2/0FOAO5_CE\6K7_@HOX(_9DM+WP4GP=U_]DGQ[\?\ 4Q/X9U.;Q\/%
M?@_XI^!OAO:Z+9>(E\1Q:+!X>OK;QJVLW/G>&KC4XKS2H[2&Z^S7CO  ?<=%
M?-_[8GQ,\;?!3]E#]I'XS_#B3P\GCGX/? _XG_%7PS#XLTJ]UKPUJ&J_#OP;
MK'B^WTG6]/T[5-%U"33M8;1_[,N9K'4[6[M([IKJ!I)(5B?O_@?XD\2>,_@Q
M\)O&?C"YTN\\5>,/AQX+\6>(9]#TZ?2-&.K>)/#VGZS>QZ5IMS?ZI<V>GP3W
MKP6D-SJ-[<""-&GN)96=B >HT5^?<G[0OQB^/O[2?QA_9]_9JN/!G@CP-^S-
M<>%O#?Q]^/GC;P_?>.;FY^+/C+PU8>.+#X-_"3P19:WX<TNZU3PIX)U?PYXA
M^(WC;Q3K<^GZ)/XNT#PWI'A76=176;W1_;OA@/VH?#?Q0UGP?\7-2^'/Q,^%
M-[X/.O>"_BQX2\-ZE\/_ !CI7BNPU:SLM4\">/O!<NN>)]!OX-0TS4(M:\+^
M+_#FIZ2LW]EZWI6K>&K66+3[^_ /SX^"W@+X;_%S_@I__P %0+77=<\9+J.C
MZ)^Q5!86_@OXI?$WX=1W,>G?"GQE::\95\!>*/#-EXAFT;4KFTL=1FN/[3N-
M#N+F"PF>R:Y6&3=^ V@> _A__P %>OVF/!OA76]?O9)_V$?V99)X/%?CKQOX
M_P!3&LZ?\9?VA+G5--M=?\=:UXAOHY=-T?5?#NI7_A^RU0+I]OK>GZI-80#5
MEGG_ %]$<8(81QJP\PA@B!@96#RD, #^\<!I.?G8!FR0#0(H@VX11!MS/O$:
M!M[J$=]P7=O9%56;.YE 4D@ 4#O^5C\I].\::%^R_P#\%*_VG/$?QOO8/A_\
M-OVN_@W^S+=?![XL^(I!IGPWO/&WP&A^*WA?X@?"[7_%UV(M%\->.%T_QAX8
M\5^&M,UV]L!XKT.ZU8Z"]]=>']5M[?TGX2>(])^.W[=_CKXY?#"Y_P"$G^#O
MPV_9FTSX#2?$JRBF?P?XQ^)_B'XI7'C_ %K1/ 6ME!8^+K+P-X?T?2$\4Z]H
MDUYHEMK/B>ST&WOY]6TO7+73_P!";VRLM2M9K'4;.UU"QN5"W%G?6\-W:3JK
M*ZK-;7"20RJKHC@.C ,JL.0#4D$$%K!#;6T,5M;6\:0V]O;QI#!!#&H2.*&&
M-5CBCC0!4C1555 "@  4"/RPT+X;_!+]IO\ :;_X*B_L_?%K0O#OQ)\!>./#
M7[+GAOQOX*U0/)%=V4?PSU]99K:XB,-S9:OX?U3[#?:=KFB7<.L>%/$5MIFI
M6-[IFLVEE/'\X?!7P[^U=\&?V^_V4OV7_P!H(^*_C-\./A)\.OVI-6_9S_;)
MU,I>ZC\3/AAK/A_X::9IGPE^/DT,:?9OVC?AFE@;:Z\6+'%I7QD\$V]OXW6.
MS\6VGB^P3]X%BB4[EBC5OG^98T5OWC!I/F"@_.P#/S\S ,V2 :>0#C(!P=RY
M .UL%<KGH=K%21@D$CH30._Y6/RV_P""SNK:=I7_  3K^,QU"Z2W:]\9?L[6
M]G%LFGN+R>U_:2^$FJW,5I:VT<UU<R6VEZ=J&HW"P0R&"PL;N\F"6UM-*GZ?
MIJ6GM8#6%OK1M):R.IKJ0GB-BVG&#[4+X70;R3:&V/GBX#^48?WF[;S5DJK%
M2RJQ0DH656*EE9"5)!VDHS(2,$JS*>"04V)L\O8GE[=GE[5\O9C;LV8V[-OR
M[<;=O&,<4"/YVO\ @G!\0OV2_ W[*GP%\8>,/BSXK_X7)HWQ]_:%N?"?PCT7
MXJ_$6]U#Q1XN^(?[2OQQ\,>"M M/@2VNS^'IX/$^C^+]/U72)6\)6&G6*7MI
MXVDU"QLXKC5Z^O/V_P!_#^J?MC_\$K?"&N>(=2\.'Q'\8OVF-,GU'P_K>I^'
MO$6BP^(/V1?BOX9T_5M+\2:.T5YX:U ^(=5TS3-!UD75F7\07>G65K)-<W*6
MTGZSB&%9/.6&%9L!?-6*,2[0H0#S H? 4!0,X"@ < "E:*)R2\4;DA02\:,2
M$<2("64G"2 .HZ*X###<T#O^OXGXU_\ !-IQ^R1XV^,/[!_QWTB_L?CL/B)X
M@^*_@K]ICQ!9Z]=G]O\ ^'_BHVZZ-\6O$?Q$UF;48-:_:-\$Z9::=\.OC1X#
MN-8ANM,E\/:+XG\$Z);?#[7=,L]'_9>FNB2;1(B/L<2)O57V2+D*Z;@=CJ&.
M&7##)P>:=0(_*[Q)K^BP_P#!:?X5:5+J5M'J,O\ P3?^,&G);,9,G4KK]H?X
M2:Q:Z:9Q&;9-2NM)TO4]4M=.>=;ZXT[3KZ]AMWMK6:5+O[<NO3?';XT_LX?L
M#>"?&=EX:UWQYXBE_:.^,VI3:#:>*[71OA#^SQJ.A>+/#'AC5O#^IM;:1JLO
MQ0^,-S\/['^P[N^CFOO!7AWQW>FUN+2S97_4'RHBVXQ1EMXDW&-"WF*AC5]Q
M7=O6,E%;.Y4)4$*<4>7'N+>7'O+!R^Q=Y=4,:L6QN++&2@8G(0E0=I(H _$;
MPIJ/BC]B+_@J?:^'_BM\4;7QSX%_X*9_"HWI\00^"M/\$Z=X7_:A_9CM-(\/
MZ1)K&G:'<7^EZ4GQ>^"_B"S\/V^OZE=6S:[XB^%.B:"C37DEE$WKGAKQCX?_
M &7?^"DG[7FL?'34K7X=> OVN_ '[,WBGX)?%#Q-*-)^'&N>(?@MX2\8_#[X
MD?#35?&5[Y.A>'O'^DBY\.>*=)T'6KVQG\3^&]>EN_#_ -ODT'6XK+]76CC<
M,'CC<,%#;XT?<$;>@.X'(1_G4'A6^88/-07UA8ZG:S6&I65IJ-C<!1/97]M#
M>6DP1UD42VUPDD,@5T5UWHVUU5A@@&@#\^_@OXATKXZ?MR?%?X^?#2X?Q%\&
M_!W[.'@/]G^T^(UO;S#PIXY^),7Q.\;?$'Q19?#_ %=T6U\6Z)X+T74/#]EK
MOB;2'N=";Q#K4FA6%_=ZAH>MQ67P%\2K[]B_Q+^W=_P4\\$?MCZ]X33X9ZW\
M'/V((DTS7=3\06%YJFN>#M"^->I:C'X/7PTT>MZ[XM\+7.H>'KV/3/#"ZGKM
MAJE]HBPV)O+NVAD_H'ABBMX8K>"*."W@BCA@@AC2*&&&)!'%%#%&%CBBC151
M(T5515"J  !2B*(%6$4097:16\M,K(_WW!VY#O\ QL#N;^(F@#\&?$7Q-^.R
M_P#!#:PU/]J6Y\5:7\<_B9X-T[X5'_A8>G+HOQ/\0Z!\2/C<GP\^&-_X]T*T
MMH)K+XCZW\&-5\->)?B':-96UWINL2^(;S6[73I;748K75\>?![XG?#O]L3X
MN_L<^!O"WB&3]ES_ (*4ZKI_[2.M>,-$B>#PS\&]1\"R:!H?[<'@2[O869M,
MF_:2\,1_"^;PC% GES^*/B!\5]96)&LY)S^Z3HDA!D1)"N[:717*[E9&VE@<
M;D9D;&,JQ4Y!(IPP    !T   'L..!CC QQQTH&?DA_P3]\5^'_!O[2G_!6O
MX1W>IV.EV?@K]LC3?C%8K<'^S]-@\(?%']FWX)ZIJ^I6,\ZPV4VEZ+XIT'Q)
MI>KSV4DEMI.HV<UC>&VGC\JO&_AY\"/$?_!2?P3^V7\='^,]IX2^#7[9S^,_
MV<O"/AJX^%.B>,-3M_V;/@XWB_X5>$=:L[_Q1>Z7K/A?4_&/C&_^(?QGTVQ^
MS1/I\GBWPYJ2>7=6T31_N>886&&AA8%9$.8HSE)FWS(<KRDK_-*IRLC?,X)Y
MIX51G"J-QRV% W' &3@#)P ,GG  Z 4"/RE_X)_?M47?QX_X)^:I-\6=?M$^
M.'[.WAKXF?L^?M(W%Z]S;K-\1/@B-?\  .I_$**>_BA?4/#GQ0T_P_9?$70=
M<M%GTW4;/Q&8;.YFFM9T3RGP;^R7_P -+?L*_L!_'C]GOQYIWP@_;._9^_9I
M^%$_[/GQW2QN+S2][?#WPU;^-/@-\;M#MQ;W_C+X$_$2YTP:!\1/!5V$U;PS
MJMO:>,?"ITOQEX<LI9?VM,,!!!@A(,:1$&*,@Q1DF.,C;S&A)*(?E4DE0#3U
M55SM55W,SL%55#.[%G<A0,LS$LS'EB222: /S'_X)>>-_B+\1?!?[5?B_P"+
M_P (/$/P%^*>K_MD^/QX]^%'B.[@U63PSXFTGX5_!CP]JTWA[Q'9QQ6'B_P'
MK]_HUSX@^'_B^PCCM_$7@_4M'U!XK:\DN[6#ZA_;2U&RTG]CS]JN^U"YAM+6
M+]G/XTQ&:<;D,]U\.O$5K:0+'M=IY[J[FAM;:VCCDENKB:*WABDED1&^E\#)
M. "<9( !..!DXR<#@9)P.!0RJXPZJX!5L,H8;E(96PP(RK ,IQD, 1@@&@/Z
M_K[C\Z_^"=?P<^'VG_LR?L=?%[P[KOQ!U+7#^R%\)_"<MMK?Q2^(?BOPK"FJ
M^!? 5WK\$7@[Q;XAU;1= UK2]:\.KIRG2].TB]TB)+_0Y(H[8&TBX3P]K^BO
M_P %I_B=I*:E;-J(_P"";OPET\VH\S/]HVG[1'Q6UB[TU9C&+9]2M=(U33-5
MN=.29KZ#3=0L[Z6W6UN(Y6_4]5500JJH+,Q"J%!9V+.Q"@#<S$LQZLQ))))-
M-\N/=N\N,-O,FX1H&\QD$;/NV[M[1@1EL[B@"$E>* /P:_X*$^,O@AXUB\8?
MM!?!#QK?_!O_ (*:?L=^-]4^%OP.L=)L7A^*GQSU&XU32KO2_P!G;Q5\,_)3
M4_CA^SQ^T FH63Z8IL]1TKP?>7W_  L?PWK_ (;UGPQK5RGTS^VQH'C;P#^T
M%^P9^W0?!VN^*/!'[-\WQM^'W[1OAOP5IFH>+?%'@CX:?M'^!O"^F7OQ8T3P
M]HUM>:SXHT;X4^._ GAB7QQ9>'['4==C\ ZOK_B33]-O4T"XMW_4*33=.EO[
M?5)=/L9=3M(9+>UU*2TMWU"VMYMWFP6]XT9N889=S>9''*J/N;<IR:NT ?&7
MCO\ ;8^#3^#X4^!'CCPM\>OBQXUMDT[X5?#CX7:UIWC+7M=U_4RMO8ZCKMMI
M-Q<1^$?!^@&1M9\9>*/%DFCZ-H&B6%])=W/VTVEC=?+G_!3"'PMJWQA_X)8>
M$O&.M7MC!JO[<K7&H3:%K_B+PCJJ6D'[,OQ^TO\ M*'Q!X4O]-UOP]82^)-7
MT'1FOXM5T^WEO=;T_19+IVU..WG_ %?L](TG3KB\N]/TK3;"ZU"3S;^YLK"U
MM;B^EW,WF7DT$4<ER^YV;?,SMN9CG))J\T43DEXHG)782\:.2FX/L)922N]5
M;;TW*&QD T#/Q2_X*.?"GX4_!^R_8A\26WB'XAVU\O\ P4?_ &/)0GC'XT?&
M/QWI*:38?$)Y]<U.YT#Q?XS\1Z)'9Z18LUW>ZW=Z:L6B1A;M[ZS.V0^D?\%;
M=3\(VWAG]ABU\8Z\^A:'/_P4;_9HU75]0M-<U;PY>Z=X:T1?&EYKNOIX@T&Z
ML=6\/Z=HUN\$VH^(;:_T^+3(IHS-?VXN$W_K*T<;_?CC?Y'C^=%?Y) !(GS
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-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex23i_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23i_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<TS86VD +%$;J"KX=5[@N.]?*1/C+]C?X_%C'-HOC#P7? [95XW@!A_O1NC
M@CAD=2.#QSU,ZJQ]G5BER2W\F?28/PUPE:OB\OJ3E'$4[N&JM*+^%[:VV=NI
M_0A:S"=,[MQ4E2<=Q4^WFO-?V5?C]IO[1_P(\/\ C#3)(I%U2 -=1QM_Q[7*
M_+-$P[%7!&/I7I0?=[5])&2E%2CLS\=KX>=&I*C45I1;3]5N.HHHJC$****
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M&X\/M/I=\9K+4)8L.XCC?]['L22')?(;?P>& .M@Z7/M6BBB@ HHHH ****
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MA:#X/\7>$;>.?['<0ZS;!89)P,N+:<';<1KP"X P3C&00/5OVKCC]EWXC_\
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MK>%OV6=-^!O@&/\ M+XL?M+:@O@C0[!%21DLI<#4+F1'&TPB!C"^XC:+@O\
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M,[+F3>W^L$C'/;:5Q7CO_!HC_P HV?'7_95=9_\ 26PKU_\ X-V_"6E^%/\
M@B/\'VTS3K/3VU;2+R_O6MXEC-Y<-=7"M-(0/F<JB#<><*HZ 5Y!_P &B)_X
MUL^.O^RJZS_Z2V%*6E2WD5'^&_5'ZH44459F%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(_W
M:6FNVU30!7N)VA SC;C))Z#%?D/_ ,%&/VJ?^&E/CC/%9;H_#?A1IK#3SNRM
MT^_$MUUQAL*%]%4]V-?9W_!4[]J[_A27PA'AG2YE7Q%XPCDMPRO\UI:]))..
MA.=HSZGTKX5_8:_9H_X:9^.-IIMYYT?AW1H_M^KSA3M6)"-L1;H"[<<G.W<<
M$"O#S.O*I..%I]=S\QXTS*>)K0RC#;RMS??U]-V>[_LZBW_8/_8EUKXFWBP?
M\)QX_A6UT"UN5^:*/)$8VYR1\S3OC&55!U KYC_9P^"6I?M2?';1_#,;7#KJ
MUP9]4NP-S06^=\TA_P!HC(!/\3BNR_X* _M$P_'SXX3+I=PC>%_"Z'3-)55*
M1LBDB255//S,O7'W5';FM?XG?$NZ_P""6O\ P3PU3Q8O_$G^,/Q=;^SO#;<-
M<:9:8#-<%3PI6,EQU_>/%G(!J<!@98_&T\'05TM/OWO_ %L>#AL&L?CZ>!I_
MP:&[[ZZOU;6GD?IM)\#/#FH_!"3X?M8C_A&6TS^QQ;YR1#Y>T$,<Y?\ BW'G
M=@]:_&GXE_L#?%SX$?&"^TW1_"OB?5FT&[673=9TRPDD@G'RO'(F V#Z@G@@
MU\UK_P %A?VF$7_DL7BK_@31DG_QV@_\%@?VF,\?&+Q5CTWQ_P#Q-?HV,\+\
M3B%&\XQMZ_=L?T1PIQW6R*,Z6'BI4YJSC+;16_%-H_3K]M+]FCQ/^V=^R+X6
M^*)\'>(M.^*GAN*/3=7TB6T=+B^@5RLA2(\G#E95;'*;QCD8X_\ X)0V7Q:_
M9@_:!32]6^'_ (RL_"/C!1:W\\NERF.SG4$PSD[1M&<HW;#J3]VOSU7_ (+"
M?M,IG_B\/BD_\"C_ /B:1?\ @L!^TT'S_P +A\5?0F,_^RU'_$+,8JT<0JD4
MUZZ^IWQ\1JJRZIE4Z2E3E=J]_=OJDO1[=C^F:-F\OEMW.>/2I1(">H^;ISUK
M^9=?^"P?[3&[YOB_XLV]\-'G_P!!K]4/^"!OBKXX?M#?#OQ#\3?BQXT\6:QH
M5])_9GAJRU$(EO=A#F>\4! 74,%B1@=IVS<9Z+->%Z^7T/;XB<;;=;O\#XJE
MBE-VBC]&T;<M+3(4\N("GU\V=04444 %,DC6="K*&4\$$9!I]&: $7[M?D_>
M,/\ B+GLESS_ ,*G?C_@!K]7\XKP_2?^">_PQTS]MW5OVAI=)NM0^*.HZ?%I
M4.HW-V[1Z9:I!Y)CMXLA$WKNW$@DECR*4=)J7:_XIK]2D_=:[V_-/]#W+'%%
M%%,D^)/VM?\ @L3^S79_##XH>"9OBOH</BZTT?5-'GTE[>Y%U#>?9Y8_(9/+
M^5]^!@^HKY,_X-[?^"GOP'_9/_X)@>#/!7Q%^(NE^$_%5C?W\ESIM];7"S0K
M)<,R$XC(P5(/6OUV7P+HL>IW=Y_8^EB[OG$EQ.+1/,N&"A0SMC+$* ,GL .U
M6/\ A%-*S_R#=/\ _ =/\*I2M%Q[V_"_^8FKV/Q#_P"#<+_@HK\%_P!D+]GW
MXO:7\2O'5CX/U#Q!\2+_ %C3K>_M;A7N[22.(),H$9^4E3U]*^L/VD/^#F_]
MG?X&_$SP'HN@2^(?B1I?B2]\O7]:\/Z=.]KX3M"&47$@:/=._F;<PQ?,(Q(_
M+"..7]"CX3TOG_B6:?\ ^ Z?X4O_  BFE?\ 0,T_G_IW3_"B4N9W?E^"L*,>
M567G^)\1_P#!5+]MK]H;P;X4^&FA_LK_  ZM?&EU\8W%I:>/GDCN])\.B6,M
M'*8LXSL/FK+,/)Q&05<G:/F*Q_X)H_%3_@DO/XP\?7'A^S_;$\"_'!QJ?QS\
M+SZ+;)JC:DL]Q<_VGID+?NYX0]U+NMW7=D!@5#?N?V$M+2*PMUBABCAC7A41
M0JK] *FJ>FA1^2?B7_@K]_P3EUKX3^(-+.C^%/!7B9=&G2+1==^&\NG7MK,8
M7"1$_9C&'##'RR$ ]Z\'_P"",G[?/[$/[+?_  3J\*>'_C=XA^$-QX\CN;S4
M+N,>')=7NK>*XF:6**:46K;I41@K!"RJ1@&OVI^(/[-'PY^+%S<3>*/ ?@WQ
M#-=*(YI=1T:WN9)5!) +.A)P22.>,FN2_P"'<WP#_P"B,?#'_P )NT_^(HCU
M\PZ6/'_^"=7_  4#_9A_:V\;7UG^SSH=U,/L[MJ&M:9\/K[2-+C\LJ1!+>26
MT47FG<"L98L1D@<5]@:DOF:?.",AHV!![\&L'X6_!_PI\$/#1T7P=X<T7POI
M#3-<FRTJSCM(#*V S[$ &XX&3CL*WM2L_P"T=/GMRSQK/&T99#AER,9'O2EJ
MK(#^?G_@CYX_O?"_P0^(EM;?#[]D/Q-&WQ)UMS>?$OQK'H^M9)A&P0M8SGR1
M@;6W\DN,#&3[!^V_\5M2U']C;XK6\GPI_8%T^.X\):G&UWX=^(\-UJ]L#;2#
MS+2(:8ADN%ZHH9<L ,BOT*^!?_!&C]FOX!^!FT.Q^$_A'7VGO)M0NM2\1:?%
MJNH7MQ,VZ222>968Y/11A0!@ 5J?%?\ X)*_LZ?%?X9>(?"\_P (? .DP^(M
M.GTV2^TK0;2UOK-94*&2"41YCE4'*N.5(!HE>4;>5BU+WN;SO^)Q/_! ?P]I
M_A[_ ((_? D:?8VEDMWX=6ZG\B%8_.F>1R\C8ZN3U)Y-9G_!Q+C_ (<Z_&C.
M/^07'U_Z[QU]2_ #X#^%_P!F#X+^&_A[X+T_^R?"OA.R33]-M3*TIBB7/5V)
M9B2222<DDUA_M=?LE^#_ -M[X%ZI\-_'UO?7GA76I(7OK>TO'M9+@12+($,B
M$,%+*,@'D9%7B9>TE*2TNV_Q)P_N.+?0_.+XB_\ !4+P9J?_  1XUCP>GPO^
M/4=_-\*I-*&H2?#;4(]-60Z:8_--R8]@AW<^9G&.:^J_^"!7EM_P1Y^ OE[<
M?\(S'DCU\Q\U]%^)_@!X7\6_ *]^&-UI[1^#=0T1O#LEE#*T96Q:'R#$K@[A
M^[XSG-3_  .^"GAC]G#X3Z%X&\%Z1;Z%X7\-VJV>G6$!)2WB';))).2223DD
MFCFNY/\ F:_"_P#F91C9179/]#\U_P!C.X>/_@Z*_:DAS^[;P=I3D8[B&UQ_
M,U^JPZFO%OA-^P?\.?@U^U1\1/C1I>FW<WQ#^)Q@35M2N[II?*@ABCB2W@3[
ML<?[I6( R6/)Z >UBE*5XQCV7ZE6]YR[V_)+]#\<_#7Q[\8?!/\ X./_ -IS
M4?!'PD\5?&&YO/!>C6\]EH.I6%C)8JBV@,CM>31*PWJ5PI)SVQDC$^+GC/XF
M_M:?\%[_ (2RZQ\%?&WPMU*'X5>)[!+36+ZQO1.)K"_CBF::SEEBB0S.L8\Q
M@=V/6OUW\%_ CP?\/O'WB3Q5HOAW2]/\2>,)DGUK5(H +O461%1/,D^\0JHH
M"YP,=*ZC[-&ETTRQIYC*$9PHW,!G )Z\9/YFEV\DU]ZM^II*5V[=;?A;_(_'
MW]JO]BOQ9_P3^_X-2/B+\-O'%[I-[XJTVSCOM0;2Y7FMH7N-=MIA&LCJI<JK
M ,VT#=G&0 QX7XG?\$M?VH_V[O\ @EE^S7X,\'?&73->^$?C3P9X0&L^%]=T
M#3[-O!D46EVC&YAO846>Y6-T($+ R!F^9GSNC_7C]KO]E?PG^VW^SQXB^%WC
MB.^F\*^*U@BU&.SN#;S2)%<17 59!RN6B4''.":Z;X1?"O1?@=\+/#O@SPU:
MM8^'O">F6^D:9;F1I#!;01K%&I9B68A5').3WIRES:RW)YFG_74TO!OA\>$?
M".E:2LC3+I=G#:"0K@R"- FXCMG&:^/_ -K']F?XE> -6\??$Z]_;&^*WP_^
M&.G6YU1=$TOPII.HG08D4&;$TEI-//'G)5=FY1P6?&:^U**0'\X__!2CXI>'
M_P!HK]HK]D?1_!7[:WB;XX:O)\5M.A#R:?I$%YX-DEN[2..]CBALXB95?HLP
M=,H,KR<_>O\ P4M_X(E?'S]L']E^Y\#V/[4WB_QQ)?:O87+Z9XQTS2;+2A%%
M,'>5WL;%;@N@^954@,P /'(^K]7_ ."3'P'UW]M?3?C_ '7@73F^(NCP+%9S
MHHCM8I5)(NC H"-<#<<2,"1U'/-?29/%',U9]0=F8?PV\,2^"/AWH.BS2K<3
MZ3I]O922H"%D:.)4+ 'G!*U\(ZOJ/PU_87_;5U3XZ?M9?%+PS9?$OQC'<Z3X
M$@:.Y_L+P7H$<@06]O*\>/M4V\//*^PL9&1!L#,_Z%UROQB^#OAOX_?#76/!
M_B[1['7/#^N6SVEW:7<*RQNK*1D!@<,,Y5ARI (((HOUZ@K;'Y@_\&[WQX\&
M^'_A7^UW\3-0\2:5IOP_D^*NI:RNOW<X@L39E-XFWO@;=I'OR!UK/^ GQNT?
M]K']O75OVZ/C#J7_  K+]G/X=P?\(;\)I_$V^PBUIYG9'U8I+]U96:39)B/A
MXXSN,+&OK[1_^"(?[.^C>%O /AH>%=0N/!/P[#S6'A6?59WT34+QF5OM]];;
MMMW<@J,/-N ]*^GM?^'GA_Q9X+;P[JFAZ3J'A^6!;9M,N;2.6S:)0 J>404V
M@ 8&,# Q3O:UNB27R5B==;]6W][N?E;I'Q:\+?MV_P#!T#\-_%'PU\::?XM\
M+_"CX47K:A+I<R75B\LLMW"62525;YKZ!6(Z- !7Z>?'?XS:'^SI\%?%GC[Q
M-=K8^'?!^D7.LZA,W\$,$32-@=2Q"X"CDD@ $FO*/V'_ /@EO\%?^"=VK^+M
M2^%WA&'1=4\;7;76IWTLS3W#)N++;QLW^K@4G(C7 SR<D UW?[4_[*?A']LK
MX;VO@[QY;WVH>%8]7LM7O-+BN6BM]7-I,)HK>Z4?ZZW,JQNT1X8QKGI4_92]
M?Q=_^ 5]IOT_)'R7_P &\'[,NM?"?]CW7?B9XMTM-'\9_M">)+KQ]J5FF]1;
MPW+%K==KJK*2C&3W$H/'2N%_;JLYO^"OW_!1OPK^SOX=EN;SX0_ O48?$WQ7
MU6!2;*YU)2&M-$\P/L>7 8R1E6V[CG#1L*_2;Q%X:CUSPC?:1#<WFE1WEG)9
MI<:?)Y$]F&0H'A8?<=<Y4@<$#TKC/V6_V5O!/[&_PBLO!/@/1_[+TBU=IYY9
M)#/>:I=/S+=W4S?/-<2M\SR,223V  #OJGVV^6WW!WOU_4\=_P""UMO':?\
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M-A)<;@$9"R%]PX$BGG-..L4^[:7G9)_?KL*2L_E=^6MOZ9]2'K1MKY)^'_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSR>2!U/)R:(223B]G!1?R::?SL%2\FY?W^9>C6J/P%_X)=?$_P -_!O]B_\
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M^$_&^JK&L*W&KVGVDHJC"A0QVC@]0,US1_X)"_LSR:%_91^#?@XZ5Y?D_83
M_P!F\O\ N>5NV;?;&*5.\:<X]9-/TLK?\$NM)3E3?2*:^]W_ . ?EG_P<Z_M
M)6?[6/\ P2G^#?Q T]H/[%\1?$&\;2'CX%U90FZ@AG&6.1(D8D!XXD' KM/^
M#E+[-<?MR?L&K=""6UE\42!Q* T;@W6F]0>".17Z6?$+_@EO^SS\6?"GA?0?
M$GP>\"ZWHO@JS.G:#8W>FJ]OI5N6W&.%/NH">>!47Q'_ ."6/[._Q@'AY?%'
MP?\ !7B >%-+BT;1C?6/G'3+.(DQPQ%CE%4L2,<_E6E*2A*+6RJ<_P DDK>N
M@3ESQ:V]R4?G)M_<K^I^:/[<-O%+_P '?W[.>^.-MO@N!^0.&":Q@_4<8_"G
M?\$SM1EA_P"#L#]K"W20"&;PQ=R2( /F*W&EXYZ\;CT]:_3KQ#_P33^ OBWX
MRVWQ$U/X5>#[[QU92P36^NS6>Z_@>!56(K+G<-BJH&/2JNA_\$NOV>_#/Q.U
M#QEI_P (_!ECXMU9;Q;W5X++R[R[%W')'<AY =S>8DKALG^+Z4J4E#EOT4U_
MX%M]Q,TI<R?7D_\ )=_OT/RU_P"#?&)M3\$?\%"H;7_2)+CQ'J8B2+YVD+)?
MA< =<]O6HO\ @VU\7_V]_P $(/C1X+\*ZW:+\1[[4/$ATK3(+I1J+2-I5OY3
MI&#O&2,!L8SWS7ZQ?L[_ /!.OX'_ +)'BZZUSX9?"_PCX'U:^MS:7-SI%B+>
M2XB)!V/C[PR,\UO_  7_ &-_A5^SKXN\0>(/ ?P\\(^$-<\52F75[[2=+BM9
M[]BQ8[V4 D;B3CIGG%9R2<9Q_F@H^C77YE<SYE*VTW)>C6Q^)/\ P1L^$/PJ
M_P""A?\ P2';X*_%#]HCXA^"[?PCKEQ!KO@.UE\-V'ESB_DO;>>W>XTJ34'+
MN>?](<F1)$X7"5ZA\2==C_9A_P"#I[X+WGCS6+BV\$7OPY31?">LZ](D2_+I
ML\1WR%4197G$@;A?FG' # 5^J5K^P#\$;#X[GXGQ_"GP%'\0MWF?V^NBP"]#
M_P#/0/MX?_;^][UL?M#_ +(_PQ_:W\.VND_$[P'X7\<Z;83>?;0:SI\=T+=^
M[(6&5S@9P><<UK[5\\9V[W7K%QNO.S_0SY5:47UV?5>\I?I8_(/]E+XS>#-?
M_P"#NSXH:AI?B+09]/UCPF^G6EU%=1B'4+L06.8XGSB5SL;&TG.TXSBOW$ R
M*\U\-_L=_"?P9XSC\1:7\-? ^GZ]#Y7DW\&B6Z7$'E((X]CA,IM10!MQ@"O2
MQP34<R5*G3_E37K=M_J5*[J2F^MOP20M%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U\[#MZXXI
MU% 'R#_P5-_X)A6_[>O@S1M:\.ZQ<^$?BQ\/V>^\(Z]!+Y:PW PRPS$*3Y19
M%Y )4\X/(/#_  >_:S_;6^'WA*/1OB#^RO;^--<L2(!KOASQWI-C97RJ HE>
M*XE\P,Q!8[5 P?N@\5]XNS8&#W]*\#_8<_X* >#OV^-%\8W7A"QUVR?P'XAF
M\-ZQ'?VWE*MY'RWE.I*R+@@D]1N&10;1K/EY9*Z1P?[/7P(^-?QF^+ND_%7X
M]7\/AB]\*R7#>%O 'A;5G;3+,2QF-I]1E!Q=W&U\*N3%&0&&3T^1KOX!?M6?
M$;_@H\OQS^*7[.LGCO3_  66A\ Z#9>.M)LK/1-LK>7=R+)*YDFVE7Z#$F#C
MY0!^M<TGDGK]T< ]S@G^AKQ6\_X*7?L\Z9>36MY\<OA):W=O(\$\$WBVRCDA
MD0D.C*9 592""" 00:"H5W%NR6NA\Y?M#_M/_MR>,/A_<:=\.?V7=/\ ".L7
M<+0'4M4\>Z5J#VH*D>9$B2HOF G@OD9[5:\'_LJ?$O\ 9'_X)(Q_"[PWX-OO
MB9\5?&>F7\OB2X&MVL*_VQJ(DFN;B>XN)%\R-'<1*5W,5B3CO7OUS_P4\_9S
MM(\R?'CX0J-A<?\ %6V1RH[C]YS3?V*?^"B7PG_X*!>"-7U_X4^*K7Q-;Z#?
M/8:E;J&2ZL)-TBQM)$?F"2B-FC8##J.,$,H=V'MK62BE9WZZ_B?(G_!-"']J
M?_@G[^QMX7^%5W^RO>>)[CP[+=NVI0_$71K9)Q-<R3#Y"[$8#XZ]JT?CE^RS
M^U#_ ,%7-2L_!?QE\/>&?@E\#(KO^T-1T[1]=35?$&M/$,V\#R*K0J@<Y8Y'
M*J0I(!'W5X9_:(\#^+_A]?>*M/\ %WANX\.:9-);7VI?;XTMM/EC;;)'.[$"
M)U8@%7VD9&1S7B\W_!6'X26O[7*?"1?$F@M<3>&W\21>(%UZR;2"B2K&UNTQ
MEPDV6!"\DC)Q@&B[#ZQ[SDHJ[ZZ_YGT)\-_ &E_"WP%H_AO1;&'3='T"SBT^
MPM(ONV\$2A(U'T4#\<UOL<"N/^"7QU\(?M'_  YL?%O@7Q)H_BSPUJ1<6VI:
M9<":"4HQ1AD="&!!!Y!%=@R[J1SZMW8M%%% !1110 W'->&_M,?M=S?";XN^
M!?A?X3T6#Q1\2_B*;F>QLKBZ-M9Z3I]J%-UJ-W(%9A%'O1515+2R.J J-SK[
MB.M?&'[6GP<\1?!O_@I1\-?VE-+T'6O%WA?3_"E_X$\56.D0&ZO])MYYTN8-
M0CMP=TT:2(5E2,%PK!E5L$5,;<Z4MG>_W-K[W9,->5M;V_77\-CU_P %_$+X
MR>"OB1X3\/>/]#\$Z]IWB,W2W/B3PT;BQ@TJ6.,/# ]I</*[>;A\2";@KC9W
MKN_"'[1OP]^('BWQ)H&@^.O!NM:YX-(7Q!IMAK5M<W>A$YP+J)'+P?=;_6!?
MNGTKSOQG\96_:^_9M\=:7\*)/%%EK6L:#J.G:;JVI:'?Z$--OGM76!R+R*&7
M/F.A#(A P3GBOS\^!O@SPS\6-*CNOB5X+_:O/BKX0^ -3T6[T;QEX,TZ;PM9
M17%H()K"(6&GI_:43M%$T<<:RC*(V%(HE*UTULK^;W?X:+Y_?48IVL]W;\OZ
M^1]\_M!_\%1_@/\ LZ?#.]\2ZQ\5?A[/';)9^3:VWB.TDFNFO&9;3 5R0DNR
M1A(1L"12N2$C=AU&@_'71?$/CJ?Q39_%;X>ZA\-6\)+K45M;7=M(R1K+(TFK
M&\68J;(Q +G;L!1FW]A\!^&_A1<:K_P;U> 8-!\"Z];^,O#EKX6LM:M%\+75
MEK4,6GZ]:7=U&8'A2XD2+_2)<(K!B79-Q;)]I\+>,?#OA?\ X+5^,O$EOX5\
M3:=9:U\*+:._UF#P1J,=OJ%Y;7<UPR2W*VVV6<6GE[5+,Y 6,?, E:5(J$W#
MLY*_2RC=/YDQ;<.9+HM.MW))I/R*GPQ_;ZU+]MVX\0>)?A7^T=\&_">D^%_$
MT^DWVA7Z6.KYTR"_^S)?&1+E)8FN_+?R7;,3+*A4,<$_8WQ"_:'\!?"#Q-H6
MB^+/&_A'PSK'BN;[-HEAJNL6UE<ZQ+D#R[:.5U:9LLHVH"<L/6OR5\2>+M-\
M>?\ !)WQ]I-]X#^(NI>*K+XSW7B72+.^^&VLR7\<$_BAKZ.\ME>S+*6LGE8N
MF&4.R-@MM/??MD:!>>)/VFOBOH7Q TW]JK5/AE^T!%H\GAV3X;^&[+4-/O+#
M^SK:!K&]^TV+W>GS0W*3S#?)&BBY+@(_F$S%>Y%?\.VU%[_-V] =O:3N]$W;
MT4K?\'^KGWC^W1^U!9_LY_!'7&TWQGX!\-_$2_TB^N?"=AXENT7^V+FWA,K1
MPVWFQRW#!1]V,D@LN>.#9_98^+/BS]H#]A?P/XT\[1X/&GB[P?::LDEQ:NUA
M%?3VJR*7B1U<Q"1AE5<$J" 0>:^1==TC4OA#K/[4'@3QIX2\<^(K[XG>&K>'
MP%J+>'Y];BU?2K?0$MUTN6>&-XH9X;M;IVCF,:N]V9$W%VKZ2_X)W>(;CX:_
M\$Q_A?>>*] \4>%[CPGX)LTU73M0TR4ZE;FUM567_1HA)*['82J*I=L@!<G%
M5RI1G=_R-/M=2NOEHF0Y2YX)>=UW^&S]-['SWX,_X*B?&3P9^R=?_'SXAZ1\
M,;_X<^&_$M[X?U_3O#UM?VVK6<-MJ[Z6U]"\TTD<HWH)3#L5MK8#Y'/U]<_M
MO?!BU\/>*-6F^+?PS@TOP/>)IWB.[E\46*0^'[IW*+;WCF4"VE+JRA)2K;E(
MQD5\-_\ !+7]D'P_^TU\#]6MO'&O?&6?1-+^(.M>(9O &O:9/H>@.TNMW5Y8
M3>7-8P7-Q&R^5/Y1N)(P[#>@/RC4_:)\%ZQX>^-G[>&AOX1\47MY\8O ^E3^
M%/L.@W%Y;:\;?1I[.=!.B&%94EV*8Y'5R-I4,*F32IZK7=+Y+_@LTBDZK72[
M5_*[M^%CUU?^"A4GP\_X*&>//"_C[QU\-?#_ ,%]'^'^B^+]%UNYNH].A4W]
MY<6R^?>S3>3)N-N2A3:K"1>"1D]/^T1^U/XT^'O[>_[-G@S0KSPS<_#SXN'6
MUU%A;--?2M9Z9+=Q-%.)/+\IB8CPF?E/S$-@?.'[/4M[\%_VP?#'Q&\>?#KQ
M[I/AWQ7\!O#O@FR$OA>?4;I=3MKN]>YT^>*V68VY9&B;,NV)@5W.",5R'PS^
M&7B']FKX^_L)^&O$F@>*H7\,ZUXNO;JWL?#U]?V?A2RU6">'3+2>Y@B>"+:T
ML<1!<+'CG:B[JTC32LM[7^>LM/NL90;DY-Z;?+W%JOF?HY\./&4MM?>/KK7/
M''A77-,TK6)&@6R6.W/AFU6"(M;7C^8P,JN)9"[;/E=1M^7)V/A!\;O!OQ^\
M&1^(O ?B[PSXV\/S2O#'JF@ZI!J5F\B'#H)H69"RG@C.1WK\LO#]KK_A_P &
M?':^^&'PS\57VC^$_CY:>.KOPC;^$;G1E\6:#'!;)<?8H[B"**X87$<DVQ<E
MW@#<EE8_>O[#?Q6\'_M#7OC/XC>%OA;X^^'=UXNN;?\ MBZ\6Z#)H=[KL]M%
MY$<GV:1BQ\N-1'YA52P51\P4$1&-U?R3MVND_P!6O5,J3L_FU]S:^_1/YG=?
MM6_&G4O@)\"=>\1:#H;^*O$T,/DZ%H:/Y;:Q?OQ#;[OX0S<LW145F. I-/\
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MGP1W%S:W4%Q)(R_N7,BS"3:=A4JIP3Y)^V_XOM];_P""!HTC3[?Q%JVI>,/
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MI7/Q0\!:IX.U*_72=+U+3]?M;FSU2]+A/(BGC=HRRG)<YQ&JLSE54D=A\/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*9-\T3#U!'7%/I'^[0!^>7_!-KXR_'+]J7Q]^TA9W/Q8MK72_AW\8O$7A?1K
M>]\+07TEK90W\XBB$PDB9E50%7?N9551N( KQW_@WG\"?$'6OAQ^T.WA[XB:
M;H,,'QIUB&ZCE\,I>_:YQ;61:56,Z[ PXV#(6OL?]E#_ ()B:)^S-XD^*FK?
M\)EXRU:X^*GCS5/&]PMGJMUH]O9/?7+S_9UCMY@) GF;?,;!; X4<5\F_P#!
MNG\(--\7_#']HZ2YU/Q=;_8/C5K-O&MAXCOK-746UDV76*50[DDY=LL>YXH
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M3/$W@WPUXKT?6O%'@V4P:YIEM*6N-+<-M*RKCY3G\ZG?;K_3!Z;_ -7V._
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MBLH."AQS\P''-97@S]M7X4_$'X>:YXMT?QYX?O?#/AM@FIZDMQMM[,D9 9F
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M$G['G[1WQO\ "_C#6/!M]JWB"R\->'M6T](6FCT72+X6+J/.1U"2W\NJS!U
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M@KH].^"?@W1OBA>>-K7PGX8MO&>IVZVMYK\.E0)J=W"H4+')<A?-= $4!2Q
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M2\-2>./ WC2^UF_T[1K:[U"'4M#O(K>.=993]F*NLRL5^RH/W4IQAU$7T_\
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MF_::\;77@WQ-\'O#_@;P=XFO_"MWI&OZU)<WD*11'R+S^SHM-CF:60E)U/\
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M?BSX;M;;QWX,\%^)M&T%6EMHM>TBVO;;3E";69%F1EC&P8)&.!Z5%\*OV?\
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MV9E%R5"2*WV(YE,6X'Z[M/%.EW>LWFFPZA8R7VEB+[7:I.IEM?-!,6] <KO
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M@663S5(MV0Q*$DPR*J@)M7:!@5G4BJE&4-G*_P M]NR_R*C+EJQDMH_CMO\
M\$^._P!B3]JBQ^%WQ6\$^&_CUINEZ'\0/&6@01_#7Q-;7RW7AWQ'IRV\)-C8
M2/M:TO1E?.AF ,S8*22+M5<'X4_\%"/B]XV\*_#'QU8^-/#FJ77Q?EUK3]6\
M#7NDP!?AG<6<%S)D^68;J0VKVZQ727,IWLY,9B!5:^VM9_8J^#>OZ3H^GWWP
MD^&=[8^'8C!I5M<>%[*2+3(RYD*0*8B(E+DMA !N.>M;2_LW_#T>(O$FK?\
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MX2^!&NMX'^$'AW2=5N)K3Q9>Z5%]O1ENC=7]S%;I$SNXOE,S(BQKOV\*J#
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M>'M+^&WQI^&?CJ9/"5WH_P /]7GOIX=+3P[#,D<NFW5DK1F&VM,"/[2'/[W
M1&PI.*^M/ W["G_"/?"CP'H=]XQU"/5/!FD:AI<EQHUA;VMC>_;C&9G6UN%N
M/+V^7MB'F,45W!+YKGM8_P""=^JZ)X-U#1O"OCS;#>^"8/ $4NMZ-!<7&FV
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M6NG:QK5G/XBUG49H?/?3]*MI8XV6&,C899I9%C#/D(N]MK'&/G/]CO\ :_\
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MXMBT71--\0^'O%&MZ#:QBROYI9?-T:\CM$A22W9(E970+/''-R\C $^C:#\
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M9E]^PK\8Y/"K6$'P!TF-_P#AG%OA.FW7M(54U5@$W##<0#!;=UPWW<\5]O\
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M!!Y8!R 22>E%1*WNW_7?_@!S--O1Z*R^2;7WL\[^-W_!5.Q\ ?\ !+[_ (:
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M?]B&^\$^!_ [>+M5\3:II$MS8SZI;Z;';6UMJ%M?3>9)*Z_>6W,0"9.Z13P
M2+J12FK;777NS*C>WO[G1_"[XT?%SXB_M(R:9#HO@&;X5:'I\<&K^(8;F[6[
MN=852MQ:V43)LDACD S*6X^9.64X[4?ME_"$^'/$^M?\+4^&_P#8_@FZ^P^(
MK[_A);+[-H%QN*>3=R>9MMY-P*[9"IR,8KXWMOV7_P!H?X37OB;X._#[3=>C
M_9]^(WA*;3[&^U;Q+:W&N?"/4;R"2-DLI#*9KJRMBZD1.Q="N(9"H5:U_A)_
MP3\\6?&C6?"\?Q(\ Z#\-=+\(_"Z_P#A?J\&BZG#=P>+HKA(85,2Q@%+.+RF
MFB6<+*CR ;1AB9>JTZ?>]_\ )+3OY%2LI>MODM/TO\UYGU9+^VK\'4G\01_\
M+8^&OF>$[6.^UM/^$GLLZ-!)L\N:Y'F_N8W\V/:SX!\Q,'YA7GW[.O\ P4(T
M7QW\(_'_ (R^)5QX/^%NB>!_&5[X6DO[_P 1P#372%XTAF:[E\N+][YB[1_M
M #)KPKX'_L,?'>R^(OPS\2>-I] N'UKP_'X+^)UE#>B2!]-TETFT>X@!'[R:
M65;WS1D8&K,#N$"5@?#O]D[X[>#/CE'\4)?AM;:A#X;^)OBG7X_!]QXALMVM
MV&M6T,$6H02[C#%>6OE.NR8J&ANYPKACAJY4GOT?WIJWWK^M"8WY=5K=?=RN
M_P"/Z=S[P\?_ +27P\^$G@?3?$WBKQYX-\,^&M9DB33]6U;6[:RL;YI5W1+%
M-(ZHY=>5"D[AR,T[Q_\ M$> ?A/<6\/BGQUX/\-3730I!'JNLVUFTS3.$B"B
M1U+%W(5<?>)P,FOASX._L"?%+]E#QAX7\767@_1?B3HUQ9>(M.O?A]_:EO!!
MX1BU;4#>*EC)< 0O"$_<S)QD'Y-RC;7B6C?\$COBY\&O!'Q(\+Z5\,]!\576
MN_!*U\ VFOQZQ80K>ZHMQ-/MS-BX^S6T4T%K$\H\SR["(8 "8BT=']Z[;O?9
M[+;N5U:[6L^]VE\MWIY'[!!^K5\N_!S]I3XR?%3XY?'_ ,'OH_PWM8?A9)#I
M^A723WSG4;RYLH;V W*[?DB6.8*XC);<,KQ7IW[-?Q*\1>(;>7PWXB\$ZMX4
MO?#>E:89)[F_MKV"YEEMP98E>%V^>)U*MG ;(9<@U\HZ9^PDGQ._:K_:.\=?
M%C]E?P%X]C\2/;7W@J\\01:%K%U="TT^"T%FIG#M;>;)$TJ[B$ /S8;BE*-I
M2]';UNM5YVN*.L;O>Z_KT/:OV3/V]K?Q5^QCX3^*WQRUWX9_"_\ X3"X>*T$
MFN"SL%;S'CC@\Z\,>^9O+8[1U[#BO9?'_P"T3X!^%%U;P>*?'/A#PU-=-"D$
M>JZQ;6;3-,X2(*)'4L7<A5Q]XG R:^"/V6?V0/C;^S_X5^$.MZK\)=)\2+X/
M\&ZGX U;P-)KNG[;1+B[-PFH6DK'[.8I(\02Q-M?8BX5@,'R?1O^"1GQ<^#7
M@3XE>%M+^&FA>++K7?@G:> ;37X]8L85O=46XFGVYFQ<"VMHIH+:)Y1YGEV$
M0P $QI-1YM-KO[M?\E]_D3&_+KO9?>VK_==_<?IY\9/VO_A+^SOK5EI?Q ^*
M/P[\#:IJ<)N;.S\0^)+/3)[N(-M,D:3R*SKNXR 1GBN _P""@7[3?C;]G+X.
M>&/%/P\L?!NO+K7B;1M F&M7-PD+)JE_;V,$T3P!MP62Y1VSP4!P<XKX*^*[
MS^*/VNO%6EZII%K:VMZWA#4/%OAA-?T:7Q%-JVD6,5PALI+J\BFA5-\<;&TM
M[E)O*<Q20RM-7V5_P57^$7C#]J7]E?0/"WA#X?S>.(]6\3:#J^K6%QJMOI7D
MV-EJ5K?SQ2&9U.^6.!H@%.0S@D@#-9RC91DMN9+Y75_PN/F;=O[M_1ZZ=-CN
MO@W\8_BI\4OVAM6@71_ [?!_2;1+=/$$%S=#4-3U(+BXCMXF7RVMXY 5\[=A
MN@R5)KO/!O[3?PW^(^@ZQJOAWXA>!]=TOP]=FPU6\T[7;6ZM],N0=IAGD1RL
M4@/&QR#GM7P_JO[(_P"T9X4\-?$7]GOPE;ZM/^S_ ./?!L^D>&?$>M^([:YU
MSX;7=S:R(;0-YAGO=/A++&NXF>->$=U5<<)^VG_P3H^+/[77@2;7O^%'^$]!
M\1:7X5TSPC%X8@UG3I;74Y;;4K:Y%XDC 1I;P0P310!MLP%RRE54L*JRE*VR
M[_YKU%JEY_\ #?GK?T/T?TS]I?X<ZSX"U[Q99^/O!5UX6\+SSVNLZQ#K=M)I
M^D30X\Z.XG#^7"\>1O5V!7(SBD^"?[2GP[_:4TV]O?AUX^\%^/K/39%AO)_#
MFN6VJ16CLNY5D:!W",5Y ."1S7YP?M=?#CQQ\+=7^-OB?7O!>E^"=,\<^._!
MFM^";[4/$.G+917NEVMM [7$7G1PX M6<)/+%'(JJIEC;;7U5_P23AATWX*>
M)H18SQZAJGB*[\1ZE?PSV$VE:G=:@QN))+'[#/<01P@G_5":1ER"SLS$T1BG
M%N^UOR3_ %')V2ONW^&O^1]84445)04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!E>*O%NF>!]%DU+5[VWT^QM\>9/,VU$SP,FO&O O[?_
M (#\2^-_'VFZEK_AG1]/\'Z[:Z+9WKZN'.J^=I]C=^84**(L/>B(*&?<8R<C
M.T>T:]K=GX9T2ZU#4KJVLK"QA::>XN)!'%#&HRS,QX  &237R3\2O#TZ?LB?
M$7QG?VLVGS?$CQC:>(D@NHS%+#:K-8V-F75@&1GM+*WD9& 9#*5/*FBG9SM+
M:R^]M?I<FI/DIN25WJ>Z?M-_M%2_L]^']-FM/#=QXDU#6+DVEI -3M-.A\T*
M7VR37$B!-Z+($."I<*A*[U)\ATO_ (*J:*]K?:GJ7@G7M)T*'04URV>XU*P%
MY*I\UMLJ&800@QHD@9K@D"0;UC R<?\ X*'^+[OX@ZW\-[/P;I^J^(=0T_Q=
M?:?J=CI=I;W,MS%%I%R^R0R3P*ENMU)8EW:>+8VS)'?YCM? L_BGPS<:"\/B
MBZM=8T4?VGIUCIM[K$-RLM_=Q7"2R6VD7L9#0IY1+/$64#''S BMKO=Z?--_
MH/F3].O>]S]-/B#\8]-^&_P[@\2W=OJ%U9W$EK%'%:1+),[7$B1Q@+N /S2+
MG!KS.V_;PL=1\(S^(+/X?^/KC18_$<_A9;K_ (EL/FWT.HRZ;(HCDO%D"BYB
M8;F4 K@]*/VG=3LOB7^R)I.I>%8=>UK1=4N=$U#3SH5K/)>269N[:598D5?,
M&(OFR0" ,G%?/-A\.=3L?V/[/[3KGB_PL\OQ=U&=-.U&-(;DPS>,[V:&XD6=
M#)N>*6.0,3AE*MR#FJY5RW_O6MY:?YLF-[:^7Y2O^*1]<:I^T=8_#WP#K'B7
MXB:?)\.=-TRX=(3JVH6DSWL("[9$%O+(,L6V[,[LCN"#7FWPQ_X*#_\ "2>.
M+'0/%'@6_P#"MUJ]Q<S6TJZ[IM]#8:;'GRKN_P!LRO:O(0 (0LC MC/ROLSO
MVR?A[8:U^Q5XR\*V.O-XX\275U%HUE/J5]%+>17M]=P+';>:B'R<^8@^Y\J8
M)! KSWQ!^QQXO\.>/O'?BJ[\.Z/'IVM:+%;1+_PG)61&A28N6SIN,$,,<]CF
MLJE3D7/:Z_X%_O9<;R?+Z:GV1=^.;>X\!#Q!H\?_  D5G-;)>6@L;B'%[$P#
M*T<DCI%@J=P)<#'>O&_%_P"WW:>"M:UJQNOAWXZDET&+2I[MX;W1&C5=1N)[
M>WPW]H ??MWW9Q@%3SFG?##X>S?$S_@F/X?\+6-Q;Z9<:]\-K?2[:XE!6&U>
M;3%B1FV\A5+ \>G%>;S?$.'X+>&?%WA'4_AO\-;J^T/3?"Z2?9]8:2UUTWEU
M=VR>>[VBLGE-;,X^63_6'WK:I!1<HI[/3SU,Z-3GHQJ/1M:^6Q[%\1/VFM<\
M ? WQIXRF\#F%_#3H+"QNM:A;^TT9HU)=[5;CR6!<_*%D)P,9W8%?7/VT;&P
M^*6BZ#9^&?$VH6=]!J<E]<KH^H)=6SVBVI40VWV4M.DAN0/,W(JE<?,3@<J/
M@[;Z+^RU\8M)UNU\,LNI7.H:M)IV@:G+-'9YA26*-I D+HX**> O&T@C-?-?
MCC3?B1X"_9HUGQW#I$MO?:/H5[XDL)_L'DKI?G6<<LL*2)XD>40$PHS#RW8E
M<[2?EJ*?O3L^ROZM:?<S1;Z]6[>BZ_D??MU\8=-M?"NEZLUCXDD@U8#;#;Z-
M=7-Q;-CYDFBC1FB93E6# 88$=17BWP1_X*,V_P 8O"7@EH_ GBB/Q7XXW7%M
MI-O:W/V:*S6X>-[C[;<P6\3>7$J22(.5+A%,GRLW2^)_A3'\'O""Z;X2\-ZI
M=+8P7>HMJ-[X@DALDEDDDGE,I$C7,LC2,S@"/:<D&1*\"_9]^&ECX+^ WAOQ
M#XJ\%:79V.O:1:CQ!J:>.)A#I%A,!+]GLX(XR_D)+(-L(*$EBS.S<DC9S:Z*
MWX]/O6H/:W5WM\OU\CZ,^+?[75I\*OB3_8;:/<ZE;0Z9<W4L]L99;NYO(]C)
M9VEI%%))<L(V>29UPMNGE%MWF?+3^"/[7.J?&OX7>#O$D/P]U[3_ /A)(+2:
M]6ZN8[.'2Q/Y9.#=B":=0L@*LD&'((&#BO#_ -K%M!\(_M2:])XF\7>'M'M(
M_ -AI_AV/Q,[-907$][=*UO:QI-#+)=7"6Z#Y79W,2_*P0*.?_9F^#]G!\-?
MV=+;7]!VWA\16L;&_P##U]HMW-Y6@7\I2>&]F>XE>.XB5O,:.)"40HN%!JJ,
M5*',^_ZN_P"']=RI:*??3\4GH?8WQ9^.NF_"C5=*TR33]8U;6]>@O9],L+"W
M#-=FUA\Z13*Y6&+*X ,KHI) SFL_7/C[-X?_ &76^)%QX=N;6:/0DUJ31;B\
MA\V M$)# TT1DBRN<%D++QD$BJ?AU5^*G[1>I:U&OFZ)X-LY-$MY"ORW%]*R
MM=%#W$:+'&2.-S,,Y1@.+\-SR:S\(O%WP/U#6(?"_B[P_I4UEI5W.?EO-).Y
M++4HOF4R!$V13#(*3Q." CQ,^<K\CMO:Z_'_ ( 1MSJ^U[/YV.9\6_\ !4O1
M?!'P4^(OB+5--T&Q\1>"XKF73=%E\1@QZ^L-O9REDN5@(C7S+V&(D(^UF'!S
MBO8/V=?VH-*_:(EU^UL[&XTO4/#-Q%;7MM->6EUS)&'5U:WED&TY(&_8_P N
M2HS7P3#\([3XN:_J7AN^2SUV-G3P*EQ97-['#J,EQJEJDUV@\YLRPVNE7UTR
MJVS9'"6&",_7W_!.CQ';ZW\%G_XGTFJ:D]S+<W=D\<2_V<#/*B<QHH)=8MYS
MDY/:MHQBZ?/Y6^?IOJM3'FE&;IOH_O3M^5[(U/&W[=_AWP'\1]2TBZT?Q%<:
M7H^IVWA^^U.UTZ>:.VU.X>U$,!41X9&6[B;S%<A?F# 8S61X&_;PNO'-_P"&
MUM? MU)#XCUK5-%B\K7;-KA9+![M)&$3,I(=K-]NXI@.NXKTKP3QG<>"M<^/
M?Q4M]:U36#'HWQ*L-5UF72-%AO#X?BMK'2KB&:ZF^SNT4+O#M;]ZK!2652H=
MEU/A3\,/$7A&;X/_ -I3>#]%NM?U?7-72QM-#:'Q)I;7]IJ5ZJS3F>4.Z"X&
M\"#[P&!Q@S9>R4NO7M9I-?C=&\HOVSBOAY6_.]ORZGL7C;_@H.OA;QM)H</P
M^\337VCW\5KKT-QJ.F0R:=');"=6CVW+K+)B2 [,H-KL=^5VMK:5^VZGB#X#
M>(_B58^"]87PCI/AZZURPOKW4K&,:O);K,SVRK%-*T9_<D!V&.O''/Y]_'/P
MW8Z=^T)I^H-H?B77-!O;^WTWQ!8Z)I]IJ^LO<W*QV5I))<7< GA43-;YCN8+
M-RI/D&ZV^57OW@_P3H=Y^Q+\2_#?AN'3_B5XFUC3)O"]CX8\+WK7TNB3-:S1
MVZWL5V;:.SF\QV,LLD-JJEOF4'DS:]/F6_ZVU*A%<\>;;2Y] >/O^"B?P[^'
M.K>&--U'7-!DU/7+I;2_LK35$GN=*8QAW?8H_>QQ,0)&4@H"&P><.^+/_!0W
MP/\ #?P;9^(=.BUSQAHSZC/97L^AZ3=WGV..WA$UQ-B.)@X2,AL9&]=VS<5(
MKDO#/PEM_BW\1?"]D=-F^'NF?#BSNS./#FL_9UAO[T1YMGEA5$:;RU:258RZ
MJS+EFW GR+XR^%/%'Q6_8L^%-Y#?:GXGN-2\7W5S!>W_ (VN=)F?3KG4;AX9
M&F2UG:2)+ K\Y \N,;ANZ5516M;NOQ=ONZD4=6E)/;7U_JQ[E%_P4G\-2> K
MG6(=,N]4OIM;N].TC1M&%QJ&H:C:VS?/=/$D&ZW^0.=L@V!]B&3<XQZ4G[4>
M@:K\+?!OBS2;+7]6M?'UU:6^B64=D;:^NA<'=YABN#&42.$23OOP1'$Q )PI
M_/7]HSP3J$W@37M9\+V.F-XB\/\ A6Z\5ZE*?$,FGW6G'4M>>\M5:2*TF,YW
M61RC^7GRR>/NGZJ^)RCX+?#+P[H>H^)-+\+_ !&UK2)-"T>:[\2+>6WA&U.U
M;N_BN;B*W:8Q1E"K/$K/(((OE4E@^5<BD]V[6]-']^FO0GF?M7!;)7OZV?X7
M_ ]]\!?$R;Q;XO\ $VBWNEMH][X?ND2-7N4F-];.N8[E0OW58AQ@\@H<UA?M
M&?M(:?\  OX/^(/$ED=(US4M$1?+TR354M//D,JQ;&D"R%,%N3L8C'2O*;GX
MD_#;XO?%'PAX<\,_$G=KUC:BVT7Q7X?UR'5)KQX IN+&\?$D3LZ*'V2Y+D.P
MPRUL?M1?!'PK^T1=I\,+/0='F;6)DOO%-[!81;M.LPQD^>0+\MQ/*!L&=QP[
MXVJ34;6_K0JF];R7FT>R+\6_#L-Q;6USKV@PZA=023K;+J$;R.L2AI2@R&=4
M!!)"\ @D#-?,<_\ P6%\$:=>7UFUE;:Q?+K6IZ99Q:)J\5PIAM(#,D]Q)<+;
MI$90K 1HTI'&"W..\^!OBKPM=ZW>^%;KP[X5TWXW^ ;)T-I)8PVMU=0R*4CU
M"SD*[GL[@(,R1DA662)]LD;(/B;XD?L^>,_@K^S+K%YX6OKS5)=)\4Z\+^;6
M+XC1/MU[((6N9Y!/#+9VL3-)+++ED6)3\I;"G.KS:J';3U;6OW!"W-&,M[Z^
MB5_\CZW_ &:?^"H^A?M'Z%J"V?@OQ5'XCTO1M'U)]*LVMKY;^?4(#*EM;3K(
M(LJ58%K@P84;V"*#CH?#'_!1GPMK?P*^)GC2^\)?$+1=1^#]U-8^+?"<^E1W
M>O:9/'!'<A5CM99H9U>WFBE22&9XRCYW## ?-'_!-3XI>(/@-^SUXK\=ZAHM
MYXS\&M:6.D^'I_!_VKQ-+JPL1]CBG6ULEN[@1S$M(9$#(L<:NH(8"O2(/$^A
MZG^Q9\?=6TKP[\4=1\3>,+&\O==O+GX:Z_I=UK6J7-C]DAM[/3KFU6^EAAAB
MM859(60(JEI&?S2-\4HQE)PVMIWOIT]+_@3A[RY.?OK]VO\ 7J>V>,/VW_#O
MACX/?#_Q58Z%XF\1:C\5#!'X5\-:?';#5]8FEM7N_+'G31V\>RWBED=Y)EC1
M8SE^F<G5_P#@H?X1B^$'AWQ-H>CZ]XGU;Q5JDVB:?X6M;C3K#6'OH"XNK=_M
MUU;VR/ 8V#[IP"=@0N9$#> Z%HFKZ3\(_P!C7XM?\(KXYN-)^#]I<:;XJT?_
M (1/4UU_3H[K1GL&N$TMK<7DIANDC5ECA9C%*\B!U&3<^#_PR\+>#/@O=:?\
M9/A3XG\2ZA\5O&>N^+]$TB+P/>:])HGVNX5H(IYX()(M,N&0Q-ON)8%0D[I%
M,;;55C%2DH^=N_2R\[H=/6$6]]+_ (Z_?8^V_!OB"Y\2^$]/U*]TC4/#]U>6
MZ3S:=?2P27-BS#)BD:"26$LO0F.1UXX8CFO&O@M_P4*\(?&[Q]I.D6>D^)M)
MTOQ:;W_A#_$.HQ6\>F>-5LRPN7LMDSSJJA6=3<10^=&/,B\Q/FK#_9T_9_\
MC-\,O@)\*_!C^+?"%KH'A_PS;:5X@L]6T6YU77)'2(IMBU".^CA#(FQ"[6\N
MYD9N0PQ\J^!OV:/B3\4/V?O@5\&K'PSX@\*^+/V>?"VK:-X@UF]TZYLM*>[_
M +%N=*L6T^]D18KU+EI%N"UNS^3&<3>5+B.B5KR:Z;+RUN_E9?>.G&]E)[[O
MSTLOGL?:WP\_;>\/_%+5=<O-#\/^*KKP!H%K<S2^.I(;>WT"ZF@?9)!;&29;
MFYY#XFB@:W)C8>;NP#-'^V;HMSK&B_9M!\43:+J5K)/<7ITJY233Y $:-'A,
M>7#AG&Y"VUDY&#N'RC_P3M^!-QX.^-/@.7PKX'^(/@'PQX<^&\_AGXHZ-XFL
MKRRTN_UB![-+ 6B77[B[=-FHEKNS+VYCDC!E)915?QAH7Q!TWXT6>A-X#\3>
M3X[EU6ZU"YM-!\'PWQM+98U@BLFDU>1(]AF0EW 8CD*&)*DDDTD[Z;^C:_'=
M>0J;<D[Z/M]S_#9^9]P?!#]H7PW^T+;:M<>&1K$UEH]U]CDN[K39[6"YDVY8
M0O(JB4+T8KD!N#S7?5Y/^QI<WW_"@-&L=6T)O#&KZ89K>[TN2'3()[8B5RC2
MQ:;<7%HDDB%)&$4A!,A.U,[1ZQ1*R=D*-VM2GK.B6?B+3Y+/4+2VOK288D@N
M(EEC<>ZL"#1HVB6?AVPCM-/M+:QM(QB."WB6*-/HJ@ 5<HJ2@HHHH **** "
MBBB@ HHHH **** "LD>"=&7Q"=6_LC3?[6(VF]^RI]H(Z8\S&[I[UK44 4M&
MT.R\.V*VNGV=K8VJDLL-O&L2 DY)"J .35VBB@ HHHH **** "BBB@ HHHH
M*R;?P1HUKXA?5HM)TR/5) 5>\6U1;AP>H,F-QZ#OVK6HH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,FZ\$Z-?:_%JLVDZ;-JD*A8[R2U1KB,#. '(W
M <GOWK6HHH **** *>LZ'9>(]/>TU"SM;ZTDX>"XB66-_JK @T:/HUGX>T^.
MTL+6WLK2$8C@MXECCC'H%4 "KE% !1110 4444 %%%% !1110 4444 %%%%
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MXC3-KDDMO>:7J5UJ+#_B<0V5]/:K/.0<-YT=NCR9^5][9!#$5-\#/@-H^O\
M[7OQ*^+TEC:Z;9_$+3-&TO3]-GA6*76%TA[AAJTD1Y+$W4<4;$;A%;Q$X#J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
G*** "BBB@ HHHH **** "BBB@ HHHH **** "C&:** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6825251568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">American BriVision (Holding) Corp<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001173313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a) may determine.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822598656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 173,537<span></span>
</td>
<td class="nump">$ 994,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepayment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,815<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">173,537<span></span>
</td>
<td class="nump">998,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposit</a></td>
<td class="nump">3,815<span></span>
</td>
<td class="nump">3,815<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Non-Current Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,815<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">177,352<span></span>
</td>
<td class="nump">1,002,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">18,370<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expense</a></td>
<td class="nump">38,100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrentAndNoncurrent', window );">Other payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">22,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent', window );">Due to shareholder</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">46,586<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">56,470<span></span>
</td>
<td class="nump">369,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock 360,000,000 authorized at $0.001 par value; shares issued and outstanding 210,821,647 and 166,273,921 at September 30, 2016 and September 30, 2015</a></td>
<td class="nump">210,822<span></span>
</td>
<td class="nump">166,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">4,733,401<span></span>
</td>
<td class="nump">1,132,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(350,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(4,823,401)<span></span>
</td>
<td class="num">(315,602)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total equity</a></td>
<td class="nump">120,882<span></span>
</td>
<td class="nump">633,357<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 177,352<span></span>
</td>
<td class="nump">$ 1,002,460<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred and payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.12(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822638672">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">360,000,000<span></span>
</td>
<td class="nump">360,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">210,821,647<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">210,821,647<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">All shares outstanding for all periods have been retroactively restated to reflect Company's 1 to 3:141 forward stock split, which was effective on April 8, 2016.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822542624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">315,602<span></span>
</td>
<td class="nump">4,497,263<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net loss from operations</a></td>
<td class="num">(315,602)<span></span>
</td>
<td class="num">(4,497,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income(expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Bank Interest Income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Gain on exchange differences</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(10,170)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(9,668)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="num">(315,602)<span></span>
</td>
<td class="num">(4,506,963)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(836)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (315,602)<span></span>
</td>
<td class="num">$ (4,507,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and Diluted loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding basic and diluted</a></td>
<td class="nump">160,823,831<span></span>
</td>
<td class="nump">193,981,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6823117232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Subscription receivable</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jul. 20, 2015</a></td>
<td class="nump">$ 897,001<span></span>
</td>
<td class="nump">$ 159,623<span></span>
</td>
<td class="nump">$ 1,087,378<span></span>
</td>
<td class="num">$ (350,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jul. 20, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,622,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="nump">51,958<span></span>
</td>
<td class="nump">$ 6,651<span></span>
</td>
<td class="nump">45,307<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,650,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="num">(315,602)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(315,602)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2015</a></td>
<td class="nump">633,357<span></span>
</td>
<td class="nump">$ 166,274<span></span>
</td>
<td class="nump">1,132,685<span></span>
</td>
<td class="num">(350,000)<span></span>
</td>
<td class="num">(315,602)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="nump">3,250,000<span></span>
</td>
<td class="nump">$ 2,032<span></span>
</td>
<td class="nump">3,247,968<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,031,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization', window );">Reverse merger recapitalization</a></td>
<td class="num">(2,696)<span></span>
</td>
<td class="nump">$ 42,359<span></span>
</td>
<td class="num">(45,055)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares', window );">Reverse merger recapitalization, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,359,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">397,960<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">397,803<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable', window );">Receipt of subscription receivable</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="num">(4,507,799)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,507,799)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2016</a></td>
<td class="nump">$ 120,882<span></span>
</td>
<td class="nump">$ 210,822<span></span>
</td>
<td class="nump">$ 4,733,401<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (4,823,401)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,821,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period receipt of subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_StockIssuedDuringPeriodReceiptOfSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period reverse merger recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_StockIssuedDuringPeriodReverseMergerRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period reverse merger recapitalization shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_StockIssuedDuringPeriodReverseMergerRecapitalizationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mtoo_SubscriptionReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mtoo_SubscriptionReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822814880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flow - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss from continuing operations</a></td>
<td class="num">$ (315,602)<span></span>
</td>
<td class="num">$ (4,507,799)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of common stock for compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,295,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Increase in deposit</a></td>
<td class="num">(3,815)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_IncreaseDecreaseInPrepayment', window );">Decrease (increase) in prepayment</a></td>
<td class="num">(3,815)<span></span>
</td>
<td class="nump">3,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseDueFromAffiliates', window );">Due to shareholder</a></td>
<td class="nump">46,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">(Decrease) increase in other payable</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">(Decrease) increase in due to related party</a></td>
<td class="nump">22,517<span></span>
</td>
<td class="num">(22,517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase in accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">18,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Increase in accrued expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">38,100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(517)<span></span>
</td>
<td class="num">(3,474,707)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by (used in) investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders', window );">(Decrease) increase in due to shareholder</a></td>
<td class="nump">46,586<span></span>
</td>
<td class="num">(46,586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_ProceedsFromSubscriptionReceivable', window );">Proceeds from subscription receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares</a></td>
<td class="nump">948,959<span></span>
</td>
<td class="nump">2,350,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">995,545<span></span>
</td>
<td class="nump">2,653,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect Of Exchange Rates On Cash</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase in cash</a></td>
<td class="nump">994,830<span></span>
</td>
<td class="num">(821,293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, beginning of period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">994,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, end of period</a></td>
<td class="nump">994,830<span></span>
</td>
<td class="nump">173,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_Prepayment', window );">Prepayment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_IncreaseDecreaseInPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to increase decrease in prepayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_IncreaseDecreaseInPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_Prepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_Prepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_ProceedsFromSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from proceeds from Subscription of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_ProceedsFromSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseDueFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from an entity that is controlling, under the control of, or within the same control group as the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseDueFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease), during an accounting period, in total obligations owed to the reporting entity's executives and owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6748420864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company&#8217;s operating company, American BriVision Corporation (&#8220;BriVision&#8221;), was incorporated in July 2015 in the State of Delaware. It is a biotechnology company focused on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center (&#8220;MSKCC&#8221;) and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept (&#8220;POC&#8221;), out-license to international pharmaceutical companies, and exploit global markets.</font></p></div><span></span>
</td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b>&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">American BriVision (Holding) Corporation (the &#8220;Company&#8221; or &#8220;Holding entity&#8221;), a Nevada corporation, thru the Company&#8217;s operating entity, American BriVision Corporation (&#8220;BriVision&#8221;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs. &#160;The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center (&#8220;MSKCC&#8221;) and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept (&#8220;POC&#8221;), out-license to international pharmaceutical companies, and exploit global markets. BriVision had to predecessor operations prior to its formation on July 21, 2015.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">REVERSE MERGER</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On February 8, 2016, a Share Exchange Agreement (&#8220;Share Exchange Agreement&#8221;) was entered into by and among American BriVision (Holding) Corporation (the&#160;&#8220;Company&#8221;), American BriVision Corporation&#160;(&#8220;BriVision&#8221;), Euro-Asia Investment &amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People's Republic of China (&#8220;Euro-Asia&#8221;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of the Company(the&#160;&#8220;BriVision Stock&#8221;).</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the&#160;&#8220;Acquisition Stock&#8221;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#8217;s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#8217;s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times
 new roman',
 times, serif; font-stretch: normal;">Pursuant to the Merger, all of the issued and outstanding shares of BriVision&#8217;s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583pre-stock split) shares of Company&#8217;s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company&#8217;s common stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company&#8217;s common stock,&#160;Because of the exchange of the BriVision Stock for the Acquisition Stock (the&#160;&#8220;Share Exchange&#8221;), BriVision became a wholly owned subsidiary (the &#8220;Subsidiary&#8221;) of the Company and there was a change of control of the Company following the closing.&#160;&#160;There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Because&#160;of the consummation of the Share Exchange,&#160;BriVision&#160;is now our wholly owned subsidiary and its shareholders own approximately&#160;79.70% of our issued and outstanding common stock.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 40.2pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Following the Share Exchange, we have abandoned our prior business plan and we are now pursuing&#160;BriVision&#8217;s&#160;historical businesses and proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs.&#160;&#160;The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (&#8220;POC&#8221;), out-license to international pharmaceutical companies, and exploit global markets.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 40.2pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Accounting Treatment of the Reverse Merger</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">For financial reporting purposes, the Share Exchange represents a&#160;&#8220;reverse merger&#8221;&#160;rather than a business combination and&#160;BriVision&#160;is deemed the accounting acquirer in the transaction. The&#160;Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision&#160;is the acquirer for financial reporting purposes and the&#160;Company&#160;is the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of&#160;BriVision&#160;and recorded at the historical cost basis of&#160;BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of&#160;BriVision&#160;and operations of the Combined Company from the closing date of the Share Exchange.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6748420864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Basis of Presentation</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The accompanying audited financial statements and related notes have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&#8217;s financial statements are expressed in U.S. dollars.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Use of Estimates</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Fair Value Measurements</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company applies the provisions of ASC Subtopic 820-10,&#160;&#8220;Fair Value Measurements&#8221;,&#160;for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.&#160;&#160;ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal;
 background-color:
 white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;&#160;When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in;">&#160;</td><td style="width: 32px; text-align: justify;">&#9679;<font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td style="text-align: justify;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</font></td></tr></table><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in;">&#160;</td><td style="width: 32px; text-align: justify;">&#9679;<font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td style="text-align: justify;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</font></td></tr></table><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in;">&#160;</td><td style="width: 32px; text-align: justify;">&#9679;<font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td style="text-align: justify;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of&#160;September 30, 2015.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Cash and Cash Equivalents</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none;
 text-indent: 0px; letter-spacing: normal;
 word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2015, the Company&#8217;s cash and cash equivalents amounted $994,830. All&#160;of the Company&#8217;s cash deposit is held in a financial institution located in Republic of China where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Income Taxes</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company accounts for income taxes using an asset and liability approach which allows for the recognition and measurement of deferred tax assets based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before the Company is able to realize their benefits, or that future deductibility is uncertain.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Under ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalties or interest relating to income taxes have been incurred during the period from July 22, 2015 (inception) to September 30, 2015. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Recent Accounting Pronouncements</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color:
 #000000; text-transform: none; text-indent: 0px;
 letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">From time to time, new accounting standards are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The recent accounting standards are not expected to have a material impact on the consolidated financial statements upon adoption.</font></p></div><span></span>
</td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Basis of Presentation</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States ("U.S. GAAP").</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&#8217;s financial statements are expressed in U.S. dollars.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Use of Estimates</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Forward Stock split</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority
 of the
 shareholders of the Company approved the amendment to Articles of Incorporation.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Fair Value Measurements</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company applies the provisions of ASC Subtopic 820-10,&#160;&#8220;Fair Value Measurements&#8221;,&#160;for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.&#160;&#160;ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;&#160;When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt;
 letter-spacing:
 normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of&#160;September 30, 2016.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Cash and Cash Equivalents</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2016, the Company&#8217;s cash and cash equivalents amounted $173,537. As of September 30, 2015, the Company&#8217;s cash and cash equivalents amounted $994,830. All&#160;of the Company&#8217;s cash deposits are held in a financial institution located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Income Taxes</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 40.2pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 40.2pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Under ASC 740, a tax position is recognized as a benefit only if it is&#160;&#8220;more likely than not&#8221;&#160;that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized
 in the first subsequent
 financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred during the period from July 21, 2015 (inception) to September 30, 2015. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">As of September 30, 2016 and September 30, 2015, the Company&#8217;s income tax expense amounted $836 and $0, respectively.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Recent Accounting Pronouncements</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">From time to time, new accounting standards issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The recent accounting standards are not expected to have a material impact on the consolidated financial statements upon adoption.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6748588896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_GoingConcernDisclosureTextBlock', window );">GOING CONCERN</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>3. GOING CONCERN</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since its inception resulting in an accumulated deficit of $315,602 as of September 30, 2015. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. These combined financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company expects to finance operations primarily through cash flow from revenue and capital contributions from principal shareholders. In the event that we require additional funding to finance the growth of the Company&#8217;s current and expected future operations as well as to achieve our strategic objectives, our principal shareholders have indicated the intent and ability to provide additional equity financing.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company&#8217;s continuation as a going concern is dependent on our ability to meet obligations as they become due and to obtain additional equity or alternative financing required to fund operations until sufficient sources of recurring revenues can be generated. There can be no assurance that the Company will be successful in its plans described above or in attracting equity or alternative financing on acceptable terms, or if at all. The financial statements do not include any adjustments that might result from the outcome of this- uncertainty.</font></p></div><span></span>
</td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>3. GOING CONCERN</b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since its inception resulting in an accumulated deficit of $4,823,401 as of September 30, 2016. The Company also incurred net losses of $4,507,799 and negative cash flow of $821,293 during the year ended September 30, 2016. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. These combined financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company expects to finance operations primarily through capital contributions from principal shareholders. In the event that we require additional funding to finance the growth of the Company&#8217;s current and expected future operations as well as to achieve our strategic objectives, our principal shareholders have indicated the intent and ability to provide additional equity financing.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company&#8217;s continuation as a going concern is dependent on our ability to meet obligations as they become due and to obtain additional equity or alternative financing required to fund operations until sufficient sources of recurring revenues can be generated. There can be no assurance that the Company will be successful in its plans described above or in attracting equity or alternative financing on acceptable terms, or if at all. The financial statements do not include any adjustments that might result from the outcome of this- uncertainty.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_GoingConcernDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Going concern disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_GoingConcernDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6614943472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CollaobrativeAgreementsAbstract', window );"><strong>Collaborative Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENT</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>4. COLLABORATIVE AGREEMENT</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">On December 29, 2015, American BriVision Corporation entered into a Collaborative Agreement with BioLite Inc., a related party, pursuant to which BioLite granted the Company sole licensing rights for drug and therapeutic use of five products: BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia, in USA and Canada. Under the Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of BriVision with equivalent value, according to the following schedule:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr><td style="width: 0.5in; font-family: calibri, sans-serif; vertical-align: bottom;">&#160;</td><td style="width: 0.3in; text-align: left; font-family: calibri, sans-serif; vertical-align: top;">&#9679;&#160;</td><td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;">upfront payment shall upon the signing of this Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.</td></tr><tr><td style="font-family: calibri, sans-serif; vertical-align: bottom;">&#160;</td><td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;">&#160;</td><td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;">&#160;</td></tr><tr><td style="font-family: calibri, sans-serif; vertical-align: bottom;">&#160;</td><td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;">&#160;</td><td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;">upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</td></tr><tr><td style="font-family: calibri, sans-serif; vertical-align: bottom;">&#160;</td><td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;">&#160;</td><td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;">&#160;</td></tr><tr><td style="font-family: calibri, sans-serif; vertical-align: bottom;">&#160;</td><td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;">&#9679;</td><td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;">at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.</td></tr><tr><td style="font-family: calibri, sans-serif; vertical-align: bottom;">&#160;</td><td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;">&#160;</td><td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;">&#160;</td></tr><tr><td style="font-family: calibri, sans-serif; vertical-align: bottom;">&#160;</td><td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;">&#9679;</td><td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;">upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</td></tr><tr><td style="font-family: calibri, sans-serif; vertical-align: bottom;">&#160;</td><td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;">&#160;</td><td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;">&#160;</td></tr><tr><td style="font-family: calibri, sans-serif; vertical-align: bottom;">&#160;</td><td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;">&#9679;</td><td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;">at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.</td></tr><tr><td style="font-family: calibri, sans-serif; vertical-align: bottom;">&#160;</td><td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;">&#160;</td><td style="text-align: justify; font-family: 'times new roman', serif; vertical-align: middle;">&#160;</td></tr><tr
 style="vertical-align: bottom;"><td style="font-family:
 calibri, sans-serif;">&#160;</td><td style="text-align: left; font-family: calibri, sans-serif; vertical-align: top;">&#9679;</td><td style="font-family: 'times new roman', serif;">upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Collaborative Agreement is attached as an exhibit to the registration statement of which this prospectus is a part. The material terms of the Collaborative Agreement are as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company is responsible to make up-front, milestone and royalty payments to BioLite, as described in the foregoing paragraph and below.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#9679;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">As between BioLite and ABVC, BioLite owns all files, data, confidential and non-public information, including, without limitation, all IND packages and clinical study reports, regarding the Compounds (collectively, the &#8220;Compound IP&#8221;), to the extent developed in Taiwan, and the Company owns all Compound IP to the extent developed in North America. BioLite grants an exclusive license to its Compound IP to the Company for the purpose of further development and commercialization of the Compounds in North America. BioLite and the Company share the responsibility of preparing for clinical trials by delivering Compound IP and preparing related materials.</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#160;</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company is responsible for all clinical trial expenses incurred in North America.&#160;&#160;BioLite paid all clinical trial expenses for trials conducted in Taiwan thus far.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Collaborative Agreement will remain in effect for fifteen years from the date of first commercial sale of Product in the U.S. or Canada. Either party may terminate upon thirty
 days&#8217; prior written notice for breach or insolvency.</font></td></tr></table><p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company agreed to pay to BioLite an aggregate of One Hundred Million Dollars ($100,000,000) (the &#8220;Aggregate Amount&#8221;) in milestone payments during the term of the agreement, payable in cash or Company equity. A percentage of the Aggregate Amount will be paid to BioLite upon each completion of a milestone by BioLite as set forth in the Collaborative Agreement. An upfront payment of $3,500,000 (the &#8220;Milestone Payment&#8221;), which is 3.5% of total payments due under the Collaborative Agreement, was to be paid by us upon signing of the Collaboration Agreement. On May 6, 2016, we and BioLite amended the payment terms under the Collaborative Agreement by entering into a Milestone Payment Agreement, pursuant to which we paid $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Milestones are reached by BioLite upon submissions of IND and NDAs for the Products, and completion of phases in the application processes, as set forth in the Collaborative Agreement.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In addition to the Aggregate Amount, the Company will pay to BioLite five percent (5%) of net sales of Products in the U.S. and Canada.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Our&#160;Licensed Compound</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">We have renamed the five
 compounds for our purposes and include below a brief description of each of the five compounds.</font></p><p style="font:
 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">I.</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">ABV- 1501 &#160;Triple Negative Breast Cancer - Combination therapy for Triple Negative Breast Cancer (TNBC)</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Maitake mushroom extract Phase I clinical trial was performed by MSKCC.&#160;&#160;&#8220;A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects:&#8221; &#8220;No dose-limiting toxicity was encountered. Oral administration of a polysaccharide extract from Maitake mushroom is associated with both immunologically stimulatory and inhibitory measurable effects in peripheral blood.&#160;&#160;Cancer patients should be made aware of the fact that botanical agents produce more complex effects than assumed, and may depress as well as enhance immune function&#8221;.&#160;&#160;The IND number is 68853 and MSKCC received filing confirmation from the FDA on Jan 22, 2004.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#160;</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">ABV-1501 US FDA Phase II IND cross reference with MSKCC Maitake and Phase II Investigational New Drug (IND) was approved in March 2016.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#160;</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">We are currently negotiating with MSKCC for Phase II clinical study. If MSKCC agreed with our terms, we anticipate to start phase II clinical trial during 2017 Q1and finish the phase II clinical trial by 2018 Q3.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch:
 normal;">&#160;</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new
 roman', times, serif; width: 0.5in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">BioLite has received approval from Institutional Review Board and (IRB) of Taipei Medical University in September 2016 in Taiwan</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 90pt; color: #000000; text-transform: none; text-indent: -18pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 90pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="font: 10pt/normal calibri, sans-serif; width: 0.25in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal calibri, sans-serif; width: 0.25in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-stretch: normal;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">II.</font></td><td style="font: 10pt/normal calibri, sans-serif; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-stretch: normal;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">ABV-1502 &#160;Solid Tumor with Anti-PD1 - Combination therapy for solid tumors with Anti-PD-1</font></td></tr></table><p style="font: 10pt/normal calibri, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="width: 0.3in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">&#9679;</font></td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">This is a kind of anti-tumor Combination therapy of Maitake mushroom extract with standard therapy and anti- PD1 drug for solid tumor.</font></td></tr><tr style="vertical-align: top;"><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">&#9679;</font></td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">Maitake mushroom extract Phase I clinical trial was performed by MSKCC.&#160;&#160;</font></td></tr><tr style="vertical-align: top;"><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">&#9679;</font></td><td style="text-align: justify; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">Currently, we are cooperating with MD Anderson Cancer Center and one of the top cancer centers in the U.S. to develop Phase II clinical trial IND package.&#160;&#160;Due to confidentiality obligations, we are not permitted to disclose the name of such cancer center at this time.</font></td></tr></table><p style="font: 10pt/normal calibri, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.25in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="width: 0.25in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">III.</font></td><td style="text-indent: 0pt; padding-right: 0pt;
 padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">ABV-1503 &#160;Chronic Lymphocytic Leukemia - Combination therapy for Chronic Lymphocytic Leukemia
 (CLL)</font></td></tr></table><p style="font: 10pt/normal calibri, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="width: 0.3in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">&#9679;</font></td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">Phase II study of Epigallocatechin gallate (EGCG) for CLL.</font></td></tr><tr style="vertical-align: top;"><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">&#9679;</font></td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">We are cooperating with MSKCC to prepare clinical trial agreement.</font></td></tr><tr style="vertical-align: top;"><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">&#9679;</font></td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">We are currently preparing the IND package.</font></td></tr></table><p style="font: 10pt/normal calibri, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.25in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="width: 0.25in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">IV.</font></td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">ABV-1504 &#160;Major Depressive Disorder - Major Depressive Disorder (MDD)</font></td></tr></table><p style="font: 10pt/normal calibri, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="width: 0.3in; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">&#9679;</font></td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">This is Polygala extract for Major Depressive Disorder</font></td></tr><tr style="vertical-align: top;"><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">&#9679;</font></td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">BioLite performed Phase I clinical trial.</font></td></tr><tr style="vertical-align: top;"><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt;
 padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt;
 padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">&#9679;</font></td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;"><font style="font-family: 'times new roman', serif; font-size: 10pt;">BioLite has obtained US FDA Phase II Part One/Part Two IND approval and the Phase II Part One was completed with good result.</font></td></tr><tr style="vertical-align: top;"><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"><p style="font: 10pt/normal 'times new roman', serif; margin: 0px; font-stretch: normal;">For ABV-1504 Phase II part one results are described below.</p><p style="font: 10pt/normal 'times new roman', serif; margin: 0px; font-stretch: normal;">Phase II part two: this phase currently is conducted in 5 clinical sites in Taiwan (started in Q3 2016) and one US site is under IRB review.</p></td></tr></table><p style="font: 10pt/normal calibri, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">V.</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">ABV-1505 &#160;Attention Deficit Hyperactivity Disorder - Attention Deficit Hyperactivity Disorder</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">This is Polygala extract for Attention Deficit Hyperactivity Disorder.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Same Active Pharmaceutical Ingredients (API) with ABV-1504.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">BioLite has obtained U.S. FDA Phase II IND approval and is currently negotiating with top medical site for Phase II clinical trial.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">BioLite intends to submit for IRB approval during 2016 Q4</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif;
 width: 0.5in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.3in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;
 font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">BioLite plans to start Phase II clinical trial during 2017 Q1 and complete by 2018 Q3.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">ABV-1501 and ABV-1502 have the same Active Pharmaceutical Ingredient:&#8221; Maitake mushroom extract&#8221;. IND and study details are as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Phase I/II clinical trial was conducted by MSKCC. A total of 34 eligible study subjects was enrolled from 3/2004 to 1/2007. The primary endpoints were safety and tolerability. The test drug was oral administration and a polysaccharide extract from Maitake mushroom is associated with both immunologically stimulatory and inhibitory measurable effects in peripheral blood. Cancer patients should be made aware of the fact that botanical agents produce more complex effects than assumed, and may depress as well as enhance immune function. (<u>A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects by Gary Deng &#183; Hong Lin &#183; Andrew Seidman &#183; Monica Fornier &#183; Gabriella D&#8217;Andrea &#183;Kathleen Wesa &#183; Simon Yeung &#183; Susanna Cunningham Rundles &#183;Andrew J. Vickers &#183; Barrie Cassileth; J Cancer Res Clin Oncol (2009) 135:1215&#8211;1221.</u>) The IND number is&#160;</font><font style="font-family: 'times new roman', serif; font-size: 10pt;">68853 and MSKCC received filing confirmation from the FDA on Jan 22, 2004</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: -18pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients&#63; A Phase II clinical trial.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Primary endpoint: To describe changes in neutrophil counts and neutrophil function in MDS patients following administration of Maitake mushroom extract.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">This study to see whether Maitake improves the neutrophil count and function in
 patients with MDS. The neutrophils are white blood cells which help to fight infection.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal;
 -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Total 45 subjects.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Start Date: April 2010</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Completion Date: September 2014</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Sponsor: Memorial Sloan Kettering Cancer Center</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Collaborator: YUKIGUNI COMPANY</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Collaborator: Weill Medical College of Cornell University</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Principal Investigator: Kathleen Wesa, MD Memorial Sloan Kettering Cancer Center</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Full Source of Clinical Trial Data: https://clinicaltrials.gov/show/NCT01099917</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Normally, for non-cancer patients, phase I clinical trials are performed with healthy subjects to test for safety and phase II clinical trials are performed with healthy patient subjects for efficacy. But for cancer patients, however, trials of cancer drugs must necessarily involve subjects with cancer, and as such, phase I/II studies include primary endpoints relating to safety and tolerability, not efficacy.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">For &#8220;Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients&#63; A Phase II clinical trial,&#8221; conclusions are described as follows: &#8220;Maitake was well tolerated. Enhanced in vitro neutrophil and monocyte function following treatment demonstrate that Maitake has beneficial immunomodulatory potential in MDS. Further study is warranted&#8221;.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Page 32 of the journal article, &#8220;Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients&#63;&#8221; indicates that there were 45 subjects were enrolled at the beginning of the study, 18 subjects completed treatment, 3 subjects had adverse effects and 24 subjects were not treated.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify;
 color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-indent: 0pt; padding-right: 0px; padding-left: 0pt;">&#160;</td><td style="width: 0.3in; text-align: justify; text-indent: 0pt; padding-right: 0px; padding-left: 0pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="text-align: justify; text-indent: 0pt; padding-right: 0px; padding-left: 0pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Hematopoiesis: is the formation of blood cellular components. All cellular blood components are derived from haematopoietic stem cells. In a healthy adult person, approximately 1011&#8211;1012 new blood cells are produced daily in order to maintain steady state levels in the peripheral circulation (Wikipedia).</font></td></tr><tr style="vertical-align: top;"><td style="text-indent: 0pt; padding-right: 0px; padding-left: 0pt;">&#160;</td><td style="text-align: justify; text-indent: 0pt; padding-right: 0px; padding-left: 0pt;">&#160;</td><td style="text-align: justify; text-indent: 0pt; padding-right: 0px; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-indent: 0pt; padding-right: 0px; padding-left: 0pt;">&#160;</td><td style="text-align: justify; text-indent: 0pt; padding-right: 0px; padding-left: 0pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="text-align: justify; text-indent: 0pt; padding-right: 0px; padding-left: 0pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Myelodysplastic: are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells (Medscape). Myelodysplastic syndromes are a group of disorders caused by poorly formed or dysfunctional blood cells. Myelodysplastic syndromes occur when something goes wrong in your bone marrow &#8212; the spongy material inside your bones where blood cells are made. Treatment for myelodysplastic syndromes usually focuses on reducing or preventing complications of the disease and its treatments. In certain cases, myelodysplastic syndromes are treated with a bone marrow transplant (Mayo Clinic).</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">For ABV-1503, we are currently preparing the IND package. BioLite is preparing the Compound IP for the Chemistry, Manufactural, and Control (CMC) part, MSKCC and the Company are collaborating to prepare for protocol design and prepare the IRB documents. The trial period, test subject number, primary and secondary endpoint and method of administration have not been decided yet, and are still being negotiated between we and MSKCC.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">ABV-1504 and ABV-1505 have the same Active Pharmaceutical Ingredient: the extract of Radix Polygalae (Polygala tenuifolia Willd/PDC-1421 Capsule). IND and study information are as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 24px; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 24px; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">A Dose Escalation Phase I Study of PDC-1421 Capsule to Evaluate the Safety in Healthy Volunteers.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">IND Number: 112567</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform:
 none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Trial period: 11/13/2012-7/5/2013, Final Report Date 11/12/2013</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt;
 text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Total 30 study subjects were enrolled. The test drug was oral administration. The primary endpoint is to assess the safety profile of PDC-1421 Capsule in healthy volunteers.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Sponsor: BioLite, Inc.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 24px; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 24px; text-align: justify; font-stretch: normal;">&#9679;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients with Major Depressive Disorder</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">IND Number: 112567</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Primary Study Objective: To assess the efficacy profile of PDC-1421 Capsule in major depressive disorder with Montgomery-Asberg Depression Rating Scale (MADRS).</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Secondary Study Objective: To evaluate the efficacy and safety profile</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Study period: 2 years.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Total 72 study subjects will be enrolled.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Study site: There are five sites in Taiwan and one site in US (Stanford University, which is currently preparing for IRB approval and Clinical Trial Agreement.)</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Sponsor: BioLite, Inc.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">For ABV-1504 Phase II part one---total subject: 12, trial period: 2/11/2016-7/14/2016, administered route: oral, test results are as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width:
 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Trial Progress Report:</font></p><p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1. Part I trial has been completed with 12 subjects (screening: 14, enrolling: 12). The six subjects were in the Part I high dosage group.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">2. Under the suicide risk assessment (C-SSRS) Subject X indicated that the suicidal ideation scores were 4 for both Visit 7 and Visit 8. The PI confirmed that the subject had external pressures (moving, etc.), which produced constant suicidal thoughts, and such observation was reflected in Dr. A&#8217;s (PI) evaluation. The subject expressed his/her intention to stay positive in a counseling session, and the subject was contacted by a researcher (Research Nurse) after leaving the facility. After reviewing by the researcher, a justification was made that the suicidal behavior was irrelevant to the drug administered.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">3. Clinical data of the six high-dosage administered subjects with data exceeding normal value:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 20pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">- NCS- Non-Clinical Significant judged by PI. CS: Clinical Significant judged by PI.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 20pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">-After data safety review board carefully reviewed, they agree to proceed to part two clinical trial.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">For ABV-1504 Phase II part two: this phase currently is conducted in 5 clinical sites in Taiwan (started in Q3 2016) and one US site is under IRB review.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">For &#8220;A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression:&#8221; Trial period: 11/13/2012-7/5/2013, final report date 11/12/2013. Enroll subject: 30, 23 PDC-1421, 7 placebo control.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Study Conclusions:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align:
 justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1;
 font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#8220;(1) No subject had serious adverse event and no subject discontinued due to adverse event;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">(2) No clinically significant findings were observed in physical examinations; vital signs,&#160;</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">electrocardiograms, laboratory measurements, and C-SSRS were observed throughout the treatment period;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">(3) The oral administration of PDC-1421 in healthy volunteers was safe and well-tolerated for the dose from 380 mg to 3800 mg&#8221;.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">For &#8220;A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients with Major Depressive Disorder&#8221;:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Part One- study period 2/11/2016-7/12/2016. Total subject: 12</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Maitake mushroom extract is sourced from YUKIGUNI COMPANY, Japan, and processed by YUSHENG PHARMACEUTICAL COMPANY in Taiwan (cGMP).</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The extract of Radix Polygalae (Polygala tenuifoliaWilld/PDC-1421 Capsule) is purchased from HERNG FA PHARMACEUTICAL TECHNOLOGY, and processed by Industrial Technology Research Institute (ITRI). There are no limits on availability to the Company on any of these ingredients.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Pursuant to the Collaborative Agreement, an upfront payment of $3,500,000 (the &#8220;Milestone Payment&#8221;), which is 3.5% of total payments due under the Collaborative Agreement, was to be paid by the Company upon signing of that agreement. On May 6, 2016, we and BioLite agreed to amend the Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby we have agreed to pay the Milestone Payment to BioLite $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were
 completed in June 2016.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal
 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">This Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company determined to fully expense the entire amount of $3,500,000 since currently the related licensing rights do not have alternative future uses. . According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount is fully expensed as research and development expense.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_CollaobrativeAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_CollaobrativeAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6746025424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES TRANSACTIONS</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>4. DUE TO RELATED PARTIES</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">As of September 30, 2015, the amount due to a related party, BioLite, Inc. (&#8220;BioLite&#8221;) was $22,517.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">As of September 30, 2015, the amount due to shareholder, YuanGene Corporation, was $46,586.</font></p></div><span></span>
</td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>5. RELATED PARTIES TRANSACTIONS</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">As of September 30, 2016 and September 30, 2015, the amount due to a related party, BioLite, Inc (&#8220;Biolite&#8221;) was $0 and $22,517 respectively.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">As of September 30, 2016 and September 30, 2015, the amount due to shareholder, YuanGene Corporation, was $0 and $46,586 respectively.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818156944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>6. ACCOUNTS PAYABLE</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">As of September 30, 2016 and September 30, 2015, the amount of Accounts Payable to LiteArt, Inc. was $18,370 and $0 respectively.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6614754368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><font style="font-size: 10pt;"><b>7. EQUITY</b></font></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>&#160;</b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">During October 2015, $350,000 of subscription receivable was fully collected from the shareholders.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">On February 8, 2016, a Share Exchange Agreement (&#8220;Share Exchange Agreement&#8221;) was entered into by and among American BriVision (Holding) Corporation (the&#160;&#8220;Company&#8221;), American BriVision Corporation&#160;(&#8220;BriVision&#8221;), Euro-Asia Investment &amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People's Republic of China (&#8220;Euro-Asia&#8221;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the&#160;&#8220;BriVision Stock&#8221;). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the&#160;&#8220;Acquisition Stock&#8221;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#8217;s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#8217;s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision&#8217;s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company&#8217;s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company&#8217;s common stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company&#8217;s common stock,&#160;Because of the exchange of the BriVision Stock for the Acquisition Stock (the&#160;&#8220;Share Exchange&#8221;), BriVision became a wholly owned subsidiary (the &#8220;Subsidiary&#8221;) of the Company and there was a change of control of the Company following the closing.&#160;&#160;There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On February 17, 2016, pursuant to the 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;), 157,050 (50,000 pre-stock split) shares were granted to the employees.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the &#8220;Forward&#160;Stock&#160;Split&#8221;) and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April
 8, 2016.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On May 6, 2016, we and BioLite agreed to amend the Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby we have agreed to issue shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of our first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">On August 26, 2016, the Company issued 1,468,750 shares (&#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.001 (the &#8220;Offering&#8221;) to BioLite, Inc., a non-U.S. accredited investor (the &#8220;Purchaser&#8221;) pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &#8220;SPA&#8221;). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to Regulation&#160;S of the Securities Act promulgated thereunder. Our sole director, Eugene Jiang, is a director of BioLite and it is therefore considered a related party.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. The proceeds may be used for general corporate purposes.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6746347312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS PER SHARE</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>5. EARNINGS PER SHARE</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Basic earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted-average number of common shares and dilutive potential common shares outstanding during the period.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">For&#160;the&#160;period from July&#160;21,&#160;<br />2015&#160;<br />(inception) to<br />September 30,<br />2015</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Numerator:</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left;">Net income</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">(315,602</td><td style="width: 15px; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Denominator:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Weighted-average shares outstanding</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Weighted-average shares outstanding - Basic</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">160,823,831</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt;">Stock options</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Weighted-average shares outstanding - Diluted</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">160,823,831</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Earnings per share</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt;">-Basic</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.00</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">-Diluted</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style:
 double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt;
 border-bottom-style: double;">0.00</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Diluted earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock.</font></p></div><span></span>
</td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>8. EARNINGS PER SHARE</b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Basic earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted earnings per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the year.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 1.5pt; font-family: calibri, sans-serif;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', serif; font-size: 10pt;"><b>For&#160;the&#160;Year</b></font><br /><font style="font-family: 'times new roman', serif; font-size: 10pt;"><b>Ended&#160;</b></font><br /><font style="font-family: 'times new roman', serif; font-size: 10pt;"><b>September&#160;30,</b></font><br /><font style="font-family: 'times new roman', serif; font-size: 10pt;"><b>2016</b></font></td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">For the period from<br />&#160;July 21,&#160;<br />2015<br />&#160;(Inception)<br />&#160;to September&#160;30,&#160;<br />2015</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>Numerator:</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;" colspan="2">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;" colspan="2">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 1191px; text-align: left;">Net loss</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">$</td>
<td style="width: 142px; text-align: right;">(4,507,799</td>
<td style="width: 16px; text-align: left;">)</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 141px; text-align: right;">(315,602</td>
<td style="width: 15px; text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td>Denominator:</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>Weighted-average shares outstanding:</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 4pt;">Weighted-average shares outstanding - Basic</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style:
 double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">193,981,153</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">160,823,831</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 4pt;">Stock options</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: left; padding-bottom: 4pt; font-family: calibri, sans-serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 4pt;">Weighted-average shares outstanding - Diluted</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">193,981,153</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">160,823,831</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td>Earnings per share</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 4pt;">-Basic</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.02</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.00</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="padding-bottom: 4pt;">-Diluted</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.02</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.00</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;<b>&#160;</b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Diluted earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6618579424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>9. COMMITMENTS AND CONTINGENCIES</b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Capital Commitment</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">On December 29, 2015, the Company entered into the agreement with Biolite, a related party, that Biolite would grant the Company sole licensing rights of a series of technology for 15 years. The total consideration of obtaining such grant would be $100,000,000.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Operating Commitment</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The total future minimum lease payments under the non-cancellable operating lease with respect to the office&#160;as of September 30, 2016 are payable as follows:</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 384.25pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 1379px;">Remaining 2016</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">5,948</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td>Year ending September 30, 2017</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">23,793</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td>Year ending September 30, 2018</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">17,845</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="padding-bottom: 4pt;">Total</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">47,586</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color:
 #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Rental expense of the Company was $29,129 and nil for the year ended September 30, 2016 and 2015, respectively.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6748588896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Event [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>6. SUBSEQUENT EVENT</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">During October 2015, $350,000 of subscription receivable was fully collected from the shareholders.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On December 29, 2015, the Company entered into the agreement with BioLite, a related party, that BioLite would grant the Company sole licensing rights of s series of technology for 10 years. The total consideration of obtaining such grant would be $100,000,000.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Reverse Merger</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On February 8, 2016, a Share Exchange Agreement (&#8220;Share Exchange Agreement&#8221;) was entered into by and among American BriVision (Holding) Corporation (the&#160;&#8220;Company&#8221;), American BriVision Corporation&#160;(&#8220;BriVision&#8221;), Euro-Asia Investment &amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People's Republic of China (&#8220;Euro-Asia&#8221;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the&#160;&#8220;BriVision Stock&#8221;).</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the&#160;&#8220;Acquisition Stock&#8221;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#8217;s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#8217;s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color:
 #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Pursuant to the Merger, all of the issued and outstanding shares of BriVision&#8217;s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company&#8217;s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company&#8217;s common stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company&#8217;s common stock,&#160;Because of the exchange of the BriVision Stock for the Acquisition Stock (the&#160;&#8220;Share Exchange&#8221;), BriVision became a wholly owned subsidiary (the &#8220;Subsidiary&#8221;) of the Company and there was a change of control of the Company following the closing.&#160;&#160;There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Forward Stock Split</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i>&#160;</i></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000. The amendment to Articles of Incorporation was approved by the majority of the shareholders of the Company and became effective on April 8, 2016.</font></p></div><span></span>
</td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>10. SUBSEQUENT EVENT</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company evaluated and concluded that no subsequent events have occurred that would require recognition or disclosure in the consolidated financial statements.&#160;</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822814736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Basis of Presentation</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The accompanying audited financial statements and related notes have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&#8217;s financial statements are expressed in U.S. dollars.</font></p></div><span></span>
</td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Basis of Presentation</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States ("U.S. GAAP").</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&#8217;s financial statements are expressed in U.S. dollars.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Use of Estimates</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</font></p></div><span></span>
</td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Use of Estimates</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_ForwardStockSplitPolicyTextBlock', window );">Forward Stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Forward Stock split</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Fair Value Measurements</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company applies the provisions of ASC Subtopic 820-10,&#160;&#8220;Fair Value Measurements&#8221;,&#160;for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.&#160;&#160;ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;&#160;When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in;">&#160;</td><td style="width: 32px; text-align: justify;">&#9679;<font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td style="text-align: justify;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</font></td></tr></table><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in;">&#160;</td><td style="width: 32px; text-align: justify;">&#9679;<font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td style="text-align: justify;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</font></td></tr></table><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in;">&#160;</td><td style="width:
 32px; text-align:
 justify;">&#9679;<font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td style="text-align: justify;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of&#160;September 30, 2015.</font></p></div><span></span>
</td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Fair Value Measurements</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company applies the provisions of ASC Subtopic 820-10,&#160;&#8220;Fair Value Measurements&#8221;,&#160;for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.&#160;&#160;ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;&#160;When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal;
 -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of&#160;September 30, 2016.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Cash and Cash Equivalents</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2015, the Company&#8217;s cash and cash equivalents amounted $994,830. All&#160;of the Company&#8217;s cash deposit is held in a financial institution located in Republic of China where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.</font></p></div><span></span>
</td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Cash and Cash Equivalents</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2016, the Company&#8217;s cash and cash equivalents amounted $173,537. As of September 30, 2015, the Company&#8217;s cash and cash equivalents amounted $994,830. All&#160;of the Company&#8217;s cash deposits are held in a financial institution located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Income Taxes</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company accounts for income taxes using an asset and liability approach which allows for the recognition and measurement of deferred tax assets based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before the Company is able to realize their benefits, or that future deductibility is uncertain.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Under ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalties or interest relating to income taxes have been incurred during the period from July 22, 2015 (inception) to September 30, 2015. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.</font></p></div><span></span>
</td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Income Taxes</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 40.2pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 40.2pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Under ASC 740, a tax position is recognized as a benefit only if it is&#160;&#8220;more likely than not&#8221;&#160;that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred during the period from July 21, 2015 (inception) to September 30, 2015. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">As of September 30, 2016 and September 30, 2015, the Company&#8217;s income tax expense amounted $836 and $0, respectively.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Recent Accounting Pronouncements</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">From time to time, new accounting standards are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The recent accounting standards are not expected to have a material impact on the consolidated financial statements upon adoption.</font></p></div><span></span>
</td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Recent Accounting Pronouncements</u></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">From time to time, new accounting standards issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The recent accounting standards are not expected to have a material impact on the consolidated financial statements upon adoption.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_ForwardStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to forward stock split policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_ForwardStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6617427120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of earnings per share</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">For&#160;the&#160;period from July&#160;21,&#160;<br />2015&#160;<br />(inception) to<br />September 30,<br />2015</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Numerator:</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left;">Net income</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">(315,602</td><td style="width: 15px; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Denominator:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Weighted-average shares outstanding</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Weighted-average shares outstanding - Basic</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">160,823,831</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt;">Stock options</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Weighted-average shares outstanding - Diluted</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">160,823,831</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Earnings per share</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt;">-Basic</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.00</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">-Diluted</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.00</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
<td class="text"><div>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 1.5pt; font-family: calibri, sans-serif;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', serif; font-size: 10pt;"><b>For&#160;the&#160;Year</b></font><br /><font style="font-family: 'times new roman', serif; font-size: 10pt;"><b>Ended&#160;</b></font><br /><font style="font-family: 'times new roman', serif; font-size: 10pt;"><b>September&#160;30,</b></font><br /><font style="font-family: 'times new roman', serif; font-size: 10pt;"><b>2016</b></font></td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">For the period from<br />&#160;July 21,&#160;<br />2015<br />&#160;(Inception)<br />&#160;to September&#160;30,&#160;<br />2015</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>Numerator:</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;" colspan="2">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;" colspan="2">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 1191px; text-align: left;">Net loss</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">$</td>
<td style="width: 142px; text-align: right;">(4,507,799</td>
<td style="width: 16px; text-align: left;">)</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 141px; text-align: right;">(315,602</td>
<td style="width: 15px; text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td>Denominator:</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>Weighted-average shares outstanding:</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 4pt;">Weighted-average shares outstanding - Basic</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">193,981,153</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">160,823,831</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 4pt;">Stock options</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: left; padding-bottom: 4pt; font-family: calibri, sans-serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 4pt;">Weighted-average shares outstanding - Diluted</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">193,981,153</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom:
 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">160,823,831</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td>Earnings per share</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: right; font-family: calibri, sans-serif;">&#160;</td>
<td style="text-align: left; font-family: calibri, sans-serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 4pt;">-Basic</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.02</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.00</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="padding-bottom: 4pt;">-Diluted</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.02</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.00</td>
<td style="text-align: left; padding-bottom: 4pt;"></td>
</tr>
</table>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818167264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum lease payments</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px;">Remaining 2016</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">5,948</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Year ending September 30, 2017</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">23,793</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Year ending September 30, 2018</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">17,845</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">Total</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">47,586</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822965648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of Business (Details)<br></strong></div></th>
<th class="th">
<div>Feb. 08, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementMember', window );">Share Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract', window );"><strong>Organization and Description of Business (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="nump">164,387,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="nump">52,336,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementOneMember', window );">Share Exchange Agreement 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract', window );"><strong>Organization and Description of Business (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="nump">166,273,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="nump">52,936,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementTwoMember', window );">Share Exchange Agreement 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract', window );"><strong>Organization and Description of Business (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="nump">163,159,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="nump">51,945,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of common shares issued and outstanding</a></td>
<td class="nump">79.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_PercentageOfIssuedShareCapital', window );">Percentage of issued share capital</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementThreeMember', window );">Share Exchange Agreement 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract', window );"><strong>Organization and Description of Business (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="nump">166,273,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="nump">52,936,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Common stock converted to exchange ratio</a></td>
<td class="nump">0.2536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementFourMember', window );">Share Exchange Agreement 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract', window );"><strong>Organization and Description of Business (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="nump">205,519,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="nump">65,431,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of common shares issued and outstanding</a></td>
<td class="nump">79.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_CommonStockIssuedAfterStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued after stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_CommonStockIssuedAfterStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_CommonStockIssuedBeforeStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued before stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_CommonStockIssuedBeforeStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and description of business textual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_OrganizationAndDescriptionOfBusinessTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_PercentageOfIssuedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of issued share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_PercentageOfIssuedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6828169952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 21, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jul. 20, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Forward split ratio</a></td>
<td class="text">1 to 3:141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">360,000,000<span></span>
</td>
<td class="nump">360,000,000<span></span>
</td>
<td class="nump">360,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents amounted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 994,830<span></span>
</td>
<td class="nump">$ 173,537<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies textual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_SummaryOfSignificantAccountingPoliciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822462544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_GoingConcernTextualAbstract', window );"><strong>Going Concern (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (315,602)<span></span>
</td>
<td class="num">$ (4,823,401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="num">(315,602)<span></span>
</td>
<td class="num">(4,507,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Negative cash flow</a></td>
<td class="nump">$ 994,830<span></span>
</td>
<td class="num">$ (821,293)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_GoingConcernTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Going concern textual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_GoingConcernTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6825214096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 06, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 29, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CollaborativeAgreementTextualAbstract', window );"><strong>Collaborative Agreement (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amount received from BriVision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,517<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock newly issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,958<span></span>
</td>
<td class="nump">$ 3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CollaborativeAgreementTextualAbstract', window );"><strong>Collaborative Agreement (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Collaborative agreement schedule of settlement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">upfront payment shall upon the signing of this Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#160;</td></tr></table><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#160;</td></tr></table><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#9679;</font></font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.</font></td></tr></table><p style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal;">&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#160;</td></tr></table><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none;
 text-indent: 0px; letter-spacing: normal;
 margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">&#160;</td></tr></table><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.</font></td></tr></table></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementRightsAndObligations', window );">Collaborative agreement material terms, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-indent: 0px; padding-left: 0px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; text-indent: 0px; padding-left: 0px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><br /></font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; text-indent: 0px; padding-left: 0px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;is responsible to make up-front, milestone and royalty payments to BioLite, as described in the foregoing paragraph and below.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.25in; text-align: justify; color: #000000; text-transform: none; text-indent: -0.25in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-size-adjust: none; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">As between BioLite and ABVC, BioLite owns all files, data, confidential and non-public information, including, without limitation, all IND packages and clinical study reports, regarding the Compounds (collectively, the &#8220;Compound IP&#8221;), to the extent developed in Taiwan, and owns all Compound IP to the extent developed in North America. BioLite grants an exclusive license to its Compound IP to for the purpose of further development and commercialization of the Compounds in North America. BioLite and share the responsibility of preparing for clinical trials by delivering Compound IP and preparing related materials.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;is responsible for all clinical trial expenses incurred in North America.&#160;&#160;BioLite paid all clinical trial expenses for trials conducted in Taiwan thus far.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Collaborative Agreement will remain in effect for fifteen years from the date of first commercial sale of Product in the U.S. or Canada. Either party may terminate upon thirty days&#8217; prior written notice for breach or
 insolvency.</font></td></tr></table><p style="font:
 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;agreed to pay to BioLite an aggregate of One Hundred Million Dollars ($100,000,000) (the &#8220;Aggregate Amount&#8221;) in milestone payments during the term of the agreement, payable in cash or Company equity. A percentage of the Aggregate Amount will be paid to BioLite upon each completion of a milestone by BioLite as set forth in the Collaborative Agreement. An upfront payment of $3,500,000 (the &#8220;Milestone Payment&#8221;), which is 3.5% of total payments due under the Collaborative Agreement, was to be paid by us upon signing of the Collaboration Agreement. On May 6, 2016, we and BioLite amended the payment terms under the Collaborative Agreement by entering into a Milestone Payment Agreement, pursuant to which we paid $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Milestones are reached by BioLite upon submissions of IND and NDAs for the Products, and completion of phases in the application processes, as set forth in the Collaborative Agreement.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In addition to the Aggregate Amount, &#160;will pay to BioLite five percent (5%) of net sales of Products in the U.S. and Canada.</font></td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amount received from BriVision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_PercentageOfPaymentsUnderCollaborativeAgreement', window );">Percentage of payments under collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_MilestonePayments', window );">Milestone payments to BioLite in cash</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock newly issued, value</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock newly issued, shares</a></td>
<td class="nump">562,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_CollaborativeAgreementTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_CollaborativeAgreementTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The payments which are paid during the term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_PercentageOfPaymentsUnderCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of payments under collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_PercentageOfPaymentsUnderCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payments which are paid during the term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementRightsAndObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of rights and obligations under the collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementRightsAndObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms and manner of settlement of the related party transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6741585200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_RelatedPartiesTransactionsTextualAbstract', window );"><strong>Related Parties Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 22,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrent', window );">Due to shareholder, YuanGene Corporation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 46,586<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_RelatedPartiesTransactionsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_RelatedPartiesTransactionsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6637217984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_AccountsPayableTextualAbstract', window );"><strong>Accounts Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable to LiteArt, Inc.</a></td>
<td class="nump">$ 18,370<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_AccountsPayableTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_AccountsPayableTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6829967280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 06, 2016</div></th>
<th class="th"><div>Mar. 21, 2016</div></th>
<th class="th"><div>Feb. 17, 2016</div></th>
<th class="th"><div>Feb. 08, 2016</div></th>
<th class="th"><div>Aug. 26, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Oct. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000,000<span></span>
</td>
<td class="nump">360,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Description of forward split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 to 3:141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (350,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,958<span></span>
</td>
<td class="nump">$ 3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mtoo_EquityIncentivePlanMember', window );">2016 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mtoo_BioliteIncMember', window );">Biolite Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,468,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementMember', window );">Share Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,387,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementOneMember', window );">Share Exchange Agreement 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,936,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementTwoMember', window );">Share Exchange Agreement 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,159,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,945,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of common shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_PercentageOfIssuedShareCapital', window );">Percentage of issued share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementThreeMember', window );">Share Exchange Agreement 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,936,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_ConversionOfExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0.2536-for-1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementFourMember', window );">Share Exchange Agreement 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,519,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,431,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of common shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock newly issued, shares</a></td>
<td class="nump">562,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_CommonStockIssuedAfterStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued after stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_CommonStockIssuedAfterStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_CommonStockIssuedBeforeStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued before stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_CommonStockIssuedBeforeStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_ConversionOfExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exchange ratio per stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_ConversionOfExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_EquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_EquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_PercentageOfIssuedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of issued share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_PercentageOfIssuedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mtoo_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mtoo_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mtoo_BioliteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mtoo_BioliteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6762630800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (315,602)<span></span>
</td>
<td class="num">$ (4,507,799)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding - Basic</a></td>
<td class="nump">160,823,831<span></span>
</td>
<td class="nump">193,981,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding - Diluted</a></td>
<td class="nump">160,823,831<span></span>
</td>
<td class="nump">193,981,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">-Basic</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">-Diluted</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1757-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Treasury Stock Method<br> -URI http://asc.fasb.org/extlink&amp;oid=6527216<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Call Option<br> -URI http://asc.fasb.org/extlink&amp;oid=6506649<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Warrant<br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6745961904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Remaining 2016</a></td>
<td class="nump">$ 5,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Year ending September 30, 2017</a></td>
<td class="nump">23,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Year ending September 30, 2018</a></td>
<td class="nump">17,845<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 47,586<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6764195184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Total consideration amount</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Commitment consderation, period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 29,129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_CommitmentsAndContingenciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_CommitmentsAndContingenciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6829136128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 21, 2016</div></th>
<th class="th"><div>Feb. 08, 2016</div></th>
<th class="th"><div>Dec. 29, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Oct. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (350,000)<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, authorized</a></td>
<td class="nump">360,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Description of forward split</a></td>
<td class="text">1 to 3:141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Total consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms', window );">Licensing rights term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementMember', window );">Share Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,387,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementOneMember', window );">Share Exchange Agreement 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,936,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementTwoMember', window );">Share Exchange Agreement 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,159,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,945,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of common shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_PercentageOfIssuedShareCapital', window );">Percentage of issued share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementThreeMember', window );">Share Exchange Agreement 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,936,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_ConversionOfExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0.2536-for-1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementFourMember', window );">Share Exchange Agreement 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,519,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mtoo_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,431,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of common shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_CommonStockIssuedAfterStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued after stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_CommonStockIssuedAfterStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_CommonStockIssuedBeforeStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued before stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_CommonStockIssuedBeforeStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_ConversionOfExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exchange ratio per stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_ConversionOfExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtoo_PercentageOfIssuedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of issued share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtoo_PercentageOfIssuedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtoo_ShareExchangeAgreementFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>43
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_A=A'UOW<[]8^.SH&[@UUWH+U!+ P04    " ":BS-*F5R<(Q &  "<)P
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MJ0*G L,ARB#YN ]11 -FB$'0WO TS H6^&T'V2=\C#*(T1NA&#9'B)+35)+
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MU+@Q+/4D9DR?=F:./0XN9C''ANIH,<T^J$2;(<=N&!HH-+9#:MF,B5S(IN[
M;.ZLMYW.-69/6S2_PZ,YX8EN$@9!%$'^=]CT'9C-'9CM/5V-%:"]FA-F#<V#
M$S8L6 @7OYC "?<LC37 .!5(J> 3_(9H#@N!DSVH4(RRC86@[9H3?HV,!!MV
M1Y ;!9\,_:O7N_83P#])]9(6]>RY;-R;8O<^=RC+QKJT[)-+>+3)_G*0V4/3
M[@9NO^I?O?N#ICP-GQ7\R[>-Y?]02P,$%     @ FHLS2C39TGC. P  DQ$
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MY&^ZD-* +26XLZ^[LKT_!1P*XZ;W=JZ&#A@"(]NQN<GTATG_ 5!+ P04
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M&_(W74AIP)82W-G77=G>GP(.A7'3>SM70P<,@9'MV-QD^L.D_P!02P,$%
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M['^-Z,!+V=WX$6K]!UL,!;4+Q\_^;*8QFPR'_?R#V/*-BW]02P,$%     @
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M--EL;*>+PCTSD^],[VD-6;:,3E9HJ'GH:_"J)A]K(J,_FB!I@DX@N13(8UJ
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MWZG809GF7+>%.]-=1_&VNZ\$_:4I_P-02P,$%     @ FHLS2C\#$K#) 0
M600  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL?53;;IPP$/T5Y ^(
M ;.7K@"INU652HVT2M7VV0O#@F)C8GN7Y.]K&P<10'W!GO$Y9\[X0MH+^:)J
M !V\<=:J#-5:=P>,55$#I^I!=-":E4I(3K4)Y16K3@(M'8DS'(?A%G/:M"A/
M7>XL\U3<-&M:.,M W3BG\OT(3/09BM!'XKFYUMHF<)YV] J_0/_NSM)$>%0I
M&PZM:D0;2*@R]#4ZG!*+=X _#?1J,@]L)Q<A7FSPH\Q0: T!@T);!6J&.YR
M,2MD;+QZ3326M,3I_$/]N^O=]'*A"DZ"_6U*76=HCX(2*GIC^EGTC^#[V:#
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M0 #$4/ XXI&COH19I!$L/A!@D7B[@#J".38/-HY,.>8YPCC2!!P)XT@VCJ#
M A0XI(@K<NV7,)-D,PD*+$&!%0]ES!W!,)5D4UDO60X7&#B*)A08<T2((ZO
M,2@P9U(IZ8J&D2,UIL#*+G ]]"21HSH<P\D1G,:T]P!%D2,.QI(C+,TO"RA2
MCCB82 X62!?4W+&AGT DQT3R,43RR41R3"0?0R2?2B3'1'*T3EH=B42NCL38
M<K!.!JY>P-CR>$)'8A8Y8M'J2)M%"F2-(Y&CM@+#*!!G9D<*>Z4,I>",N3;8
M A,I$&PF^5#D(%]@(@4@TK4W$YA(,8%(X?C.M8DD:7R=WO6B4=L[@5D4X-.3
ME!D'L!@V'UF.4)A$84-F;H[OA/UMJ= 9@7]Q&-6<H?Z=%&_[0SE[S:LJS]K3
MIVV>5[KV&=S4>>]TLCG?I'I;-9=1?5UT9Y?=394?^W-9_WPXO/P)4$L#!!0
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MP<%!=W@XZAX/![@<X#=PGBF 4\M$>JKVYQKNCV>S$/D(0&GEA[,>L,; 7X4
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M(,R@OCNSU'FSW& >P7L[;SGA>W.Z@#AZ@:"T!P4T!F14<C0O]S\U;:/]-PW
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MY&AV%NF:U8 :2.$34:1T-$C62Q7%OP&BA\?]P]W_J#"(:GQS ^_QPB7*84!
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M4B<P$LT6L[ =2P@A.7 :)VA:VN0R"MZ*)5U-TY9<)S0$ F3'B,X62$ =\"5
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MB_FI<*D]>MVR&R@6'X/P&"QTJ[CYTR1.4/ZPRON6_'SADL09_O\NQ5V=3U*
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M3K0%S7NXUL6%9$@[8-#Z\5. H*[?VDE$36CTMWEKP&CFP"_3=6^<P3;F9IN
M@;?,4"8!9O!U+L=GMQ/ [8DA]Z8M*A<Z9I-$"^6+XY<U[@UUQT)&J<-A#:4D
M7\UB%2^ _N03*<LCEH=GK,8"M-N???Y8X>-UL!<0D.7,L52=S+(F?E]S.Q.G
M+AN?-CUHIPW?-L=)>KT>^V+EY( 7PVZ)(P.P7@W0WSHX #H=[+WBW#--352?
M!KH(@B4A@9)SKRL;?BFE>M/*-VDR)R\B$SI\M,^!'^TD-!VQ*A$@4!/-%77
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M]\E/8PK4W\ A"!^>?F*3,VM\>W5Q]6[BW9S?>I,?QK<U5]Y^WZL_Y+WQLS
M<UD^92$:,D,H)%MH%H(1RKF^N9XE*$;_H\+@@)KU?)R6,7=9F29JX92. EZ;
MUM@'>1S1UWZ?S5"  +](7;U,Y<UG[?BM;J'9.F_R"E0MJ<>[LGM]Z77TV+8=
M+*]-* HE17OE[3=L9)MG>G*Q Y#M.,3F:#00!J85P]Z6Z^A;<5<ZK]]0C[^'
MS-KKZ7?H7QNN%3,7,C&6V"O,X#2WP1>4R-S<@$Q<+K$([S&IW8R*UUHN*<^^
ME/2QF*Z;<\!RTR#,Q"PTQAUOQ'V\1K1'7X^&<#30UZ(@C(E^,?U\T49^"_70
M;E]HVOD%YQN=M\PW:J*P%Y:F7ESI_0-%V0%+.PYYO7#)Z\46*+_50Y:^CL&>
M/P*+=G_D4LB+"JUMN::AM995ZW3WPM+=D,CMA4M\PW\]"@2QO0QE!(HNPX$S
MH7M4;0K"GEY?7E[<X5B1B3>^.L-Y97= QN=7IQ?GM2CL,<XDV? \YBN1Q\KN
MIF58B:MIE,(Q9 C5II%$W(.[&JPDV,O/,NF=S-ZR[[9Q_@BUCL#40W%5VFPH
MU%= 0NFD?DQO2&3^$^E@QK2P,[XHS9F_;.;-NXUU01TT_: <T-BU)=L XS'+
M8HGIQ9G36M<&<TR!-YIS=@P9+,NO$+PD)J@5N@1S\%3KJ#:NC920HY->_^*6
M4EM,<YJ7WG[W>._HQ2\R=XW**ZJK'7I D8?'H\U/':%WY&AO_P6G[;WT]@XI
M>'N+C7]-5^BJK<Q1^./N8"BCXK#3@K#!C</@N/"5T&YCN'1BAY^?8TKI4[]O
MH*K)AS>3\[]_P&$]YS\U#/<!Z['ZR.\55OWMQ/A^,S&^_R)BS#80X^Y7)L9;
M\9Z+>_8YUOP_&&O&UY[CS<_QYN=X\W.\^3G>_!QO?HXW/\>;G^/-V\6;&Z*C
MWWIP]_<,VLH0\.W.4NH?+UK49T5R:>X7H68]0*S-BJK)Z7U:1B?9R@_47[\C
M!IT^J.^^'^PV6(=WKHTFU7;&2T0MRZ2HFXLFM:%*M9$RP9G<4ZE^[E'D% ^E
M1F5V'DMY0ZH;=A>VR!T-+NR SM6$#7-Y^U[=7EY2.PAT.SB5F)+GC!1T RN2
M?ZJC_VNGN@BZ\62&" DPNJVM'N+;#\1DH0!6P>'.QK'"+/39HHT35/<(:-0Y
M0)K.$(GR-%/?C"R0T!8*9YIHC+=B3R@3M2,[ON5#3'N8Y*128MXW6W!>AZ*R
M[\9C+AV$ TWUL9P%I;N=%*4XHV#X,;!B(_=Q01!!!^P3:"9$XT]ST)GU[!I"
M *0\ZM*$/E'=J]74G^ _T*VLFM_1D\":!V\W0YU8FZ[KQ_X6"(093Z>J>6C:
M[_E)]-SR-A&JO^U&.]^9>_SN^2);+O(#ZPWGV+X8H?;4[Q)=QGLS0'KZREF@
M8@,CFC"#]VON1G,^M!UC?ZZTA* )D<I\E]M%9L52Q#A7=K+08V,4J^;53.HX
M^)(!!,)0HI"+9$,3&C)\530,\M'GK>_P5]Q:NZ>/K6U96UI20A6#!$[HB8]!
MZ$T!)>SB%^0%M07@YBL<X9B%F Q@VK!%)DT R\KET=IEE]444A"V>.19D]DV
M_<S[7=//:E?G@_'^$QWCTFF#L.5CY8F&R 6%(^+&0C,R#2LV09?/DU48>$=#
M+-TT'3Q;5A:%GS/*[O$9AK7;JP&7MB3DT*#]8Y6"GU@MQ@X[^ET0"TO-,LI<
MUJI8BMI^.BOJV;*-*A;" 8X/AG66()?RIU&8+7!KZ+59JL<D94N+]T6MG^S2
M0OT^CB2PG A>GF)+BI93@9GA; ZGX-Z3G\W7]Q0&RM4HI\IV_J9VU=C8/6;@
M4A-%F=I(70R1F?@&QN3B\Z4O)Q;^VCI2TS\/-,J/F+5$?5S#%0]Z92[I[)HX
M9M_[>4%=^K@4V?;K:;X]RCQL9L,B*^C>2H-M^+"XW\HUEMUY.EIA0"9-I?&B
MDBS'3B8^S;S$/BAR0M,%--20U>#0&6)VU9J$:H(2+X(6.\EXO#CCR=278V["
MHEH%RRSP%B%H2<"?U_Q)(T_1+0-RC1M#+/U/X1)0GCXCW@+I!\6C0%>%P)MB
MGY4GB[C^+&V^";V;M\R#O*65*_I.>!6!DLU2P[TR-I26).>,.:BMI,=V2MB;
MC-PO<M8B9D<JK/9KD5!D#(DC8SV36#;?"^,:3U$*+.-QX$\VT7O<-(@<%TMW
MC'2/DL?J!DKHS/HE^=@<XZL)HO*A4?E#$FVK@*]"0!8T;<TA]2$TW-E193I\
M2:M-#O;A&F7(=2Q,=[8"6@W4_<I.AEOM1'<!+^^&NJ #DF)?XQ9.4?M^5Q0%
MBW6^:0GDZ_'*A@9+YP$=7_HX<)HH.KM2Z@W'_V+1AL8^MF!C=8SN!WO,NS-X
M'8EDO4Y5P(RVOJ(2#E'+#0?!Y.T*#3FNL>9[$]2K"L.$G<]HC5!#-;*CG,@%
M*<=6IZZF!1MQV5*SOZTR\ZRE/&LIW[R6\JQR?.,JQ[.&\:QA/&L8_ZLTC'I/
MGU/=/8W^ \M 81]-#I/6!TO*B&7(R"_@>J(0GM0574O;;W'IYR8E^5Z(CMI_
M,:!4EG6%2>LV@UTQ<*G#FK+??ZH%4BUJK ]274@<E H[R1WO=8]&NSP[I"V3
M U^?*>KPBR*>HMR4G5#&/IEP[/'85GJDGE?&TR(X\%OJF9W:DJ\E;)I60'\S
MC[E-J$@2Q^I)CM#4CS]J-WU6;H$V5: F,C</LY8]<E2 .D=S,1[P YJKNSW>
M?+/H</#EZ# X''7W1T\VV_H],(TC&Y^!:](#] ^'8!=<@G7G?ZJ'8]S?RK:0
M[EE%DI.?RNFI(N.HE2AZKA03OS-F!K*ZZ9-$-W+*C47S- ZK,<-A9C@RGL+8
M_B?-ZZ?4%Y5R(4ES"3\";!8)S_!(%6:RV;P\>(VG37&(2'+O)<78]FO?M/%N
M:1?*#!AZH'D@^B!8181?TP.8*+5YB9[T="VA%.SAEQFS@>([?IIRM/K)B!(W
M@-37[L1PI+:R$@G*;#VFO2I;B.F-'8E,5\*3.+/RP9K ']Y+Q2IUHB3HDXH>
M\W@I;@-+9B;-0A"=@YI)8DR62EQ+*6]H[7$'-+X\)4F"^MXD PU%.=_>#,?T
MY*$VT+!F0NJ3]952T\>]7<QBIF,GDH,49J[)2SE \A4@2^QIJL\FAGS3$76S
M;=/$O?0%8W%FH&9RDBJQ$D(-VW.ZJV?]5/XNB<X86BV6;*Y2)H?T%[9W1B4M
MU;/YV-^\!^KM2G<"YO>X6I[^SG-*3,=.,UW27FF/S]O#\_;X2BDN5CZFC+FP
MIR1Z+)V0M5X;=<P2J:+"O<=KDX !=*9HV!_J<+D>,"]D+D1.50*DJ&,"A:X#
MAWWI'4E%/\W\<$^JK;#*_MF*52IG^ZOEW+!G#*:5(5:.MFKTL?$!0:[-3I/:
MU;D:*W$U[!2*IGO]2[AU>&-.0Z-2QLM]ZJN _44TNM(;5':A)+>7;JB(.-J-
M^;UY)+EE=\YFQ*S \5?8J1VCOGX8::>YRMOAY;)R"SN;<]L$G)1G-ND,)JEP
M+ U%LTL1F'(<WFKVYJR9UP^!;:R3&+,D-^\\ )3"&+>SV9GJ;;'?1H;\U!G<
M7>%I5.Q'QID74@D)];:0!"Y-)N02 .;F=,AV.#NE]$8XU/<^9-;F_*B+K.08
M5$!ETSZP1;]C<JW,?I+4;L<=B%F2_3;5QNRX5B3N%H4/I2B\@XU_R:=$K2L:
M_+6<ND%^11%*@/2@X+*V%#M7Q/Q&'S\P_$?V3K4'^E3=<EX./Q4N=2Y$M^R&
MC,4M%C:&P[]857I*Y2CK2E^H)S%+>M:6_E#:TF]4DYXUI&<-Z=O4D+)GY>A9
M.?H<Y2@#+,]0F?E65:3UM@I2]CGZT> /K!]]65?TJD>NX5:L2^]H="#MT)\H
M\+]51/!N 4*:Q D*PL:<Q:>>]]Y2\FNX)!&,_[]+I:8.M*C0S4]GK/-(H8^4
ME[PUQ.!\86)>X$1770#]=CQY8VN8=#&17IZX$\4ODAGG)D@8R)\EJUS5!M;8
MF20(+D9^FUC*8>D//$J$/O089AP&*;),!K UN2&%%X?P0R")QX&246I<9VA.
M9W:(_&0-S,9^GL2D'>KA#'V6=6.:KFQYB9$+26KRE3'HNY+^ !FS<H*%D7J\
MM?:[P@T@K@7"1=HWDV^5E5W>PC\5U7XW-'O&L#\.AC5TS>O<H?E0K[F:! LP
M%B(IX*_V1MJJANVY!=PV+> :RB (:,^]O_[9O;\^KWW6-H2RL8735C33W'#)
MVZKATN:G=,,EK])PJ7J>ZW3NQ]KY@V X4[;C$-;HHZL*67;G3($%&]4A\E9-
M^]ZN%*3P?=: UM97YS\O:=.U9DK;[^I.?<*BI=JN3MT:>A$4P-)SM_!]JW?*
MM?);GVS0>K;65X:MK]RPW>KK*G6WLV!SEX7:*!]J2;%YW:;&$-4W!KM(2K6%
M6L\T:CU3"=BV[1V6994Z/&S]J;UVB']&5;+&<F!#'R9G7N=E#;,NL<&D+E"K
M_@CR#GX4P^:W[*,-K]^62M4:(60KUEHS2EJS)5I\VXX55GWB7<(M[M"U&&\#
MO\H+;0>]PC86J+G17N^CY+&.0<U#'+>ZP[6W>]!\A6<JZ)M.:5M_L^T88W9.
MF<QCTHI,:XN-1.$.V.QR[MJVVVDG.O=YV^<M<Z2:]7JA$]^PW>I2.M&O.K*5
M1FC:2$-I1&K[Y,V3YF&M=L Z@@_7J7ZN#$\SS([\+>2.C. [*;6EH7GCV!_=
M;72#[> ?E?IH,Q?-UMF5=7%UANZL92C#Y.W;?%+82->;%NQ)L]Y&TW,/_1N(
M9B?>P78G%-_L9QX0MPG:Q4?DY4^?46PJ:7,O0I7/N]+3G\OSU+<^N-5$Y.2'
M)_!?VQP<\"/]['/7M\NCHV6V>144;MI;PY7KU2Z^UK4?G<#_;G-X;K+U^U^Z
M.?&77_#QR7"K^\49N9]]1'LC7^6"K\[&7^%:4< WO E,;*N[SL)/GP\(W/F3
M=[TMOS<.!PS69)OX?(NMKP%+@<)LA3FH$I:D;@K%JD=LN@O&D1ZZ0=U6DC6Y
MS$V?6W=<A9_)/J9.."%)U9P4!NP#,4_]U4+Z[H!"8.]W;$/$[DR%\9N?3BU
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M 0\6PZSE(!'#T?Z(,]*PU[;@^ <C^0Y02P,$%     @ FHLS2A-+IYR[ @
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MBU'C<?8WV#CU)T+=_0\[?@-02P,$%     @ FHLS2FF&>SB( 0  U!,  !,
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M[.N3_#-O^@-02P$"% ,4    " ":BS-*'R// \     3 @  "P
M    @ $     7W)E;',O+G)E;'-02P$"% ,4    " ":BS-*9O,+8((   "Q
M    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( )J+,TK#I_.^[@   "L"   1              "  9D!  !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( )J+,TJ97)PC$ 8  )PG   3
M      "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ FHLS
M2B]-CU<3 @  (08  !@              ( !]P@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( )J+,THZ\V-S6 ,  )L.   8
M      "  4 +  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" ":BS-*MEC$U3X"  #,!@  &               @ '.#@  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ FHLS2G/YO'H- P  90P  !@
M             ( !0A$  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( )J+,TH@*YDUR ,  .<0   8              "  844  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " ":BS-*--G2>,X#  "3
M$0  &               @ &#&   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ FHLS2E^[ X_1 0  ;00  !@              ( !AQP
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( )J+,THA"-74
MSP$  &T$   8              "  8X>  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " ":BS-*FZ/Z$]$!  !M!   &
M@ &3(   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ FHLS
M2AOOCGBU 0  T@,  !D              ( !FB(  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " ":BS-*@C,,=,\!  !M!   &0
M        @ &&)   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( )J+,TH20XE'M@$  -$#   9              "  8PF  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ FHLS2F.7 J6U 0  T@,
M !D              ( !>2@  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " ":BS-*>)+-_,X!  !M!   &0              @ %E*@
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( )J+,TI?-69U
MM@$  -$#   9              "  6HL  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ FHLS2IE*C4/1 0  ;00  !D
M ( !5RX  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " ":
MBS-*VB/XT3L"  "$!P  &0              @ %?,   >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( )J+,TJA M8^T $  &T$   9
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M970R,BYX;6Q02P$"% ,4    " ":BS-*=Q.93X,"  ! "0  &0
M    @ %G/@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M )J+,TH_ Q*PR0$  %D$   9              "  2%!  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ FHLS2OP1<I&P 0  T0,  !D
M             ( !(4,  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " ":BS-*-XUU"#4$   H%@  &0              @ $(10  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( )J+,TJF@"<77@(
M ,$'   9              "  71)  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ FHLS2O=W*839 0  D00  !D              ( !
M"4P  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " ":BS-*
M*Z/XL=X!  #V!   &0              @ $93@  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( )J+,TJBTFT;> ,  '@0   9
M      "  2Y0  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ FHLS2M;5&)^02   FT0! !0              ( !W5,  'AL+W-H87)E
M9%-T<FEN9W,N>&UL4$L! A0#%     @ FHLS2B=P=V5B @  ;0P   T
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52P4&     "< )P"#"@  <:4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.6.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>44</ContextCount>
  <ElementCount>119</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>12</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/Condensedconsolidatedbalancesheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/Condensedconsolidatedbalancesheetsparenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/CondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Consolidated Statements of Cash Flow</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/Condensedconsolidatedstatementsofcashflow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flow</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Collaborative Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/CollaborativeAgreement</Role>
      <ShortName>Collaborative Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Related Parties Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/RelatedPartiesTransactions</Role>
      <ShortName>Related Parties Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/AccountsPayable</Role>
      <ShortName>Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/EarningsPerShare</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/OrganizationAndDescriptionOfBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/OrganizationAndDescriptionOfBusiness</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/GoingConcernDetails</Role>
      <ShortName>Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/GoingConcern</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Collaborative Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/CollaborativeAgreementDetails</Role>
      <ShortName>Collaborative Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/CollaborativeAgreement</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Related Parties Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/RelatedPartiesTransactionsDetails</Role>
      <ShortName>Related Parties Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactions</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/AccountsPayableDetails</Role>
      <ShortName>Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/AccountsPayable</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/Equity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/EarningsPerShareTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mtoo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SubsequentEvent</ParentRole>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mtoo-20160930.xml</File>
    <File>mtoo-20160930.xsd</File>
    <File>mtoo-20160930_cal.xml</File>
    <File>mtoo-20160930_def.xml</File>
    <File>mtoo-20160930_lab.xml</File>
    <File>mtoo-20160930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>49
<FILENAME>0001213900-17-000495-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-17-000495-xbrl.zip
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M%=A4W;[6+?/<.=''5J#;.X7_N6M49R$^"[=ASS<\:XQ[=<,-;MWK/9OOQ%%
MX?1^WOK4,8B/P0T/=,OAYIGN.6!!^3MQ *+'BA>W[=AO D[Y>!K[1=^76E/J
M5)NEV"2E*6V.,+8$YTI34F=!:4KJ&"A-:3NQ?Q+Z@3OZUM"*%>72JTJP"UYP
M"JA+:Y1::M]3O\= FYD7LAN;_+KQC57JU?JHZ16=$Z62J?.CU+CRJ'&OZ.@H
MU6^W3TQL*UP90>&!F?J^5,IB3J76ZFLTJ!J=;Z?<*' ]%WX_&?.K?M?S=&=
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M:V:"9!<X?=F-7;$'K@W[-RD08H7?*\?VAAW;@/U6M=Y>&UG56PK]Y4+_-+^
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M9E87\ZU1OGWTK#^HR1L(M*2;*Z<,2\I8!>'',HR9=0<>%_50*-G]H^5^@?W
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M"EHV;L;H$SE"'I:X; A9@JGUBW[;*!FSD7!Z"MS>)-DN'YM^R7A2RYEW$0Z
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M[5PN*;?(A"ZT7VG\3Z#KQ@Z"^-A@BW**2Q3'0[0^$W7P>Q@]C?7Q:UF#=IU
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M<]1Q4M]&>C4=H=/;1/D7[C;4?7(VS)P6)04':<6^N5=R7-2VE4N;H]!&X4G
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MBZG".U VJE.2N'\]NP&"_=3-T^S=V<FOEU=?KC[_64#GYXX)R**;JCMN#!U
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M25G32GJ>5R0\;\IZFN9X5%(B+B(!PP<P7L(P2(SA4/5:H]5L5P$K5:TBBUX
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M8))J+Y3^G5%W<,&RS![,N,*U4RL:C9O^7MG17WIE16&6PJS]PJR*9^SAHU>
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M8]Z;&%J %19@Q:5MKC*8YA"=9.P6?2\ZY!> @5@MB-@F?)5AZOVMR+@'$<F
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M\?>^946;YA(+CN&91Q.AF+GV3'Y2;8!G-[C4<QT2G+.(YR1YXD0_SX'?(SR
M,=S:^=]<:^+EUEFSW<0&7X@[E'OQ-#ZQF!?NA<2MC/*0"$RXQ$V*$Y=9VJG<
MF'C\KY.4E%!L)S.34EQ%D; S_'_X\_\!4$L#!!0    ( )J+,TH/(/,<'0H
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M!K)^A6O[&91&+*@2'T)A4<N2_I;][#.]S=C*\_ZY46E_=,:-#2F#+5?%!A-
M\&06/_W5O,3FKR3W>294]1EHQV@_/!;G1N5Y+L[4@<5O_\/2=*Z+CQ0KJJM*
M:-NC[^&9( ?P@T=)'2U'Y[.I[69CU,<$8DR[<H;%?TLV/K] ;!K=&' $?')
M'W1##7Q.A+XIR+]%)$1;#KL+\RX5TNT$^50\N,?>W]L%5$F":2S&BOL%Q+LG
M@6/!E;E@MST48";5D"I\AC=10E+^A-64SY-IU*/%$SK$T02NJ< Y+1)T3CGM
MKD!9J5U!X)PO-A%>W9=^="6WPUY;_2O7,=YXSVQ-I75 3\D Y A>"R29<#4U
M=^ LF2&:&YS?*DBHLM  =BU.@E$3SV[ ,W^71NRE+:%/2[Q3K,V6;6U[9VB;
MT1EUT8P5XRY9PHUT(F&.P.DHF_R0FX:FP?GJLPRS!\FFJQ4-H.A<=W;4=8:N
M>>DFR#HNFM*)3/R.THD["EUP,DS4L/!3,:)\KM-Q1S^0G(LYI$IH%7#(-!!T
M3<]C']^/,NKAKKUGD]+(FMP<6LLW@]5=Q_-W?PMRE-.[N8(W!;HL XTXT,U
M^"P?4K1#N#>#N]!,B="EQ(1".TV3$G+5!$U(9)AM-/$"6==>S#)%/60D&IBZ
M%NS(H.OF)(0SS<E13N_0=HHM7HG&+@7>.,>[H?3/3@=YYO.[9X-U\#H7+BG5
MV39'(]5E2+/56\3D;K!D'2>]B C).CCR"G1NQT<&^#1 .102]1,-N1<(T1[%
M&5V-[W;,NL=!#3S="X,:@>N;&D:+2L1.AT!F6(5B<H"21^$=C #D<FP9 $B%
M^*6<P]8-#CI^!2IRZ#PX3<]@\S/6!4MV7O,;QI5JQ+>EXQ0[SA.TXXUVS,=]
MMGR\T=F=9-T_> %Z_'P(F=9Q[KVH#;@MF8=/.!G]3H?I5Z&CA]X&K^U.!RDX
MOL ['9:BU.5.AYT<O12EZ^C =;_BF /7'QRIB]KD++]AONI;YL9U] H@/S#\
M$/ 8)BMBF'&&H:]@!7087 M=#&V&3>AB9C# K>@Y";W0'SMT,?VJHZ&+^>"U
MA2ZK@N,+#%TL1:E+Z&(G1^!;IHO5BOC4STW#9?F);?N-""57=W8E6L";[9X6
M?/A=A3(G!T*2SM#5&ZG I[#Z$$J[S+^&G'<X_4VMBX_Q,F'GO'JHJJ3!#K2"
MDA;<JF 61(A1C585R;K(=#>,W"6[7P;)"N3=(Q;1/0E9_"&P;O:0[\UNM"J!
MKU=1M8??X4#KR%,,6]=)WSJUUW#2-DWCA4KE+A5WD!>KTBO2NM%1.R.H@$@'
MHEI02>ERMF,U%[7G3^GR=2?OI:R;QUTOO_!ULOEVXI:Q:]N)XX]2+5/WOR"5
M,&(*872[,UNML)\N5K.O/K^F?T.CHT7($-!U#_O/[(^,NNJ 76[4=8U&/*&\
MI"'PJBX(<E:RM6" &(<$+4)N29QQF#83K/2=%K,[GC@W=T-43ZFN\TV=IA%O
M:!=I.!"-"6.6\>(_E#A,BJ+%#5DS)];C/0W %5LGDJ=\\<J6K@YY]L[8TOT#
MR[O,GP]DNOI3/!-?;:'1(ZX(Z(C1CNTV^L+E-HC@SYR;EE;29PAVRL  <DVH
M!2V:[_:+J?G:1>Z<?LBJ2C9G\CL"+C)K9<2NQ.,=15!K:]Q0H#OE[!7U653)
MM#&KLJ@2<8HZ'@-67K%\9@"JNUURXUH]=JR&O[P0BA;2T6NV9IM-P NO>T%1
M>'V^J[=C7'9?DQU8!7YMN+6:JR5*M"2)'T1)%HM:FT4X6ZY4Y(Q_,)QA=95^
MH^D=\[ &M8K485U[9&FZ!-VCA5YB5H#4CU6(/Z,-_;LS=D\U"YJ7CVI3,.I!
MGVB-[[RO.)&(C^S0Q!X9X%&=2O<;SN+0%BAE3< $1VL,-4^6-(S[>.*RB!^\
M,']Y\S0*DR@@2V'\PN6UJ%C'_W>QRN-F+]B^;6)]%K.?CT(;M[Z&KBK@9;Y\
MO7:&]PX_G&0)"7$"_7#."#-L8G3[E*D7HGYGV[#M#G]-3P*#HPF]?Q?*7PPP
M@#5]O/DXO9K_U_1NOKA"TZLS=#:[/;V97_/_7YRCDT^W\ZO9[:T3Z2*'QP/,
M+P^E9$K'/I"&C?B D:AMP5X6H'WWU<\0*9V!@A.T#U>"K*^9UVLO?F8^^)8\
MA&1%?"],T8X'*IBX[)K;YU7+W[9.ZGB26@1$I3B)*EF]@\9>TIPQE!NT&8*:
M>'^ZO)S>_,9,^.W\X]7\?'XZO;I#T]/3Q:>KN_G51W2]N)B?SF=N>#I8R&#.
MS%K8E=[*5M([[)=\C-C3%FP$8E5>5IZ:;F0 NH<B@525.MX,Y>U<=!6M\].^
M!Z"8G)YDQF+UH\4#Y&V$=F!J(=K1H-\9%>)DD.\"V<):,*M[NK@ZG=U<.?#,
M@^W$^/G$[+960#;VS,5?Y2T,]*>#DI]&0>!%]S$_7#5]B+%=LE&+%ZB[: =:
M.W/'*.XC08&V)$.>6;'?\#:'YY8#U)3#=E^H)X0CGH M2]$TCMD17=:C#OE$
M$Y90:R0SV"VJMR,?S??:+)(Z8EY<7$Q/%C?3N_FO,S3]>#.;7<ZN[L =60=!
M5JZ"S*5X/*4MU:Y^OJ,]2]C9O0[U4%KY0:?F- #7']G:*V./RF0NKK-,YU8K
M,:<YL?"2V\'=F+"$<C=FL&NB/+N8WLW.T/7TYFX^NT5W-].KV^DIVV-Q(_TV
M'CPP]V(AN$KW8BZU(UYZ%Q7,$Y'UBS,OL/8L*E;03D4-LRJEU2<(7/8A&A.H
MY3[:9V_T+<BBO'[1I;TJWAV\B"U[*(]B/QPUP18;'+?4_OXV/;F8.>%1QH,'
MYE$Z"K32NW23YA&OD_^1D?39UKE4J*']20U,[1(X;^"RXVB>#RU?T3@9(U[V
M*-5<$UVYBE+<P2'H,P2[\&$ N2:*__%I?O>;,[;0>/;45SD,IVY$>^?%['UO
M=F?XEA5*LK9\,C[@-E .L":">5-6(0#QQDY;QI:9T[.1ZFF#DT-CZRAG %:@
M10%)1_3<V"FW0C.]N9I??:01[NP&W?X\O7$GQFV5,W7IF!8A&W.7;+TFJ=BI
M"Y>B$M,##OV],-K6F)LQA[;PID-1WSO;THN*,64.@ 47X$ [Y^NLI%VO@HJ%
MJ#NFY1;;X49<X7;$#<'7-X@O+^=W;$_XEM\$.5WP4[.S*V=."8\+$7 GW$:,
M6S;#+61XS$H/]PG^(Z/=FSUUN8LJY0/M=!4 ZQ=3BJ:(MW5Y4=4V;UH^I672
MX*30/.4D90!74T0.J4WP$M?65$9@/IW<SO[C$[7T:/:K2\><6H6LI<B)6L)&
MO*?E)219K"JW2I[%OU6:HS0HFERAS;DV^*I8<D)VY[!\:]0YLVXVMUI&WFAB
MQY/B3PE>K&9)2M:LF*^NG:]001GW6N>KTD8;,%G;-G'&"#8/N]+R-8YYAXL)
MYU'\Q8O%4S^WFX"DEI9+CQGHU00-J%7)R4G$ U@H840.74:P '2#-\+B)N5"
M:&B#X]0C+$G)'L!:Y:B3'6JTX:P=*^2G*[SMUQDT)7<\BWSND?A7+\CP)?;8
MHI1)B&YHT6AK]!E"V7$3R#5%I;2($Z,2M3N6WG@ZE4[ ="[!"]%WBX;UF$('
MP[K0M6O..V-KK2:W2R5R8"'>UJ^S-+52>O "A.W2F%<BY,7[G+&>;1.B5XT0
M6JRN\)?2NB^.0OJC+_Q4+TD#8_[0%M-B0.KQK(\KY8KV^#AG0VV%0/,1)BL)
M&#&U[#_B91:P)6SE3 1+C/C4%9R1($OQ\HX=]S5//%NR!TM+6P]'+<^;<^)Y
MCMJIH GB_$3A3<$1_<YY(M<N]PXS)+@8$KK0%4\[.N/;.JJ$.DW>21\@S,)Y
MEM+US"4)R3I;W_ BYM>B['Y"E^CY@W'APP5[FB9I-1+J3;M>/@KM0_L:.I7V
M",XH9XT$;U0P9^DBM&6/!/\QS(OY*QMC#MI*#-HZ'[2 /S65/R'A7EC2JP;J
M;7?WJ'[C6:H[^H'%JE1&8?J5:.^7-!-#!1\R*+6GS&D[)M#E\B LD+B*P@.O
M]+M*80+*#.2@AL'(Z[A0U9R->&ET]WUV<(D.?6GDRP-_B=?W.#9UA:;LH9V>
M^7#4;E.6.&A(\UFT]DCHWL$C2[G0*X9K)10=MB)Y8%H\K[HM*265Z'H9."4#
MD!*(+9!J\0._PK%]6;=4"TV0P"[17@8B\W*(AI!*CRFQA\"I?..'2%30+BG(
MA+TO&F1+%A+?9RD*HQ0%9$W8TCN-D+]7><NK6J.06B-Y$T>J+NKHJ[SDHH:R
M]FY+%B$V<Y!:O$ /-;0#U59)2C2<6EH^B=@CO",I.-A##)JBVGZ&04].>U>J
MNR]19Q^]X^&0FRX#TY8R2@2D1(/">@NJ/.9B9.E^JG+8O[)0FOY\4)F;@UYH
M'ZR^"C&R%^*)+"$>ORA?U""TMMZH+K&]J]@YE8C.#JG$Q"&/M =-6]@8E>,^
MR0[8NQ?AE.KR:.J5:L)HFGA,L/_Z(7IZL\2$Y1S?L1^8/KTKI1KIKSY?X <O
MF(4I*X#4G-=N-!U-I%#NJ!E&5:1X"R2: .:JM4=3Q^K*9V$H<1$?$KG1-EM;
M:S^V66WH<*T 22X/@-E>]9BI[(=D@#NXU^D:Q^PUN).8_$H2$H4_1\&2OY,1
M;WA:*@HM(EE]KJ 1K0GXVN9"3HNVQ.B;G/Q;5&( EM;]1X5M?Y6F"^Z[1XP2
MG+($<,#]"F9JR*K >$D2^827;_]"TD?DH1A3=JECUVB,%;T]^C?5\@YF:I;%
MT30AWCQ\P@FO[3 -E^+]4<P^=R&R[@9+ C..(.L#4] U5T?I#Q@#M.. _I^W
MWOP;RKEPC7V-<D8.[4#]XT WWZKJBOV%F*JN*MFZSK+1\#XCJ9Y#*-=C)\OH
MX86%2BZC[#$R^M\9$O49"PT0!"U*+[.S8]V[)V\7J^(=7'9J,O,"15&INMVU
MX0L2$-D-0%5NRUS0E-V6V/%!BQ4J.*&<U9!U'@T3JP,,@%<9@*@T -_DO+YU
M("H:"/IR'_I] 3T5K!R)C#IHOCP^LE?[3F^DKM=1R$LPS),DP\OIBNK KB2#
M48S4R@SXE=16J$VE5ZD@BDHD@@AQJOQ7MX,4)['<++7')VJ.$(%O$R7I0>)D
M[96>$'I\!DL0'8N#='52Y\%8+87LTWZ<X%448Z4!J=O3=BX@\8T..!V3(<C@
M;$:OR/:-18Q!;<5PR.[%G$%;"1M=:8TT=-5M[+><+G'Z&"UW^:'%EY"*]2/9
M7..8E1SP'K!N/&+.&/I^C<D05 5X]T<6-/NY.+-S#<G6Z='@.LK2)*4_D/#!
MB92.&]#!+Q09"[_!FUKZDM\A"-CQ6JR$0>%G:DZ]#4F]FC0T6K46%B#NOQ66
M0A87J\+YBY-4.1&TW^\"B:I7KE!<O9 _$"1SGS\ *D><O9YFR3V]EEI!/[2W
MBSM.(VJH8I:NO6&S?V3J[8WY0SM]BP&IG=0LL?A7E#\3R;A,R@N."=JQ0IR7
M VF+'D=A+X3W>?O\UA\NSK#&3:C!G;^M2NC5>[#3AR['P[/UVHN?%ZM;\A"2
M%=N"22N%MPFVVA6QXPQSD-QR$.JO(G ^+)@H<=HKO);S<G!OI.]!B-H'P:7]
MD0'@)R7XW@[^IH#OUAY))TN@.*W?P0Q !CHWF%E:=6+4T%'46;H7SC3!KHIX
M9;MS6PE]D(QBESR%';SS,IX7$X5(Y=4R\) ):X=8XV/$#[=2U'%H$U&HZ$'B
M!C6@JESQUBAO[F  T 6-2Y[<!H>?XW#+)6LHC-SQMFL+1.W*TW+!EGKU)%_R
MYW(I)5[=SM@;]]\#<.<]Q*"JJC7N?08U5@?S94TJM<+XY]RY3CB\G!J6>^Q9
M2,=\5K>Y9WHW2S2YP#V;VP*NGN62J8,#5\W[0M5:K@RLHJ6>,+8\AJLAB?#J
M96 7+DB(YRE>:]]<'^3;T,ZSYX'45GQS5\D^@_AWW/.70XBCYMORO<MBIT-U
MY<]MR[A8+''U. $=KM,#J>LMW%L ]XU0NBB&.HAF(*6JPVCZ(CJ>8[S! ;LO
M=>W%Z7-)R^]PO&8VX=(+0QPO5K<X30/>85/O9_X!:!=G,R3UIX,X#\29E!W3
M!'$^W)L)3GS#9\O+H=WJ/L9A7\6]K8HGI>5QLF4P*5^+<<YI6ZN*EF>VU1/X
M&/J&/#SR &)Q'Y 'GF_4?K7 B*=KRU<)<.V8=H($!VX,2CP<7MM:0=ZI/7M7
M.B8T>$F96(.K>W>1[+(45LAXAYCZTX;B"]/BD1-==]U("WJ-K0ZD]O2Z:+%]
M+,@!WVG8<]F3/8/O_G3I/+M_[ZW9003FO;,*%/3ED?B/B!TQW7ADB999S%_^
MID1,Z7DE^\(>.'8?3:(Z[=?/FO6FIX/F!==/X1+'S8L(K26R*4_PH^AZP-5G
MT[?OB'$FU9V8@@U\W:%><5,5VVICQG'[S?[8@4UG&.".[%-;JKG>,7A]'>]@
MJ"Y)@),T"K%5O%&G!HTXFL!4I6W;QKFHPZSW6SU)(W1"H@N28D1"Y'O)HT/!
MB XF%H[\ P0?4DUJ#S]D:C3B.15VV>8Z)G[3^9+FEVEW%& /))<[W5P7G/_5
M@>6X1E<W@W35ZI5ERW&%>R6Y)KWJAX^KHMO!?Y:R?NPT=_D82NLNF-R6Z',%
M];<FX%4)=GXOI+SW"[U%!@ 9=,^L#TG4]G:FPCV>%SS+\%VT6*VH98B315P^
M&WZ:Q;'&0MV $Y37U )9N_F0819H%F0HR@M+Y803E),ZX&J[X.,WJT7C"?HM
M\\*/.,3E&IS.N#Q]456Z0FTY[5+?5EQZ2FAP6SS/;>L76UC!UK5M@UFK]IH3
MH)S"8:_7'9NC[DU/-C6JN.H(YHC+N>P^(4O"KA_&]?(J&-]Z[*PUU_:3YWKC
MHIGLPD%S$-[G-\&6E/T.7/V.;$'!/&A> D%\ 16T$\0^P@^5\!H!]\^HD:QH
M#WFG8'A!T%K/]2]Y'=S="8D"DN)YZ%L4;Z\1@[JT!BA5B<Z;4&GT7:Q/KH'@
MQ5<CEPE<N]>22-MX?NJ:SL25M\:2]^0:S<L>#92?J'2\MJ5%_P^QOP,^']<^
M>#JVM6&TQQ</Z2-RRN-^%6KH4ZDU, JA 7QCSF1(=0R-<C:Z/.R4^VZV74J>
M,&-O\HB3E!KFP28%F-H+147XES=&7&X<N%9GC(1-ZL"]MWA$R7PJR'8J-O3/
MCAQ-:-4/Q?M'+<H!L8XMQ? 7MO?X6KA!.XA6L/+59'7-Z/3=.;U)U;LWKC.C
MG9V,S7VV9DI Y]*>L\NM&706LC, QVZ?*66HS0B#)Q)W:L4WS*]QS'?/C4VO
MC ^XT94#K)G;LHF=B",0Z)H]L<(('$C56V"ZIKUZ])+\] G:L.=&FM# .XT6
M0=1S%VHI''%A&T<^QLODG()GU8[9RY+SD*3$"ZZS^X#XB]4*LY-OVDD1;89@
M&1,#R#4IS6D1$Q944*.<' EZ5#!P8 ^Z"]@KG%)M+ ..),#@LDBFXJM.,1G*
M;J=Z!449X<5JEI=;Y@6%C9+T<B[ SX;)P=7O]VUK;"]6J&CM3+UM8SPS9>UL
MP T($Q!L)V*_"+APR Z__]6B3CH/?ZEUJ8.R7]$IBUEKHX5;G0IDT=;4^9JG
M*-H,N58SO@EEU/,?P7V:6E3DZS.9G'00V#,<1FL2MHBL7!V;Z$$]4C.@>E7E
M;2L'CSX98P 1:3.AT+;.<HD:;ZWT5\RNV>/EE%HB[P%3O;OG=33XRUF+W6M9
MNE;>FB_4RLEB *KB6;! .0\DF/!LAGB!K,1G@LY(D+'63J0 !QB& R\?AOSY
MM=*;:_ .J:O<*]=:ED+OGK:?> GQ=;VC'7/HU*3I4'14>L[&J5<,^AH A;JC
M@V;<X/E.*SW02H+:*,%X^C\/_9C?[O6"_/%7WJ]IFL;D/DOYX>KHU N"!2\Z
MQ*KO_-5C)7D:;ZXW&M8NGX"* ;H-2U4Q2MQ0\0RT4(TR0W8AAD<"[&3#;+7"
M/C\DR;Z"\L_PPE?%AQR($?H=)K&7'FT::WJ!Q04]:(@R1.BN'N#10AZ_UDQ:
M3_&"E+VC$8-B./I9*#BP5N]_"-11@P2YJW%#FT9TB1Q:U&'$M]F].*3?38IM
M7=D:H=&L-A-#^7L9E-J^1]YN=PX!*)#OA.( + 8W$ 4=WZD2(C@]R!74U/O)
MV$![.3D\'>UPSV7IXSEPU>NT2)R6=U&+VWC:L]BP?1W:DPOL)3@YS](LQI<D
M).ML7=1G.LNP:;K9E"V4YS&'7Y72+0<D6$R08()R+KN:CO+\,ICMMYQ]I5>P
MFWKG)%Y> D5I&PRY0WL7X\&P%W_*9H*N\-<4W7W!P1-M$87IHPOU"'L;C!O,
M;GNQP6"RYYS?LI-\+7=F)?;.Z?P\O/L2_8:]6#N[:L[8<4^W-P36RCYAVLX*
M=%)FB'-S(%W:QPBPWR,LTB*W5 _Y13%T?#AA&O_]2_/K=7GOP[/7A-U%/:=?
MQ3)-[\.([GWBA7CYRK#TH/V,W4#ZWV6KM9_Q4-J"'UZJ]V_2C3Y#@ ;%<,X^
M].S]7??Y7</Z_GU[E'K!$+Z] >D=^]9+<]Q]NNL^[IFLUR0MWN4\I<LZ^E$<
M^JS>:8?RAP9L@6^B&,"O7TW9$B-*C?;(P6\GCP#:JX%VM'BBN93KW <Q%/'Q
M7.5%%#ZPU_R*.[.[KD[Y8TJZ/K*5#Y1SU !8E5M&<L!?9MC>)-Y139"@<V"E
M:P&-NT%$E2,A2RRJ_^:O9CGC&W4E4ND4-<5Q7#U+&SMTC6,2&>]CMO*#7HQJ
M #;4.T'G@&?L ''7A"MAH8,3=B>R 1SX:E)7;+66CIHR"[9.O*$]F7W=X##!
M5]AV#[3"Q)$U80U:^TJ0D:"<ANWHN.#Q3%%Q#%BT<,;!:4F=R9*O4>3&K6>&
M_\A8)Y[HOV3UM5O+9]5X0+LP";"FBF6B&>+M(&M7FP^RB0%7S!*<N-'OF53:
ME9%#%F=OAM,J9ZRM:[5X6V:GM>2Y?&I )<RN6*^<D6NFK0Q14^Y<+>?;.GM6
MIJXZ=6#2J%</6$WLB*V3EJ"M>U1)*5U7S)Q&$5J=&0$3JHLNU6<;^3AFX"Y:
M*L[N2]N%XX5F53-G8]VJTS:>'-[@!--1>9R&RS/\A(-HPW-T[.;= [^OQY+E
M+#%^%UWC>!7%Z_,H7J2/=.5XAA,_)ORZ'J5FR3[M&+#GKT*9T]X'K[Y\%A_@
MNS>E3Z#2-R:H^ J[6IM_!]%_(?&E"2I]BS/B7W,@F3#X\%T0GZ[)64XE9G?,
M$O[:LS,N;!C54_J^(?1.#">U8'_[B?Y,_W/O)9C^X?\#4$L#!!0    ( )J+
M,TH;B WEOAX  #\? @ 5    ;71O;RTR,#$V,#DS,%]P<F4N>&UL[5U;=]LX
MDG[?<_8_>#.OX]B2T^E.SF3FR):=\:YM^=A.S^R3#D5!$G8H4@.2OO2O7X 4
M)9("0( $623CETZB!L#ZJ@JW0EW^\K?7M7/TC(B//??;A\''TP]'R+6].7:7
MWS[\>+HZ_NW#W_[ZG__QE_\Z/O[G^</-T=BSPS5R@Z-;VF:!T?SH!0>KH\L_
MCB_G./#(T>_Q6$>#CY\_GGX\/:)_O2)X;KW]^>B_+3>TR-O1X.S/1\/3P:]'
MIV=?A\.OGWXY&MT>'1^SSSC8_=?,\M$1)<OUOWU8!<'FZ\G)R\O+Q]<9<3YZ
M9'DR/#T].TD:?HA;?GWU<:;URUG2=G#RS]N;1WN%UM8Q=OW <NU]+S8,K]_@
MRY<O)]'_I4U]_-6/^M]XMA5$C"JDZTC8@OWK.&EVS'XZ'@R/SP8?7_WY!\8#
MXCGH 2V.HL]_#=XVZ-L''Z\W#B,[^FU%T.+;AW7@>;3_X//IE[-3UOM/B7!&
M[OS2#7#P=NTN/+*.:/YPQ,;]\7"](WZ-@G#FA0'^=X@^VM[ZA#4XD8YQ4HV^
M"\^=(]='<]MS?<^A6A&@^<QRF$C\%4*!KTJEPDBUT[JQ".73"@78MAQSA&>'
M-87B(O6YQX#^E\G8GRPF&T0BV>JS7F'(NJE_##S[7RO/F=-%Y_+?(=568R@X
M0]>A4?[ND]["MOS5PO%>*ND2=\"*E$_(TG+Q'Y%0Z;HP1KY-\(;]:[(X#WWL
M(E]9?93&JDCO8[A>TXV&"A$O7;I+V19=SVS;"^F"YB[O*:MLC)0I5ARM(LW?
M/3H8E:B-B/):G>E363L=QYIY;.8^H]&2H$B)U%61V[LB30_(82I];Y& <OB)
M6*YOV5J+E62$BK1M-<"_M]ZL&6NN1E"^6T4J]!8],^O8I45<JG?^/2*/*[I9
M*7\]WZ^RQJ[7.(B6.KJ0T&G IB,]O&I,;=D0E=>@F8_HQ]S@\EEC(N6[-;(2
MUK,BFEH9\WKSQ":.,JV"WN9TS\HICAYYQ0,UL'>/46!AQ^@6G@S9B/YJTJ\W
MJ,%]79-.7M=:=GE-NN2#U+;G:U)9/)#9$X F>8+>1LX#FJ1D.QE>K75I$72O
M[ZR@K?R%(]5.ZQ-Z#4(=FX/J@&;//-K+,K>W%DT\JYM#2/P!%RW9BL!L;E^8
MS6WP.:)Z^_.--4,<EN8->%\R8\6=3OYZU 2%=$Y@;W[IEB,UU[M1FA\#N@I7
MH#K5OR&ZG[S <DI1G.K9$*UWJ!QO=_V:XBDB/BK'TWU/@[0&AW1J,W+/0;I*
M;0CRZ<H5'8QO*!D9 ND2B]PYFB<DL@&JV.*CYQ+/SGS#80\4'BE:I]DO4]G@
MHYD?$'I:2@9R&,AH^*ERW^EIO'0KT;AE0\1B']D?E][SR1QARNK!)_871O^G
MX]/!]IWD3_2G:?SE![3$[(-N<&>M$8=@4=/I(*8O+;01R=)J$3L9D?XU(['#
MAYUMBY/8@']LK["S$_:">&M]_B6T>(5(CCPR1^3;!]HG]"F17G0=2W;TFD5P
M09$0R[FFVOWZ/^A-*H-<V^FPNT(XA))(8="P&$84QIQ!N7*LI8#]F3;3LRZR
M/0\A8?<0BMTIRT<1UU--IY\ZS?PLDD0&9PW+( 'R1(<5\#[=9/I+%WF>0Y#P
M^A,0KW<WB#$]DQ4P/=-V^KG+W,]#2<3P"\AF>X4=1"XH)4N/R+?:3,OIKUT4
M 1]((H#/? &<Y(_A>=PFCN8*#BBEE&%A^;.(R:%_O+2L#=.(SR?("?SDE^@H
MGU*-[<_3G?/"9'&%74H'MIQ[S\<%YWF=[J6/].51C7R?\E*!_FQ#H,.])C-S
M&B^$(CS='U%\"T3(UA EH3\B/DA?HR'D>!$2QCYE<>;: ]T6Q'*1R>^0]AZ(
M\<+R5\R&3/]@KP;/EA-9E8,+BY W["Y_MYR0=S30Z@]T.RD4'U_:JI!Z(/U[
M@C86GE^^;MC6M^601-K<]D#7GY+2%4$07_4UQ?F,R,QKQ:JLNAH#W:5*"C!/
MNMAHH#L/TW9^"+'=>:ZMN9\>=@&ZFI7;4KGD]V,FCM&&G0_]/%")2$5=@*YZ
MNB*5D&]NCD(?>)4$><"!WSHA0 [98FM@UQ;70G%-OW1(2)18L?&P.Z*YP=8,
M.YCY<]$3]V&$AL(^J#K$='#:80N"#DIC^R?D8IMUIDL.A^Y<;?TM[CT=P!J4
MM 0J6 G44)JZIL+>:VR;A)30/=?T54)A@.D UB!E1BL4@?9PG9@$*T2J+1;"
M(:8#6"N6^15#"K4/1_9QB)Z\K-NXIG(HCC =P-K #.B&!E)SEP)@U9@L%MBF
M-$Q(FF5E5$1]I.D UMIF2E7T$)N[K,"I3(IS:O>1Z0#6%F= U#DT8D^)[MPY
MI5&FXG<N<:_I -8^9T#,!>C$_AE=ND.4,B_(V EKU3,@=CFX1.J_=EKJ3+4]
M-T):^):=:SH=P)H$"\0CGLIY$#UXJ1[-YS@F^M["\VOWPMK@@"$0W^OX/:9#
M:#M@":%*L/3A%I_2V2A&E 4.V@3/T/P\#'ZXV/=#--_^&*'S'Y"-\'.<IT-E
M/FL/.QU".YQ5F_NE %>_\_.#*9O5I@<69^JB>1)Y/++M<!U&%]LQHI<6+-OO
MBSM/A[ VPE*:H0:K#Q=[7@8QC=/== AKY2LE73Z,G^&!L,+#X'38>9N="L1$
M"WXSK04M\<K/9E=\=]$W>QR[MP@S\#&N1[>)?8HPE5.7J'>GG?G5\/7BU35_
MGO1'8;#R"/YC/X<5CMVI7L#^_L8$S\'5#Z_% XS7T9U!1]IQ#V"7?\.2WF$R
M]BK:+BE/PH#ET69)PG5$G>H&' 1@6-Y98+5=BYH]0BFD=VY8#Z]=2B7:T:)P
M8A+T #@D/:!GY(;2-Z.D"?!Q1\PSH;%@1[>I8XP#M,[Y=$'8PI$N;*EVP&<4
M;6GEB>_'0>0[\7S_GG@+J;4NU0KXP*$MMBSI?0ABVNXC[G(;6Z<2Y"WL WR>
MT!:G#(BQ\P/L\SERZ)C+[\BE2)V1.Q_-U]B-LE:QM+%;W#)KA]( P,&(4CD*
MK*^JN+J]F>XX$\^-&\^7G7TXK8$C$\M/Z0R$/EC5[SS7RX+;*JG"BEW8%SA:
M45O,*H#,^;W!/8Q=N\_(CWR\8I37+B6&_B*];?&[ ,<S*DF,+VP)HFZOSE<>
M07CIQOZW]ELJ._IW"[ML[3I'"X]52WB5"%QC%.!PR0HZH ?2V'4*1B\2!2\^
MGN5:0L=+5IKD!TCZX=DBY$F9_1HZ K*"@*68^A"ROC]Q7E&^Q?[8(06[-]7&
M2U3<CBY4R+]\I4RCT+%KD;=K>OB) OEI3XK%B?BDL-W7]E7HP$KM4V'-O##F
M40^NI!3Z=O*=TPNPW%PGZ $=65E2.;@XJCO-MV*C08'2+3_3#CH(4O_FEZ>^
M-E^I!D67K[=S;OG89D6]L!-2?5*XX2N. !W(J"UN#5R)(GSIM,6V '!Y%8 .
M;-219"E=2,<Z=MCD\P]ZSUTQAE UM);H+ES/$)DL(L0I%P=UO2@W('2 9'5U
M*8^[#O-!.]Q&.,[8<-ZW)6,[%?H#N);LZ'HJ"'#*-FR/5ZV4FZ)7M#R6;MMC
M=W!B_!?>>N.Y47SU*Y:=J*7]VN(^NQ-1@2@%&+HMV1RHL;>V,*]:C+1]6]QC
M11(2G)H$4+HMT)3WYRUB&[N:"VS<%MA/12@1O@!YY/?@G"L(CRZ4IK0?L".*
MIF2+H,"&B0LJ%J9#D?>1R$*Q%?8!]C!1%)D*C#YD7\O''!=.1WX'8'\2S7DH
MQ-"/V.KML8%>,%'TPJ%RDMTU!G8;T3Z^I@GON!M U:AXZ$0X/(F(I,<AWM09
M9W-8O+IA.6J$:QV&,K4E!;:*&'G$&YN$\')D6AI'%8Y#0N'%-0FC*.([]!+]
M'_GBJM ?VL-#>]JJ .K#R4@ -M;Y"N+/#0#M=&% _AQ$L <IT4V&3SZ+RJ(?
MN45DB0@]YL>7,OQ'7/!==,,I,1:T"X6*J"N!,^9V7_)%UJ#<8YTV*?UX1&C_
MBUIU8 ^Q#[[XR3,D>UU;,Q<BT8(@[P#M@J%]H.,B,.<+U](=75_:^J-!NV08
MV^O%\*#ST>IN 3;"&_88RK7T:2__TM&@/2RJ+_V%\,SYYL&M$B7=*EMB-E.8
MV0>$]\.1KJKU##R/="7SV2 =!&7&\G+I CDV5[.?@:>.KF(_2^>*-F1 RXH1
M+B&DOW-+\Q:VY:\6CO<"Z(S&*H=?41)4$F#(N@&XGM$%G)%Q3[QG3 5S_O:#
MLOK:W87"C^P /\=5Q3@A,2KAXT8^T!Y7-Y[0Q)NC&>C==K<I=PB"M62:$YW*
MN:GK'G*C^?^%<9"]STJ*T97:Q@[*8'SR%/FI4@F]AL\!^^?5K6\UL:P/C^2"
M-RB^62)*XE7RF4XR(K!385W:H?_R)^=1Y56R#:&6E*<$481C%/^9XN+6AT\M
M+:;B(,!>C<VJEA9;^E!(YQ#P&&U8&MRHU&M<.EY+C0Z[ _M80BL0ER'0V44$
MENE#ZN\)VEAOC'LB^[.L#[ G9C.B5^%"=1>$-NX\XQ"Q7!>CQ0([F)*ELU(<
M] 7V]81=)GC<J.[ T$:=H0R+5L)L87&]DPIG &!_4^A-1L 28YX/H(\IG#WU
ML/2XWB'EL#^TJRNT!@E8T@=7BT.P55:?_"P#=IF%UAL..Z#=+FK4&A)2TI6J
MNJMTAW:W;8'N<#C2$[^-"N;8VE[#H)U^&W@5J<B=/I15$' ASF1<XY.LY@=:
MXWULXDVV!/:.OWU48T1MV@7MX6Q0/^I0P+3[=/^6N&TEM_J6.,T/M,;'VL02
M5P*[L=T49HD3W)(GBP6VZ=DR5T%9WP(A& C:-]N@_+6L#Q)V@*:<$3R64/[8
M",VC=,]Z+OO%/:%=N&M3 0W\_2A+E\;*?!98'7*Z&N_3*DF6C<*^T'[BM:\4
M2ASH^"Y3C8FUG6&@?==KUZWJ[.E#X8C+Q0+9]'QX^6JO+'>)'NB)<>(RQM!M
MF/W!8CJ>+8<9"26ZIC/,= A<1Z1NS=)EAK%0=:!TB%Q@L5->_J@G42&=8:;#
MEB2JT+I8Z2+LP_K"QSRB,Y"0-SJQ(J]-;:W(]9\.6Y+,PH Z<* 96Q_ LQ@U
MI U=-"PK0S/FU $<6<EJ'5&P>\.E.]]MP5&LHEIM4;4QIL.6)+[0L\3IP#/F
MJF$VVT&Q!VG*4W((:R_5XS?7LI&&TH-$R8_A9N-$BFLYB>)>NPN/K&/9*,2K
MJHTP';8D(876!-4 9\PK!LH6'M>B8\FBI9;N?;/I$#@/A89P1(;J+)IN1UFF
M*@\62C'3<CH$3D=A0) '@#I;9V="EI:[37+&2@>AG?U\LC@/?>PBWV\ZET&:
MIGWYGYC ^Q3^R6*[GUK.OC*0PB9B9'R [ B5Z!YCWW8\/R3HB:K)N2-_+##]
M*>",":8D+E@0:N"6J<WA\/C=R++R&*[7%GF;+![QTL4+;%MNL'7N92&VE$$V
M\WAM.C/  04J\?W"3@!+0+(DI]9IJF.')*K,<>VQ@">Q5!""F5D&8\>GWG>/
MQ1?3NR<BKOH$$]RWTX-)YHJPK=844:!!;1=3Z0:DS#).\6P Q2CJL@LTE$_+
MH7+SV&O8,QHM"8KVQ,IJ&PWKS7+#RE9[E6X ZWV6/X2P!T!&D]YI3F,4R&E1
MS'Z1M5L+7\?7]VQ8W1,%ZU/F1-X;C5=8VE'REJ9#X5!5U!5@JHE(TIMJ&J,
M'Z<41""8;GH8.S[=\M&=37O\Q9_UXU,K"2U'97I)>@',K!P+$Z(RL7IZLZSD
MB, S3BX5P60K#[7C$P^FJ+=R]>X6E.G.ITJ^\P*D-X^4QP">.>I5O-7QU/#\
MTLR\V)9VO$<DRD_7^ S)?5]EK@BZ ,R:/"DJLT38!WI6B-DJF!\R)!VW(ZS7
M.$X^P-R>(D_;)7(AC,P24O8+D<*DT1H'Q#2A0)^:=4)G(. YIRL5H<5"$W/'
M#W,L, O17]S@\EG+P&?*\2CS>:7,^((N$">]'"E*)SM1'^C<]6*VBLYT$B2=
MWK/4WDC?WTI+OY5:/O8GBQQ-;_%_E1Y(E0;HXJNH*K!NNZC]\-%D<>D'>%V0
M3C3;$+C80QF!'@  2P<C>)"[\LB+1>)(_,>-@X/B6:C4#[A0@HZL5/%T/ #Y
MRL(DBBZY118[Q+(SKN["JSP&=*6"$E-5!YNQD+U6A7(JJX%2?^B* B540!57
MQR-Y=V[2ZA(7=8'.^E]"R!(HQF+NH%),O*080CR7_M6.735T%WK=H:!+ )30
M@Q(0C<7>03]-/$7/G>\/%%K&'GN%YJ'#SO,YHMBMS68Q&M@) S2/F*MD"BHW
M8N<>-\KC[+AQ-65,MG+&9)@9^+,\@>PU[BH,*"FWV,7K</T0Q9;=QZ&[/KWR
M[5(&W[!D''Z)F5MA_'X\F)AB1:<MQBK!>F,46-AYC]EK2<S>CHBG@MH0V8;]
MCI<[P-IM._,3_<!DD?(['[UBF;F9VQ[8ZGPH$K[H1+1W6X(I/&R7NJ.4[W])
MNSC?HO4,$8EL-4<"ME\+I<D7OCXX*+40/$-$MX$DD=XNPD0HU,(^T/9G?7EP
MWB0* -9W.3(OR8F+R@ASUPW:F%RC/-,886O-:DGTZ<4K(]%=-VC+<8T236,T
M5VFF?HG2/J5F::HCM!VX3JEF4)I+VEF[7*^\D)01Z[X?=-'6&J6: 6GL7:]R
M*C<?V1^7WO/)'&%V6/[$_L($_BEU1J8_36_0TG(NW8 %8?#O-IQ6P%54BVXT
M?(K%6V.]'(Z)&'MK"[L"]J:;0!48%3#MD+-Y8H6GR,JKT6B-"/.=/"?X=^S3
M0?_N.?,H:0+9>'&:;?FRI#P 5'5.+C\Y2X\6D'8>ZR]#XHU\;,5),Z,;:9(U
M$S$8-WB- S27"U1K$*BRF:I"U08#7>E$=9J6GY\<?88QHY2>F%P$QL[PH"5J
M=MON#791E.96Q>B]:]R:.HX%=E ^Y6"^FX))I_)@Q%['0LLIRHU38BCHZHD"
M&7$F:$EP;2PDEBIGQ&H<H?EH08??.QR+Y%O4#ZKZ8"7Y<$2M@K,3<CU'"X^@
M$H+-=X2J$%B[9'E 84V?)G-4W*)@Q2J]),?"R8M+25KAS3TB-A/C4O;<K#P&
M5/% @]I1"C/T:4Q4 &%'Y&01:WED<+JP-CA@M/'7 'DOJ,)_IA> 8I2PYM0Z
M\[[L5[D+CZHV8;>,!\;4@?3XK3<45!6_&M:",M!KL]NV*-P8R'T,,MI8],JA
MQ"_%VU.IP3H465P)9!\JVQPL)P^(K1_R\[E&;R#WL&IR55UZ>6B![=/F'.&W
M5Y)[BTQ(9)&81^&?N_1=8K50Z WD/U:'6JBAA;9N&]>+")@_"NFEA. _]CNZ
M7!_RO8 <T6K6 PY*Z&M9G9'1IBM7PEA?:]$)1;S&[G>@VK$+';Y\W2#71^?(
M10OI 4+0 \CYK0X-$",T=BMK0;T.[=M71\IV*-Z2)%TZ6*ZCEQ>=!Z:A+IHG
M(;9T2H?K,,H'/Z83TI8N4\6=(:\Y!;+CKTM*D'IQE[E#0;P(WWB^[$T_TP[R
M?E)*GGGJ>W+?X&><B4IV4[B$Q<J.4?RG]K&3/PSDC:24Y#7!U7@1 :R\9.H
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M.3,P+GAM;%!+ 0(4 Q0    ( )J+,TH/(/,<'0H  *Q?   1
M  "  ;."  !M=&]O+3(P,38P.3,P+GAS9%!+ 0(4 Q0    ( )J+,TKGWOYH
MK <  !-=   5              "  ?^,  !M=&]O+3(P,38P.3,P7V-A;"YX
M;6Q02P$"% ,4    " ":BS-*<[.!=/8,   IS@  %0              @ '>
ME   ;71O;RTR,#$V,#DS,%]D968N>&UL4$L! A0#%     @ FHLS2N<2!F"M
M+0  8ZH" !4              ( !!Z(  &UT;V\M,C Q-C Y,S!?;&%B+GAM
M;%!+ 0(4 Q0    ( )J+,TH;B WEOAX  #\? @ 5              "  >?/
M  !M=&]O+3(P,38P.3,P7W!R92YX;6Q02P4&      8 !@"* 0  V.X

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
